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Preface 
“We believe that it would be useful for researchers to keep up databases … over 
several years so that changes over time and their consequences on quality of care 
can be quantified” (Norton, Dunn and Soberman, 1994) 
In Australia the general practice profession has a unique opportunity to assess its strengths 
and weaknesses, and see the changes in its practice over time, through the reports from the 
BEACH program. This 31st book in the General practice series describes clinical activity at 
GP–patient encounters in 2011–12 and is accompanied by the 32nd book, A decade of 
Australian general practice 2002–03 to 2011–12. 
The General practice series provides timely information to the profession of general practice, 
professional organisations, researchers, health planners and policy makers. When BEACH 
began in 1998 as a paper based survey program, many believed it would only last about two 
years … just until we could organise the secure download of data from GP electronic health 
records (EHRs). The BEACH program is now in its 15th year.  
It took over 20 years of extensive research and development to get to the national BEACH 
program—testing validity and reliability of each aspect of the methods (funded by small 
NHMRC grants), followed by ‘proof of concept’ in 1990–91 in the conduct of the national 
Australian Morbidity and Treatment Survey (AMTS). The AMTS data provided the basis on 
which we further developed the standards for GP encounter data—national sample size 
requirements, data structures, data elements and their definitions, and coding and 
classification systems. Many used the AMTS data and over the next seven years the need for 
more up-to-date information became clearly recognised.  
So BEACH was born, the only continuous, national, representative study of GP activity in 
the world that links management actions with morbidity. This linkage is essential for the 
understanding of what treatments are given for which morbidity, but Medicare and the 
Pharmaceutical Benefits Scheme do not have such linkages. Governments were not prepared 
to fund the program in full but were willing to help, so the program has somewhat tenuous 
research funding from multiple organisations, many of which have changed over time. 
BEACH remains a paper based study. The barriers to reliable electronic measurement of GP 
clinical activity remain large. Most people assumed that with EHRs, there was no need for 
research and development of the type leading to the BEACH program. As a result, we still 
have no mandated standards for EHR structure, data elements, definitions, terminologies 
and classification systems, and no minimum data set required about the patient, their past 
history, family history and their encounter.  
Over the years much of the ground work has been done. For example in the early 90’s, as 
part of the Aus–Read trial, we developed detailed specifications for GP EHRs, and these 
were regarded as a major achievement by the independent reviewers of the project. 
However, no-one took up these specifications and Government decided not to proceed with 
development of standards for computerised data recording and collation. We assume these 
specifications remain in someone’s drawer. 
Then in 1997, IBM produced a Functional Requirements Specification for Clinical and 
Administrative General Practice Computer Systems for the (then) Commonwealth 
Department of Health and Family Services. In 2000, in collaboration with the profession and 
the FMRC, Simsion Bowles and Associates developed a comprehensive general practice data 
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model and core data set, funded by the Department of Health and Ageing through the 
General Practice Computer Group (GPCG). Later the GPCG did considerably more work in 
the area of standards for EHRs. In 2003, the International Classification of Primary Care 
(ICPC–2) was declared the recommended standard for classifying patient reported and GP 
recorded morbidity data. Sadly, this again failed to become an enforced standard.  
In 2005, following the establishment of the National eHealth Transition Authority (NeHTA), 
government funding for the GPCG ended and it was effectively shut down with the 
cessation of dedicated government funded GP IT development. NeHTA has subsequently 
concentrated on developing the Personally Controlled Electronic Health Record (PCEHR). 
The RACGP is currently reviewing GP EHR standards, but without substantial funding 
support this work is likely to be protracted. 
So while much work has been done, none has resulted in implementation of the necessary 
GP EHR standards. Currently we have multiple EHR systems with different structures, data 
elements and terminologies. This lack of adherence to standards has increasingly restricted 
practice freedom to change EHR systems; it has a negative effect on interoperability, and has 
ensured that national data collection programs cannot rely on passive data collection from 
GP desktops to provide a reliable picture of the care provided to the population. Such lack of 
data standards is amazing in a country with 125 million GP services claimed through 
Medicare in the 2011–12 financial year, at a cost to government of about $5 billion dollars.  
With increasing prevalence of multimorbidity in an ageing population, and growing 
acceptance of the need for a more holistic approach to an individual’s care within the 
healthcare system, the care given in general practice has become more than that provided by 
the GPs alone. Since the introduction of Medicare item numbers for selected practice nurse 
and Aboriginal health worker activities, the work of individual GPs has changed. 
It is likely that more and more of the services provided by other health professionals will be 
conducted independently of the GP–patient encounter. As this occurs, BEACH is likely to 
show a decrease in some clinical activities by GPs. However, we will not know whether this 
is due to others in the practice taking over this role, or whether, in fact, there has been a 
decrease in provision of such care in general practice. 
Therefore, until we have standardised GP EHRs that are constantly updated by all healthcare 
providers within general practices, we need a parallel study of the work undertaken by 
practice nurses and other health professionals within general practices. These data could be 
combined with BEACH data to provide a complete picture of the care provided by all clinical 
staff in the care of their practice population.  
Together with the profession and other stakeholders, we have learned an enormous amount 
about general practice quality and changes over time in the last 14 years as a result of the 
BEACH program. BEACH has made a significant contribution to the debate and policy 
change driving primary care reform and professional GP development. How much more 
could we learn if we were able to collect reliable, valid, representative longitudinal patient 
based data from GP EHRs and how much more could this contribute to the continuing 
development of primary care in Australia? Why are we still waiting? 
Helena Britt BA, PhD     Graeme Miller MB BS, PhD, FRACGP  
Associate Professor, Director    Associate Professor, Medical Director 
Principal Investigators, the BEACH Program. 
Family Medicine Research Centre, University of Sydney 
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Summary 
This report describes clinical activity at, or associated with, general practitioner (GP) 
encounters, from April 2011 to March 2012, inclusive. It summarises results from the 
14th year of the Bettering the Evaluation and Care of Health (BEACH) program, using a 
sample of 98,400 patient encounters with 984 randomly selected GPs. After post-
stratification weighting, 99,030 encounters were analysed in this report. 
BEACH is a continuous cross-sectional national study that began in April 1998. Every year 
each of about 1,000 randomly selected GPs records details of 100 consecutive encounters on 
structured paper recording forms, and provides information about themselves and their 
practice. BEACH is the only continuous randomised study of general practice activity in the 
world, and the only national program that provides direct linkage of management (such as 
prescriptions, referrals, investigations) to the problem under management.  
The BEACH database now includes information for almost 1.4 million encounters from 
13,815 participants representing 9,111 individual GPs.  
In subsamples of the BEACH encounters smaller patient-based (rather than encounter-
based) studies are conducted. This publication includes results for patient body mass index, 
smoking status and alcohol consumption, and abstracts (with the research tools) are 
provided for each of the other substudies conducted in 2011–12.  
The companion report highlighting major change over the most recent 10 years of BEACH,  
A decade of Australian general practice activity 2002–03 to 2012–12,1 is available at 
<purl.library.usyd.edu.au/sup/9781743320204>. 
The general practitioners 
Of the 984 participating GPs in 2011–12: 
• 59% were male, 41% were aged 55 years and over, 67% had graduated in Australia 
• spent an average of 36.9 hours per week (median 38 hours) in direct patient care  
• more than 50% were Fellows of the Royal Australian College of General Practitioners 
(RACGP), and 7% were Fellows of the Australian College of Rural and Remote Medicine 
(ACRRM) 
• 29% bulk-billed Medicare for all patients and 71% bulk-billed for selected patients 
• 50% had provided care in a residential aged care facility in the previous month 
• 71% practised in Major cities (using Australian Standard Geographical Classification) 
• 57% were in practices of fewer than five full-time equivalent (FTE) GPs 
• 77% worked in a practice employing practice nursing staff 
• nearly two-thirds (62%) had a co-located pathology laboratory or collection centre and 
almost half (47%) had a psychologist in or within 50 metres of the practice 
• 42% worked in a practice that provided their own or cooperative after-hours care 
• 63% worked in a practice teaching undergraduates, junior doctors, and or registrars  
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• 94% of GPs were producing prescriptions electronically, 93% were receiving pathology 
results online, 81% were producing and printing pathology orders, and 36% were 
ordering pathology electronically. Almost two-thirds (65%) reported they used 
electronic medical records exclusively (that is, were paperless). 
There were no significant differences in the characteristics of the final sample of BEACH 
participants and all GPs in the sample frame in terms of sex, age, place of graduation, state, 
or location by the Australian Standard Geographical Classification.  
Participating GPs were slightly less ‘busy’ than non-participants, with an average 6.8 fewer 
MBS claims for GP consultation service items per week over the previous year. 
The encounters 
After weighting the data for non statistically significant minor differences in GP activity and 
the age–sex distribution of the GP participants, the age–sex distribution of patients at 
BEACH encounters had an excellent fit (precision ratios 0.91–1.09), with that of patients at 
all GP services claimed under the Medicare Benefits Schedule (MBS).  
• On average, patients gave 155 RFEs, and GPs managed about 154 problems per 
100 encounters. 
• Chronic problems accounted for 36%, and new problems for 38% of all problems. 
• Work-related problems were managed at a rate of 2.6 per 100 encounters. 
• Medications were the most common treatment choice, (107 per 100 encounters). Most 
were prescribed (87 per 100 encounters), rather than supplied by the GP (10 per 100) or 
advised for over-the-counter (OTC) purchase (11 per 100). 
• At an ‘average’ 100 encounters, problem management involved: 47 pathology 
tests/batteries of tests; 37 clinical treatments; 17 procedures; 15 referrals [most 
commonly to medical specialists (9) and to allied health services (5)]; and 10 imaging 
tests. 
• Direct encounters (patient seen) accounted for 98% of encounters at which a payment 
source was recorded. Of these: 95% were claimable either through the MBS or the DVA; 
2% through workers compensation, 1% through other sources. 
In a subsample of 33,096 BEACH MBS/DVA-claimable encounters at which start and finish 
times were recorded, mean consultation length was 15.2 minutes, median 13.0 minutes 
Who were the patients?  
• Females accounted for 57% of encounters, and the greater proportion of encounters in 
all adult age groups. Children (aged < 15 years) accounted for 12% of encounters;  
15–24 years 9%; 25–44 years 23%, 45–64 years 28%; 65–74 years 13%; and 75 years and 
over 16%. 
• The patient was new to the practice at 8% of encounters, held a Commonwealth 
concession card at 45%, and was from a non-English-speaking background at 11%. 
• At 1.6% of encounters the patient identified themselves as an Aboriginal and/or Torres 
Strait Islander person. 
For every 100 encounters, patients gave 155 reasons for encounter (RFEs): 67 symptom and 
complaint RFEs, 29 diagnosis/disease RFEs, 59 requests for processes of care (e.g. 
procedures, referrals). 
 xvi 
What problems do GPs manage at patient encounters? 
There were 152,286 problems managed, average 154 per 100 encounters: one problem was 
managed at 62% of encounters, two or three being managed at 35%, and four at 3%. The 
number managed increased with age group of patients. 
Two-thirds (68%) of problems were described as diagnoses or diseases, 18% in terms of 
symptoms or complaints, and 9% as diagnostic or preventive procedures (e.g. check-ups). 
• The most common managed were: respiratory problems (20 per 100 encounters); 
problems of a general and unspecified nature (19); musculoskeletal problems (17); 
cardiovascular (17); and skin problems (17 per 100 encounters). 
• Individual problems managed most often were hypertension (9.1 per 100 encounters), 
check-ups (6.4), upper respiratory tract infection (URTI) (6.0), immunisation/vaccination 
(4.7), and depression (4.4 per 100 encounters). 
• At least one chronic problem was managed at 42% of encounters and 56 chronic 
problems were managed per 100 encounters.  
• Almost half of all chronic problems managed were accounted for by the top six chronic 
problems: non-gestational hypertension (16% of chronic conditions), depressive disorder 
(8%), non-gestational diabetes (7%), chronic arthritis (7%), lipid disorder (6%), and 
oesophageal disease (5%). Extrapolation of these results suggests that, across Australia 
in 2011–12, there were 11.0 million encounters involving hypertension, 5.4 million 
involving depression and 5.0 million involving diabetes. 
An example of the relationship between a problem managed and other data fields is 
provided for GP management of gastro-oesophageal reflux disease in 2011–12 in Section 7.8. 
What management actions were recorded for problems managed? 
For an ‘average’ 100 patient problems, GPs provided 57 prescriptions and 24 clinical 
treatments, undertook 11 procedures, made 6 referrals to medical specialists and 3 to allied 
health services, and placed 31 pathology test orders and 7 imaging test orders. 
Medications  
There were 106,007 medications, 107 per 100 encounters but only 70 per 100 problems 
managed: 81% were prescribed, 10% supplied by the GP and 11% recommended for OTC 
purchase. 
Extrapolation to the 122.5 million Medicare GP consultation items claimed in 2011–12 
suggests GPs wrote about 106 million prescriptions, supplied 11.9 million medications 
directly to the patient, and advised medications for OTC purchase 12.9 million times. 
• At least one medication (most commonly prescribed) was given for 55% of problems 
managed. 
• No repeats were given for 35% of prescriptions, and five repeats were ordered for 36%. 
The ordering of one repeat was also quite common (16%).  
• Medication types most often prescribed were those acting on: the nervous system  
(22.8% of scripts), particularly opioids (6.8%) and antidepressants (4.7%); and the 
cardiovascular system (19.3%), particularly antihypertensives and lipid lowering agents. 
The most commonly prescribed individual medications were: the antibiotics amoxycillin 
(3.7% of all prescriptions), cephalexin (3.2%) and amoxycillin with potassium 
clavulanate (2.1%); the analgesics paracetamol (3.4%) and paracetamol/codeine (2.2%); 
the lipid modifying agent atorvastatin (1.8%); and the opioid oxycodone (1.7%). 
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• Medications were GP-supplied at a rate of 10 per 100 problems managed and vaccines 
accounted for the vast majority of these. 
• Medications were advised for OTC purchase at a rate of 7 per 100 problems managed. 
Paracetamol accounted for 27% of these and ibuprofen for 7%.  
The pattern of GP prescription or supply of proton pump inhibitors (to whom and for what) 
is provided as an example of pharmaco-epidemiological analysis in Section 9.5.  
Other treatments  
At least one other treatment was provided at 41% of encounters and 53,395 other treatments 
were recorded, 69% being clinical treatments.  
Clinical treatments: 36,610 clinical treatments were recorded, 37 per 100 encounters, or 24 
per 100 problems managed. General advice and education (16% of clinical treatments), and 
counselling about the problem being managed (13%) were most common. Preventive 
counselling/advice about nutrition and weight, exercise, smoking, lifestyle, prevention, and 
alcohol was also frequently provided by GPs (together at a rate of 7.7 per 100 encounters).  
Of all problems for which clinical treatments were provided, the top ten accounted for 29%. 
The most common were depression (5.5% of problems with clinical treatments), URTI 
(5.2%), hypertension (3.4%) and diabetes (3.4%).  
Procedural treatments: 16,785 procedural treatments were recorded, 17 per 100 encounters, 
or 11 per 100 problems. The most common were: excisions (2.8 per 100 encounters), 
dressings (2.5 per 100), local injections (2.2) and rehabilitation (1.4). 
Practice nurse (PN)/Aboriginal health worker (AHW) activity  
These data are limited to PN/AHW work associated with recorded GP–patient encounters.  
• PNs/AHWs were involved in 7% of encounters and in management of 5% of the 
problems managed. A practice nurse Medicare item number was recorded for 27% of 
those encounters involving a practice nurse, the most common claims being for 
immunisation (55% of PN/AHW item number claims) and wound treatment (33%). 
• The majority of their activities were procedural (89%) and these procedures represented 
35% of all procedures recorded. Clinical treatments accounted for 11% of practice nurse 
activity, but only 2% of all recorded clinical treatments.  
• The most common procedures done by PNs/AHWs were injections (36% of recorded 
procedures), dressings (20%), check-ups (8%) and INR tests (7%).  
Referrals and admissions  
There were a total of 14,382 referrals, 15 per 100 encounters or 9 per 100 problems. The most 
frequent were to medical specialists (9 per 100 encounters, 6 per 100 problems managed), 
followed by referrals to allied health services (5 per 100 encounters, 3 per 100 problems). 
Very few patients were referred to hospitals or emergency departments (0.6 per 100 
encounters, 0.4 per 100 problems).  
Referrals to specialists were most often to surgeons (10% of specialist referrals), orthopaedic 
surgeons (9%), cardiologists (8%), dermatologists (8%) and ophthalmologists (7%). Diabetes, 
malignant skin neoplasms, pregnancy and osteoarthritis were the problems most often 
referred to specialists. 
For the first time, this report incorporates information about what problems are referred by 
GPs to each of the most common medical specialties: surgeons, orthopaedic surgeons, 
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cardiologists, dermatologists, ophthalmologists, gastroenterologists, ear, nose and throat 
(ENT) specialists, gynaecologist, urologist, and neurologist. When analysed by individual 
medical specialty, the top ten problems accounted for 39.9% of all referrals to surgeons 
(indicative of the broad range of conditions referred to them), and for 74.9% of all referrals to 
dermatologists, consistent with a more defined range of problems referred. 
Referrals to allied health services were most often to physiotherapists (28% of allied health 
referrals), psychologists (19%), podiatrists (10%) and dietitians/nutritionists (8%). Problems 
most likely to be referred to allied health services were depression, diabetes and back 
complaints.  
Tests and investigations 
Pathology tests ordered: GPs recorded 46,544 orders for pathology tests/batteries, at a rate 
of 47 per 100 encounters (31 per 100 problems managed). At least one pathology test was 
recorded at 18% of encounters (for 14% of problems managed). 
• Chemistry tests accounted for 59% of pathology test orders, the most common being: 
lipid tests (2.9 per 100 problems managed); electrolytes, urea and creatinine (2.1); multi-
biochemical analysis (1.9); and thyroid function tests (1.7 per 100).  
• Haematology tests accounted for 18% of pathology and included full blood count, the 
most frequently ordered individual test (14% of all pathology), ordered at a rate of 4.3 
per 100 problems managed. 
• Microbiology accounted for 13% of pathology orders. Urine microscopy, culture and 
sensitivity was the most frequent test ordered within the group.  
• Almost 40% of all pathology tests were generated by orders for ten problems, led by 
diabetes, hypertension, general check-ups, and lipid disorders.  
Imaging ordered: There were 9,978 imaging test orders recorded, 10 per 100 encounters and 
7 per 100 problems managed. At least one imaging test was ordered at 9% of encounters (for 
6% of problems managed). Diagnostic radiology accounted for 46%, ultrasound 39%, and 
computerised tomography for 12% of all imaging orders.  
Patient risk factors 
Overweight and obesity in adults (18 years and over): Of 32,372 adults, 62% (69% of males 
and 57% of females) were overweight or obese: 35% being overweight and 27% obese.  
Overweight and obesity in children (2–17 years): Of 3,093 children, 29% were overweight 
(18%) or obese (11%). Prevalence and age pattern did not differ between the sexes. 
Smoking status (adults 18 years and over): Of 33,086 adults, 15% (18% of men and 13% of 
women) were daily smokers and this was most prevalent among 25–44 year olds (21.2%). 
Alcohol consumption in adults (18 years and over): Of 32,257 adult patients 25% (29% of 
men and 23% of women) reported drinking at-risk levels of alcohol. It was most prevalence 
among 18–24 year olds. 
Adult risk profile (18 years and over): Of the 31,401 patients for whom all three risk factor 
data were available: 25% had no risk factors, 52% had one, 19% had two, and 4% had three.  
 
 
  
1 Introduction 
This publication is the 14th annual report and the 31st book in the General Practice Series 
from the BEACH (Bettering the Evaluation and Care of Health) program, a continuous 
national study of general practice activity in Australia. It provides the annual results for the 
period April 2011 to March 2012 inclusive, using details of 98,400 encounters between general 
practitioners (GPs) and patients (almost a 0.1% sample of all general practice encounters) 
from a random sample of 958 practising GPs across the country. 
Released in parallel with this report is a summary of results from the most recent ten years of 
the BEACH program, A decade of Australian general practice activity 2002–03 to 2011–12,1 
available at <purl.library.usyd.edu.au/sup/9781743320204>. The BEACH program began in 
April 1998 and was the culmination of about 20 years research and development work at the 
University of Sydney. BEACH is currently supported financially by government and private 
industry (see Acknowledgments). 
From 1998 to 2011 the BEACH program was conducted by the Family Medicine Research 
Centre (FMRC), University of Sydney, in collaboration with the Australian Institute of 
Health and Welfare (AIHW), under the AIHW Act. The collaboration ceased in March 2011. 
The FMRC continues to conduct the BEACH program.  
BEACH is the only continuous randomised study of general practice activity in the world, 
and the only national program that provides direct linkage of management actions (such as 
prescriptions, referrals, investigations) to the problem under management. The BEACH 
database now includes information for almost 1.4 million encounters from 13,815 
participants representing 9,111 individual GPs. 
1.1 Background 
In June 2011, the population of Australia was estimated to be 22.6 million people.2 
Australia’s health expenditure in 2009–10 was $121.4 billion, an average $5,479 per 
Australian, and accounted for 9.4% of GDP. Governments funded 69.9%, with the remainder 
(30.1%) being paid by the non-government sector.3 Government expenditure on general 
practice services (including those of the practice nurses) was almost $5.6 billion dollars in 
the 2011–12 financial year.4 
GPs are usually the first port of call in the Australian healthcare system. Payment for GP 
visits is largely on a fee-for-service system, there being no compulsory patient lists or 
registration. People are free to see multiple practitioners and visit multiple practices of their 
choice. There is a universal medical insurance scheme (managed by Medicare Australia), 
which covers all or most of an individual’s costs for a GP visit.  
In 2009 in Australia, there were 25,707 practising primary care practitioners (vocationally 
recognised GPs and other medical practitioners), making up 24,614 full-time equivalents 
(based on a 40-hour week), or 112.1 per 100,000 people.5 While more recent labor force data 
have been published,6 the national figures reported do not include data from Queensland 
and Western Australia, so are not quoted here. 
In the April 2011 – March 2012 year, about 83% of the Australian population claimed at least 
one GP service from Medicare (personal communication, Department of Health and Ageing 
[DoHA], April 2012). From April 2011 to March 2012, Medicare paid rebates for about 
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122.5 million claimed general practice service items (excluding practice nurse items),7 at an 
average of about 5.36 GP visits per head of population or 6.55 visits per person who visited 
at least once. This equates to about 2.36 million GP–patient encounters per week.  
While Medicare statistics provide information about frequencies and costs of visits claimed 
from Medicare for GP service items, they cannot tell us about the content of these visits. The 
BEACH program fills this gap. 
1.2 The BEACH program 
In summary, the BEACH program is a continuous national study of general practice activity 
in Australia. Each year an ever changing random sample of about 1,000 practising GPs 
participate, each recording details of 100 patient encounters on structured paper-based 
recording sheets (Appendix 1). This provides details of about 100,000 GP–patient encounters 
per year. They also provide information about themselves and their major practice 
(Appendix 2). The BEACH methods are described in Chapter 2 of this report. 
Aims 
The three main aims of the BEACH program are to: 
• provide a reliable and valid data collection process for general practice that is 
responsive to the ever-changing needs of information users, and provides insight into 
the evolving character of GP–patient encounters in Australia 
• establish an ongoing database of GP–patient encounter information 
• assess patient risk factors and health states, and the relationship these factors have with 
health service activity. 
Current status of BEACH 
BEACH began in April 1998 and is now in its 15th year. The BEACH database now includes 
records for 1,381,500 GP–patient encounters from 13,815 participating GPs. Each year we 
publish an annual report of BEACH results collected in the previous 12 months. This 
publication reports results from April 2011 to March 2012. A companion publication  
A decade of Australian general practice activity 2002–03 to 2011–12,1 provides summaries of 
changes in the most frequent events that have occurred over the decade.  
The strengths of the BEACH program 
• BEACH is the only national study of general practice activity in the world that is 
continuous, relying on a random ever-changing sample of GPs, and directly linking 
management actions to the morbidity under management.  
• The sheer size of the GP sample (1,000 per year) and the relatively small cluster of 
encounters around each GP provide more reliable estimates than a smaller number of 
GPs with large clusters of patients and/or encounters.8 Our access to a regular random 
sample of recognised GPs in active practice, through DoHA, ensures that the GP sample 
is drawn from a very reliable sample frame of currently active GPs. 
• There are sufficient details about the characteristics of all GPs in the sample frame to test 
the representativeness of the final sample, and to apply post-stratification weighting to 
correct for any under or over-representation in the sample when compared with the 
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sample frame. The ever-changing nature of the sample (where each GP can participate 
only once per triennium) ensures reliable representation of what is happening in general 
practice across the country. The sampling methods ensure that new entrants to the 
profession are available for selection because the sample frame is based on the most 
recent Medicare data.  
• Where data collection programs use a fixed set of GPs over a long period, they are 
measuring what that group is doing at any one time, or how that group has changed 
over time, and there may well be a ‘training effect’ inherent in longer-term participation. 
Such measures cannot be generalised to the whole of general practice. Further, where 
GPs in the group have a particular characteristic in common (for example, all belong to a 
professional organisation to which not all GPs belong; all use a selected software system 
which is not used by all GPs), the group is biased and cannot represent all GPs. 
• Each GP records for a set number of encounters (100), but there is wide variance among 
them in the number of patient consultations they conduct in any one year. DoHA 
therefore provides an individual count of activity level (that is, number of Medicare GP 
service items claimed in the previous period) for all randomly sampled GPs, allowing us 
to give a weighting to each GP’s set of encounters commensurate with his or her 
contribution to total general practice encounters. This ensures that the final encounters 
represent encounters with all GPs. 
• The structured paper encounter form leads the GP through each step in the encounter, 
encouraging entry of data for each element (see Appendix 1), with instructions and an 
example of a completed form. In contrast, systems such as electronic health records rely 
on the GP to complete fields of interest without guidance. 
• BEACH includes all patient encounters and management activities provided at these 
encounters, not just those encounters and activities funded by Medicare.  
• The medication data include all prescriptions, rather than being limited to those 
prescribed medications covered by the Pharmaceutical Benefits Scheme (PBS).  
• BEACH is the only source of information on medications supplied directly to the patient 
by the GP, and about the medications GPs advise for over-the-counter (OTC) purchase, 
the patients to whom they provide such advice and the problems managed in this way.  
• The inclusion of other (non-pharmacological) treatments such as clinical counselling and 
procedural treatments provides a broader view of the interventions used by GPs in the 
care of their patients than other data sources.  
• The link from all management actions (for example, prescribing, ordering tests) to the 
problem under management provides a measure of the ‘quality’ of care rather than just 
a count of the number of times an action has occurred (for example, how often a specific 
drug has been prescribed). 
• The use of an internationally standard well-structured classification system (ICPC-2)9 
designed specifically for general practice, together with the use of an extended 
vocabulary of terms which facilitates reliable classification of the data by trained 
secondary coders, removes the guesswork often applied in word searches of available 
records (in free text format) and in classification of a concept.  
• The use of the World Health Organization’s (WHO) Anatomical Therapeutic Chemical 
(ATC) classification for pharmaceuticals at the generic level ensures reporting of 
medications data is in terms of the international standard. 
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• The analytical techniques applied to the BEACH data ensure that the clustering inherent 
in the sampling methods is dealt with. Results are reported with 95% confidence 
intervals. Users are therefore aware of how reliable any estimate might be. 
• Reliability of the methods is demonstrated by the consistency of results over time where 
change is not expected, and by the measurement of change when it might be expected.  
1.3 Using BEACH data with other national data 
Users of the BEACH data might wish to integrate information from multiple national data 
sources, as this can provide a more comprehensive picture of the health and health care of 
the Australian community. It is therefore important that readers are aware of how the 
BEACH data differ from those drawn from others. This section summarises differences 
between BEACH and other national sources of data about general practice in Australia. 
The Pharmaceutical Benefits Scheme  
Prescribed medications paid for under the PBS are recorded by Medicare Australia. The PBS 
data: 
• count the prescription each time it crosses the pharmacist’s counter (so that one 
prescription written by the GP with five repeats in BEACH would be counted by the 
PBS six times if the patient filled all repeats) 
• count only those prescribed medications subsidised by the PBS and costing more than 
the minimum subsidy (and therefore covered by the PBS for all patients), or medications 
prescribed for those holding a Commonwealth concession card or for those who have 
reached the safety net threshold  
• will change with each change in the PBS co-payment level for non-Commonwealth 
concession cardholders – when the co-payment level increases, those medications  
that then fall under the new level will no longer be counted in the PBS for  
non-Commonwealth concession cardholders10 
• have no record of the problem being managed (with the exception of authority 
prescriptions, which require an indication and account for a small amount of PBS data). 
The morbidity cannot be reliably assumed on the basis of the prescription type.11–13 
In BEACH: 
• total medications include those prescribed (whether covered by the PBS or not), those 
supplied to the patient directly by the GP, and those advised for OTC purchase 
• each prescription recorded reflects the GP’s intent that the patient receives the 
prescribed medication, and the specified number of repeats; the prescription, 
irrespective of the number of repeats ordered, is counted only once  
• the medication is directly linked to the problem being managed by the GP 
• there is no information on the number of patients who do not present their prescription 
to be filled (this also applies to the PBS). 
These differences have a major impact on the numbers of prescriptions counted and also 
affect their distribution. For example, the majority of broad spectrum antibiotics such as 
amoxycillin fall under the PBS minimum subsidy level and would not be counted in the 
PBS data, except where patients received the medication under the PBS because they are 
Commonwealth concession cardholders or had reached the annual safety net threshold.10 
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Medicare Benefits Schedule 
Consultations with GPs that are paid for in part or in full under the Medicare Benefits 
Schedule (MBS) are recorded by Medicare Australia. 
• Publicly available MBS claims data do not include data about patients and encounters 
funded through the Department of Veterans’ Affairs (DVA).  
• The MBS data include GP services that have been billed to Medicare. BEACH includes 
all consultations, irrespective of whether a charge is made or who pays for them.  
• The MBS data reflect the item number charged to Medicare for a service and some 
patient demographics, but hold no information about the content of the consultation. 
• BEACH participants were limited to recording three Medicare item numbers for each 
encounter. In contrast, MBS data include all Medicare item numbers claimed. In the 
BEACH data set this may result in a lower number of ‘other’ Medicare items than would 
be counted in the Medicare data.  
• In activities of relatively low frequency with a skewed distribution across individual 
GPs, the relative frequency of the event in the BEACH data may not reflect that reported 
in the MBS data. For example, a study of early uptake of some enhanced primary care 
items by GPs demonstrated in 2002 that almost half the enhanced primary care items 
claimed through the MBS came from about 6% of active GPs.14 Where activity is so 
skewed across the practising population, a national random sample will provide an 
underestimate of activity because the sample reflects the population rather than the 
minority. 
• One of the advantages of BEACH over the MBS is also the relative consistency over time 
of the data collection form. BEACH is relatively resilient to changes in MBS payment 
policies, such as the inclusion or removal of items from the MBS.  
Pathology data from the MBS 
Pathology tests undertaken by pathologists that are charged to Medicare are recorded by 
Medicare Australia. However, these Medicare data are not comparable with BEACH data. 
• MBS pathology data reflect pathology orders made by GPs and other medical 
specialists. About 70% of the volume of MBS pathology data are generated by GP 
orders.15 
• Each pathology company can respond differently to a specific test order label recorded 
by the GP. So the tests completed by a pathologist in response to a GP order for a 
multibiochemical analysis may differ between companies. 
• The pathology companies can charge through the MBS only for the three most 
expensive items undertaken, even when more were actually done. This is called ‘coning’ 
and is part of DoHA pathology payment system. This means that the tests recorded in 
the MBS include only those charged for, not all those that were done. Coning applies 
only to GP pathology orders, not to those generated by medical specialists. 
• This means that the MBS pathology data reflect those tests billed to the MBS after 
interpretation of the order by the pathologist, and after selection of the three most 
expensive items.  
• Pathology MBS items contain pathology tests that have been grouped on the basis of 
cost (for example, ‘any two of the following … tests’). Therefore an MBS item often does 
not give a clear picture of the precise tests performed. 
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In BEACH, the pathology data: 
• include details of pathology tests ordered by the participating GPs; however, the GP is 
limited to the recording of five tests or battery of tests at each encounter, and as the 
number of tests/batteries ordered on any single occasion is increasing,16 an increasing 
number of additional tests ordered will be lost 
• reflect the terms used by GPs in their orders to pathologists, and for reporting purposes 
these have been grouped by the MBS pathology groups for comparability.  
The distributions of the two data sets will therefore differ, reflecting on the one hand the GP 
order and on the other the MBS-billed services from the pathologist. 
Pathology ordering by GPs is described in Chapter 12 of this report. Those interested in 
pathology test ordering by GPs should also view the following publications: 
• Are rates of pathology test ordering higher in general practices co-located with pathology 
collection centres?17 This publication investigated the independent effect of general 
practice co-location with pathology collection centres on GP pathology test ordering in 
Sydney and Melbourne metropolitan areas.  
• Evidence-practice gap in GP pathology test ordering: a comparison of BEACH pathology data 
and recommended testing.18 
• Changes in pathology ordering by general practitioners in Australia 1998–2001.19  
Imaging data from the MBS 
Some of the issues discussed regarding pathology data also apply to imaging data. Although 
coning is not an issue for imaging, radiologists can decide whether the test ordered by the 
GP is the most suitable and whether to undertake other tests of their choosing. The MBS 
data therefore reflect the tests that are actually undertaken by the radiologist, whereas the 
BEACH data reflect those ordered by the GP.  
The National Health Survey 
The National Health Survey, conducted by the Australian Bureau of Statistics, provides 
estimates of population prevalence of specific diseases, and a measure of the problems taken 
to the GP by people in the two weeks before the survey. 
• Prevalence estimates are based on self-reported morbidity from a representative sample 
of the Australian population, using a structured interview to elicit health-related 
information from participants.20  
• Community surveys such as the National Health Survey have the advantage of 
accessing people who do not go to a GP as well as those who do. They can therefore 
provide an estimate of population prevalence of disease and a point estimate of 
incidence of disease. 
• Self-report has been demonstrated to be susceptible to misclassification because of a lack 
of clinical corroboration of diagnoses.21 
Management rates of health problems in general practice represent GP workload for a health 
problem. BEACH can be used to estimate the period incidence of diagnosed disease 
presenting in general practice through the number of new cases of that disease. The 
management rates of individual health problems and management actions can be 
extrapolated to national management rates.  
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The general practice patient population sits between the more clinical hospital-based 
population and the general population,22,23 with about 83% of Australians visiting a GP at 
least once in 2011–12 (personal communication, DoHA, April 2012). Disease management 
rates are a product of both the prevalence of the disease/health problem in the population, 
and the frequency with which a patient visits a GP for the treatment of that problem. Those 
who are older and/or have more chronic disease are therefore likely to visit more often, and 
have a greater chance of being sampled in the encounter data.  
There was a substudy of disease prevalence among patients seen in general practice (using 
the Supplementary Analysis of Nominated Data method, see Section 2.6). Those interested 
in disease prevalence should refer to the following papers: Estimating prevalence of common 
chronic morbidities in Australia,24 and Prevalence and patterns of multimorbidity in Australia.25  
1.4 Access to BEACH data 
Different bundles of BEACH data are available to the general public, to 
BEACH-participating organisations, and to other organisations and researchers. 
Public domain 
This annual publication provides a comprehensive view of general practice activity in 
Australia. The BEACH program has generated many papers on a wide variety of topics in 
journals and professional magazines. All published material from BEACH is available at 
<sydney.edu.au/medicine/fmrc/publications/index.php>. 
Since April 1998, a section at the bottom of each encounter form has been used to investigate 
aspects of patient health or healthcare delivery not covered by general practice 
consultation-based information. These additional substudies are referred to as SAND 
(Supplementary Analysis of Nominated Data). The SAND methods are described in 
Section 2.6. Abstracts of results and the research tools used in all SAND substudies from 
April 1998 to March 2011 have been published. Those from: 
• April 1998 to March 1999 were published in Measures of health and health care delivery in 
general practice in Australia26 
• April 1999 to July 2006 were published in Patient-based substudies from BEACH: abstracts 
and research tools 1999–200627 
• August 2006 to March 2011 were published in each of the BEACH annual reports28–32 
• April 2011 to March 2012 are included in Chapter 14 of this report. 
Abstracts of results for all SAND substudies are also available on the FMRC website 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts/index.php> where you can 
search by topic. 
Participating organisations 
Organisations providing funding for the BEACH program receive summary reports of the 
encounter data quarterly, and standard reports or specifically designed analyses about their 
subjects of interest. Participating organisations also have direct access to straightforward 
analyses on any selected problem, medication, pathology or imaging test through an 
interactive web server. All data made available to participating organisations have been 
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further ‘de-identified’. Patients’ encounter data are not identifiable even from the original 
forms, but are further stripped of date of birth (replaced with age in years and months) and 
postcode of residence (replaced with state and area type). GP characteristics data are 
provided only in the form of grouped output (for example, GPs aged less than 35 years) to 
any organisation. 
External purchasers of reports 
Non-contributing organisations may purchase standard reports or other ad hoc analyses. 
Charges are outlined at <sydney.edu.au/medicine/fmrc/beach/data-reports/for-
purchase/index.php>. The FMRC should be contacted for specific quotations. Contact 
details are provided at the front of this publication. 
Analysis of the BEACH data is a complex task. The FMRC has designed standard reports 
that cover most aspects of a subject under investigation. Examples of a problem-based 
standard report (subject: ischaemic heart disease in patients aged 45 years and over), a 
group report (subject: female patients aged 15–24 years) and a pharmacological-based 
standard report (subject: allopurinol) for a single year’s data are available at 
<sydney.edu.au/medicine/fmrc/beach/data-reports/for-purchase/index.php>. 
Customised data analyses can be done where the specific research question is not 
adequately answered through standard reports.  
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2 Methods  
In summary: 
• each year, BEACH involves a new random sample of about 1,000 GPs 
• each GP records details about 100 doctor–patient encounters of all types  
• the GP sample is a rolling (ever-changing) sample, with about 20 GPs participating in 
any one week, 50 weeks a year (with two weeks break over Christmas) 
• each GP can be selected only once per Quality Improvement & Continuing Professional 
Development (QI & CPD)Program triennium (that is, once in each three-year period) 
• the encounter information is recorded by the GPs on structured paper encounter forms 
(Appendix 1) 
• GP participants also complete a questionnaire about themselves and their practice 
(Appendix 2). 
2.1 Sampling methods 
The source population includes all vocationally registered GPs and all general practice 
registrars who claimed a minimum of 375 Medicare general practice items of service in the 
most recently available three-month Medicare data period (which equates to 1,500 such 
claims in a year). This ensures inclusion of the majority of part-time GPs, while excluding 
those who are not in private practice but claim for a few consultations a year. 
The Medicare statistics section of the DoHA updates the sample frame from the Medicare 
records quarterly from the Medicare claims data, then removes from the sample frame any 
GPs already randomly sampled in the current triennium, and draws a new sample from 
those remaining in the sample frame. This ensures the timely addition of new entries to the 
profession, and timely exclusion of those GPs who have stopped practising, or have already 
participated or been approached in the current triennium. 
2.2 Recruitment methods 
The randomly selected GPs are approached by letter, posted to the address provided by 
DoHA. 
• Over the following ten days, the telephone numbers generated from the Medicare data 
are checked using the electronic white and yellow pages. This is necessary because 
many of the telephone numbers provided from the Medicare data are incorrect. 
• The GPs are then telephoned in the order they were approached and, referring to the 
approach letter, asked whether they will participate. 
• This initial telephone contact with the practice often indicates that the selected GP has 
moved elsewhere, but is still in practice. Where new address and/or telephone number 
can be obtained, these GPs are followed up at their new address. 
• GPs who agree to participate are set an agreed recording date several weeks ahead. 
• A research pack is sent to each participant before the planned start date. 
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• Each GP receives a telephone reminder early in the agreed recording period – this also 
provides the GP with an opportunity to ask questions about the recording process. 
• GPs can use a ‘freecall’ (1800) number to ring the research team with any questions 
during their recording period. 
• Non-returns are followed up by regular telephone calls for 3 months. 
• Participating GPs earn clinical audit points towards their QI & CPD requirements 
through the Royal Australian College of General Practitioners (RACGP) and/or the 
Australian College of Rural and Remote Medicine (ACRRM). As part of this QI process, 
each receives an analysis of his or her results compared with those of nine other de-
identified GPs who recorded at about the same time. Comparisons with the national 
average and with targets relating to the National Health Priority Areas are also 
provided. In addition, GPs receive some educational material related to the 
identification and management of patients who smoke or consume alcohol at hazardous 
levels. Additional points can be earned if the participant chooses to do a follow-up audit 
of smoking and alcohol consumption among a sample of patients about six months later. 
2.3 Ethics approval and informed patient consent 
Ethics approval for this study in 2011–12 was obtained from the Human Ethics Committee 
of the University of Sydney.  
Although the data collected by the GPs is not sufficient to identify an individual patient, 
informed consent for GP recording of the encounter details is required from each patient. 
GPs are instructed to ensure that all patients presenting during their recording period are 
provided with a Patient Information card (Appendix 3) and that they ask the patient if they 
are happy for their data to be included in the study. If the patient refuses, details of the 
encounter are not recorded. This is in accordance with the Ethics requirements for the 
BEACH program. 
2.4 Data elements 
BEACH includes three interrelated data collections: GP characteristics, encounter data and 
patient health status. An example of the form used to collect the encounter data and the data 
on patient health status is included in Appendix 1. The GP characteristics questionnaire is 
provided in Appendix 2. The GP characteristics and encounter data collected are 
summarised below. Patient health status data are described in Section 2.6. 
GP profile form (Appendix 2) 
• GP characteristics: age and sex, years in general practice, number of direct patient care 
hours worked per week, country of graduation, postgraduate general practice training 
status, Fellow of the RACGP status, Fellow of the ACRRM status, usual bulk-billing 
behaviour, use of computers at work, work undertaken in other clinical settings. 
• Practice characteristics: postcode and GP Division of major practice, number of 
individual, and number of full-time equivalent GPs working in the practice, number of 
individual and number of full-time equivalent practice nurses working in the practice, 
usual after-hours care arrangements, whether the practice is accredited, whether it is a 
teaching practice. 
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Encounter recording form (Appendix 1) 
• Encounter data: date of consultation, type of consultation (direct/indirect) (tick box 
options), up to three MBS/DVA item numbers (where applicable), and other payment 
source (where applicable) (tick boxes). 
• Patient data: date of birth, sex and postcode of residence. Tick boxes (yes/no options) 
are provided for Commonwealth concession cardholder, holder of a Repatriation health 
card (from DVA), non-English-speaking background (patient self-report – a language 
other than English is the primary language at home), Aboriginal person (self-
identification), and Torres Strait Islander person (self-identification). Space is provided 
for up to three patient reasons for encounter (RFEs) (see ‘Glossary’). 
• The problems managed at encounter (at least one and up to four). Tick boxes are 
provided to denote the status of each problem as new or continuing for the patient and 
whether the problem is considered by the GP to be work-related. 
• Management of each problem, including: 
– medications prescribed, supplied by the GP and advised for over-the-counter 
purchase including brand name, form (where required), strength, regimen, status 
(new or continuing medication for this problem), number of repeats 
– other treatments provided for each problem, including counselling, advice and 
education, and procedures undertaken, and whether the recorded other treatment 
was provided by practice nurse (tick box) 
– new referrals to medical specialists, allied health services, emergency departments, 
and hospital admissions 
– investigations, including pathology tests, imaging and other investigations ordered.  
2.5 The BEACH relational database 
The BEACH relational database is described diagrammatically in Figure 2.1. Note that:  
• all variables can be directly related to the encounter, the GP and the patient 
characteristics 
• all types of management are directly related to the problem being managed  
• RFEs have only an indirect relationship with problems managed, as a patient may 
describe one RFE (such as ‘repeat prescriptions’) that is related to multiple problems 
managed, or several RFEs (such as ‘runny nose’ and ‘cough’) that relate to a single 
problem (such as upper respiratory tract infection) managed (see Section 6.3). 
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The encounter 
• date 
• direct (face to face) 
— Medicare/DVA item 
number(s) claimable 
— workers compensation 
— other paid 
— no charge 
• indirect (e.g. telephone) 
Patient substudies (SAND) 
• risk factors 
— body mass 
— smoking status 
— alcohol consumption  
• other topics 
Management of each problem 
Medications (up to four per problem) 
• prescribed 
• over-the-counter advised 
• provided by GP 
— drug class 
— drug group 
— generic 
— brand name 
— strength 
— regimen 
— number of repeats  
— drug status (new/continued) 
 
Other treatments (up to two per 
problem) 
• procedural treatments 
• clinical treatments (e.g. advice, 
counselling) 
• practice nurse involvement 
 
Other management 
• referrals (up to two) 
— to specialists 
— to allied health professionals 
— to emergency departments 
— hospital admissions 
• pathology tests ordered (up to five) 
• imaging ordered (up to three) 
GP characteristics 
• age and sex 
• years in general practice 
• country of graduation 
• direct patient care hours/week 
• usual bulk-billing practice 
• postgraduate GP qualifications 
• FRACGP status (yes/no) 
• FACRRM status (yes/no) 
• currently a registrar (yes/no) 
• clinical use of computers  
Practice characteristics 
• practice size (no. & FTE GPs) 
• practice nurse(s) (no. & FTE) 
• after-hours arrangements 
• postcode  
• teaching practice (yes/no) 
Problems managed 
• diagnosis/problem label 
• problem status (new/old) 
• work-related problem status 
The patient 
• age and sex 
• practice status (new/old) 
• Commonwealth concession 
card status 
• DVA Status 
• postcode of residence 
• NESB/Indigenous status 
• reasons for encounter 
Note: FRACGP – Fellow of the Royal Australian College of General 
practitioners; FACRRM – Fellow of the Australian College of Rural 
and Remote Medicine; FTE – full-time equivalent; DVA – Department 
of Veterans’ Affairs; NESB – non-English-speaking background;  
SAND – Supplementary Analysis of Nominated Data. 
Figure 2.1: The BEACH relational database 
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2.6 Supplementary Analysis of Nominated Data  
A section at the bottom of each recording form investigates aspects of patient health or 
health care delivery in general practice not covered by the consultation-based data. These 
additional substudies are referred to as SAND, Supplementary Analysis of Nominated Data. 
• Each year the 12 month data period is divided into ten blocks, each of five weeks, with 
three substudies per block. The research team aims to include data from about 100 GPs 
in each block.  
• Each GP’s pack of 100 forms is made up of 40 forms that ask for the start and finish 
times of the encounter, and include questions about patient risk factors: patient height 
and weight (used to calculate body mass index, BMI), alcohol intake and smoking status 
(patient self-report). The methods and results of topics in the SAND substudies for 
alcohol consumption, smoking status and BMI are reported in Chapter 13. The start and 
finish times collected on these encounters are used to calculate the length of 
consultation. The length of consultation for Medicare-claimable encounters is reported 
in Section 5.3. 
• The remaining 60 forms in each pack are divided into two blocks of 30, so each SAND 
block includes about 3,000 records. Some topics are repeated to increase sample size. 
Different questions are asked of the patient in each block and these vary throughout 
the year. 
• The order of SAND sections is rotated in the GP recording pack, so that 40 patient risk 
factor forms may appear first, second or third in the pad. Rotation of ordering ensures 
there was no order effect on the quality of the information collected. 
Abstracts of results and the research tools used in all SAND substudies from April 1998 to 
March 2012 have been published. Those: 
• from April 1998 to March 1999 were published in Measures of health and health care 
delivery in general practice in Australia26 
• from April 1999 to July 2006 were published in Patient-based substudies from BEACH: 
abstracts and research tools 1999–200627 
• conducted between August 2006 and March 2011 have been published in each of the 
general practice activity annual reports28–32 
• conducted in the 2011–12 BEACH year are provided in Chapter 14 of this publication. 
Abstracts of results for all SAND substudies are also available on the FMRC’s website 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts/index.php>. 
2.7 Statistical methods 
The analysis of the 2011–12 BEACH data was conducted with Statistical Analysis System 
(SAS) version 9.2,33 and the encounter is the primary unit of inference. Proportions are used 
only when describing the distribution of an event that can arise only once at a consultation 
(for example, patient or GP age and sex), or to describe the distribution of events within a 
class of events (for example, problem A as a percentage of total problems). Due to rounding, 
proportions may not always add to exactly 100%. 
Rates per 100 encounters are used when an event can occur more than once at the 
consultation (for example, RFEs, problems managed or medications). 
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Rates per 100 problems are also used when a management event can occur more than once 
per problem managed. In general, the results present the number of observations (n), the 
rate per 100 encounters, and (in the case of management actions) the rate per 100 problems 
managed, and the 95% confidence interval. 
BEACH is a single stage cluster sample study design, each 100 encounters forming a cluster 
around each GP participant. In cluster samples, variance needs to be adjusted to account for 
the correlation between observations within clusters. Procedures in SAS version 9.2 were 
used to calculate the intracluster correlation, and adjust the confidence intervals 
accordingly.33  
Post-stratification weighting of encounter data adjusts for: any difference in the age–sex 
distribution of the participating GPs and those GPs in the sample frame from which the 
samples were drawn; and for the varying activity level of each GP (measured by number of 
claims each has made in the previous 12 months from Medicare Australia) (see Chapter 3). 
Statistical significance is tested by chi square statistic for GP characteristics, but significance 
of differences in/for rates is judged by non-overlapping confidence intervals of the results 
being compared. The magnitude of this difference can be described as at least p < 0.05. 
Assessment using non-overlapping CIs is a conservative measure of significance,34–36 
particularly when differences are assessed by comparing results from independent random 
samples, as is the case when changes over time are investigated using BEACH data. Due to 
the number of comparisons made in this and the companion publication we believe a 
conservative approach is warranted. 
2.8 Classification of data 
The following data elements are classified according to the International Classification of 
Primary Care – Version 2 (ICPC-2), a product of the World Organization of Family Doctors 
(Wonca):9 
• patient reasons for encounter (RFEs) 
• problems managed 
• clinical treatments (for example, counselling, advice) 
• procedural treatments 
• referrals 
• investigations ordered (including pathology, imaging and other investigations). 
The ICPC-2 is used in more than 45 countries as the standard for data classification in 
primary care. It is accepted by the World Health Organization (WHO) in the WHO Family 
of International Classifications,37 and is the declared national standard in Australia for 
reporting of health data from general practice and patient self-reported health information.38 
The ICPC-2 has a biaxial structure, with 17 chapters on one axis (each with an alphabetic 
code) and seven components on the other (numeric codes) (Figure 2.2). Chapters are based 
on body systems, with additional chapters for psychological and social problems. 
Component 1 includes symptoms and complaints. Component 7 covers diagnoses – it can 
also be expanded to provide data about infections, injuries, neoplasms, congenital anomalies 
and ‘other’ diagnoses.  
Component 2 (diagnostic, screening and prevention) is often applied in describing the 
problem managed (for example, check-up, immunisation). Components 3 to 6 cover other 
processes of care, including referrals, other (non-pharmacological) treatments and orders for 
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pathology and imaging. The components are standard and independent throughout all 
chapters. The updated component groupings of ICPC-2 codes, released by the Wonca 
International Classification Committee in 200439 have been used in this report. 
The ICPC-2 is an excellent epidemiological tool. The diagnostic and symptom rubrics have 
been selected for inclusion on the basis of their relative frequency in primary care settings, 
or because of their relative importance in describing the health of the community. ICPC has 
about 1,370 rubrics and these are sufficient for meaningful analyses. However, reliability of 
data entry, using ICPC-2 alone, requires a thorough knowledge of the classification for 
correct classification of a concept to be ensured. 
In 1995, recognising a need for a coding and classification system for general practice 
electronic health records, the Family Medicine Research Centre (FMRC) (then Unit) 
developed an extended clinical terminology classified according to the ICPC, now called 
ICPC-2 PLUS.40 This is an interface terminology, developed from all the terms used by GPs 
in studies such as the Australian Morbidity and Treatment Survey 1990–91 (113,468 
encounters),41 A comparison of country and metropolitan general practice 1990–91 
(51,277 encounters),42 the Morbidity and Therapeutic Index 1992–1998 (a clinical audit tool 
that was available to GPs) (approximately 400,000 encounters), and BEACH 1998–2011 
(about 1.3 million encounters), that together make up about 2.7 million encounter records, 
involving more than 4 million free text descriptions of problems managed and a further 
4 million for patient reasons for encounter. These terms are classified according to ICPC-2 to 
ensure data are able to be compared internationally. Readers interested in seeing how 
coding works can download the ICPC-2 PLUS Demonstrator at 
<sydney.edu.au/medicine/fmrc/icpc-2-plus/demonstrator/index.php>. 
When the free-text data are received from the GPs, trained secondary coders (who are 
undergraduate students), code the data in more specific terms using ICPC-2 PLUS. This 
ensures high coder reliability and automatic classification of the concept, and provides the 
ability to ‘ungroup’ such ICPC-2 rubrics as ‘other diseases of the circulatory system’ and 
select a specific disease from the terms within it. 
 
                    
 Components A B D F H K L N P R S T U W X Y Z  
 1. Symptoms, complaints                    
 2. Diagnostic, screening, prevention                   
 3. Treatment, procedures, medication                   
 4. Test results                   
 5. Administrative                   
 6. Other                   
 7. Diagnoses, disease                   
 A General and unspecified L Musculoskeletal U Urinary 
 B Blood & blood-forming organs N Neurological W Pregnancy, family planning 
 D Digestive P Psychological X Female genital  
 F Eye R Respiratory Y Male genital  
 H Ear S Skin Z Social  
 K Circulatory T Endocrine, nutritional & metabolic   
 
Figure 2.2: The structure of the International Classification of Primary Care – Version 2 (ICPC-2) 
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Presentation of data classified in ICPC-2 
Statistical reporting is usually at the level of the ICPC-2 classification (for example, acute 
otitis media/myringitis is ICPC-2 code H71). However, there are some exceptions where 
data are grouped either above the ICPC-2 level or across the ICPC-2 level. These grouped 
morbidity, pathology and imaging codes are defined in Appendix 4 available at: 
<purl.library.usyd.edu.au/sup/9781743320181>. 
Reporting morbidity with groups of ICPC-2 codes 
When recording problems managed, GPs may not always be very specific. For example, in 
recording the management of hypertension, they may simply record the problem as 
‘hypertension’. In ICPC-2, ‘hypertension, unspecified’ is classified as ‘uncomplicated 
hypertension’ (code K86). There is another code for ‘complicated hypertension’ (K87). In 
some cases the GP may simply have failed to specify that the patient had hypertension with 
complications. The research team therefore feels that for national data reporting, it is more 
reliable to group the codes K86 and K87 and label this ‘Hypertension*’ – the asterisk 
indicating that multiple ICPC-2 codes (as in this example) or ICPC-2 PLUS codes (see below) 
are included. Appendix 4, Table A4.1 lists the codes included in these groups.  
Reporting morbidity with groups of ICPC-2 PLUS codes 
In other cases, a concept can be classified within (but be only part of) multiple ICPC-2 codes. 
For example, osteoarthritis is classified in ICPC-2 in multiple broader codes according to 
site, such as L92 – shoulder syndrome (includes bursitis, frozen shoulder, osteoarthritis of 
shoulder, rotator cuff syndrome). When reporting osteoarthritis in this publication, all the 
more specific osteoarthritis ICPC-2 PLUS terms classified within all the appropriate ICPC-2 
codes are grouped. This group is labelled ‘Osteoarthritis*’ – the asterisk again indicating 
multiple codes, but in this case they are PLUS codes rather than ICPC-2 codes. Appendix 4, 
Table A4.1 lists the codes included in these groups. 
Reporting chronic morbidity 
Chronic conditions are medical conditions characterised by a combination of the following 
characteristics: duration that has lasted or is expected to last six months or more, a pattern of 
recurrence or deterioration, a poor prognosis, and consequences or sequelae that affect an 
individual’s quality of life.  
To identify chronic conditions, a chronic condition list43 classified according to ICPC-2 was 
applied to the BEACH data set. In general reporting, both chronic and non-chronic 
conditions (for example, diabetes and gestational diabetes) may have been grouped together 
when reporting (for example, diabetes – all*). When reporting chronic morbidity, only 
problems regarded as chronic have been included in the analysis. Where the group used for 
the chronic analysis differs from that used in other analyses in this report, they are marked 
with a double asterisk. Codes included in the chronic groups are provided in Appendix 4, 
Table A4.2. 
Reporting pathology and imaging test orders 
All the pathology and imaging tests are coded very specifically in ICPC-2 PLUS, but ICPC-2 
classifies pathology and imaging tests very broadly (for example, a test of cardiac enzymes 
is classified in K34 – Blood test associated with the cardiovascular system; a CT scan of the 
lumbar spine is classified as L41 – Diagnostic radiology/imaging of the musculoskeletal 
16
  
system). In Australia, the MBS classifies pathology and imaging tests in groups that are 
relatively well recognised. The team therefore regrouped all pathology and imaging ICPC-2 
PLUS codes into MBS standard groups. This allows comparison of data between data 
sources. The groups are marked with an asterisk, and inclusions are provided in 
Appendix 4, Tables A4.8 and A4.9. 
Classification of pharmaceuticals 
Pharmaceuticals that are prescribed, provided by the GP or advised for over-the-counter 
purchase are coded and classified according to an in-house classification, the Coding Atlas 
for Pharmaceutical Substances (CAPS). 
This is a hierarchical structure that facilitates analysis of data at a variety of levels, such as 
medication class, medication group, generic composition and brand name. 
When strength and regimen are combined with the CAPS code, we can derive prescribed 
daily dose for any prescribed medication or group of medications. 
CAPS is mapped to the Anatomical Therapeutic Chemical (ATC)44 classification, which is 
the Australian standard for classifying medications at the generic level.38 The ATC has a 
hierarchical structure with five levels. For example: 
• Level 1: C – Cardiovascular system 
• Level 2: C10 – Serum lipid reducing agents 
• Level 3: C10A – Cholesterol and triglyceride reducers 
• Level 4: C10AA – HMG CoA reductase inhibitors 
• Level 5: C10AA01 – Simvastatin (the generic drug). 
Use of the pharmaceutical classifications in reporting 
For pharmaceutical data, there is the choice of reporting in terms of the CAPS coding 
scheme or the ATC. They each have advantages in different circumstances. 
In the CAPS system, a new drug enters at the product and generic level, and is immediately 
allocated a generic code. Therefore, the CAPS classification uses a bottom-up approach. 
In the ATC, a new generic may initially enter the classification at any level (1 to 5), not 
always at the generic level. Reclassification to lower ATC levels may occur later. Therefore, 
the ATC uses a top-down approach. 
When analysing medications across time, a generic medication that is initially classified to a 
higher ATC level will not be identifiable in that data period and may result in 
under-enumeration of that drug during earlier data collection periods. 
• When reporting the 2010–11 annual results for pharmaceutical data, the CAPS database 
is used in tables of the ‘most frequent medications’ (Tables 9.2 to 9.4). 
• When reporting the annual results for pharmaceuticals in terms of the ATC hierarchy 
(Table 9.1), ATC levels 1, 3, and 5 are used. The reader should be aware that the results 
reported at the generic level (Level 5) may differ slightly from those reported in the 
‘most frequent medication’ tables for the reasons described above. 
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Practice nurse and Aboriginal health worker activities associated with the 
encounter 
The BEACH form was changed in 2005–06 to capture ‘other treatments’ performed by 
practice nurses (PNs) following the introduction of MBS item numbers for defined PN 
activities. GPs were asked to tick the ‘practice nurse’ box if a treatment was provided by the 
PN. If not ticked, it was assumed that the GP provided the ‘other treatment’. 
Over the years new PN item numbers were added to the MBS and some items were 
broadened to include work done by Aboriginal health workers (AHWs). In past years we 
have reported the results referring to PNs alone. However in 2011–12 a few GPs indicated 
(of their own accord) that the recorded action was done by an AHW rather than a PN. This 
information is now included, and now refer to work undertaken at encounters by PNs and 
AHWs in conjunction with the GPs, though the vast majority will have been done by PNs. 
There is a limitation to this approach. Few GPs specifically indicated that the work was done 
by an AHW. Others may have thought that because the question referred specifically to 
PNs, and recording of work done by AHWs was not specifically requested. These results 
therefore have the potential to be an underestimate of the work undertaken at GP–patient 
encounters by PNs and AHWs. 
2.9 Quality assurance 
All morbidity and therapeutic data elements were secondarily coded by staff entering key 
words or word fragments, and selecting the required term or label from a pick list. This was 
then automatically coded and classified by the computer. To ensure reliability of data entry 
we use computer-aided error checks (‘locks’) at the data entry stage, and a physical check of 
samples of data entered versus those on the original recording form. Further logical data 
checks are conducted through SAS regularly. 
2.10 Validity and reliability 
A discussion of the reliability and validity of the BEACH program has been published 
elsewhere.45 This section touches on some aspects of reliability and validity of active data 
collection from general practice that should be considered by the reader.  
In the development of a database such as BEACH, data gathering moves through specific 
stages: GP sample selection, cluster sampling around each GP, GP data recording, secondary 
coding and data entry. At each stage the data can be invalidated by the application of 
inappropriate methods. The methods adopted to ensure maximum reliability of coding and 
data entry have been described above. The statistical techniques adopted to ensure valid 
analysis and reporting of recorded data are described in Section 2.7. Previous work has 
demonstrated the extent to which a random sample of GPs recording information about a 
cluster of patients represents all GPs and all patients attending GPs,46 the degree to which GP-
reported patient RFEs and problems managed accurately reflect those recalled by the patient,47 
and reliability of secondary coding of RFEs48 and problems managed.41 The validity of ICPC as 
a tool with which to classify the data has also been investigated in earlier work.49 
However, the question of the extent to which the GP-recorded data are a reliable and valid 
reflection of the content of the encounter must also be considered. In many primary care 
consultations, a clear pathophysiological diagnosis is not reached. Bentsen50 and Barsky51 
suggest that a firm and clear diagnosis is not apparent in about half of GPs’ consultations, 
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and others suggest the proportion may be even greater.52 Further, studies of general 
ambulatory medical practice have shown that a large number of patients presenting to a 
primary care practitioner are without a serious physical disorder.53,54 As a result, it is often 
necessary for a practitioner to record a problem in terms of symptoms, signs, patient 
concerns, or the service that is requested, such as immunisation. For this reason, this report 
refers to patient ‘problems’ rather than ‘diagnoses’. 
A number of studies have demonstrated wide variance in the way a GP perceives the patient’s 
RFE and the manner in which the GP describes the problem under management. Further, in a 
direct observational study of consultations via a one-way mirror, Bentsen demonstrated that 
practitioners differ in the way they labelled problems, and suggested that clinical experience 
may be an important influence on the identification of problems within the consultation.50 Two 
other factors that might affect GPs’ descriptions of patient RFEs have been identified: 
although individuals may select the same stimuli, some label each stimulus separately, 
whereas others cluster them under one label; and individuals differ in the number of stimuli 
they select (selective perception).55 
The extent to which therapeutic decisions may influence the diagnostic label selected has also 
been discussed. Howie56 and Anderson53 argue that, while it is assumed that the diagnostic 
process used in general practice is one of symptom  diagnosis  management, the 
therapeutic method may well be selected on the basis of the symptom, and the diagnostic label 
chosen last. They suggest that the selection of the diagnostic label is therefore influenced by the 
management decision already made. 
Alderson contends that to many practitioners ‘diagnostic accuracy is only important to the 
extent that it will assist them in helping the patient’. He further suggests that if major 
symptoms are readily treatable, some practitioners may feel no need to define the problem in 
diagnostic terms.57 Crombie identified ‘enormous variability in the rates at which doctors 
perceive and record illnesses’. He was unable to account statistically for this variation by the 
effect of geography, age, sex or class differences in the practice populations.58 Differences in the 
way male and female GPs label problems also appear to be independent of such influences.59 
These problems are inherent in the nature of general practice. Knottnerus argues that the GP 
is confronted with a fundamentally different pattern of problems from the medical 
specialist, and often has to draw up general diagnostic hypotheses related to probability, 
severity and consequences.60 Anderson suggests that morbidity statistics from family practice 
should be seen as ‘a reflection of the physician’s diagnostic opinions about the problems that 
patients bring to them rather than an unarguable statement of the problems managed’.53  
While these findings regarding limitations in the reliability and validity of 
practitioner-recorded morbidity should be kept in mind, they apply equally to data drawn 
from health records, whether paper or electronic, as they do to active data collection 
methods.61,62 There is as yet no more reliable method of gaining detailed data about 
morbidity and its management in general practice. Further, irrespective of the differences 
between individual GPs in their labelling of the problems, morbidity data collected by GPs 
in active data collection methods have been shown to provide a reliable overview of the 
morbidity managed in general practice.63 
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2.11 Extrapolated national estimates 
A section at the end of each chapter highlights changes that have occurred over the decade 
2002–03 to 2011–12. These sections summarise results published in the companion 
publication, A decade of Australian general practice activity 2002–03 to 2011–12.1 Where the 
results demonstrate a significant change over time, the estimated national change across 
total GP Medicare services from 2002–03 to 2011–12 can be calculated using the method 
detailed below. Note that extrapolations are always based on rate per 100 encounters rather 
than rate per 100 problems because there is no independent measure of the total number of 
problems managed in Australian general practice. In contrast, the number of national 
encounters can be drawn from Medicare claims data. 
In this report, we also occasionally extrapolate data for the single year 2011–12 to give the 
reader some feeling of the real size of the issue across Australian general practice. 
When extrapolating from a single time point we: 
• divide the ‘rate per 100 encounters’ of the selected event by 100, and then multiply by 
the total number of GP service items claimed through Medicare in that year, 
122.5 million in 2011–12 (rounded to the nearest 100,000, see Table 2.1), to give the 
estimated number of the selected event across Australia in 2011–12.  
When extrapolating measured change over the decade to national estimates, we: 
• divide the ‘rate per 100 encounters’ of the selected event for 2002–03 by 100, and then 
multiply by the total number of GP service items claimed through Medicare in that year, 
96.9 million (rounded to the nearest 100,000, see Table 2.1), to give the estimated 
national number of events in 2002–03.  
• repeat the process using data for 2011–12.  
The difference between the two estimates gives the estimated national change in the 
frequency of that event over the decade. Estimates are rounded to the nearest 100,000 if 
more than a million and to the nearest 10,000 if below a million. 
Change is expressed as the estimated increase or decrease over the study period (from 
2002–03 to 2011–12), in the number of general practice contacts for that event (for example, 
an increase or decrease in the number of GP management contacts with problem X); or an 
increase or decrease in the number of times a particular medication type was prescribed in 
Australia in 2011–12, when compared with 2002–03. 
Table 2.1 provides the rounded number of GP service items claimed from Medicare in each 
financial year from 2002–03 to 2011–12.  
Table 2.1: Number of general practice professional services claimed from Medicare Australia each 
financial year, 2002–03 to 2011–12 (million) 
 2002–03 2003–04 2004–05 2005–06 2006–07 2007–08 2008–09 2009–10 2010–11 2011–12(a) 
Rounded number of 
MBS GP items of 
service claimed 
96.9 96.3 98.2 101.1 103.4 109.5 113.0 116.6 118.1 122.5 
(a) Medicare data for the 2011–12 year included data from the April 2011 to March 2012 quarters because the 2011–12 financial year data 
were not available at the time of preparation of this report. 
Source: Medicare statistics7 
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Examples of extrapolation:  
1. Number of GP encounters at which hypertension was managed nationally in 2011–12 
Hypertension was managed at a rate of 9.1 per 100 GP encounters (95% CI: 8.5 to 9.6) in 
2011–12 (shown in Table 7.3). How many times does this suggest that hypertension was 
managed in GP encounters across Australia in 2011–12?  
Our best estimate is: 11.15 million times [(9.1/100) x 122.5 million], but we are 95% confident 
that the true number lies between 10.4 million [(8.5/100) x 122.5 million] and 11.8 million 
[(9.6/100) x 122.5 million]. 
2. National increase in the number of problems managed from 2002–03 to 2011–12 
There was a statistically significant increase in the number of problems managed at 
encounter, from 144.9 per 100 encounters in 2002–03 to 153.8 in 2011–12 (see Table 7.2 in  
A decade of Australian general practice activity 2002–03 to 2011–12.1 The calculation used to 
extrapolate the effect of this change across Australia is:  
 (144.9/100) x 96.9 million = 140.4 million problems managed nationally in 2002–03, and 
(153.8/100) x 122.5 million = 188.4 million problems managed nationally in 2011–12.  
This suggests there were 48.0 million (188.4 million minus 140.4 million) more problems 
managed at GP–patient encounters in Australia in 2011–12 than in 2002–03.  
This is the result of the compound effect of the increase in the number of problems managed 
by GPs at encounters plus the increased number of visits over the decade across Australia. 
Considerations and limitations in extrapolations 
The extrapolations to the total events occurring nationally in any one year are only 
estimates. They may provide: 
• an underestimate of the true ‘GP workload’ of a condition/treatment because the 
extrapolations are made to GP Medicare items claimed, not to the total number of GP 
encounters per year – an additional 5% or so of BEACH encounters annually include 
encounters paid by sources other than Medicare, such as DVA, state governments, 
workers compensation insurance, and employers, or not charged to anyone. 
• an underestimate of activities of relatively low frequency with a skewed distribution 
across individual GPs. Where activity is so skewed across the practising population, a 
national random sample will provide an underestimate of activity because the sample 
reflects the population rather than the minority. 
Further, the base numbers used in the extrapolations are rounded to the nearest 100,000, and 
extrapolation estimates are rounded to the nearest 100,000 if more than a million and to the 
nearest 10,000 if below a million, so can only be regarded as approximations. However, the 
rounding has been applied to all years, so the effect on measures of change will be very 
small. Therefore, the extrapolation still provides an indication of the size of the effect of 
measured change nationally.  
Extrapolations are based on the unit of the encounter because the number of national 
encounters is quantifiable using Medicare claims data. However, the reader should be aware 
that where an event can occur more than once per encounter, the extrapolation represents 
the number of occasions at which that event occurs in general practice encounters, rather 
than the number of encounters where that event occurs. 
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3 The sample 
This chapter describes the GP sample and sampling methods used in the BEACH program. 
The methods are only summarised in this chapter. A more detailed explanation of the 
BEACH methods are described in Chapter 2. 
A summary of the BEACH data sets is reported for each year from 2002–03 to 2011–12 in the 
companion report A decade of Australian general practice activity 2002–03 to 2011–12.1 
3.1 Response rate 
A random sample of GPs who claimed at least 375 general practice Medicare items of service 
in the previous three months is regularly drawn from Medicare claims data by the 
Australian Government Department of Health and Ageing (DoHA) (see Chapter 2). 
Contact was attempted with 4,309 GPs but 15.4% could not be contacted. More than one-
third of these had moved (and were untraceable), or had retired or died (Table 3.1), although 
more than half were those with whom contact could not be established after five calls. 
Younger GPs were harder to contact. Of the GPs approached who were aged less than 
35 years, 27.1% were no longer at that practice and could not be traced. These would largely 
be registrars moving through practices during training. In contrast, 14.3% of GPs aged 
35 years and over were not traceable (results not shown). 
The final participating sample consisted of 984 practitioners, representing 27.0% of those 
who were contacted and available, and 22.8% of those with whom contact was attempted 
(Table 3.1). 
Table 3.1: Recruitment and participation rates 
Type of contact Number 
Per cent of  
approached  
(n = 4,309) 
Per cent of contacts 
established  
(n = 3,644) 
Letter sent and phone contact attempted 4,309 100.0 — 
No contact  665 15.4 — 
 No phone number 26 0.6 — 
 Moved/retired/deceased 241 5.6 — 
 Unavailable (overseas, maternity leave, etc) 48 1.1 — 
 No contact after five calls 350 8.1 — 
Telephone contact established 3,644 84.6 100.0 
 Declined to participate 2,395 55.6 65.7 
 Agreed but withdrew 265 6.2 7.3 
 Agreed and completed 984 22.8 27.0 
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3.2 Representativeness of the GP sample 
Whenever possible, the study group of GPs should be compared with the population from 
which the GPs were drawn (the sample frame) to identify and, if necessary, adjust for any 
sample bias that may affect the findings of the study. Comparisons between characteristics 
of the final GP sample and those of the GPs in the sample frame are provided below. The 
methods by which weightings are generated as a result of these comparisons and applied to 
the data are described in Section 3.3.  
Statistical comparisons, using the chi-square statistic (χ2) (significant at the 5% level), were 
made between BEACH participants, and all recognised GPs in the sample frame during the 
study period (Table 3.2). The GP characteristics data for BEACH participants were drawn 
from their GP profile questionnaire. DoHA provided the data for all GPs in the sample 
frame, drawn from Medicare claims data. 
Table 3.2 demonstrates that there were no significant differences in GP characteristics 
between the final sample of BEACH participants and all GPs in the sample frame, in terms 
of sex, age, place of graduation, state, or practice location as classified by the Australian 
Standard Geographical Classification.  
Occasionally, the random sampling process produces a sample that may be slightly 
disproportionate to the national sample frame, which can then impact on the final 
representativeness of the BEACH participants. In 2011–12 the sample provided by DoHA 
and the final BEACH participant sample were both highly representative of the national 
sample frame (Table 3.3). 
23
  
Table 3.2: Comparison of BEACH participants and all active recognised GPs in Australia 
(the sample frame) 
Variable 
BEACH(a)(b)  Australia(a)(c) 
Number 
Per cent of GPs 
(n = 984)  Number 
Per cent of GPs 
(n = 20,360)  
Sex (χ2 = 1.2, p = 0.27)      
 Males 582 59.2  12,399 60.9 
 Females 402 40.9  7,961 39.1 
Age (χ2 = 1.96, p = 0.57)      
 < 35 years 65 6.6  1,453 7.1 
 35–44 years 190 19.4  4,027 19.8 
 45–54 years 322 32.9  6,279 30.8 
 55+ years 402 41.1  8,601 42.2 
 Missing 5 —  0 — 
Place of graduation (χ2 = 0.79 p = 0.37)      
 Australia 661 67.2  13,409 65.9 
 Overseas 322 32.8  6,951 34.1 
 Missing 1 —  0 — 
State (χ2 = 13.3, p = 0.07)      
 New South Wales 375 38.3  6,738 33.1 
 Victoria 220 22.5  5,116 25.1 
 Queensland 168 17.2  3,966 19.5 
 South Australia 78 8.0  1,703 8.4 
 Western Australia 88 9.0  1,861 9.1 
 Tasmania 28 2.9  528 2.6 
 Australian Capital Territory 15 1.5  308 1.5 
 Northern Territory 7 0.7  140 0.7 
ASGC (χ2 = 0.62, p = 0.96)      
 Major Cities of Australia 700 71.5  14,553 71.5 
 Inner Regional Australia 185 18.9  3,843 18.9 
 Outer Regional Australia 79 8.1  1,596 7.8 
 Remote Australia 9 0.9  241 1.2 
 Very Remote Australia 6 0.6  127 0.6 
(a) Missing data removed. 
(b) Data drawn from the BEACH GP profile completed by each participating GP. 
(c) All GPs who claimed at least 375 MBS GP consultation services during the most recent three month Medicare Australia data period. 
Data provided by the Department of Health and Ageing. 
Note: ASGC – Australian Standard Geographical Classification. 
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Table 3.3: Comparison of all active recognised GPs in Australia (the sample frame), GPs in the 
sample from Medicare claims data (drawn by DoHA), and BEACH participants 2011–12 
 Sample frame  
(all Australia)(a)  
Sample from Medicare 
claims data(b)  BEACH participants  
Variable Number 
Per cent  
of GPs  Number 
Per cent  
of GPs  Number 
Per cent  
of GPs 
Sex (missing) (0)   (2)   (0)  
 Males 12,399 60.9  2,642 61.3  582 59.2 
 Females 7,961 39.1  1,665 38.7  402 40.9 
Age (missing) (0)   (3)   (5)  
 < 35 years 1,453 7.1  365 8.5  65 6.6 
 35–44 years 4,027 19.8  899 20.9  190 19.4 
 45–54 years 6,279 30.8  1,402 32.6  322 32.9 
 55+ years 8,601 42.2  1,640 38.0  402 41.1 
State (missing) (0)   (1)   (0)  
 New South Wales 6,738 33.1  1,506 35.0  375 38.3 
 Victoria 5,116 25.1  1,064 24.7  220 22.5 
 Queensland 3,966 19.5  807 18.7  168 17.2 
 South Australia 1,703 8.4  344 8.0  78 8.0 
 Western Australia 1,861 9.1  390 9.1  88 9.0 
 Tasmania 528 2.6  106 2.5  28 2.9 
 Australian Capital Territory 308 1.5  65 1.5  15 1.5 
 Northern Territory 140 0.7  26 0.6  7 0.7 
Total 20,360 100.0  4,309 100.0  984 100.0 
(a) Sample frame – all recognised (see ‘Glossary’) GPs in Australia who claimed at least 375 general practice service items in the previous 
quarter (from Medicare claims data). 
(b) Random sample of GPs from the sample frame, drawn from Medicare claims data and supplied by DoHA to approach for BEACH 
participation. 
GP activity in the previous quarter 
Data on the number of MBS general practice service items claimed in the previous quarter 
were also provided by DoHA for each GP in the drawn samples, and for all GPs (as a group) 
in the sample frame. These data were used to determine the ‘activity level’ of each GP 
drawn in the samples, and to compare the activity level of the final participants with that of 
GPs in the samples who declined to participate.  
There were significant differences in the distribution of BEACH participants and non-
participants across activity levels. A greater proportion of participants than non-participants 
were in the low activity group (375–750 services), and a smaller proportion in the high 
activity group (> 1,500 services). There were similar proportions in the 750–1,500 services 
group (Table 3.4).  
Participants had a significantly (p < 0.01) lower mean number of consultation items claimed 
in the previous quarter (1,311.1) compared with GPs who declined to participate (1,412.6). 
Comparisons of these groups showed a median difference of 7.7 consultations per week 
(median difference 7.8 per week) (Table 3.4).  
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GP activity in the previous year 
When comparing GP activity level in the previous 12 months, there was a significant 
(p = 0.017) difference between the proportions of participating and non-participating GPs in 
each of the claims categories with the exception of the 3,001–6,000 services category. 
However, comparison of the median and mean number of claims for each group showed a 
difference in the median of 6.5 consultations per week (based on a difference of 339 
per year), and 6.8 consultations per week in the mean (based on 355 per year) (Table 3.5). 
Table 3.4: Quarterly activity level of participating and non-participating GPs 
Variable 
Participants(a)  
(n = 984)  
Non-participants(a)  
(n = 2,660) 
Number of GPs Per cent  Number of GPs Per cent 
Activity (χ2 = 6.7, p = 0.0349)      
 375–750 services in previous quarter 259 26.3  605 22.7 
 750–1,500 services in previous quarter 404 41.1  1,088 40.9 
 > 1,500 services in previous quarter 321 32.6  967 36.4 
 Number of claims   Number of claims  
Mean activity level (t = 3.42, p = 0.0006) 1,311.1 —  1,412.6 — 
Median activity level 1,130.5 —  1,231.0 — 
Standard deviation 770.2 —  805.8 — 
(a) Missing data removed. 
Table 3.5: Annual activity level of participating and non-participating GPs 
Variable 
Participants(a)  
(n = 984)  
Non-participants(a)  
(n = 2,660) 
Number of GPs Per cent  Number of GPs Per cent 
Activity (χ2 = 10.1, p = 0.0174)      
 1–1,500 services in previous year 45 4.6  127 4.8 
 1,500–3,000 services in previous year 237 24.1  528 19.6 
 3,001–6,000 services in previous year 394 40.0  1,057 39.7 
 > 6,000 services in previous year 308 31.3  948 35.6 
 Number of claims   Number of claims  
Mean activity level (t = 3.02, p = 0.0025) 5,099.2 —  5,453.8 — 
Median activity level 4,459.5 —  4,798.5 — 
Standard deviation 3,034.0 —  3,187.3 — 
(a) Missing data removed. 
The similarity of the BEACH participants to the national sample frame in terms of age, sex, 
place of graduation, state and practice location, and the marginal difference in activity level 
(equating to about one consultation per day), shows a final BEACH participant sample that 
is highly representative of GPs in the Australian sample frame. 
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3.3 Weighting the data 
Age–sex weights  
As described in Section 3.2, comparisons are made annually to test how representative 
BEACH participants are of the Australian sample frame. Occasionally, where participants in 
a particular age or sex group are over-represented or under-represented, GP age–sex 
weights are applied to the data sets in post-stratification weighting to achieve comparable 
estimates and precision. The BEACH participants were representative in all age and sex 
categories, but because there are always marginal (even if not statistically significant) 
differences, post-stratification weighting was applied for consistency over recording years. 
Activity weights  
In BEACH, each GP provides details of 100 consecutive encounters. There is considerable 
variation among GPs in the number of services each provides in a given year. Encounters 
were therefore assigned an additional weight directly proportional to the activity level of the 
recording GP. GP activity level was measured as the number of MBS general practice service 
items claimed by the GP in the previous 12 months (data supplied by DoHA). 
Total weights  
The final weighted estimates were calculated by multiplying raw rates by the GP age–sex 
weight and the GP sampling fraction of services in the previous 12 months. Table 3.6 shows 
the precision ratio calculated before and after weighting the encounter data. 
3.4 Representativeness of the encounter sample 
BEACH aims to gain a representative sample of GP–patient encounters. To assess the 
representativeness of the final weighted sample of encounters, the age–sex distribution of 
patients at weighted BEACH encounters with GP consultation service items claimed 
(excluding those with Department of Veterans’ Affairs [DVA] patients) was compared with 
that of patients at all encounters claimed as GP consultation service items through Medicare 
in the 2011–12 study period (data provided by DoHA).  
As shown in Table 3.6, there is an excellent fit of the age–sex distribution of patients at the 
BEACH (weighted) with that of the MBS claims distribution, with precision ratios all within 
the 0.91–1.09 range. Even prior to the weightings, the range of raw precision ratios (0.91–
1.08) indicates that the BEACH sample is a good representation of Australian GP–patient 
encounters, as no age–sex category varied by more than 9% from the population 
distribution. 
The age–sex distribution of patients at BEACH encounters and for MBS GP consultation 
service item claims is shown graphically for all patients in Figure 3.1, for males in Figure 3.2, 
and for females in Figure 3.3. 
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Table 3.6: Age–sex distribution of patients at BEACH and MBS GP consultation service items 
Sex/age 
BEACH–raw(a)  BEACH–weighted(b)  Australia(c)  
Precision ratios 
(Australia = 1.00) 
Number 
Per cent  
(n = 82,465)  Number 
Per cent 
(n = 83,395)  
Per cent 
(n = 103,753,815)  Raw(a) Weighted(c) 
All           
 < 1 year 1,747 2.1  1,617 1.9  2.0  1.07 0.98 
 1–4 years 4,082 5.0  3,968 4.8  5.2  0.96 0.92 
 5–14 years 4,649 5.6  4,761 5.7  6.2  0.91 0.92 
 15–24 years 7,066 8.6  7,135 8.6  8.7  0.98 0.98 
 25–44 years 18,715 22.7  18,685 22.4  22.9  0.99 0.98 
 45–64 years 22,613 27.4  23,074 27.7  27.3  1.01 1.01 
 65–74 years 11,223 13.6  11,483 13.8  13.0  1.05 1.06 
 75+ years 12,370 15.0  12,672 15.2  14.8  1.01 1.03 
Male           
 < 1 year 937 1.1  858 1.0  1.1  1.07 0.97 
 1–4 years 2,174 2.6  2,159 2.6  2.7  0.96 0.94 
 5–14 years 2,381 2.9  2,466 3.0  3.2  0.91 0.93 
 15–24 years 2,354 2.9  2,594 3.1  3.2  0.90 0.98 
 25–44 years 6,365 7.7  7,023 8.4  8.6  0.90 0.98 
 45–64 years 9,018 10.9  9,995 12.0  11.8  0.93 1.02 
 65–74 years 4,986 6.1  5,482 6.6  6.0  1.01 1.09 
 75+ years 4,873 5.9  5,276 6.3  6.1  0.97 1.04 
Female           
 < 1 year 810 1.0  759 0.9  0.9  1.07 0.99 
 1–4 years 1,908 2.3  1,809 2.2  2.4  0.95 0.89 
 5–14 years 2,268 2.8  2,295 2.8  3.0  0.91 0.91 
 15–24 years 4,712 5.7  4,541 5.5  5.5  1.03 0.98 
 25–44 years 12,350 15.0  11,662 14.0  14.3  1.05 0.98 
 45–64 years 13,595 16.5  13,079 15.7  15.5  1.06 1.01 
 65–74 years 6,237 7.6  6,001 7.2  7.0  1.08 1.03 
 75+ years 7,497 9.1  7,396 8.9  8.7  1.04 1.02 
(a) Unweighted GP consultation Medicare service items only, excluding encounters with patients who hold a DVA Repatriation health card. 
(b) Calculated from BEACH weighted data, excluding encounters with patients who hold a DVA Repatriation health card. 
(c) MBS claims data provided by the Australian Government Department of Health and Ageing. 
Note: GP consultation Medicare services – see ‘Glossary’. Only encounters with a valid age and sex are included in the comparison. 
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 Figure 3.1: Age distribution of all patients at BEACH and MBS GP consultation services 2011–12 
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 Figure 3.2: Age distribution of male patients at BEACH and MBS GP consultation services 
2011–12 
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 Figure 3.3: Age distribution of female patients at BEACH and MBS GP consultation services 
2011–12 
3.5 The weighted data set 
The final unweighted data set from the 14th year of collection contained encounters, reasons 
for encounters, problems and management/treatments. The apparent number of encounters 
and number of medications increased after weighting, and the number of reasons for 
encounter, problems managed, other treatments, referrals, imaging and pathology all 
decreased after weighting. Raw and weighted totals for each data element are shown in 
Table 3.7. The weighted data set is used for all analyses in the remainder of this report. 
Table 3.7: The BEACH data set, 2011–12 
Variable Raw Weighted 
General practitioners 984 984.0 
Encounters 98,400 99,030.0 
Reasons for encounter 152,696 153,217.8 
Problems managed 154,963 152,285.5 
Medications 103,320 106,007.4 
Other treatments(a) 55,890 53,395.0 
Referrals and admissions 15,219 14,382.0 
Pathology 50,339 46,544.3 
Imaging 10,280 9,978.2 
Other investigations 969 896.5 
(a) Other treatments excludes injections for immunisations/vaccinations (raw n = 3,656, weighted  
n = 3,459) (see Chapter 10). 
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4 The participating GPs 
This chapter reports data collected between April 2011 and March 2012 about the 
participating GPs and their practices from the 14th year of the BEACH program. Details of 
GP and practice characteristics are reported for each year from 2002–03 to 2011–12 in the ten-
year summary report A decade of Australian general practice activity 2002–03 to 2011–12.1 
4.1 Characteristics of the GP participants 
All participants returned a GP profile questionnaire, although some were incomplete. The 
results are provided in Table 4.1. Of the 984 participants: 
• 59% were male, and 41% were aged 55 years and over 
• 59% had been in general practice for more than 20 years 
• 67% had graduated in Australia 
• 34% spent more than 40 hours each week on direct patient care services (mean hours 
worked was 36.9; median was 38.0 hours)  
• 27% conducted some consultations in a language other than English 
• more than 50% were Fellows of the RACGP, and 7% were Fellows of the ACRRM 
• 29% bulk-billed Medicare for all patients and 71% bulk-billed for selected patients; only 
1% did not bulk bill Medicare for any patient consultations 
• 50% had provided care in a residential aged care facility in the previous month 
• 71% practised in Major cities (using Australian Standard Geographical Classification)64 
• 37% were in practices of fewer than five individual GPs, and 21% were in practices of 
ten or more individual GPs 
• 57% were in practices of fewer than five full-time equivalent (FTE) GPs 
• 77% of the GPs worked in a practice that employed practice nursing staff—for more 
than a third of these (36.6%) the practice employed less than two full-time equivalents 
(35–45 hours per week). On average, there were 0.3 FTE practice nurses per FTE GP. 
• 89% worked in an accredited practice 
• nearly two-thirds (62%) had a co-located pathology laboratory or collection centre and 
almost half (47%) had a psychologist in or within 50 metres of the practice 
• 42% worked in a practice that provided their own or cooperative after-hours care, and 
53% in a practice that used a deputising service for after-hours patient care (multiple 
responses allowed) 
• 63% worked in a practice teaching undergraduates, junior doctors, registrars, or all 
three. 
Those interested in the clinical activity of overseas trained doctors will find more 
information in Bayram et al. (2007) Clinical activity of overseas trained doctors practising in 
general practice in Australia.65 Readers interested in the effects of GP age on clinical practice 
will find more information in Charles et al. (2006) The independent effect of age of general 
practitioner on clinical practice.66 For more information about the effect of the sex of the GP on 
clinical practice see Harrison et al. (2011) Sex of the GP.67  
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Table 4.1: Characteristics of participating GPs and their practices 
GP characteristic Number(a) 
Per cent of GPs(a) 
(n = 984) 
Sex (missing = 0)   
 Male 582 59.2 
 Female 402 40.8 
Age (missing = 5)   
 < 35 years 65 6.6 
 35–44 years 190 19.4 
 45–54 years 322 32.9 
 55+ years 402 41.1 
Years in general practice (missing = 5)   
 < 2 years 14 1.4 
 2–5 years 102 10.4 
 6–10 years 109 11.1 
 11–19 years 182 18.6 
 20+ years 572 58.4 
Place of graduation (missing = 1)   
 Australia 661 67.2 
 Overseas 322 32.8 
 Asia 123 12.5 
 United Kingdom/Ireland 80 8.1 
 Africa and Middle East 55 5.6 
 Europe 33 3.4 
 New Zealand 16 1.6 
 Other 15 1.5 
Direct patient care hours (worked) per week (missing = 13)   
 ≤ 10 hours 12 1.2 
 11–20 hours 118 12.2 
 21–40 hours 515 53.0 
 41–60 hours 312 32.1 
 61+ hours 14 1.4 
Consult in languages other than English (missing = 3)   
 < 25% of consultations 213 21.7 
 25–50% of consultations 28 2.9 
 > 50% of consultations 27 2.8 
Currently in general practice training program (missing = 9) 38 3.9 
Fellow of RACGP (missing = 3) 557 56.8 
Fellow of ACRRM (missing = 29) 70 7.3 
(continued) 
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Table 4.1 (continued): Characteristics of participating GPs and their practices 
GP characteristic Number(a) 
Per cent of GPs(a) 
 (n = 984) 
Bulk-billing(b) (missing = 2)   
 All patients 282 28.7 
 Some patients 690 70.3 
 No patients 10 1.0 
Patient care provided in previous month(b)    
 In a residential aged care facility (missing = 3) 497 50.1 
 As a salaried/sessional hospital medical officer (missing = 19) 108 11.2 
Practice location by RRMA (missing = 5)   
 Capital 649 66.3 
 Other metropolitan 74 7.6 
 Large rural 66 6.7 
 Small rural 69 7.1 
 Other rural 104 10.6 
 Remote central 6 0.6 
 Other remote, offshore 11 1.1 
Practice location by ASGC remoteness structure (missing = 5)   
 Major cities 700 71.1 
 Inner regional 185 18.9 
 Outer regional 79 8.1 
 Remote 9 0.9 
 Very remote 6 0.6 
Size of practice – number of individual GPs (missing = 16)   
 Solo 104 10.7 
 2–4  257 26.6 
 5–9  409 42.3 
 10–14 142 14.7 
 15+  56 5.8 
Size of practice – full-time equivalent GPs (missing = 111)   
 < 1 7 0.8 
 1.0–1.99 113 12.9 
 2.0–2.99 134 15.3 
 3.0–3.99 120 13.7 
 4.0–4.99 127 14.5 
 5.0–9.99 303 34.7 
 10.0–14.99 51 5.8 
 15+ 18 2.1 
(continued) 
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Table 4.1 (continued): Characteristics of participating GPs and their practices 
GP characteristic Number(a) 
Per cent of GPs(a) 
 (n = 984) 
Practice nurse at major practice address (missing = 7) 747 76.5 
Number of individual practice nurses (missing = 25)   
 0 230 24.0 
 1 148 15.4 
 2  185 19.3 
 3 134 14.0 
 4–5  175 18.2 
 6+ 87 9.1 
Number of full-time equivalent practice nurses (missing = 134)   
 0 230 27.1 
 < 1 64 7.5 
 1.0–1.99  247 29.1 
 2.0–2.99 157 18.5 
 3.0–3.99 81 9.5 
 4.0+ 71 8.3 
Accredited practice (missing = 11) 862 88.6 
Co-located services(c) (missing = 2)   
 Pathology laboratory/collection centre 609 62.0 
 Psychologist 465 47.4 
 Physiotherapist 336 34.2 
 Medical specialist 227 23.1 
 Imaging 154 15.7 
After-hours arrangements(b) (missing = 7)   
 Practice does own and/or cooperative with other practices 410 42.0 
  Practice does its own 299 30.6 
  Cooperative with other practices 122 12.5 
 Deputising service 518 53.0 
 Other arrangement 109 11.2 
Teaching status of major practice(b) (missing = 4)   
 Yes – a teaching practice 620 63.3 
   For undergraduates 518 52.9 
   For junior doctors 114 11.6 
   For registrars 389 39.7 
(a) Missing data removed. 
(b) Multiple responses allowed. 
(c) Services located/available on the same premises, in the same building or within 50 metres, available on a daily or regular basis. 
Note: RRMA – Rural, Remote and Metropolitan Areas classification; ASGC – Australian Standard Geographical Classification;  
RACGP – Royal Australian College of General Practitioners; ACRRM – Australian College of Rural and Remote Medicine. 
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4.2 Computer use at GP practices 
As computers are increasingly being used by GPs in their clinical activity, the GP profile 
questionnaire was redesigned in 2010–11 so that more comprehensive information could be 
gained about the uses to which computers are put in a general practice clinical environment 
(see Appendix 2). In particular, more specific information was collected about pathology 
and imaging test ordering and receipt of results, and whether the medical records used were 
paper only, a mix of paper and electronic medical records, or whether the practice was 
completely paperless in this regard. 
Table 4.2 shows the proportion of individual participating GPs who used computers for 
each of nine listed activities. 
• Only 4.1% of GPs did not use a computer at all for clinical purposes. 
• Computers were used mainly for prescribing, receiving pathology results electronically 
and for internet use. 
• 93.9% of GPs were producing prescriptions electronically. 
• 92.7% were receiving pathology results online, 81.1% were producing and printing 
pathology orders, and 35.5% were ordering pathology electronically. 
• 74.5% were receiving imaging results online, 73.4% were producing and printing 
imaging orders, and 20.0% were ordering imaging tests electronically. 
• Almost two-thirds (65.0) reported they had electronic medical records exclusively (that 
is, were paperless). 
• Over one-quarter (29.3%) reported maintaining a hybrid record where some patient 
information is kept electronically and some on paper records. 
Table 4.2: Computer applications available/used at major practice address 
Computer use Number 
Per cent of GPs  
(n = 984) 
Not available 31 3.2 
Not used at all 40 4.1 
Internet/email only 4 0.4 
Prescribing 924 93.9 
Internet 832 84.6 
Email 655 66.6 
Pathology ordering (online)(a) 350 35.5 
Produce/print pathology orders(a)  798 81.1 
Pathology results receipt (on line)(a) 912 92.7 
Imaging ordering (online)(a) 197 20.0 
Produce/print imaging orders(a)  722 73.4 
Imaging results receipt (on line)(a) 733 74.5 
Medical records – complete (paperless) 640 65.0 
Partial/hybrid records 288 29.3 
Paper records only 54 5.5 
(a) Multiple responses allowed. 
35
  
Those interested in the effect of computerisation on quality of care in general practice will 
find more detailed information in Henderson (2007) The effect of computerisation on the quality 
of care in Australian general practice.68 
4.3 Changes in characteristics of the GPs over the 
decade 2002–03 to 2011–12 
Changes over the decade 2002–03 to 2011–12 are described in detail in the accompanying 
report A decade of Australian general practice activity 2002–03 to 2011–12.1 Briefly, the major 
changes in the characteristics of the participating GPs were: 
• the proportion of GP participants who were female increased over time 
• the proportion of GPs who were younger than 44 years decreased, whereas the 
proportion aged 55 years or more increased over the decade 
• reflecting the increase in the age of GP participants, the proportion who had worked in 
general practice for more than 20 years also increased significantly over time 
• the proportion of GPs working 21–40 hours per week on direct patient care significantly 
increased, and the proportion working 41–60 hours, or more than 60 hours, significantly 
decreased 
• the proportion of GPs who graduated from their primary medical degree in Australia 
decreased over the decade 
• the proportion of GPs who provide < 25% of their consultations in a language other than 
English increased 
• the proportion of participants holding the Fellowship of the RACGP increased over the 
decade 
• the proportion of GPs in solo practice decreased over time, and the proportion in 
practices with more than ten individual GPs almost doubled 
• fewer practices are providing after-hours care on their own, or in cooperation with other 
practices, but more practices are using deputising services for after-hours care 
• computers have become increasingly available at practices, as has their use for clinical 
activity.  
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5 The encounters 
This chapter describes the content and types of encounters recorded in the 2011–12 
BEACH year. Data about the encounters are reported for each year from 2002–03 to 2011–12 
in the ten-year report A decade of Australian general practice activity 2002–03 to 2011–12.1  
5.1 Content of the encounters 
In 2011–12, details of 99,030 encounters (weighted data) were available for 984 GPs. A 
summary of these encounters is provided as Table 5.1. Reasons for encounter (RFEs) and 
problems managed are expressed as rates per 100 encounters. Each management action is 
presented in terms of both a rate per 100 encounters and a rate per 100 problems managed, 
with 95% confidence limits. 
• On average, patients gave 155 RFEs, and GPs managed about 154 problems per 
100 encounters. 
• Chronic problems accounted for 36.2% of all problems managed, and an average of 55.6 
chronic problems were managed per 100 encounters. 
• New problems accounted for 38.1% of all problems, and on average 58.6 new problems 
were managed per 100 encounters. 
• Work-related problems were managed at a rate of 2.6 per 100 encounters. 
• Medications were the most common treatment choice (107 per 100 encounters), most of 
these medications were prescribed (86.8 per 100), rather than supplied by the GP (9.7 per 
100) or advised for over-the-counter purchase (10.5 per 100). 
• For an ‘average’ 100 GP–patient encounters, GPs provided 107 medications and 
37 clinical treatments (such as advice and counselling), undertook 17 procedures, made 
9 referrals to medical specialists and 5 to allied health services, and placed 47 pathology 
test orders and 10 imaging test orders (Table 5.1). 
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Table 5.1: Summary of morbidity and management at GP–patient encounters 
Variable Number 
Rate per 100 
encounters 
(n = 99,030) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems  
(n = 152,286) 
95% 
LCL 
95% 
UCL 
General practitioners 984 — — — — — — 
Encounters 99,030 — — — — — — 
Reasons for encounter 153,218 154.7 152.8 156.7 — — — 
Problems managed 152,286 153.8 151.4 156.1 — — — 
 New problems 58,014 58.6 57.1 60.0 38.1 37.1 39.1 
 Chronic problems 55,080 55.6 53.6 57.7 36.2 35.2 37.2 
 Work-related 2,559 2.6 2.4 2.8 1.7 1.5 1.8 
Medications 106,007 107.0 104.1 110.0 69.6 68.0 71.2 
 Prescribed 85,980 86.8 84.0 89.7 56.5 54.9 58.1 
 GP-supplied 9,630 9.7 8.9 10.5 6.3 5.8 6.8 
 Advised OTC 10,397 10.5 9.7 11.3 6.8 6.3 7.4 
Other treatments(a) 53,395 53.9 51.2 56.6 35.1 33.5 36.7 
 Clinical* 36,610 37.0 34.6 39.3 24.0 22.6 25.5 
 Procedural* 16,785 16.9 16.1 17.8 11.0 10.5 11.5 
Referrals 14,382 14.5 13.9 15.1 9.4 9.1 9.8 
 Medical specialist* 8,488 8.6 8.2 8.9 5.6 5.3 5.8 
 Allied health services* 4,629 4.7 4.4 5.0 3.0 2.8 3.2 
 Hospital* 345 0.3 0.3 0.4 0.2 0.2 0.3 
 Emergency department* 311 0.3 0.3 0.4 0.2 0.2 0.2 
 Other referrals* 609 0.6 0.5 0.7 0.4 0.3 0.5 
Pathology 46,544 47.0 44.9 49.1 30.6 29.3 31.8 
Imaging 9,978 10.1 9.6 10.5 6.6 6.3 6.8 
Other investigations(b) 897 0.9 0.8 1.0 0.6 0.5 0.7 
(a) Other treatments includes treatment given by practice nurses in the context of the GP–patient encounter as well as treatment given by 
GPs. 
(b) Other investigations reported here include only those ordered by the GP. Other investigations in Chapter 12 include those ordered by the 
GP and those done by the GP or practice staff. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, <purl.library.usyd.edu.au/sup/9781743320181>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; OTC – over-the-counter. 
5.2 Encounter type 
During the first seven years of the BEACH program, where one (or more) MBS/DVA item 
number was claimable for the encounter, GP participants were asked to record only one 
item number. Where multiple item numbers (e.g. an A1 item such as ‘standard surgery 
consultation’ and a procedural item number) were claimable for an encounter, GPs were 
instructed to record the lower of the item numbers (usually an A1 item number). 
Changes to the BEACH form were made in the 2005–06 BEACH year to capture practice 
nurse activity associated with GP–patient consultations. One of these changes was to allow 
GPs to record up to three Medicare item numbers per encounter. For comparability with 
earlier years, in Tables 5.3, 5.4 and 5.5 only one item number per MBS/DVA-claimable 
encounter has been counted. Selection of one item number was undertaken on a priority 
38
  
basis: consultation item numbers override incentive item numbers, which override 
procedural item numbers, which override other Medicare item numbers. Table 5.6 provides 
a breakdown of all item numbers recorded by the GPs.  
Table 5.2 provides an overview of the MBS/DVA item numbers recorded in BEACH in  
2011–12. At least one MBS/DVA item number was recorded at 87,323 encounters (88.2% of 
all BEACH encounters). A single item number was recorded at three-quarters (77.5%) of 
BEACH encounters said to be claimable from the MBS/DVA. 
Table 5.2: Overview of MBS items recorded 
Variable Number 
Per cent of MBS/DVA 
encounters 
(n = 87,323) 
Encounters at which one MBS item was recorded  67,704 77.5 
Encounters at which two MBS items were recorded  18,501 21.2 
Encounters at which three MBS items were recorded  1,118 1.3 
Total encounters at which at least one item was recorded  87,323 100.0 
Note: MBS – Medicare Benefits Schedule; DVA – Department of Veterans’ Affairs. 
In previous years we have reported the breakdown of MBS/DVA services into groups for 
GPs and practice nurses in Table 5.3. The MBS has continued to expand, with some services 
provided by Aboriginal health workers and other allied health services (e.g. 
physiotherapists and speech pathologists) claimable through the MBS/DVA. In addition, 
some items can be claimed by more than one of these health professionals, for example 
practice nurses or Aboriginal health workers. To account for these changes, we have 
modified Table 5.3 to group MBS/DVA items according to whether the service was 
provided by a GP or an ‘other health professional’. The group for other health professionals 
includes practice nurses, Aboriginal health workers and allied health services.  
Of the 87,323 MBS/DVA items of service recorded (counting only one item number per 
encounter), 94.9% related to GP items of service. Items with other health professionals not 
accompanied by a GP item of service were recorded at 0.1% of encounters. Direct encounters 
are defined as those where the patient was physically seen by the GP. At indirect 
encounters, the patient was not physically seen by the GP (Table 5.3). More detail about item 
numbers recorded for practice nurse items is given in Chapter 10. 
Table 5.3: Breakdown of MBS/DVA items of service according to provider (counting one item 
number per encounter) 
Type of encounter Number 
Per cent of encounters(a) 
(n = 91,956) 
95% 
LCL 
95% 
UCL 
MBS/DVA GP item of service  87,243 94.9 94.4 95.3 
MBS/DVA item of service with other health professional(b)  
(no related GP item)  80 0.1 0.0 0.1 
Direct encounters   27 0.0 0.0 0.0 
Indirect encounters   48 0.1 0.0 0.1 
Unspecified as direct or indirect  5 0.0 0.0 0.0 
MBS/DVA item of service (all encounters)(c)  87,323 95.0 94.5 95.4 
(a) Missing data removed from analysis (n = 7,074). 
(b) ‘Other health professional’ includes practice nurses, allied health services and Aboriginal health workers. 
(c) Includes direct encounters at which either a GP or a practice nurse item was recorded. 
Note: LCL – lower confidence limit; UCL – upper confidence limit; MBS – Medicare Benefits Schedule; DVA – Department of Veterans’ Affairs. 
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Table 5.4 reports the breakdown of encounter type by payment source, counting a single 
Medicare item number per encounter (where applicable).  
• Indirect encounters (where the patient was not seen by the GP) accounted for 1.7%, and 
direct encounters for 98.3% of encounters at which a payment source was recorded. 
• The vast majority of all direct encounters (94.9%) were claimable either through 
Medicare or the DVA. 
• Direct encounters where the GP indicated that no charge was made occurred rarely, 
accounting for 0.5% of encounters. 
• Encounters claimable through workers compensation accounted for 2.0% of encounters. 
• Encounters claimable through other sources (e.g. hospital-paid encounters) accounted 
for 0.9% of encounters. 
Table 5.4: Type of encounter at which a source of payment was recorded for the encounter 
(counting one item number per encounter) 
Type of encounter Number 
Per cent of 
encounters(a) 
(n = 91,956) 
95% 
LCL 
95% 
UCL 
Per cent of direct 
encounters 
(n = 90,429) 
Indirect encounters(b) 1,522 1.7 1.4 1.9  
Direct encounters 90,429 98.3 98.1 98.6 100.0 
 MBS/DVA items of service (direct encounters only)(c)  87,264 94.9 94.4 95.4 96.5 
 Workers compensation 1,853 2.0 1.8 2.2 2.0 
 Other paid (hospital, state, etc) 862 0.9 0.7 1.2 1.0 
 No charge 450 0.5 0.3 0.7 0.5 
Other health professional only items (unspecified as 
direct or indirect)  5 0.0 0.0 0.0 
— 
Total  91,956 100.0 — — — 
(a) Missing data removed from analysis (n = 7,074). 
(b) Five encounters involving chronic disease management or case conference items were recorded as indirect encounters. 
(c) Includes direct encounters at which either a GP or an item with an other health professional (or both) was recorded. 
Note: LCL – lower confidence limit; UCL – upper confidence limit; MBS – Medicare Benefits Schedule; DVA – Department of Veterans’ Affairs. 
Table 5.5 provides a summary of the MBS items recorded in BEACH, counting one item 
number per encounter. This provides comparable results about item numbers recorded to 
those reported in previous years.  
• Standard surgery consultations accounted for 81.8% of MBS/DVA-claimable GP 
consultations, and for 77.6% of all encounters for which a payment source was recorded.  
• 8.6% of MBS/DVA claimable encounters were long or prolonged surgery consultations. 
• Home or institution visits, and visits at residential aged care facilities were all relatively 
rare, together accounting for 2.5% of MBS/DVA claimable encounters. 
• About 1% of encounters were claimable as GP mental healthcare items, with another 1% 
claimable as chronic disease management items. Health assessments and case 
conference items were not recorded often.  
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Table 5.5: Summary of GP only MBS/DVA items recorded (counting one item number 
per encounter) 
MBS/DVA item Number 
Rate per 100 
encounters(a) 
(n = 91,956) 
95% 
LCL 
95% 
UCL 
Per cent of 
MBS/DVA 
recorded 
GP items  
(n = 87,243) 
Short surgery consultations 1,619 1.8 1.4 2.1 1.9 
Standard surgery consultations 71,386 77.6 76.5 78.8 81.8 
Long surgery consultations 7,403 8.1 7.5 8.6 8.5 
Prolonged surgery consultations 479 0.5 0.4 0.6 0.5 
Residential aged care facility (RACF) visits 1,624 1.8 1.1 2.4 1.9 
Home or institution visits (excluding RACF) 637 0.7 0.5 0.9 0.7 
GP mental health care 1,221 1.3 1.2 1.5 1.4 
Chronic disease management items 1,137 1.2 1.1 1.4 1.3 
Health assessments 387 0.4 0.3 0.5 0.4 
Case conferences 5 0.0 0.0 0.0 0.0 
Attendances associated with Practice 
Incentives Program payments 
153 0.2 0.1 0.2 0.2 
Other items 1,193 1.3 0.9 1.7 1.4 
Therapeutic procedures 339 0.4 0.3 0.5 0.4 
Surgical operations 266 0.3 0.2 0.3 0.3 
Acupuncture 220 0.2 0.1 0.4 0.3 
Other items 368 0.4 0.1 0.7 0.4 
Total MBS/DVA items of service (GPs only)  87,243  94.9 94.4 95.3 100.0 
(a) Encounters with missing payment source were removed from analysis (n = 7,074). Denominator used for analysis n = 91,956. 
Note: LCL – lower confidence limit; UCL – upper confidence limit; MBS – Medicare Benefits Schedule; DVA – Department of Veterans’ Affairs; 
GP – general practitioner; RACF – residential aged care facility. 
Table 5.6 provides the distribution of all Medicare item numbers recorded across Medicare 
item number groups and the number of encounters at which at least one of each type of item 
number was recorded. Overall, there were 108,060 MBS item numbers recorded at 87,323 
Medicare/DVA claimable encounters in 2011–12, an average of 1.2 items per encounter 
claimable through Medicare/DVA.  
Surgery consultations (including short, standard, long and prolonged) were the most 
commonly recorded type of item number, accounting for 75% of all MBS items, one of these 
items being recorded at 92.6% of MBS claimable encounters.  
The second most commonly recorded were items for bulk-billed incentive payments, which 
accounted for 14.7% of all items recorded. Items for hospital, residential aged care and home 
visits together accounted for 2% of all MBS items. Items for other practice nurse, Aboriginal 
health worker and allied health services accounted for 2% of all MBS items, and were 
recorded at least once at 2.3% of claimable encounters at which at least one MBS item was 
recorded. A more detailed breakdown of practice nurse item numbers and related data on 
practice nurse activity, is provided in Section 10.4. 
41
  
Table 5.6: Distribution of all MBS/DVA item numbers recorded, across item number groups and 
encounters 
Items/encounters 
All MBS/DVA 
items(a) 
(n = 108,060) 
 Encounters with at least one item 
recorded(b) 
(n = 87,323) 
Number Per cent  Number Per cent  
95% 
LCL 
95% 
UCL 
Surgery consultations 80,887 74.9  80,887 92.6 91.7 93.5 
GP bulk-billed incentive payment 15,860 14.7  15,860 18.2 16.1 20.2 
Home, institution and residential aged care visits 2,261 2.1  2,261 2.6 1.9 3.3 
Chronic disease management items (including 
case conferences) 2,054 1.9  1,464 1.7 1.5 1.9 
Other practice nurse/Aboriginal health 
worker/allied health worker services 2,031 1.9  1,999 2.3 2.0 2.6 
GP mental health care items 1,442 1.3  1,441 1.7 1.5 1.8 
Surgical operations 1,023 0.9  992 1.1 1.0 1.3 
Diagnostic procedures and investigations 582 0.5  573 0.7 0.6 0.8 
Health assessments 458 0.4  457 0.5 0.4 0.6 
Therapeutic procedures 417 0.4  416 0.5 0.4 0.6 
Acupuncture 226 0.2  226 0.3 0.1 0.4 
Pathology services 219 0.2  219 0.3 0.2 0.3 
Attendances associated with Practice Incentives 
Program payments 182 0.2  182 0.2 0.2 0.3 
Diagnostic imaging services 7 0.0  7 0.0 0.0 0.0 
Other items 411 0.4  411 0.5 0.1 0.8 
Total items  108,060  100.0  — — — — 
(a) Up to three MBS/DVA items could be recorded at each encounter.  
(b) Identifies encounters where at least one item from the MBS group was recorded. 
Note: LCL – lower confidence limit; UCL – upper confidence limit; MBS – Medicare Benefits Schedule. 
5.3 Consultation length 
In a subsample of 33,096 BEACH MBS/DVA-claimable encounters at which start and finish 
times had been recorded by the GP, the mean length of consultation in 2011–12 was 
15.2 minutes (95% CI: 15.0–15.5). The median length was 13.0 minutes (results not tabled). 
For A1 MBS/DVA-claimable encounters, the mean length of consultation in 2011–12 was 
14.9 minutes (95% CI: 14.6–15.1), and the median length was 13.0 minutes (results not 
tabled). Methods describing the substudy from which data on consultation length are 
collected are described in Section 2.6. 
The determinants of consultation length were investigated by Britt et al. (2004) in 
Determinants of GP billing in Australia: content and time69 and Britt et al. (2005) in Determinants 
of consultation length in Australian general practice.70  
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5.4 Changes in the encounters over the decade 
2002–03 to 2011–12 
The companion report A decade of Australian general practice activity 2002–03 to 2011–12,1 
provides an overview of changes in general practice encounters over the last decade. The 
major changes between 2002–03 and 2011–12 are summarised below. 
• There was an increase in the average number of problems managed at encounter, from 
145 per 100 encounters in 2002–03 to 154 in 2011–12. This change was reflected in an 
increase in the number of chronic problems managed per 100 encounters. However 
these changes did not result in an increase in the average length of GP–patient 
encounters which remained static over the decade. 
• The number of work-related problems managed marginally decreased over the last 
eight years from 3.1 to 2.6 per 100 encounters.  
Of the encounters claimable from Medicare/DVA: 
• short surgery consultations as a proportion of all Medicare/DVA claimed consultations 
increased over the study period 
• the proportion designated chronic disease management items or health assessments 
both increased significantly. 
The changes in management actions described below are measured in terms of rates per 100 
encounters. As there was a significant increase in the number of problems managed at 
encounters, it may be more informative to consider changes in management actions in terms 
of rates per 100 problems managed as described in Section 8.1. 
• The number of procedures undertaken per 100 encounters rose significantly from 14.6 to 
16.9 per 100 encounters.  
• There was an increased rate of referrals, which was reflected in referrals to medical 
specialists, allied health services, emergency departments and ‘other’ services.  
• Pathology test/battery order rates increased by nearly 50%. Orders for imaging tests 
also increased.  
5.5 Discussion 
The number of GP encounters with patients, measured by MBS attendance items for both 
GPs and other medical practitioners claiming primary care attendance items, increased from 
96.9 million in 2002–03 to 122.5 million in 2011–12 (see Section 2.11), an increase of 26.4% 
over the last decade. This is a great deal more than the increase in the Australian population 
during this period and may be driven by an ageing population with an increased number of 
chronic diseases requiring more frequent encounters. This is also reflected in the increase in 
the number of problems managed at encounter, from 145 to 154 for 100 encounters, and the 
increase in chronic problems managed from 49.1 to 55.6 per 100 encounters between 2002–03 
and 2011–12. 
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A significant decrease in long surgery consultations occurred in 2008–09 and the rate has 
remained relatively low since. This coincided with concern being expressed by the Medicare 
Professional Services Review regarding the number of longer GP consultations being 
claimed from Medicare. A significant rise in chronic disease management items occurred in 
2008–09, and may be attributed to an increased use of chronic disease management items 
(including GP management plans and team care arrangements) and may be a partial 
substitute for long consultations for this group of patients. 
The significant drop in clinical treatments given at GP encounters in 2005–06 coincided with 
the introduction of the MBS practice nurse items. This may represent a shift of some of this 
activity from GPs to practice nurses but undertaken by the nurse outside the encounter and 
therefore not recorded on the BEACH form. The rate of GP clinical treatments has steadily 
increased since and is now back to 2002–03 levels. The recent removal of practice nurse 
Medicare items may alter this pattern further in the future. 
There was a decrease in home visits in the decade to 201071 and this has important 
implications for ageing patients wishing to be managed at home rather than in institutional 
care. The changes to the Medicare schedule in May 2010 mean that it is no longer possible to 
separate home visits from institutional visits using Medicare item numbers. The BEACH 
collection form has been altered from the 2012–13 BEACH data year onwards to ensure we 
can identify home visits in the future and provide information regarding this important 
aspect of GP care. 
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6 The patients 
This chapter reports data collected between April 2011 and March 2012 about the 
characteristics of patients at GP encounters and their reasons for encounter, from the 
14th year of the BEACH program. Data on patient characteristics and reasons for encounter 
are reported for each year from 2002–03 to 2011–12 in the ten-year report A decade of 
Australian general practice activity 2002–03 to 2011–12.1  
6.1 Age–sex distribution of patients at encounter 
The age–sex distribution of patients at encounters is shown in Figure 6.1. Females accounted 
for the greater proportion (56.5%) of encounters (Table 6.1). This was reflected across all age 
groups except among children aged less than 15 years (Figure 6.1). 
Patients aged less than 25 years accounted for 20.0% of encounters those aged 25–44 years 
for 22.6%, those aged 45–64 years accounted for 27.7% and those aged 65 years and over for 
29.7% of encounters (Table 6.1). 
 
 
0
5
10
15
20
25
30
Female 0.8 2.0 2.6 5.4 13.9 15.5 6.8 9.5
Male 0.9 2.4 2.8 3.1 8.7 12.2 6.5 6.9
< 1 1–4 5–14 15–24 25–44 45–64 65–74 75+
 
 
Note: Missing data removed. The distributions will not agree perfectly with those in Table 6.1 because of missing data in either age or  
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Figure 6.1: Age–sex distribution of patients at encounter 
 
The relationship between patient age, patient general practice attendance rates and the age 
distribution of the Australian population was reported in General practice activity in Australia, 
health priorities and policies 1998 to 2008.72  
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6.2 Other patient characteristics 
Table 6.1 presents other characteristics of the patients at GP encounters. In summary: 
• the patient was new to the practice at 7.9% of encounters 
• nearly half of the encounters were with patients who held a Commonwealth concession 
card (44.7%) and/or a Repatriation health card (2.4%) 
• at 11.3% of encounters the patient was from a non-English-speaking background 
• at 1.6% of encounters the patient identified themselves as an Aboriginal and/or Torres 
Strait Islander person. 
Table 6.1: Characteristics of the patients at encounters 
Patient characteristics Number 
Per cent of encounters 
(n = 99,030) 
95% 
LCL 
95%  
UCL 
Sex (missing)(a) (842) — — — 
 Males 42,737 43.5 42.7 44.3 
 Females 55,451 56.5 55.7 57.3 
Age group (missing)(a) (793) — — — 
 < 1 year 1,764 1.8 1.7 1.9 
 1–4 years 4,342 4.4 4.2 4.7 
 5–14 years 5,251 5.3 5.1 5.6 
 15–24 years 8,332 8.5 8.1 8.9 
 25–44 years 22,179 22.6 21.7 23.4 
 45–64 years 27,195 27.7 27.1 28.3 
 65–74 years 13,138 13.4 12.8 13.9 
 75+ years 16,036 16.3 15.3 17.3 
New patient to practice (missing)(a) (1,713) — — — 
 New patient to practice 7,715 7.9 7.0 8.8 
 Patient seen previously 89,602 92.1 91.2 93.0 
Commonwealth concession card status (missing)(a) (8,704) — — — 
 Has a Commonwealth concession card 41,295 44.7 43.1 46.2 
 No Commonwealth concession card 51,133 55.3 53.8 56.9 
Repatriation health card status (missing)(a) (10,695) — — — 
 Has a repatriation health card 2,223 2.4 2.2 2.7 
 No repatriation health card 88,854 97.6 97.3 97.8 
Language status (missing)(a) (10,783) — — — 
 Non-English-speaking background(b) 9,978 11.3 9.4 13.2 
 English-speaking background 78,268 88.7 86.8 90.6 
Indigenous status (missing)(a) (10,707) — — — 
 Aboriginal and/or Torres Strait Islander(C) 1,394 1.6 1.2 1.9 
 Non-Indigenous 86,928 98.4 98.1 98.8 
(a) Missing data removed. 
(b) Speaks a language other than English as their primary language at home. 
(c) Self identified.  
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
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6.3 Patient reasons for encounter 
Patient reasons for encounter (RFEs) reflect the patient’s demand for care and can provide 
an indication of service use patterns, which may benefit from intervention on a population 
level.73  
RFEs are those concerns and expectations that patients bring to the GP. Participating GPs 
were asked to record at least one and up to three patient RFEs in words as close as possible 
to those used by the patient, before the diagnostic or management process had begun. These 
reflect the patient’s view of their reasons for consulting the GP. RFEs can be expressed in 
terms of one or more symptoms (for example, ‘itchy eyes’, ‘chest pain’), in diagnostic terms 
(for example, ‘about my diabetes’, ‘for my hypertension’), a request for a service (‘I need 
more scripts’, ‘I want a referral’), an expressed fear of disease or a need for a check-up. 
Patient RFEs can have a one-to-one, one-to-many, many-to-one or many-to-many 
relationship to problems managed. That is, the patient may describe a single RFE that relates 
to a single problem managed at the encounter, one RFE that relates to multiple problems, 
multiple RFEs that relate to a single problem managed, or multiple RFEs that relate to 
multiple problems managed at the encounter. GPs may also manage a problem that was 
unrelated to the patient’s RFE (e.g. a patient presents about their diabetes but while they are 
there the GP also provides an immunisation/vaccination and performs a Pap smear). 
Number of reasons for encounter 
There were 153,218 RFEs recorded at 99,030 encounters in 2011–12. At 57.9% of encounters 
only one RFE was recorded, at 29.6% two RFEs were recorded and at 12.6% of encounters 
three RFEs were recorded (Table 6.2). On average patients presented with 154.7 RFEs per 
100 encounters, or about one and a half RFEs per encounter (Table 6.3). 
Table 6.2: Number of patient reasons for encounter 
Number of RFEs at encounter 
Number of encounters 
(n = 99,030) 
Per cent of 
encounters 
95% 
LCL 
95% 
UCL 
One RFE 57,290 57.9 56.6 59.1 
Two RFEs 29,293 29.6 28.9 30.3 
Three RFEs 12,447 12.6 11.8 13.3 
Total 99,030 100.0 — — 
Note: RFEs – reasons for encounter; LCL – lower confidence limit; UCL – upper confidence limit. 
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Reasons for encounter by ICPC-2 component 
The distribution of patient RFEs by ICPC-2 component is presented in Table 6.3, expressed 
as a percentage of all RFEs and as a rate per 100 encounters with 95% confidence limits. In 
the ‘diagnosis, diseases’ group we provide data about infections, injuries, neoplasms, 
congenital anomalies and ‘other’ diagnoses.  
More than four out of ten (43.0%) patient RFEs were expressed in terms of a symptom or 
complaint (for example, ‘tired’, ‘fever’). RFEs described in diagnostic terms (for example, 
‘about my diabetes’, ‘for my depression’) accounted for 18.9% of RFEs. The remaining 38.1% 
of RFEs were described in terms of processes of care, such as requests for a health check, 
requests for prescriptions, referrals, test results or medical certificates. 
At an average 100 encounters, patients described 66.6 symptom and complaint RFEs, 29.3 
diagnosis/disease RFEs, made 24.6 requests for a procedure and 15.0 requests for treatment. 
Table 6.3: Patient reasons for encounter by ICPC-2 component 
ICPC-2 component Number 
Per cent of  
total RFEs 
(n = 153,218) 
Rate per 100 
encounters 
(n = 99,030) 
95%  
LCL 
95%  
UCL 
Symptoms and complaints 65,941 43.0 66.6 64.7 68.5 
Diagnosis, diseases 29,028 18.9 29.3 27.8 30.8 
 Infections 7,220 4.7 7.3 6.8 7.8 
 Injuries 4,391 2.9 4.4 4.2 4.7 
 Neoplasms 964 0.6 1.0 0.9 1.1 
 Congenital anomalies 242 0.2 0.2 0.2 0.3 
 Other diagnoses, diseases 16,211 10.6 16.4 15.2 17.5 
Diagnostic and preventive procedures 24,370 15.9 24.6 23.7 25.6 
Medications, treatments and therapeutics 14,870 9.7 15.0 14.2 15.8 
Results 8,450 5.5 8.5 8.1 9.0 
Referrals and other RFEs 7,658 5.0 7.7 7.3 8.2 
Administrative 2,901 1.9 2.9 2.7 3.2 
Total RFEs 153,218 100.0 154.7 152.8 156.7 
Note: RFEs – reasons for encounter; LCL – lower confidence limit; UCL – upper confidence limit. 
Reasons for encounter by ICPC-2 chapter 
The distribution of patient RFEs by ICPC-2 chapter and the most common RFEs within each 
chapter are presented in Table 6.4. Each chapter and individual RFE is expressed as a 
percentage of all RFEs and as a rate per 100 encounters with 95% confidence limits.  
RFEs of a general and unspecified nature were presented at a rate of 42.2 per 100 encounters, 
with requests for prescriptions and test results the most frequently recorded of these. RFEs 
related to the respiratory system arose at a rate of 21.3 per 100 encounters, while those 
related to the musculoskeletal system were recorded at a rate of 15.8 per 100, and those 
relating to skin at a rate of 15.1 per 100 encounters (Table 6.4).  
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Table 6.4: Patient reasons for encounter by ICPC-2 chapter and most frequent individual reasons 
for encounter within chapter  
Reasons for encounter Number 
Per cent of 
total RFEs(a) 
(n = 153,218) 
Rate per 100 
encounters 
(n = 99,030) 
95%  
LCL 
95%  
UCL 
General and unspecified 41,818 27.3 42.2 41.0 43.5 
 Prescription NOS 8,580 5.6 8.7 8.1 9.2 
 Results tests/procedures NOS 7,217 4.7 7.3 6.9 7.7 
 General check-up* 4,438 2.9 4.5 4.2 4.8 
 Administrative procedure NOS 2,653 1.7 2.7 2.5 2.9 
 Immunisation/vaccination NOS 2,104 1.4 2.1 2.0 2.3 
 Fever 1,892 1.2 1.9 1.7 2.1 
 Weakness/tiredness  1,418 0.9 1.4 1.3 1.5 
 Blood test NOS 1,198 0.8 1.2 1.0 1.4 
 Other referrals NEC 1,184 0.8 1.2 1.1 1.3 
 Observation/health education/advice/diet NOS 981 0.6 1.0 0.9 1.1 
 Chest pain NOS 910 0.6 0.9 0.8 1.0 
 Other reason for encounter NEC 908 0.6 0.9 0.7 1.1 
 Follow-up encounter unspecified 871 0.6 0.9 0.7 1.0 
 Clarify or discuss patient’s RFE 828 0.5 0.8 0.7 0.9 
 Trauma/injury NOS 770 0.5 0.8 0.7 0.9 
Respiratory 21,083 13.8 21.3 20.3 22.2 
 Cough 6,602 4.3 6.7 6.2 7.1 
 Throat symptom/complaint 3,183 2.1 3.2 2.9 3.5 
 Upper respiratory tract infection 1,904 1.2 1.9 1.7 2.1 
 Immunisation/vaccination – respiratory 1,870 1.2 1.9 1.5 2.3 
 Sneezing/nasal congestion 1,462 1.0 1.5 1.3 1.7 
 Shortness of breath/dyspnoea 808 0.5 0.8 0.7 0.9 
Musculoskeletal 15,648 10.2 15.8 15.3 16.3 
 Back complaint* 3,105 2.0 3.1 2.9 3.3 
 Knee symptom/complaint 1,390 0.9 1.4 1.3 1.5 
 Shoulder symptom/complaint 1,209 0.8 1.2 1.1 1.3 
 Foot/toe symptom/complaint 1,105 0.7 1.1 1.0 1.2 
 Leg/thigh symptom/complaint 930 0.6 0.9 0.9 1.0 
 Neck symptom/complaint 807 0.5 0.8 0.7 0.9 
 Musculoskeletal injury NOS 774 0.5 0.8 0.7 0.9 
Skin 14,911 9.7 15.1 14.5 15.6 
 Rash* 2,587 1.7 2.6 2.5 2.8 
 Skin symptom/complaint, other 1,560 1.0 1.6 1.4 1.7 
 Skin check-up* 1,156 0.8 1.2 0.9 1.4 
 Swelling (skin)* 1,058 0.7 1.1 1.0 1.2 
(continued) 
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Table 6.4 (continued): Patient reasons for encounter by ICPC-2 chapter and most frequent 
individual reasons for encounter within chapter  
Reasons for encounter Number 
Per cent of 
total RFEs(a) 
(n = 153,218) 
Rate per 100 
encounters 
(n = 99,030) 
95%  
LCL 
95%  
UCL 
Digestive 10,134 6.6 10.2 9.9 10.6 
 Abdominal pain* 1,814 1.2 1.8 1.7 2.0 
 Diarrhoea 1,350 0.9 1.4 1.2 1.5 
 Vomiting 890 0.6 0.9 0.8 1.0 
Cardiovascular 10,054 6.6 10.2 9.6 10.7 
 Cardiovascular check-up* 4,472 2.9 4.5 4.2 4.9 
 Hypertension/high blood pressure* 1,745 1.1 1.8 1.5 2.0 
 Prescription – cardiovascular 918 0.6 0.9 0.7 1.1 
Psychological 8,804 5.7 8.9 8.4 9.4 
 Depression* 2,157 1.4 2.2 2.0 2.3 
 Anxiety* 1,188 0.8 1.2 1.1 1.3 
 Sleep disturbance 1,024 0.7 1.0 0.9 1.1 
 Acute stress reaction 704 0.5 0.7 0.6 0.8 
 Prescription – psychological 699 0.5 0.7 0.6 0.8 
Endocrine and metabolic 6,218 4.1 6.3 5.9 6.6 
 Diabetes – (non-gestational)* 1,261 0.8 1.3 1.1 1.4 
 Prescription – endocrine/metabolic 996 0.7 1.0 0.9 1.1 
Female genital system 4,715 3.1 4.8 4.4 5.1 
 Female genital check-up/Pap smear* 1,642 1.1 1.7 1.5 1.8 
 Menstrual problems* 704 0.5 0.7 0.6 0.8 
Neurological 4,503 2.9 4.5 4.3 4.8 
 Headache 1,504 1.0 1.5 1.4 1.7 
 Vertigo/dizziness 1,092 0.7 1.1 1.0 1.2 
Ear 3,401 2.2 3.4 3.3 3.6 
 Ear pain 1,306 0.9 1.3 1.2 1.4 
Pregnancy and family planning 3,306 2.2 3.3 3.1 3.6 
 Oral contraception* 750 0.5 0.8 0.7 0.8 
Urology 2,557 1.7 2.6 2.4 2.7 
Eye 2,272 1.5 2.3 2.1 2.4 
Blood and blood forming organs 1,650 1.1 1.7 1.5 1.8 
 Blood test – blood and blood forming organs 1,123 0.7 1.1 1.0 1.3 
Male genital system 1,211 0.8 1.2 1.1 1.3 
Social 932 0.6 0.9 0.8 1.0 
Total RFEs 153,218 100.0 154.7 152.8 156.7 
(a) Only individual RFEs accounting for ≥ 0.5% of total RFEs are included. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781743320181>). 
Note: RFEs – reasons for encounter; LCL – lower confidence limit; UCL – upper confidence limit; NEC – not elsewhere classified; NOS – not 
otherwise specified. 
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Most frequent patient reasons for encounter 
The 30 most commonly recorded RFEs (Table 6.5), accounted for more than half of all RFEs. 
In this analysis the specific ICPC-2 chapter to which an across-chapter concept belongs is 
disregarded, so that, for example, ‘check-up – all’ includes all check-ups from all ICPC-
chapters, irrespective of whether or not the body system was specified.  
Table 6.5: Most frequent patient reasons for encounter 
Patient reason for encounter Number 
Per cent of  
total RFEs 
(n = 153,218) 
Rate per 100 
encounters 
(n = 99,030) 
95%  
LCL 
95%  
UCL 
Check-up – all* 13,518 8.8 13.7 13.0 14.3 
Prescription – all* 12,481 8.1 12.6 11.9 13.3 
Test results* 8,450 5.5 8.5 8.1 9.0 
Cough 6,602 4.3 6.7 6.2 7.1 
Immunisation/vaccination – all* 4,125 2.7 4.2 3.8 4.6 
Throat symptom/complaint 3,183 2.1 3.2 2.9 3.5 
Back complaint* 3,105 2.0 3.1 2.9 3.3 
Administrative procedure – all* 2,901 1.9 2.9 2.7 3.2 
Blood test – all* 2,784 1.8 2.8 2.6 3.1 
Rash* 2,587 1.7 2.6 2.5 2.8 
Depression* 2,157 1.4 2.2 2.0 2.3 
Upper respiratory tract infection 1,904 1.2 1.9 1.7 2.1 
Fever 1,892 1.2 1.9 1.7 2.1 
Abdominal pain* 1,814 1.2 1.8 1.7 2.0 
Hypertension/high blood pressure* 1,745 1.1 1.8 1.5 2.0 
Observation/health education/advice/diet – all* 1,595 1.0 1.6 1.5 1.8 
Skin symptom/complaint, other 1,560 1.0 1.6 1.4 1.7 
Headache 1,504 1.0 1.5 1.4 1.7 
Sneezing/nasal congestion 1,462 1.0 1.5 1.3 1.7 
Weakness/tiredness 1,418 0.9 1.4 1.3 1.5 
Knee symptom/complaint 1,390 0.9 1.4 1.3 1.5 
Diarrhoea 1,350 0.9 1.4 1.2 1.5 
Ear pain/earache 1,306 0.9 1.3 1.2 1.4 
Diabetes – all* 1,268 0.8 1.3 1.1 1.4 
Shoulder symptom/complaint 1,209 0.8 1.2 1.1 1.3 
Anxiety* 1,188 0.8 1.2 1.1 1.3 
Other referrals NEC 1,184 0.8 1.2 1.1 1.3 
Foot/toe symptom/complaint 1,105 0.7 1.1 1.0 1.2 
Vertigo/dizziness 1,092 0.7 1.1 1.0 1.2 
Swelling (skin)* 1,058 0.7 1.1 1.0 1.2 
Subtotal 88,940 58.0 — — — 
Total RFEs 153,218 100.0 154.7 152.8 156.7 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <purl.library.usyd.edu.au/sup/9781743320181>). 
Note: RFEs – reasons for encounter; LCL – lower confidence limit; UCL – upper confidence limit; NEC – not elsewhere classified. 
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The top 30 most common RFEs accounted for 58% of all RFEs recorded. Of the top 30 RFEs, 
over half were symptom descriptions such as cough, throat complaint, back complaint and 
rash. However, four of the top five RFEs reflected requests for a process of care (that is, 
requests for check-up, prescription, test result and immunisation), and together accounted 
for a quarter of all RFEs (25.1%) (Table 6.5). 
6.4 Changes in patients and their reasons for 
encounter over the decade 2002–03 to 2011–12 
An overview of changes in the characteristics of patients at encounters and their reasons for 
encounter over the decade 2002–03 to 2011–12 can be found in Chapter 6 of the companion 
report A decade of Australian general practice activity 2002–03 to 2011–12.1  
Major changes are summarised below.  
With the ageing of the Australian population, the proportion of the Australian population 
that was aged 45 years and over increased from 36.1% in 2002 to 38.8% in 2011.2 Over the 
same period the proportion of BEACH encounters with patients aged 45 years and over 
increased from 50.7% to 57.4%. When extrapolated, this change (in combination with the 
increased number of encounters nationally) means that in 2011–12 there were only about 
4.4 million more encounters with younger patients, and about 21.2 million more with older 
patients nationally compared with a decade earlier. 
The increase in the proportion of encounters with older patients was greater than the 
population increase in this age group, because older patients attend general practice more 
often than do younger patients.74 This change in the age distribution of patients at GP 
encounters will effect all aspects of general practice as older patients are more likely to have 
more problems managed at encounters (see Section 7.1), more chronic conditions managed 
and are more likely to have multimorbidity.25 
There was a significant decrease in the proportion of encounters with patients who were 
new to the practice (from 9.9% in 2002–03 to 7.9% in 2011–12). This may be due to the need 
for continuity of care for chronic conditions. The proportion of encounters with patients 
holding a Commonwealth concession card was relatively stable through the decade. The 
proportion of encounters with patients holding a Repatriation health card decreased by 
about a third, from 3.7% in 2002–03 to 2.4% in 2011–12. This is probably due to a decline in 
the number of veterans from World War 2 and their partners. 
There was a significant increase in the number of reasons for encounter recorded per 100 
encounters across the decade, from 150.9 in 2002–03 to 154.7 in 2011–12, fewer patients 
giving a single RFE and more giving two RFEs. This increase in RFEs is also probably 
related to the increasing proportion of encounters with older people, who are more likely to 
visit for multiple chronic disease management. There was a significant decrease in the rate 
of RFEs described as symptoms and complaints, and increases in rates of patient 
presentations for medications, tests and test results. This is also probably due to the 
increased proportion of encounters that are with older patients and the increase in chronic 
condition management which requires regular attendance and monitoring. The increase in 
patients’ requests for tests and test results ties in with the increased use of pathology and 
imaging testing over the decade (see Chapter 12). One increase unrelated to the ageing of the 
population was a large increase in requests for administrative procedures such as doctor’s or 
sickness certificates. This is probably due to increasing number of policies forcing workers to 
provide such documentation to claim sick days. 
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7 Problems managed 
A ‘problem managed’ is a formal statement of the provider’s understanding of a health 
problem presented by the patient, family or community, and can be described in terms of a 
disease, symptom or complaint, social problem or ill-defined condition managed at the 
encounter. As GPs were instructed to record each problem at the most specific level possible 
from the information available, the problem managed may at times be limited to the level of 
a presenting symptom. 
At each patient encounter, up to four problems could be recorded by the GP. A minimum of 
one problem was compulsory. The status of each problem to the patient – new (first 
presentation to a medical practitioner) or old (follow-up of previous problem) – was also 
indicated. The concept of a principal diagnosis, which is often used in hospital statistics, is 
not adopted in studies of general practice where multiple problem management is the norm 
rather than the exception. Further, the range of problems managed at the encounter often 
crosses multiple body systems and may include undiagnosed symptoms, psychosocial 
problems or chronic disease, which makes the designation of a principal diagnosis difficult. 
Thus, the order in which the problems were recorded by the GP is not significant. All 
problems managed in general practice are included in this section, including those that 
involved management by a practice nurse at the recorded encounter. Problems that included 
management by a practice nurse are reported specifically in Chapter 10. 
There are two ways to describe the relative frequency of problems managed: as a percentage 
of all problems managed in the study or as a rate at which problems are managed per 
100 encounters. Where groups of problems are reported (for example, cardiovascular 
problems) it must be remembered that more than one of that type of problem (such as 
hypertension and heart failure) may have been managed at a single encounter. In 
considering these results, the reader must be mindful that although a rate per 100 
encounters for a single ungrouped problem, for example, ‘asthma, 2.0 per 100 encounters’, 
can be regarded as equivalent to ‘asthma is managed at 2.0% of encounters’, such a 
statement cannot be made for grouped concepts (ICPC-2 chapters and those marked with 
asterisks in the tables). 
Data on problems managed in Australian general practice from the BEACH study are 
reported for each year from 2002–03 to 2011–12 in the ten-year report A decade of Australian 
general practice activity 2002–03 to 2011–12.1  
7.1 Number of problems managed at encounter 
There were 152,286 problems managed, at a rate of 153.8 per 100 encounters in 2011–12 
(Table 5.1 and total row Table 7.2). Table 7.1 shows the number of problems managed at 
each encounter. Only one problem was managed at 62.1% of encounters, two problems were 
managed at 25.5% of encounters, and 9.1% involved the management of three problems. The 
management of four problems at an encounter was less common (3.4% of encounters). 
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Table 7.1: Number of problems managed at an encounter 
Number of problems managed at encounter Number of encounters Per cent 95% LCL 95% UCL 
One problem 61,470 62.1 60.8 63.4 
Two problems 25,212 25.5 24.7 26.2 
Three problems 9,000 9.1 8.6 9.6 
Four problems 3,348 3.4 3.0 3.8 
Total 99,030 100.0 — — 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
Figure 7.1 shows the age–sex-specific rates of problems managed. The number of problems 
managed at encounter increased steadily with the age of the patient, from young adulthood 
onward.  
Significantly more problems were managed overall at encounters with female patients 
(156.0 per 100 encounters, 95% CI: 153.6–158.5) than at those with male patients (151.0 per 
100 encounters, 95% CI: 148.5–153.5) (results not tabled). Figure 7.1 demonstrates that this 
difference was particularly evident in the 15–24 year age group. 
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Note: Missing data removed.  
Figure 7.1: Age–sex-specific rates of problems managed per 100 encounters with 95% CI 
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7.2 Problems managed by ICPC-2 component 
Problems managed in general practice may also be examined using the components of the 
ICPC-2 classification to provide a broader view of the types of problems managed during 
general practice encounters. Table 7.2 lists the distribution of problems managed by ICPC-2 
component.  
Two-thirds (67.7%) of problems were expressed as diagnoses or diseases. The majority of 
other problems were described as symptoms or complaints (18.1%), or as diagnostic or 
preventive procedures (9.1%) such as check-ups. However, in some situations, rather than 
providing clinical details about the problem under management, other processes were 
recorded: that is, the problem was described in such terms as a prescription, test result, 
referral, or an administrative procedure.  
At an ‘average’ 100 encounters GPs managed 104 diagnoses/diseases: 25 infections; 8 
injuries; and 4 neoplasms. They also managed 28 symptoms and complaints, and conducted 
14 diagnostic and preventive procedures.  
Table 7.2: Problems managed by ICPC-2 component 
ICPC-2 component Number 
Per cent of 
total problems 
(n = 152,286) 
Rate per 100 
encounters 
(n = 99,030) 
95% 
 LCL 
95% 
 UCL 
Diagnosis, diseases 103,101 67.7 104.1 102.1 106.1 
 Infections 24,465 16.1 24.7 24.0 25.5 
 Injuries 7,514 4.9 7.6 7.3 7.9 
 Neoplasms 4,143 2.7 4.2 3.9 4.5 
 Congenital anomalies 681 0.5 0.7 0.6 0.8 
 Other diagnoses 66,298 43.5 66.9 64.9 69.0 
Symptoms and complaints 27,636 18.1 27.9 27.0 28.8 
Diagnostic and preventive procedures 13,832 9.1 14.0 13.3 14.7 
Medications, treatments and therapeutics 3,356 2.2 3.4 3.1 3.7 
Results 1,812 1.2 1.8 1.6 2.0 
Referrals and other RFEs 1,275 0.8 1.3 1.1 1.5 
Administrative 1,274 0.8 1.3 1.1 1.4 
Total problems  152,286 100.0 153.8 151.4 156.1 
Note: LCL – lower confidence limit; UCL – upper confidence limit; RFE – reason for encounter.  
7.3 Problems managed by ICPC-2 chapter 
The frequency and the distribution of problems managed, by ICPC-2 chapter, are presented 
in Table 7.3. Rates per 100 encounters and the proportion of total problems are provided at 
the ICPC-2 chapter level, and for frequent individual problems within each chapter. Only 
those individual problems accounting for at least 0.5% of all problems managed are listed in 
the table, in decreasing order of frequency. 
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The most common problems managed were: 
• those classified to the respiratory system (20.0 per 100 encounters), in particular upper 
respiratory tract infection, acute bronchitis, respiratory immunisations and asthma 
• problems of a general and unspecified nature (18.5 per 100 encounters), such as general 
check-ups, general immunisations and unspecified test results  
• musculoskeletal problems (17.4 per 100 encounters), particularly arthritis and back 
complaints  
• cardiovascular problems (17.2 per 100 encounters), led by hypertension and atrial 
fibrillation 
• skin problems (16.7 per 100 encounters), contact dermatitis and malignant neoplasms 
being the most common (Table 7.3).  
Table 7.3: Problems managed by ICPC-2 chapter and frequent individual problems within chapter  
Problem managed  Number 
Per cent total 
problems  
(n = 152,286) 
Rate per 100 
encounters(a) 
(n = 99,030) 
95%  
LCL 
95%  
UCL 
Respiratory 19,811 13.0 20.0 19.3 20.7 
 Upper respiratory tract infection 5,902 3.9 6.0 5.5 6.4 
 Acute bronchitis/bronchiolitis 2,494 1.6 2.5 2.3 2.7 
 Immunisation/vaccination – respiratory 2,304 1.5 2.3 1.9 2.7 
 Asthma 1,972 1.3 2.0 1.9 2.1 
 Sinusitis  1,211 0.8 1.2 1.1 1.3 
 Chronic obstructive pulmonary disease 919 0.6 0.9 0.8 1.0 
 Tonsillitis* 900 0.6 0.9 0.8 1.0 
 Allergic rhinitis 721 0.5 0.7 0.6 0.8 
General and unspecified 18,345 12.1 18.5 17.8 19.2 
 General check-up* 2,757 1.8 2.8 2.6 3.0 
 Immunisation/vaccination NOS 2,068 1.4 2.1 1.9 2.2 
 Results tests/procedures NOS 1,359 0.9 1.4 1.2 1.5 
 Prescription NOS 1,326 0.9 1.3 1.2 1.5 
 Viral disease, other/NOS 1,196 0.8 1.2 1.0 1.4 
 Administrative procedure NOS 1,170 0.8 1.2 1.0 1.3 
 Abnormal result/investigation NOS 970 0.6 1.0 0.9 1.1 
Musculoskeletal 17,245 11.3 17.4 16.9 17.9 
 Arthritis – all* 3,401 2.2 3.4 3.2 3.6 
  Osteoarthritis* 2,924 1.9 3.0 2.8 3.2 
 Back complaint* 2,756 1.8 2.8 2.6 3.0 
 Sprain/strain* 1,409 0.9 1.4 1.3 1.6 
 Bursitis/tendonitis/synovitis NOS 1,128 0.7 1.1 1.1 1.2 
 Fracture* 908 0.6 0.9 0.8 1.0 
 Injury musculoskeletal NOS 905 0.6 0.9 0.8 1.0 
 Osteoporosis 800 0.5 0.8 0.7 0.9 
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Table 7.3 (continued): Problems managed by ICPC-2 chapter and frequent individual problems 
within chapter 
Problem managed  Number 
Per cent total 
problems  
(n = 152,286) 
Rate per 100 
encounters(a) 
(n = 99,030) 
95%  
LCL 
95%  
UCL 
Cardiovascular 17,006 11.2 17.2 16.4 18.0 
 Hypertension* 8,971 5.9 9.1 8.5 9.6 
 Atrial fibrillation/flutter 1,375 0.9 1.4 1.2 1.5 
 Ischaemic heart disease* 1,042 0.7 1.1 0.9 1.2 
 Cardiovascular check-up* 1,019 0.7 1.0 0.9 1.2 
Skin 16,503 10.8 16.7 16.1 17.2 
 Contact dermatitis 1,804 1.2 1.8 1.7 1.9 
 Malignant neoplasm skin 1,055 0.7 1.1 0.9 1.2 
 Solar keratosis/sunburn 1,046 0.7 1.1 0.9 1.2 
 Laceration/cut 958 0.6 1.0 0.9 1.1 
 Skin disease, other 779 0.5 0.8 0.7 0.9 
Endocrine and metabolic 13,407 8.8 13.5 13.0 14.1 
 Diabetes – non-gestational* 4,097 2.7 4.1 3.9 4.4 
 Lipid disorder 3,463 2.3 3.5 3.3 3.7 
 Vitamin/nutritional deficiency 1,335 0.9 1.3 1.2 1.5 
 Hypothyroidism/myxoedema  788 0.5 0.8 0.7 0.9 
Psychological 12,831 8.4 13.0 12.3 13.6 
 Depression* 4,361 2.9 4.4 4.1 4.7 
 Anxiety* 1,892 1.2 1.9 1.8 2.1 
 Sleep disturbance 1,504 1.0 1.5 1.4 1.6 
 Acute stress reaction 727 0.5 0.7 0.6 0.8 
 Tobacco abuse 721 0.5 0.7 0.7 0.8 
Digestive 11,003 7.2 11.1 10.8 11.4 
 Oesophageal disease 2,629 1.7 2.7 2.5 2.8 
 Gastroenteritis* 1,500 1.0 1.5 1.4 1.6 
Female genital system 5,406 3.6 5.5 5.1 5.8 
 Female genital check-up/Pap smear* 1,661 1.1 1.7 1.5 1.9 
 Menopausal complaint 715 0.5 0.7 0.6 0.8 
Pregnancy and family planning 3,810 2.5 3.9 3.6 4.1 
 Pregnancy* 1,287 0.8 1.3 1.2 1.4 
 Oral contraception* 1,186 0.8 1.2 1.1 1.3 
Ear 3,627 2.4 3.7 3.5 3.8 
 Acute otitis media/myringitis 1,016 0.7 1.0 0.9 1.1 
 Excessive ear wax 750 0.5 0.8 0.7 0.8 
Neurological 3,553 2.3 3.6 3.4 3.8 
Urology 3,148 2.1 3.2 3.0 3.3 
 Urinary tract infection* 1,686 1.1 1.7 1.6 1.8 
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Table 7.3 (continued): Problems managed by ICPC-2 chapter and frequent individual problems 
within chapter 
Problem managed  Number 
Per cent total 
problems  
(n = 152,286) 
Rate per 100 
encounters(a) 
(n = 99,030) 
95%  
LCL 
95%  
UCL 
Eye 2,421 1.6 2.5 2.3 2.6 
Male genital system 1,810 1.2 1.8 1.7 2.0 
Blood and blood forming organs 1,637 1.1 1.7 1.5 1.8 
Social 724 0.5 0.7 0.6 0.8 
Total problems 152,286 100.0 153.8 151.4 156.1 
(a) Only those individual problems accounting for ≥ 0.5% of total problems are included in the table. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781743320181>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified. 
7.4 Most frequently managed problems 
Table 7.4 shows the most frequently managed individual problems in general practice, in 
decreasing order of frequency. These 30 problems accounted for 57.2% of all problems 
managed, and the top ten problems accounted for 30.9%. 
In this analysis, the specific chapter to which ‘across chapter concepts’ (for example, 
check-ups, immunisation/vaccination and prescriptions) apply is ignored, and the concept 
is grouped with all similar concepts regardless of body system. For example, immunisation/ 
vaccination includes vaccinations for influenza, childhood diseases, hepatitis and many 
others. 
The most common problems managed were hypertension (9.1 per 100 encounters), 
check-ups (6.4 per 100), upper respiratory tract infection (URTI) (6.0 per 100), 
immunisation/vaccination (4.7 per 100), and depression (4.4 per 100) (Table 7.4).  
The far right-hand column in Table 7.4 lists the percentage of each problem that was new to 
the patient. The problem is considered new if it is a new problem or a new episode of a 
recurrent problem, and the patient has not been treated for that problem or episode by any 
medical practitioner before. This can provide a measure of general practice incidence. For 
example, only 4.6% of all contacts with diabetes were new diagnoses. In contrast, 78% of 
URTI problems were new to the patient, suggesting that the majority of people attend the 
GP for URTI only once per episode.  
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Table 7.4: Most frequently managed problems 
Problem managed Number 
Per cent of 
total problems 
(n = 152,286) 
Rate per 100 
encounters 
(n = 99,030) 
95% 
LCL 
95% 
UCL 
New as per 
cent of all 
problems(a) 
Hypertension* 8,971 5.9 9.1 8.5 9.6 5.3 
Check-up – all* 6,351 4.2 6.4 6.0 6.8 44.9 
Upper respiratory tract infection 5,902 3.9 6.0 5.5 6.4 77.6 
Immunisation/vaccination – all* 4,623 3.0 4.7 4.2 5.1 55.8 
Depression* 4,361 2.9 4.4 4.1 4.7 15.9 
Diabetes – all* 4,123 2.7 4.2 3.9 4.4 4.6 
Arthritis – all* 3,875 2.5 3.9 3.7 4.1 18.6 
Lipid disorder 3,463 2.3 3.5 3.3 3.7 10.3 
Back complaint* 2,756 1.8 2.8 2.6 3.0 23.9 
Oesophageal disease 2,629 1.7 2.7 2.5 2.8 15.9 
Acute bronchitis/bronchiolitis 2,494 1.6 2.5 2.3 2.7 71.5 
Prescription – all* 2,357 1.5 2.4 2.1 2.7 6.8 
Asthma 1,972 1.3 2.0 1.9 2.1 20.0 
Anxiety* 1,892 1.2 1.9 1.8 2.1 19.8 
Test results* 1,812 1.2 1.8 1.6 2.0 31.5 
Contact dermatitis 1,804 1.2 1.8 1.7 1.9 45.1 
Urinary tract infection* 1,686 1.1 1.7 1.6 1.8 64.1 
Sleep disturbance 1,504 1.0 1.5 1.4 1.6 21.7 
Gastroenteritis* 1,500 1.0 1.5 1.4 1.6 76.0 
Sprain/strain* 1,409 0.9 1.4 1.3 1.6 62.1 
Atrial fibrillation/flutter 1,375 0.9 1.4 1.2 1.5 6.4 
Vitamin/nutritional deficiency 1,335 0.9 1.3 1.2 1.5 36.1 
Pregnancy* 1,287 0.8 1.3 1.2 1.4 41.4 
Administrative procedure – all* 1,274 0.8 1.3 1.1 1.4 44.0 
Sinusitis acute/chronic 1,211 0.8 1.2 1.1 1.3 65.6 
Viral disease, other/NOS 1,196 0.8 1.2 1.0 1.4 73.9 
Oral contraception* 1,186 0.8 1.2 1.1 1.3 18.0 
Abnormal test results* 1,171 0.8 1.2 1.1 1.3 46.7 
Bursitis/tendonitis/synovitis NOS 1,128 0.7 1.1 1.1 1.2 59.2 
Malignant neoplasm skin 1,055 0.7 1.1 0.9 1.2 52.5 
Subtotal  87,033 57.2 — — — — 
Total problems 152,286 100.0 153.8 151.4 156.1 38.1 
(a) The proportion of total contacts with this problem that were accounted for by new problems. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781743320181>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified. 
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7.5 Most common new problems 
For each problem managed, participating GPs are asked to indicate whether the problem 
under management was a new problem for the patient (see definition in Section 7.4). Table 
7.5 lists the most common new problems managed in general practice, in decreasing order of 
frequency. Overall, 58,014 problems (38.1% of all problems) were specified as being new, 
being managed at a rate of 58.6 per 100 encounters. 
The most common new problems managed were largely acute or preventive, and included 
upper respiratory tract infection (4.6 per 100 encounters), check-up (2.9 per 100), 
immunisation/vaccination (2.6 per 100), acute bronchitis (1.8 per 100) and gastroenteritis 
(1.2 per 100) (Table 7.5). 
The far right-hand column of this table shows the new cases of this problem as a proportion 
of total contacts with this problem. This provides an idea of the incidence of each problem. 
For example, the 694 new cases of depression represented only 16% of all GP contacts with 
diagnosed depression, suggesting that by far the majority of contacts for depression were for 
ongoing management. In contrast, 70% of acute otitis media contacts were first consultations 
to a medical practitioner for this episode, the balance (30%) being follow-up consultations 
for this episode. This indicates that most patients only require one visit to a GP for the 
management of an episode of acute otitis media. 
Table 7.5: Most frequently managed new problems 
New problem managed Number 
Per cent of total 
 new problems 
(n = 58,014) 
Rate per 100 
 encounters 
(n = 99,030) 
95% 
 LCL 
95% 
UCL 
New as per 
cent of all 
problems(a) 
Upper respiratory tract infection 4,578 7.9 4.6 4.3 5.0 77.6 
Check-up – all* 2,853 4.9 2.9 2.6 3.1 44.9 
Immunisation/vaccination – all* 2,582 4.5 2.6 2.3 2.9 55.8 
Acute bronchitis/bronchiolitis 1,783 3.1 1.8 1.6 2.0 71.5 
Gastroenteritis* 1,140 2.0 1.2 1.0 1.3 76.0 
Urinary tract infection* 1,081 1.9 1.1 1.0 1.2 64.1 
Viral disease, other/NOS 883 1.5 0.9 0.7 1.1 73.9 
Sprain/strain* 876 1.5 0.9 0.8 1.0 62.1 
Contact dermatitis  814 1.4 0.8 0.7 0.9 45.1 
Sinusitis acute/chronic  794 1.4 0.8 0.7 0.9 65.6 
Arthritis – all* 722 1.2 0.7 0.7 0.8 18.6 
Acute otitis media/myringitis 711 1.2 0.7 0.6 0.8 69.9 
Depression* 694 1.2 0.7 0.6 0.8 15.9 
Bursitis/tendonitis/synovitis NOS 668 1.2 0.7 0.6 0.7 59.2 
Back complaint* 659 1.1 0.7 0.6 0.7 23.9 
Tonsillitis* 659 1.1 0.7 0.6 0.7 73.2 
Test results* 572 1.0 0.6 0.5 0.7 31.5 
Administrative procedure – all* 561 1.0 0.6 0.5 0.6 44.0 
Malignant neoplasm skin 554 1.0 0.6 0.5 0.6 52.5 
(continued) 
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Table 7.5 (continued): Most frequently managed new problems 
New problem managed Number 
Per cent of total 
 new problems 
(n = 58,014) 
Rate per 100 
 encounters 
(n = 99,030) 
95% 
 LCL 
95% 
UCL 
New as per 
cent of all 
problems(a) 
Abnormal test results* 547 0.9 0.6 0.5 0.6 46.7 
Pregnancy* 533 0.9 0.5 0.5 0.6 41.4 
Solar keratosis/sunburn 511 0.9 0.5 0.4 0.6 48.8 
Conjunctivitis, infectious 497 0.9 0.5 0.4 0.6 78.8 
Vitamin/nutritional deficiency 482 0.8 0.5 0.4 0.6 36.1 
Hypertension* 477 0.8 0.5 0.4 0.5 5.3 
Excessive ear wax 464 0.8 0.5 0.4 0.5 61.9 
Observation/health education/ 
advice/diet – all* 439 0.8 0.4 0.4 0.5 53.8 
Skin disease, other 437 0.8 0.4 0.4 0.5 56.1 
Injury musculoskeletal NOS 436 0.8 0.4 0.4 0.5 48.1 
Laceration/cut 433 0.7 0.4 0.4 0.5 45.1 
Subtotal 35,732 61.6 — — — — 
Total new problems 58,014 100.0 58.6 57.1 60.0 — 
(a) The proportion of total contacts with this problem that were accounted for by new problems. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781743320181>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified. 
7.6 Most frequently managed chronic problems 
To identify chronic conditions, a list classified according to ICPC-2, based on work 
undertaken by O’Halloran et al. in 200443 and regularly updated by O’Halloran (see  
‘Chronic conditions’ grouper G84 <sydney.edu.au/medicine/fmrc/icpc-2-plus/ 
demonstrator/index.php>), was applied to the BEACH data set. More than one-third 
(36.2%) of the problems managed in general practice were chronic. At least one chronic 
problem was managed at 41.6% of encounters (95% CI: 40.5–42.7) (Table 5.1), and chronic 
problems were managed at an average rate of 55.6 per 100 encounters (Table 7.6). 
In other parts of this chapter, both chronic and non-chronic conditions (for example, 
diabetes and gestational diabetes) may have been grouped together when reporting (for 
example, diabetes – all*, Table 7.4). In this section, only problems regarded as chronic have 
been included in the analysis. For this reason, the condition labels and figures in this 
analysis may differ from those in Table 7.4. Where the group used for the chronic analysis 
differs from that used in other analyses in this report, they are marked with a double 
asterisk (for example, Diabetes [non-gestational]**). Codes included can be found in 
Appendix 4, Table A4.2. 
Table 7.6 shows the most frequently managed chronic problems in decreasing order of 
frequency. These 30 chronic problems together accounted for 79.9% of all chronic problems 
managed, and for 28.9% of all problems managed. Almost half (49.7%) of all chronic 
problems managed were accounted for by the top six chronic problems: non-gestational 
hypertension (16.3% of chronic conditions), depressive disorder (7.8%), non-gestational 
diabetes (7.4%), chronic arthritis (7.1%), lipid disorder (6.3%), and oesophageal disease 
(4.8%) (Table 7.6).  
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Extrapolation of these results suggests that, across Australia in 2011–12, there were 
11.0 million encounters involving hypertension, 5.4 million involving depression and 
5.0 million involving diabetes.  
Table 7.6: Most frequently managed chronic problems 
Chronic problem managed Number 
Per cent of total 
chronic problems 
(n = 55,080) 
Rate per 100 
encounters 
(n = 99,030) 
95% 
 LCL 
95% 
UCL 
Hypertension (non-gestational)** 8,955 16.3 9.0 8.5 9.6 
Depressive disorder** 4,318 7.8 4.4 4.1 4.6 
Diabetes (non-gestational)** 4,097 7.4 4.1 3.9 4.4 
Chronic arthritis** 3,910 7.1 3.9 3.7 4.2 
Lipid disorder 3,463 6.3 3.5 3.3 3.7 
Oesophageal disease 2,629 4.8 2.7 2.5 2.8 
Asthma 1,972 3.6 2.0 1.9 2.1 
Atrial fibrillation/flutter 1,375 2.5 1.4 1.2 1.5 
Malignant neoplasm of skin 1,055 1.9 1.1 0.9 1.2 
Ischaemic heart disease** 1,042 1.9 1.1 0.9 1.2 
Back syndrome with radiating pain** 922 1.7 0.9 0.8 1.0 
Chronic obstructive pulmonary disease 919 1.7 0.9 0.8 1.0 
Osteoporosis 800 1.5 0.8 0.7 0.9 
Hypothyroidism/myxoedema 788 1.4 0.8 0.7 0.9 
Chronic skin ulcer 655 1.2 0.7 0.6 0.7 
Obesity (BMI > 30) 629 1.1 0.6 0.5 0.7 
Migraine 628 1.1 0.6 0.6 0.7 
Dementia (including senile, Alzheimer’s) 611 1.1 0.6 0.5 0.8 
Gout 607 1.1 0.6 0.5 0.7 
Heart failure 569 1.0 0.6 0.5 0.6 
Shoulder syndrome (excluding arthritis)** 525 1.0 0.5 0.5 0.6 
Anxiety disorder** 515 0.9 0.5 0.4 0.6 
Schizophrenia 486 0.9 0.5 0.4 0.6 
Back syndrome without radiating pain 
(excluding arthritis, sprains and strains)** 405 0.7 0.4 0.3 0.5 
Chronic acne** 398 0.7 0.4 0.4 0.5 
Chronic back pain** 365 0.7 0.4 0.3 0.4 
Chronic kidney disease** 364 0.7 0.4 0.3 0.4 
Chronic pain NOS 351 0.6 0.4 0.3 0.4 
Vertiginous syndrome 345 0.6 0.3 0.3 0.4 
Malignant neoplasm prostate 338 0.6 0.3 0.3 0.4 
Subtotal 44,036 79.9 — — — 
Total chronic problems 55,080 100.0 55.6 53.6 57.7 
** Includes multiple ICPC-2 or ICPC-2 PLUS codes and indicates that this group differs from that used for analysis in other sections of this 
chapter, as only chronic conditions have been included in this analysis (see Appendix 4, Table A4.2 
<purl.library.usyd.edu.au/sup/9781743320181>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; BMI – body mass index; NOS – not otherwise specified. 
62
  
7.7 Work-related problems managed 
The work-related status of a problem under management was determined by the GP, and is 
defined as any problem that is (in the GP’s view) likely to have resulted from work-related 
activity or workplace exposure, or that has been significantly exacerbated by work activity 
or workplace exposure. Work-related problems accounted for 1.7% of problems and were 
managed at a rate of 2.6 per 100 encounters in 2011–12 (Table 7.7). This suggests that there 
were 3.2 million problems managed in general practice nationally that were likely to be 
work related.  
Table 7.7: Work-related problems, by type and most frequently managed individual problems 
Work-related problem managed Number 
Per cent of total 
WR problems 
(n = 2,559) 
Rate per 100 
encounters 
(n = 99,030) 
95% 
 LCL 
95% 
UCL 
WR as per 
cent of all 
problems(a)  
Musculoskeletal problems 1,520  59.4 1.5 1.4 1.7 8.8 
 Back complaint* 379  14.8 0.4 0.3 0.4 13.8 
 Sprain/strain* 268  10.5 0.3 0.2 0.3 19.0 
 Injury musculoskeletal NOS 230  9.0 0.2 0.2 0.3 25.4 
 Bursitis/tendonitis/synovitis NOS 83  3.3 0.1 0.1 0.1 7.4 
 Shoulder syndrome 67  2.6 0.1 0.0 0.1 12.8 
 Acute internal knee damage 60  2.4 0.1 0.0 0.1 19.2 
 Fracture* 59  2.3 0.1 0.0 0.1 6.5 
 Tennis elbow 54  2.1 0.1 0.0 0.1 25.1 
 Arthritis – all* 43  1.7 0.0 0.0 0.1 1.1 
Psychological problems 281  11.0 0.3 0.2 0.3 2.2 
 Depression* 95  3.7 0.1 0.1 0.1 2.2 
 Acute stress reaction 85  3.3 0.1 0.1 0.1 11.7 
 Post traumatic stress disorder 41  1.6 0.0 0.0 0.1 29.7 
 Anxiety* 36  1.4 0.0 0.0 0.1 1.9 
Other work-related problems 759  29.7 0.8 0.7 0.9 0.6 
 Administrative procedure – all* 75  2.9 0.1 0.0 0.1 5.9 
 General check-up* 73  2.8 0.1 0.0 0.1 1.1 
 Injury skin, other 71  2.8 0.1 0.0 0.1 12.9 
 Laceration/cut 57  2.2 0.1 0.0 0.1 5.9 
Total work-related problems 2,559 100.0 2.6 2.4 2.8 — 
(a) The proportion of total contacts with this problem that was accounted for by work-related problems. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781743320181>). 
Note: WR – work-related; LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified. Only the most frequent 
individual work-related problems accounting for ≥ 1.4% of total work-related problems are reported. 
The most common work-related problems were musculoskeletal problems, accounting for 
59.4% of work-related problems and managed at a rate of 1.5 per 100 general practice 
encounters. Almost one in ten 10 (8.8%) of musculoskeletal problems managed in general 
practice were work related. The most common musculoskeletal work-related problems were 
back complaint (14.8% of work-related problems), sprain and strain (10.5%), unspecified 
musculoskeletal injury (9.0%) and unspecified bursitis/tendonitis/synovitis (3.3%). 
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Work-related psychological problems accounted for 11.0% of total work-related problems, 
and were managed at a rate of 0.3 per 100 encounters. The most common were depression 
(3.7% of work-related problems), acute stress reaction (3.3%), post-traumatic stress disorder 
(1.6%) and anxiety (1.4%). Psychological work-related problems accounted for only 2.2% of 
total psychological problems managed in general practice.  
7.8 Management of gastro-oesophageal reflux 
disease in 2011–12 
Each year in the annual report we select one morbidity with which to demonstrate how 
BEACH data pertaining to a selected problem can be analysed and viewed. This section uses 
the example of the management of gastro-oesophageal reflux disease (GORD). 
Although GORD is not a National Health Priority Area, it causes a well-documented high 
disease burden on the Australian community, and large health expenditures for both health 
services and pharmaceuticals.  
• Knox et al. (2008) estimated the prevalence of GP-diagnosed GORD in Australia to be 
10.4% (95% CI: 9.3–11.5) of patients attending GPs and 9.2% (95% CI: 8.2–10.1) of the 
Australian population.24 The prevalence of GORD in the Australian community is 
similar to that of osteoarthritis, asthma or depression.24 
• In 1992, proton pump inhibitor (PPI) pharmaceuticals were introduced onto the 
Pharmaceutical Benefits Scheme (PBS) for the treatment of oesophagitis due to GORD.  
• In 2010–11, the cost to the PBS of prescribed drugs for acid related disorders was more 
than $417 million, and the cost of the most frequently prescribed drug in this group 
(esomeprazole) was approximately $169 million.75  
Results are summarised in Figure 7.2. 
Results 
GORD (defined as ICPC-2 PLUS codes D84004, D84008 and D84011) is commonly managed 
in general practice, with 2,557 recorded contacts with the problem, a management rate of 2.6 
per 100 encounters with patients in 2011–12 (Figure 7.2). This represents about 3.2 million 
encounters at which a GORD was managed in general practice across Australia in that year. 
Patient age, sex and reasons for encounter  
There was no difference in the rate of GORD management between the sexes: 2.6 per 100 
male encounters compared with 2.5 per 100 female encounters. Patients aged 65–74 years 
were most likely to have GORD managed (4.0 per 100 encounters with patients in this age 
group), followed by those aged 75 years and over (3.7) and 45–64 years (3.6). The rate among 
infants aged less than one year (2.1, 95% CI: 1.3–2.9) was significantly higher than the rate 
for 1–4 year-olds (0.1, 95% CI: 0.0–0.2).  
The most common reasons for encounter given by patients were: need for a prescription 
(45.7 per 100 GORD encounters), oesophageal disease (20.6), test result (7.4) or a 
cardiovascular check-up (6.2).  
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Other problems managed 
Hypertension was the co-morbidity most often managed with GORD (22.6 per 100 GORD 
encounters), followed by lipid disorder (9.9), depression (7.1), diabetes (6.1) and 
osteoarthritis (5.8). The high management rates of these co-morbidities with the 
management of GORD is not surprising considering about 45% of patients at these 
encounters were aged 65 or more years.  
Medications and other treatments 
Medications were prescribed, supplied by the GP, or advised for over-the-counter purchase 
in the management of GORD (96.1 per 100 GORD problems, 95% CI: 94.3–97.9) significantly 
more often than the average for all problems (69.6 per 100 problems, 95% CI: 68.0–71.2) in 
the 2011–12 BEACH year (Table 5.1).  
The medications most often prescribed, supplied or advised for GORD were esomeprazole 
(41.6 per 100 GORD problems), pantoprazole (20.0), rabeprazole (12.4), omeprazole (10.0), 
and ranitidine (3.9). 
Other treatments were provided at a rate of 16.4 per 100 GORD problems. The vast majority 
(93%) of these were clinical treatments (15.2 per 100 GORD problems), the most common 
being counselling and advice about nutrition and weight (5.6), unspecified advice and 
education (2.3), and advice and education about medication (2.0). Procedural treatments 
were provided at a rate of 1.1 per 100 GORD problems.  
Referrals 
Referrals were provided at a rate of 4.9 per 100 GORD problems. Referrals to medical 
specialists (4.5 per 100 GORD problems, 95% CI: 3.4–5.5) were significantly more frequent 
than referrals to allied health services (0.3, 95% CI: 0.0–0.6). 
Tests and investigations 
Imaging was rarely ordered in the management of GORD (2.0 per 100 GORD problems). 
Pathology was ordered in the management of GORD (14.0 per 100 problems, 95% CI:  
10.6–17.3) significantly less often than the average for all problems (30.6) in the 2011–12 
BEACH year. The pathology tests ordered most often were full blood count (2.5 per 100 
GORD problems), H pylori (2.2), electrolytes, urea and creatinine (1.5), and liver function 
tests (1.1) (Table 5.1). 
Changes in GORD management since 2006–08  
Data about the management of GORD in general practice in 2006–08 are reported in  
Chapter 16 of General practice activity in Australia, health priorities and policies 1998 to 2008.72  
There has been a significant increase in the management rate of GORD in general practice, 
from 2.2 per 100 encounters in 2006–08 (95% CI: 2.1–2.3)72 to 2.6 per 100 encounters in  
2011–12 (95% CI: 2.4–2.8). This represents an increase in the estimated national annual 
number of encounters at which GORD is managed in general practice from 2.3 million to  
3.2 million between 2006–08 and 2011–12.  
The age and sex distributions of patients were similar in 2011–12 to those of 2006–08, and 
further analysis demonstrated that the sex specific rate of GORD per 100 encounters in 
females was marginally higher in 2011–12 (2.5 per 100 encounters, 95% CI: 2.3–2.7) than in 
2006–08, (2.2 per 100 encounters, 95% CI: 2.0–2.3); and the age specific rate of GORD per 100 
65
  
encounters with 45–64 year-olds was marginally higher in 2011–12 (3.6 per 100 encounters, 
95% CI: 3.2–3.9) than in 2006–08, (3.0 per 100 encounters, 95% CI: 2.8–3.2).  
Patient reasons for encounter were recorded at a rate of 188.7 per 100 GORD encounters in 
2011–12 and 187.4 in 2006–08, the two most common being request for prescription (45.7 and 
38.2 per 100 GORD encounters) and oesophageal disease (20.6 and 19.5 respectively).  
There were 145.9 other problems managed per 100 GORD encounters in 2011–12 and 141.3 
in 2006–08, the two most common being hypertension (22.6 per 100 GORD encounters and 
19.8 respectively) and lipid disorder (9.9 and 8.9 respectively).  
Medications were prescribed, supplied or advised at a rate of 96.1 per 100 GORD problems 
in 2011–12 and 94.5 in 2006–08, the two most common being esomeprazole (41.6 per 100 
GORD problems and 33.4 respectively) and pantoprazole (20.0 and 16.0 respectively).  
There were 4.5 specialist referrals per 100 GORD problems in 2011–12 and 4.2 per 100 in 
2006–08, the most common being to a gastroenterologist (2.8 per 100 GORD problems and 
3.2 respectively).  
There was no significant difference in the total pathology orders for GORD: 14.0 (95% CI: 
10.6–17.3) per 100 GORD problems in 2011–12 and 10.6 (95% CI: 8.7–12.5) in 2006–08. The 
two most commonly ordered tests were full blood count (2.5 per 100 GORD problems in 
2011–12 and 2.0 in 2006–08) and H pylori (2.2 per 100 GORD problems, 95% CI: 1.5–2.9 in 
2011–12 and 1.8 per 100 GORD problems, 95% CI: 1.3–2.2 in 2006–08). The H pylori testing 
rate was significantly higher in the management of new cases of GORD (which accounted 
for 15.4% of all GORD problems managed in 2011–12) than for all GORD: 7.8 per 100 new 
GORD problems (95% CI: 4.4–11.3) in 2011–12 and 4.3 (95% CI: 2.8–5.8) in 2006–08.  
Imaging occurred at a rate of 2.0 per 100 GORD problems in 2011–12 and 2.1 in 2006–08, the 
most commonly ordered test being abdominal ultrasound.  
Clinical treatments were provided at a rate of 15.2 per 100 GORD problems in 2011–12 and 
13.4 in 2006–08, the most common being ‘counselling/advice – nutrition/weight’ (5.6 per 
100 GORD problems and 4.7 respectively).  
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Reasons for encounter 
n = 4,826 (188.7 per 100 GORD 
encounters) 
Rate per 100 encounters(c) 
Prescription – all* 45.7 
Oesophageal disease 20.6 
Test results* 7.4 
Cardiovascular check-up* 6.2 
Abdominal pain* 5.6 
General check-up* 5.5 
Heartburn 4.3 
Cough 3.9 
Pain, abdominal epigastric 3.9 
Dyspepsia/indigestion 3.7 
GORD(a) 
n = 2,557 (2.6 per 100 encounters) 
New cases n = 395 (15.4% of all  
GORD cases) 
The patients  
Sex  Per cent Rate(b) 
Males    44.3 2.6 
Females   55.8 2.5 
Age group Per cent Rate(b) 
<1 years  1.4 2.1 
1–4 years  0.2 0.1 
5–14 years  0.3 0.1 
15–24 years 2.6 0.8 
25–44 years 12.9 1.5 
45–64 years 38.1 3.6 
65–74 years 20.9 4.0 
75+ years  23.6 3.7 
Pathology 
n = 357 (14.0 per 100 GORD problems) 
Rate per 100 problems(d) 
Full blood count* 2.5 
H pylori* 2.2 
Electrolytes, urea and creatinine* 1.5 
Liver function* 1.1 
Lipids* 0.9 
(a) GORD includes the ICPC-2 PLUS codes D84004, D84008 and D84011. 
(b) Age and sex-specific rate per 100 encounters in each age/sex group.  
(c) Expressed as a rate per 100 encounters at which GORD problems were managed. 
(d) Expressed as a rate per 100 GORD problems managed. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, <purl.library.usyd.edu.au/sup/9781743320181>). 
Note: GORD – Gastro-oesophageal reflux disease; NEC – not elsewhere classified. 
 Figure 7.2: Management of GORD in general practice 2011–12 
Medications 
n = 2,457 (96.1 per 100 GORD problems) 
Rate per 100 problems(d) 
Esomeprazole 41.6 
Pantoprazole 20.0 
Rabeprazole 12.4 
Omeprazole 10.0 
Ranitidine 3.9 
Lansoprazole 1.6 
Domperidone 1.4 
Simethicone/Magnesium/Al hydroxide 1.0 
Other problems managed 
n = 3730 (145.9 per 100 GORD 
encounters) 
Rate per 100 encounters(c) 
Hypertension* 22.6 
Lipid disorder 9.9 
Depression* 7.1 
Diabetes – all* 6.1 
Osteoarthritis* 5.8 
Immunisation/vaccination – all* 4.0 
Back complaint * 2.9 
Asthma 2.6 
Ischaemic heart disease* 2.5 
Sleep disturbance 2.4 Imaging 
n = 50 (2.0 per 100 GORD problems) 
Rate per 100 problems(d) 
Ultrasound; abdomen 0.7 
Referrals 
n = 126 (4.9 per 100 GORD problems) 
Rate per 100 problems(d) 
Medical specialists* 4.5 
 Gastroenterologist 2.8 
Allied health services* 0.3 
 
Other treatments 
n = 418 (16.4 per 100 GORD problems) 
Rate per 100 problems(d) 
Clinical treatments 15.2 
 Counsel/advice – nutrition/weight* 5.6 
 Advice/education NEC* 2.3 
 Advice/education – medication* 2.0 
 Counselling – problem* 1.9 
 Counsel/advice – lifestyle* 1.0 
Procedural treatments 1.1 
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7.9 Changes in problems managed over the decade 
2002–03 to 2011–12 
Data about the problems managed in general practice from each of the past ten years of the 
BEACH study, 2002–03 to 2011–12 are reported in the companion report A decade of 
Australian general practice activity 2002–03 to 2011–12.1 Major changes that have occurred over 
the decade are summarised below. 
There was a significant increase in the average number of problems managed at encounter, 
from 144.9 per 100 encounters in 2002–03 to 153.8 in 2011–12 (Table 7.2). When this change is 
extrapolated to estimate the national it combines with the increase in GP attendances over 
the decade (see Methods) and suggests there were an additional 48.0 million problems 
managed at GP encounters in Australia in 2011–12 than in 2002–03. This was reflected in a 
significant increase in the management rate of chronic conditions (49.0 rising to 55.6 per 100 
encounters) over the decade. 
Changes in the most common individual problems managed in general practice are 
summarised below. 
• The management rate of depression increased from 3.5 per 100 encounters in 2002–03  
to 4.4 in 2011–12, an estimated national increase of 2.0 million occasions of depression 
management in 2011–12 since 2002–03.  
• The management rate of diabetes increased significantly from 2.9 per 100 encounters in 
2002–03 to 4.2 in 2011–12, suggesting about 2.3 million more occasions of diabetes 
management in 2011–12 than in 2002–03. 
• The management rate of general check-up increased from 1.9 per 100 encounters in  
2002–03 to 2.8 in 2011–12. This represents an estimated national increase of 1.6 million 
occasions where a general check-up was managed in 2011–12 since 2002–03. This 
increase possibly reflects the many MBS items for health assessments including the 
annual assessment of patients aged 75 years and over, the health assessment for  
45–49 year olds at risk of developing chronic disease and the assessment of 40–49 year 
olds at risk of Type 2 diabetes.76 
• The management rate of immunisation/vaccinations did not change between 2002–03 
(4.6 per 100 encounters) and 2011–12 (4.7). However there was a significant spike in the 
management rate in 2009–10 (7.3 per 100) that coincided with the concern about H1N1 
influenza. 
• The management rate of lipid disorder increased significantly from 3.0 per 100 
encounters in 2002–03 to 3.5 in 2011–12, an estimated national increase of 1.4 million 
occasions of lipid disorder management in 2011–12 since 2002–03.  
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8 Overview of management 
The BEACH survey form allows GPs to record several aspects of patient management for 
each problem managed at each encounter. Pharmaceutical management is recorded in 
detail. Other modes of treatment, including clinical treatments (for example, counselling) 
and procedures, recorded briefly in the GP’s own words, are also related to a single 
problem. The form allows for referrals, hospital admissions, pathology and imaging test 
orders to be related to a single problem or to multiple problems (see Appendix 1). 
A summary of management at general practice encounters from 2002–03 to 2011–12 is 
reported for each year in the ten-year report A decade of Australian general practice activity  
2002–03 to 2011–12.1  
At the 99,030 encounters, GPs undertook 231,203 management activities in total. The most 
common management form was medication, either prescribed, GP-supplied, or advised for 
over-the-counter purchase. ‘Other treatments’ were the second most common management 
activity, with clinical treatments more frequent than procedural treatments (Table 8.1). 
For an ‘average’ 100 patient problems, GPs provided 57 prescriptions and 24 clinical 
treatments, undertook 11 procedures, made 6 referrals to medical specialists and 3 to allied 
health services, and placed 31 pathology test orders and 7 imaging test orders. 
Table 8.1: Summary of management 
Management type Number 
Rate per 100 
encounters 
(n = 99,030) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems  
(n = 152,286) 
95% 
LCL 
95% 
UCL 
Medications 106,007 107.0 104.1 110.0 69.6 68.0 71.2 
 Prescribed 85,980 86.8 84.0 89.7 56.5 54.9 58.1 
 GP-supplied 9,630 9.7 8.9 10.5 6.3 5.8 6.8 
 Advised OTC 10,397 10.5 9.7 11.3 6.8 6.3 7.4 
Other treatments 53,395 53.9 51.2 56.6 35.1 33.5 36.7 
 Clinical* 36,610 37.0 34.6 39.3 24.0 22.6 25.5 
 Procedural* 16,785 16.9 16.1 17.8 11.0 10.5 11.5 
Referrals and admissions 14,382 14.5 13.9 15.1 9.4 9.1 9.8 
 Medical specialist* 8,488 8.6 8.2 8.9 5.6 5.3 5.8 
 Allied health services* 4,629 4.7 4.4 5.0 3.0 2.8 3.2 
 Hospital* 345 0.3 0.3 0.4 0.2 0.2 0.3 
 Emergency department* 311 0.3 0.3 0.4 0.2 0.2 0.2 
 Other referrals* 609 0.6 0.5 0.7 0.4 0.3 0.5 
Pathology 46,544 47.0 44.9 49.1 30.6 29.3 31.8 
Imaging 9,978 10.1 9.6 10.5 6.6 6.3 6.8 
Other investigations(a) 897 0.9 0.8 1.0 0.6 0.5 0.7 
Total management activities 231,203 233.5 — — 151.8 — — 
(a) Other investigations reported here include only those ordered by the GP. Other investigations in Chapter 12 include those ordered by the 
GP and those done by the GP or practice staff. 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, <purl.library.usyd.edu.au/sup/9781743320181>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; OTC – over-the-counter. 
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Analysing the number of encounters or problems for which at least one form of 
management was recorded by the GPs gives us another perspective (Table 8.2). At least one 
management action was recorded at 91.9% of encounters, for 86.8% of problems managed. 
• At least one medication or other treatment was given for nearly three-quarters (73.4%) 
of the problems managed. 
• At least one medication (most commonly prescribed) was prescribed, supplied or 
advised for more than half (54.8%) of the problems managed. 
• At least one other treatment (most commonly clinical) was provided for nearly one-third 
(30.7%) of problems managed. 
• At least one referral (most commonly to a medical specialist) was made for 9.3% of 
problems managed. 
• At least one investigation (most commonly pathology) was requested for 18.6% of 
problems managed (Table 8.2). 
Table 8.2: Encounters and problems for which management was recorded 
Management type 
Number of 
encounters 
Per cent of all 
encounters 
(n = 99,030) 
Number of 
problems 
Per cent of all 
problems 
(n = 152,286) 
At least one management type 90,983 91.9 132,169 86.8 
 At least one medication or other treatment 81,127 81.9 111,828 73.4 
  At least one medication  64,464 65.1 83,426 54.8 
  At least one prescription 53,996 54.5 69,096 45.4 
  At least one GP-supplied 7,348 7.4 7,672 5.0 
  At least one OTC advised 9,175 9.3 9,445 6.2 
  At least one other treatment 40,086 40.5 46,729 30.7 
  At least one clinical treatment 28,199 28.5 32,556 21.4 
  At least one procedural treatment 15,034 15.2 15,664 10.3 
 At least one referral or admission 13,219 13.3 14,228 9.3 
  At least one referral to a medical specialist 8,126 8.2 8,584 5.6 
  At least one referral to allied health services 4,291 4.3 4,587 3.0 
  At least one referral to hospital 345 0.3 354 0.2 
  At least one referral to emergency department 311 0.3 316 0.2 
  At least one other referral 609 0.6 636 0.4 
 At least one investigation 24,467 24.7 28,378 18.6 
  At least one pathology order 17,894 18.1 20,702 13.6 
  At least one imaging order 8,562 8.6 8,888 5.8 
  At least one other investigation(a) 861 0.9 888 0.6 
(a) Other investigations reported here only include those ordered by the GP. Other investigations in Chapter 12 include those ordered by the 
GP and those done by the GP or practice staff. 
Note: OTC – over-the-counter. 
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The combinations of management types related to each problem were investigated. The 
majority of treatments occurred either as a single component or in combination with one 
other component. Management was provided: 
• as a single component for almost two-thirds (61.8%) of the problems managed 
• as a double component for 19.6% of problems managed 
• rarely with more than two components (results not tabled). 
Table 8.3 lists the most common management combinations. Medication alone was the most 
common management, followed by a clinical treatment alone, and the combination of a 
medication and a clinical treatment. When a problem was referred it was most likely that no 
other treatments were given for the problem at the encounter.  
Table 8.3: Most common management combinations 
1+ 
medication 
1+ clinical 
treatment 
1+ procedural  
treatment 1+ referral 
1+ imaging 
order 
1+ pathology 
order 
Per cent of 
total problems  
(n = 152,286) 
Per cent  
of total 
encounters 
 (n = 99,030) 
No recorded management 13.2 8.1 
1+ management recorded 86.8 91.9 
      36.4 30.1 
      9.5 6.6 
      6.7 10.7 
      5.0 3.1 
      4.6 3.5 
      4.1 3.5 
      3.1 4.7 
      2.7 4.3 
      2.2 1.7 
      1.4 2.9 
      1.2 1.3 
      1.2 1.1 
      1.1 1.9 
      1.0 1.2 
      0.6 1.8 
      0.5 0.6 
      0.4 1.3 
      0.4 0.7 
      0.4 1.2 
      0.3 1.0 
      0.3 0.4 
Note: 1+ – at least one specified management type. 
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8.1 Changes in management over the decade 
2002–03 to 2011–12 
Changes over the decade 2002–03 to 2011–12 are described in detail in the accompanying 
report A decade of Australian general practice activity 2002–03 to 2011–12.1 In that publication, 
changes over time are largely reported in terms of changes in management actions as a rate 
per 100 problems. This reflects change in how GPs are managing problems after accounting 
for the significant increase in the number of problems managed per encounter over the 
decade. 
The major changes over the ten years to 2011–12 are summarised below. 
• There was a marginal increase in the rate at which procedural treatments were 
undertaken, from 10.1 per 100 problems managed in 2002–03 to 11.0 per 100 problems in 
2011–12. 
• There was significant decrease in the rate of clinical treatments given by GPs from a 
peak in 2004–05 to a low point of 19.9 per 100 problems managed in 2006–07. This is 
likely to be related to the introduction of MBS item numbers for practice nurse activity 
in 2005–06. However since then, the rate of GP-provided clinical treatments gradually 
increased again such that there was no significant difference between the start and end 
of the decade. The original impact of practice nurses on this area of GP workload was no 
longer observed, suggesting that by 2011–12 GPs were again performing clinical 
treatments at a similar rate to that prior to the introduction of practice nurse item 
numbers.  
• The rate of referrals to other health providers significantly increased, from 7.7 to 9.4 per 
100 problems between 2002–03 and 2011–12, influenced by referrals to allied health 
services, which almost doubled over the period (1.7 to 3.0 per 100 problems managed). It 
was further influenced by a significant increase in referrals to emergency departments 
(0.1 to 0.2), and in ‘other referrals’ (0.2 to 0.4 per 100 problems managed). Conversely, 
the rate of referrals to hospital halved between 2002–03 and 2011–12. 
• The rate at which pathology tests/batteries of tests were ordered significantly increased 
by 35%, from 22.7 tests/batteries of tests per 100 problems managed in 2002–03 to 30.6 in 
2011–12.  
• The rate at which imaging was ordered increased significantly, from 5.9 imaging orders 
per 100 problems managed in 2002–03 to 6.6 per 100 in 2011–12. 
Between 2002–03 and 2011–12, there was no significant change in total (including 
prescribed, GP–supplied, and advised for over-the-counter purchase) medication rates per 
100 problems managed or per 100 encounters. However the increasing number of GP 
encounters over the decade, led to an extrapolated national effect of 24.6 million more 
prescriptions given nationally by GPs in 2011–12 than a decade earlier. 
There were some significant increases in GP prescribing rate per 100 problems managed for 
a specific drug groups including: agents acting on the renin-angiotensin system, 
psychoanaleptic, and lipid modifying agents. 
There were also some significant decreases in the prescribing rate per 100 problems 
managed of some medications including: drugs for obstructive airway disease, anti-
inflammatory and antirheumatic products, sex hormones and modulators of the genital 
system, and diuretics.  
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9 Medications 
GPs could record up to four medications for each of four problems – a maximum of 
16 medications per encounter. Each medication could be recorded as prescribed (the 
default), supplied by the GP, or recommended for over-the-counter (OTC) purchase. 
• GPs were asked to: 
– record the generic or brand name, the strength, regimen and number of repeats 
ordered for each medication 
– designate this as a new or continued medication for this patient for this problem. 
• Generic or brand names were entered in the database in the manner recorded by the GP. 
• Medications were coded using the Coding Atlas of Pharmaceutical Substances (CAPS) 
system (developed by the FMRC) which is able to capture details of products at the 
brand and generic level. Every medication in the CAPS coding system is mapped to the 
international Anatomical Therapeutic Chemical (ATC) classification.77 
• The reporting of results at drug group, subgroup and generic level uses 
ATC levels 1, 3 and 5. The most frequently prescribed, supplied or advised individual 
medications are reported at the CAPS generic level (the equivalent of ATC level 5) 
because ATC does not include many over-the-counter medications that arise in BEACH. 
Further, some ATC level 5 labels are not sufficiently specific for clarity. 
Data on medications are reported for each year from 2002–03 to 2011–12 in the 10-year 
summary report, A decade of Australian general practice activity 2002–03 to 2011–12.1 
Readers interested in adverse drug events will find more detailed information from the 
BEACH program in Miller et al. (2006) Adverse drug events in general practice patients in 
Australia.78 
9.1 Source of medications 
As reported in Chapter 8, a total of 106,007 medications were recorded, at rates of 107 per 
100 encounters and 70 per 100 problems managed. We can derive from Table 8.1 that: 
• four out of five medications (81.1%) were prescribed 
• less than one in ten (9.1%) medications was supplied to the patient by the GP 
• 9.8% of medications recommended by the GP for over-the-counter purchase. 
When medication rates per 100 encounter are extrapolated to the 122.5 million general 
practice Medicare-claimed encounters in Australia April 2011 – March 2012, we estimated 
that GPs in Australia: 
• wrote a prescription (with/without repeats) for more than 106.3 million medications 
• supplied 11.9 million medications directly to the patient 
• recommended medications for OTC purchase 12.9 million times. 
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9.2 Prescribed medications 
There were 85,980 prescriptions recorded, at rates of 87 per 100 encounters and 
57 per 100 problems managed (Table 8.1). GPs recorded 83.0% of prescribed medications by 
brand (proprietary) name and 17.0% by their generic (non-proprietary) name. Some of the 
medications most likely to be recorded as a generic were warfarin, prednisolone and 
thyroxine (results not tabled). 
On a per problem basis: 
• no prescription was given for 54.6% of all problems managed 
• one prescription was given for 37.0% of problems managed 
• two prescriptions were given for 6.3% of problems managed 
• three or four prescriptions were given for 2.1% of problems managed (Figure 9.1). 
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Figure 9.1: Number of medications prescribed per problem 
Number of repeats 
For 66,626 prescriptions (77.5% of all prescriptions) the GPs recorded ‘number of repeats’. 
The distribution of the specified number of repeats (from nil to more than five) is provided 
in Figure 9.2. For 34.7% of these prescriptions, the GP specified that no repeats had been 
prescribed, and for 35.5% five repeats were ordered. The latter proportion reflects the PBS 
provision of one month’s supply and five repeats for many medications used for chronic 
conditions such as hypertension. The ordering of one repeat was also quite common (16.2%). 
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Figure 9.2: Number of repeats ordered per prescription 
Age–sex-specific rates of prescribed medications 
Age–sex-specific analysis found similar prescription rates for male (88 per 100 encounters) 
and female patients (86 per 100). It also showed the well-described tendency for the number 
of prescriptions written at each encounter to rise with the advancing age of the patient, with 
the rate of 57 per 100 encounters with patients aged less than 25 years almost doubling to 
111 per 100 encounters for patients aged 65 years and over (results not tabled). 
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Figure 9.3: Age–sex-specific prescription rates per 100 problems managed 
Per cent of prescriptions 
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However, Figure 9.3 demonstrates that this age-based increase lessens if the prescription 
rate is considered in terms of the number of problems being managed in each age group. 
This suggests that a substantial part of the higher prescription rate for older patients is due 
to the increased number of health problems they have managed at an encounter. The 
remaining increase in prescription rate associated with patient age is probably a reflection of 
the problems under management, which are more likely to be chronic at encounters with 
older patients.  
Types of medications prescribed 
Table 9.1 shows the distribution of prescribed medications using the WHO ATC 
classification.77 This allows comparison with other data sources such as those produced by 
Medicare Australia for PBS data. The table lists medications in frequency order within ATC 
levels 1, 3 and 5. Prescriptions are presented as a percentage of total prescriptions, as a rate 
per 100 encounters, and as a rate per 100 problems managed, with 95% confidence intervals.  
The high number of opioids shown in this table (compared with BEACH data published 
before 2010) is due to our re-classification of some medications in 2010. We decided to 
recode codeine combinations which contained 30 mg of codeine as opioids in the ATC 
Index, whereas pre-2010 they were coded as ‘other analgesics and antipyretics’. In the ATC 
classification, either grouping is correct. We took the decision to place high-dose codeine 
products in the opioid group in accordance with MIMS grouping79 and following the 
Poisons Regulations of the Therapeutic Goods Administration,80 which stipulates that high-
dose codeine combinations are Schedule 4 (prescription only) medications. However, a few 
combination analgesics containing less than 30 mg of codeine but classified as Schedule 4 
may be missed because there are other criteria which form part of the scheduling of 
prescription-only codeine. One of these is pack-size, which is not recorded in BEACH. 
Similarly, before 2010 all aspirin (acetylsalicylic acid) was classified in the analgesic group of 
neurological medications. In 2010 we split aspirin into two different codes depending on 
dosage. We reclassified low-dose (100 mg) plain aspirin as an antithrombotic medication in 
the blood medications group, while higher doses and combinations with other 
analgesic/antipyretics remain in the neurological group. 
If readers are making comparisons with previous BEACH publications, they should note 
that this change has caused the opioid and antithrombotic groups to increase, and ‘other 
analgesics and antipyretics’ to decrease. In the companion report to this publication, A decade 
of Australian general practice activity 2002–03 to 2011–12,1 medications have been re-analysed 
across all ten years to incorporate the adjustment.  
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Table 9.1: Prescribed medications by ATC levels 1, 3 and 5  
 
ATC Classification level 
Number 
Per cent of 
prescribed 
medications 
(n = 85,980) 
Rate per 100 
encounters 
 (95% CI) 
(n = 99,030) 
Rate per 100 
problems 
 (95% CI)  
(n = 152,286) 1 3 5 
Nervous system  19,617 22.8 19.8 (18.9–20.7) 12.9 (12.3–13.4) 
  Opioids 5,813 6.8 5.9 (5.5–6.2) 3.8 (3.6–4.0) 
  Codeine, combinations excluding 
psycholeptics 
1,918 2.2 1.9 (1.8–2.1) 1.3 (1.1–1.4) 
  Oxycodone 1,488 1.7 1.5 (1.4–1.6) 1.0 (0.9–1.1) 
  Tramadol 913 1.1 0.9 (0.8–1.0) 0.6 (0.5–0.7) 
 Buprenorphine 559 0.7 0.6 (0.5–0.7) 0.4 (0.3–0.4) 
  Antidepressants 4,050 4.7 4.1 (3.8–4.3) 2.7 (2.5–2.8) 
  Escitalopram 551 0.6 0.6 (0.5–0.6) 0.4 (0.3–0.4) 
  Sertraline 522 0.6 0.5 (0.5–0.6) 0.3 (0.3–0.4) 
  Other analgesics and antipyretics 3,061 3.6 3.1 (2.8–3.4) 2.0 (1.8–2.2) 
  Paracetamol [plain] 2,917 3.4 2.9 (2.7–3.2) 1.9 (1.7–2.1) 
  Anxiolytics 1,894 2.2 1.9 (1.7–2.1) 1.2 (1.1–1.4) 
  Diazepam 1,094 1.3 1.1 (1.0–1.2) 0.7 (0.6–0.8) 
  Hypnotics and sedatives 1,473 1.7 1.5 (1.4–1.6) 1.0 (0.9–1.0) 
  Temazepam 969 1.1 1.0 (0.9–1.1) 0.6 (0.6–0.7) 
  Antipsychotics 1,191 1.4 1.2 (1.1–1.3) 0.8 (0.7–0.9) 
  Drugs used in addictive disorders 773 0.9 0.8 (0.6–0.9) 0.5 (0.4–0.6) 
  Antiepileptics 681 0.8 0.7 (0.6–0.8) 0.4 (0.4–0.5) 
Cardiovascular system 16,556 19.3 16.7 (15.7–17.7) 10.9 10.3–11.5) 
 Lipid modifying agents, plain 3,669 4.3 3.7 (3.4–4.0) 2.4 (2.3–2.6) 
 Atorvastatin 1,568 1.8 1.6 (1.5–1.7) 1.0 (1.0–1.1) 
 Rosuvastatin 1,086 1.3 1.1 (1.0–1.2) 0.7 (0.6–0.8) 
 Simvastatin 576 0.7 0.6 (0.5–0.7) 0.4 (0.3–0.4) 
 Angiotensin II antagonists, plain 2,371 2.8 2.4 (2.2–2.6) 1.6 (1.4–1.7) 
 Irbesartan 941 1.1 1.0 (0.9–1.0) 0.6 (0.6–0.7) 
 Candesartan 618 0.7 0.6 (0.6–0.7) 0.4 (0.4–0.5) 
 Telmisartan 583 0.7 0.6 (0.5–0.7) 0.4 (0.3–0.4) 
 ACE inhibitors, plain 2,151 2.5 2.2 (2.0–2.3) 1.4 (1.3–1.5) 
 Perindopril 1,174 1.4 1.2 (1.1–1.3) 0.8 (0.7–0.8) 
 Ramipril 614 0.7 0.6 (0.5–0.7) 0.4 (0.4–0.5) 
 Beta blocking agents 1,711 2.0 1.7 (1.6–1.9) 1.1 (1.0–1.2) 
 Atenolol 727 0.8 0.7 (0.7–0.8) 0.5 (0.4–0.5) 
 Metoprolol 528 0.6 0.5 (0.5–0.6) 0.3 (0.3–0.4) 
 Angiotensin II antagonists, combinations 1,579 1.8 1.6 (1.5–1.7) 1.0 (0.9–1.1) 
 Irbesartan and diuretics 666 0.8 0.7 (0.6–0.8) 0.4 (0.4–0.5) 
(continued) 
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Table 9.1 (continued): Prescribed medications by ATC levels 1, 3 and 5  
 
ATC Classification level 
Number 
Per cent of 
prescribed 
medications 
(n = 85,980) 
Rate per 100 
encounters 
 (95% CI) 
(n = 99,030) 
Rate per 100 
problems 
 (95% CI)  
(n = 152,286) 1 3 5 
 Selective calcium channel blockers with mainly 
vascular effects 
1,345 1.6 1.4 (1.2–1.5) 0.9 (0.8–1.0) 
 Amlodipine 637 0.7 0.6 (0.6–0.7) 0.4 (0.4–0.5) 
 ACE inhibitors, combinations 709 0.8 0.7 (0.6–0.8) 0.5 (0.4–0.5) 
 High-ceiling diuretics 623 0.7 0.6 (0.5–0.7) 0.4 (0.4–0.5) 
 Frusemide 621 0.7 0.6 (0.5–0.7) 0.4 (0.4–0.5) 
Anti-infective for systemic use 15,829 18.4 16.0 (15.4–16.6) 10.4 (9.9–10.8) 
  Beta-lactam antibacterials, penicillins 6,051 7.0 6.1 (5.8–6.4) 4.0 (3.7–4.2) 
 Amoxycillin 3,205 3.7 3.2 (3.0–3.5) 2.1(1.9–2.3) 
 Amoxycillin and enzyme inhibitor 1,840 2.1 1.9 (1.7–2.0) 1.2 (1.1–1.3) 
 Other beta-lactam antibacterials 3,321 3.9 3.4 (3.1–3.6) 2.2 (2.0–2.3) 
 Cephalexin 2,755 3.2 2.8 (2.6–3.0) 1.8 (1.7–1.9) 
 Macrolides, lincosamides and streptogramins 2,606 3.0 2.6 (2.4–2.9) 1.7 (1.6–1.9) 
 Roxithromycin 1,115 1.3 1.1 (1.0–1.3) 0.7 (0.6–0.8) 
 Clarithromycin 667 0.8 0.7 (0.6–0.8) 0.4 (0.4–0.5) 
 Erythromycin 603 0.7 0.6 (0.5–0.7) 0.4 (0.3–0.5) 
 Sulfonamides and trimethoprim 698 0.8 0.7 (0.6–0.8) 0.5 (0.4–0.5) 
 Viral vaccines 692 0.8 0.7 (0.6–0.8) 0.5 (0.4–0.5) 
 Tetracyclines 690 0.8 0.7 (0.6–0.8) 0.5 (0.4–0.5) 
 Doxycycline 616 0.7 0.6 (0.6–0.7) 0.4 (0.4–0.5) 
Alimentary tract and metabolism 8,860 10.3 8.9 (8.5–9.4) 5.8 (5.5–6.1) 
 Drugs for peptic ulcer and gastro-oesophageal 
reflux 
3,314 3.9 3.3 (3.1–3.6) 2.2 (2.1–2.3) 
 Esomeprazole 1,472 1.7 1.5 (1.4–1.6) 1.0 (0.9–1.0) 
 Pantoprazole 742 0.9 0.7 (0.7–0.8) 0.5 (0.4–0.5) 
 Blood glucose lowering drugs, excluding insulins 2,307 2.7 2.3 (2.1–2.5) 1.5 (1.4–1.7) 
 Metformin 1,293 1.5 1.3 (1.2–1.4) 0.8 (0.8–0.9) 
 Gliclazide 538 0.6 0.5 (0.5–0.6) 0.4 (0.3–0.4) 
 Propulsives 616 0.7 0.6 (0.5–0.7) 0.4 (0.4–0.5) 
 Metoclopramide 519 0.6 0.5 (0.5–0.6) 0.3 (0.3–0.4) 
 Insulins and analogues 566 0.7 0.6 (0.5–0.7) 0.4 (0.3–0.4( 
Respiratory system 5,335 6.2 5.4 (5.0–5.8) 3.5 (3.3–3.7) 
 Adrenergics, inhalants 2,740 3.2 2.8 (2.6–3.0) 1.8 (1.7–1.9) 
 Salbutamol 1,288 1.5 1.3 (1.2–1.4) 0.8 (0.8–0.9) 
 Salmeterol and other drugs for obstructive 
airways disease 
842 1.0 0.9 (0.8–1.0) 0.6 (0.5–0.6) 
 Decongestants and other nasal preparations for 
topical use 
901 1.0 0.9 (0.8–1.0) 0.6 (0.5–0.7) 
(continued) 
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Table 9.1 (continued): Prescribed medications by ATC levels 1, 3 and 5  
 
ATC Classification level 
Number 
Per cent of 
prescribed 
medications 
(n = 85,980) 
Rate per 100 
encounters 
 (95% CI) 
(n = 99,030) 
Rate per 100 
problems 
 (95% CI)  
(n = 152,286) 1 3 5 
 Other drugs for obstructive airway diseases, 
inhalants 
794 0.9 0.8 (0.7–0.9) 0.5 (0.5–0.6) 
Musculoskeletal system 4,248 4.9 4.3 (4.0–4.5) 2.8 (2.6–3.0) 
 Anti-inflammatory and antirheumatic products, 
non-steroid 
3,002 3.5 3.0 (2.8–3.2) 2.0 (1.8–2.1) 
 Meloxicam 826 1.0 0.8 (0.7–0.9) 0.5 (0.5–0.6) 
 Diclofenac 588 0.7 0.6 (0.5–0.7) 0.4 (0.3–0.4) 
 Celecoxib 526 0.6 0.5 (0.4–0.6) 0.3 (0.3–0.4) 
 Antigout preparations 522 0.6 0.5(0.5–0.6) 0.3 (0.3–0.4) 
 Drugs affecting bone structure and mineralization 516 0.6 0.5 (0.4–0.6) 0.3 (0.3–0.4) 
Dermatologicals 3,790 4.4 3.8 (3.6–4.0) 2.5 (2.4–2.6) 
 Corticosteroids, plain 2,268 2.6 2.3 (2.1–2.4) 1.5 (1.4–1.6) 
 Betamethasone 844 1.0 0.9 (0.8–0.9) 0.6 (0.5–0.6) 
 Mometasone 584 0.7 0.6 (0.5–0.7) 0.4 (0.3–0.4) 
Genitourinary system and sex hormones 3,202 3.7 3.2 (3.0–3.4) 2.1 (2.0–2.2) 
 Hormonal contraceptives for systemic use 1,380 1.6 1.4 (1.3–1.5) 0.9 (0.8–1.0) 
Blood and blood forming organs 3,032 3.5 3.1 (2.8–3.3) 2.0 (1.8–2.1) 
 Antithrombotic agents 2,443 2.8 2.5 (2.2–2.7) 1.6 (1.5–1.7) 
 Warfarin 1.398 1.6 1.4 (1.3–1.6) 0.9 (0.8–1.0) 
Systemic hormonal preparations, excluding sex 
hormones  
2,382 2.8 2.4 (2.2–2.6) 1.6 (1.5–1.7) 
  Corticosteroids for systemic use, plain  1,439 1.7 1.5 (1.3–1.6) 0.9 (0.9–1.0) 
   Prednisolone 877 1.0 0.9 (0.8–1.0) 0.6 (0.5–0.6) 
  Thyroid preparations  722 0.8 0.7 (0.7–0.8) 0.5 (0.4–0.5) 
   Levothyroxine sodium 713 0.8 0.7 (0.6–0.8) 0.5 (0.4–0.5) 
Sensory organs  2,247 2.6 2.3 (2.1–2.4) 1.5 (1.4–1.6) 
  Anti-infectives ophthalmological  849 1.0 0.9 (0.8–0.9) 0.6 (0.5–0.6) 
  Chloramphenicol ophthalmological 782 0.9 0.8 (0.7–0.9) 0.5 (0.5–0.6) 
  Corticosteroids and anti-infective in combination 
otological  
594 0.7 0.6 (0.5–0.7) 0.4 (0.3–0.4) 
Antineoplastic and immunomodulating agents  423 0.5 0.4 (0.4–0.5) 0.3 (0.2–0.3) 
Various  256 0.3 0.3 (0.2–0.3) 0.2 (0.1–0.2) 
Antiparasitic products, insecticides and repellent 203 0.2 0.2 (0.2–0.2) 0.1 (0.1–0.2) 
Total prescribed medications 85,980 100.0 86.8 (84.0–89.7) 56.5 (54.9–58.1) 
Note: ATC – Anatomical Therapeutic Chemical classification; CI – confidence interval; ACE – angiotensin-converting enzyme. 
 
 
79
  
Most frequently prescribed medications 
The most frequently prescribed individual medications are reported at the CAPS generic 
level (ATC level 5 equivalent) in Table 9.2. Together these 30 medications made up 43.4% of 
all prescribed medications.  
Table 9.2: Most frequently prescribed medications  
Generic medication Number 
Per cent of 
prescribed 
medications 
(n = 85,980) 
Rate per 100 
encounters  
(95% CI) 
(n = 99,030) 
Rate per 100 
problems 
(95% CI) 
(n = 152,286) 
Amoxycillin 3,205 3.7 3.2 (3.0–3.5) 2.1 (1.9–2.3) 
Paracetamol 2,917 3.4 2.9 (2.7–3.2) 1.9 (1.7–2.1) 
Cephalexin 2,755 3.2 2.8 (2.6–3.0) 1.8 (1.7–1.9) 
Paracetamol/Codeine 1,912 2.2 1.9 (1.8–2.1) 1.3 (1.1–1.4) 
Amoxycillin/potassium clavulanate 1,840 2.1 1.9 (1.7–2.0) 1.2 (1.1–1.3) 
Atorvastatin 1,568 1.8 1.6 (1.5–1.7) 1.0 (1.0–1.1) 
Oxycodone 1,488 1.7 1.5 (1.4–1.6) 1.0 (0.9–1.1) 
Esomeprazole 1,472 1.7 1.5 (1.4–1.6) 1.0 (0.9–1.0) 
Warfarin sodium 1,398 1.6 1.4 (1.3–1.6) 0.9 (0.8–1.0) 
Salbutamol 1,319 1.5 1.3 (1.2–1.5) 0.9 (0.8–0.9) 
Metformin 1,293 1.5 1.3 (1.2–1.4) 0.8 (0.8–0.9) 
Perindopril 1,174 1.4 1.2 1.1–1.3) 0.8 (0.7–0.8) 
Roxithromycin 1,115 1.3 1.1 (1.0–1.3) 0.7 (0.6–0.8) 
Diazepam 1,094 1.3 1.1 (1.0–1.2) 0.7 (0.6–0.8) 
Rosuvastatin 1,086 1.3 1.1 (1.0–1.2) 0.7 (0.6–0.8) 
Temazepam 969 1.1 1.0 (0.9–1.1) 0.6 (0.6–0.7) 
Irbesartan 941 1.1 1.0 (0.9–1.0) 0.6 (0.6–0.7) 
Tramadol 913 1.1 0.9 (0.8–1.0) 0.6 (0.5–0.7) 
Betamethasone topical 844 1.0 0.9 (0.8–0.9) 0.6 (0.5–0.6) 
Fluticasone/Salmeterol 842 1.0 0.9 (0.8–1.0) 0.6 (0.5–0.6) 
Meloxicam 826 1.0 0.8 (0.7–0.9) 0.5 (0.5–0.6) 
Levonorgestrel/Ethinyloestradiol 823 1.0 0.8 (0.8–0.9) 0.5 (0.5–0.6) 
Chloramphenicol eye 782 0.9 0.8 (0.7–0.9) 0.5 (0.5–0.6) 
Pantoprazole 742 0.9 0.7 (0.7–0.8) 0.5 (0.4–0.5) 
Atenolol 727 0.8 0.7 (0.7–0.8) 0.5 (0.4–0.5) 
Thyroxine 713 0.8 0.7 (0.6–0.8) 0.5 (0.4–0.5) 
Clarithromycin 667 0.8 0.7 (0.6–0.8) 0.4 (0.4–0.5) 
Irbesartan/Hydrochlorothiazide 666 0.8 0.7 (0.6–0.8) 0.4 (0.4–0.5) 
Amlodipine 637 0.7 0.6 (0.6–0.7) 0.4 (0.4–0.5) 
Frusemide 621 0.7 0.6 (0.5–0.7) 0.4 (0.4–0.5) 
Subtotal 37,349 43.4 — — 
Total prescribed medications 85,980 100.0 86.8 (84.0–89.7) 56.5 (54.9–58.1) 
Note: CI – confidence interval. 
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9.3 Medications supplied by GPs 
GPs supplied patients with 9,630 medications in 2011–12, at a rate of 9.7 medications per 100 
encounters. At least one medication was supplied at 7.4% of encounters for 5.0% of 
problems. Table 9.3 shows the medications supplied most often at CAPS generic level (ATC 
level 5 equivalent), with vaccines accounting for over half the supplied medications.  
Table 9.3: Medications most frequently supplied by GPs  
Generic medication Number 
Per cent of GP 
supplied 
medications 
(n = 9,630) 
Rate per 100 
encounters 
(95% CI) 
(n = 99,030) 
Rate per 100 
problems 
(95% CI) 
(n = 152,286) 
Influenza virus vaccine 1,931 20.1 1.9 (1.6–2.3) 1.3 (1.0–1.5) 
Pneumococcal vaccine 635 6.6 0.6 (0.6–0.7) 0.4 (0.4–0.5) 
Diphtheria/pertussis/tetanus/hepatitis B/polio/Hib vaccine 419 4.4 0.4 (0.4–0.5) 0.3 (0.2–0.3) 
Vitamin B12 (Cobalamin) 376 3.9 0.4 (0.3–0.4) 0.2 (0.2–0.3) 
Triple antigen (diphtheria/pertussis/tetanus) 351 3.6 0.4 (0.3–0.4) 0.2 (0.2–0.3) 
Mumps/measles/rubella vaccine 322 3.3 0.3 (0.3–0.4) 0.2 (0.2–0.2) 
Rotavirus vaccine 265 2.8 0.3 (0.2–0.3) 0.2 (0.1–0.2) 
ADT/CDT (diphtheria/tetanus) vaccine 178 1.8 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Meningitis vaccine 164 1.7 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Haemophilus B vaccine 156 1.6 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Chickenpox (Varicella zoster) vaccine 147 1.5 0.1 (0.1–0.2) 0.1 (0.1–0.1) 
Typhoid vaccine (Salmonella typhi) 121 1.3 0.1 (0.1–0.2) 0.1 (0.1–0.1) 
Hepatitis A vaccine 116 1.2 0.1 (0.1–0.1) 0.1 (0.1–0.1) 
Hepatitis B vaccine 112 1.2 0.1 (0.1–0.1) 0.1 (0.1–0.1) 
Diphtheria/pertussis/tetanus/polio vaccine 112 1.2 0.1 (0.1–0.1) 0.1 (0.1–0.1) 
Allergen treatment 101 1.0 0.1 (0.1–0.1) 0.1 (0.1–0.1) 
Esomeprazole 90 0.9 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Salbutamol 88 0.9 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Medroxyprogesterone 88 0.9 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Immunisation 86 0.9 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Hepatitis A/Typhoid vaccine (Salmonella typhi) 83 0.9 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Methylprednisolone 82 0.9 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Celecoxib 72 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Amoxycillin 70 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Hepatitis A and B vaccine 69 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Local anaesthetic injection 69 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Metoclopramide 68 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Meloxicam 65 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Paracetamol 61 0.6 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Dabigatran etexilate 58 0.6 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Subtotal 6,555 68.1 — — 
Total supplied medications 9,630 100.0 9.7 6.3 
Note: CI – confidence interval; NEC – not elsewhere classified. 
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9.4 Medications advised for over-the-counter 
purchase 
The GPs recorded 10,397 medications as recommended for OTC purchase, at rates of 10.5 
per 100 encounters and 6.8 per 100 problems managed. At least one OTC medication was 
advised at 9.3% of encounters and for 6.2% of problems. Table 9.4 shows the top 30 advised 
medications at the CAPS generic level (ATC level 5 equivalent). A wide range of 
medications was recorded in this group, the most common being paracetamol, which 
accounted for 27.2% of these medications. The re-classification of aspirin described in 
Section 9.2 also affected rates of advised OTC medications so higher-dose analgesic aspirin 
and low-dose aspirin for antithrombotic purposes are presented separately here. 
Table 9.4: Most frequently advised over-the-counter medications  
Generic medication Number 
Per cent of OTC 
medications 
(n = 10,397) 
Rate per 100  
encounters (95% CI) 
(n = 99,030) 
Rate per 100 
 problems (95% CI) 
(n = 152,286) 
Paracetamol (plain) 2,826 27.2 2.9 (2.5–3.2) 1.9 (1.6–2.1) 
Ibuprofen 693 6.7 0.7 (0.6–0.8) 0.5 (0.4–0.5) 
Saline bath/solution/gargle 251 2.4 0.3 (0.2–0.3) 0.2 (0.1–0.2) 
Sodium/potassium/citric/glucose 245 2.4 0.2 (0.2–0.3) 0.2 (0.1–0.2) 
Simple analgesics NEC 235 2.3 0.2 (0.1–0.3) 0.2 (0.1–0.2) 
Sodium chloride topical nasal 223 2.1 0.2 (0.2–0.3) 0.1 (0.1–0.2) 
Ergocalciferol (Vitamin D analogue) 186 1.8 0.2 (0.1–0.2) 0.1 (0.1–0.2) 
Diclofenac topical 162 1.6 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Loratadine 157 1.5 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Cetirizine 155 1.5 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Cream/ointment/lotion NEC 148 1.4 0.1 (0.1–0.2) 0.1 (0.1–0.1) 
Paracetamol/codeine (all) 116 1.1 0.1 (0.0–0.2) 0.1 (0.0–0.1) 
Hydrocortisone/clotrimazole 114 1.1 0.1 (0.1–0.1) 0.1 (0.1–0.1) 
Clotrimazole topical 107 1.0 0.1 (0.1–0.1) 0.1 (0.1–0.1) 
Fexofenadine 99 1.0 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Fish oil 90 0.9 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Clotrimazole vaginal 90 0.9 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Bromhexine 85 0.8 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Vitamin D 85 0.8 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Hyoscine butylbromide 84 0.8 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Aspirin cardiovascular 79 0.8 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Cold and Flu medication NEC 76 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Cholecalciferol 73 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Loperamide 72 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Docusate otic 70 0.7 0.1 (0.1–0.1) 0.0 (0.0–0.1) 
Folic acid 68 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Hydrocortisone topical 65 0.6 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
(continued) 
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Table 9.4 (continued): Most frequently advised over-the-counter medications  
Generic medication Number 
Per cent of OTC 
medications 
(n = 10,397) 
Rate per 100  
encounters (95% CI) 
(n = 99,030) 
Rate per 100 
 problems (95% CI) 
(n = 152,286) 
Aspirin (analgesic) 66 0.6 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Sorbolene/glycerol/cetomacrogol 63 0.6 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Multivitamins with minerals 63 0.6 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Subtotal 6,848 65.9 — — 
Total advised medications 10,397 100.0 10.5 6.8 
Note: OTC – over-the-counter medication; CI – confidence interval; NEC – not elsewhere classified. 
9.5 Proton pump inhibitors prescribed or supplied 
in 2011–12  
In our examination of the management of gastro-oesophageal reflux (GORD) in general 
practice (Section 7.8) we demonstrated that medications most often prescribed for GORD 
were proton pump inhibitors (PPIs). 
This section examines PPIs as classified in ATC group A02BC. The relationships between 
patients, their reasons for encounter and the problems managed with PPIs are presented in 
Figure 9.4. 
PPIs were prescribed or supplied by GPs at a rate of 3.2 per 100 total encounters, and 2.1 per 
100 problems managed, and they accounted for 3.0% of all medications recorded. For every 
100 problems managed with a PPI, 94 PPIs were prescribed and 6 were supplied by the GP. 
An extrapolation of the above results to estimate the number of these medications 
prescribed or supplied nationally suggested that almost 4 million PPIs were prescribed or 
supplied by GPs to patients in 2011–12. The ten-year summary report, A decade of Australian 
general practice activity 2002–03 to 2011–12,1 details significant increases over the decade in 
prescribing rates of drugs for acid related disorders and the most common PPI, 
esomeprazole. The extrapolated national effect was 1.7 million more prescriptions for drugs 
for acid related disorders (which included 1.5 million more prescriptions for esomeprazole) 
given by GPs in 2011–12 than in 2002–03.  
Patient age and sex, and reasons for encounter 
At encounters with infants aged less than one year, 0.3 PPI were prescribed per 100 
encounters, while among 1–4 year olds the rate was 0.1 and for 5–14 year old children it was 
0.2 per 100 encounters. Patients aged less than 45 years were significantly less likely to 
receive a PPI than those aged 45 years and over, with the rate more than doubling for the 
older age groups. Patients aged 65–74 years were the most likely to be prescribed or 
supplied a PPI (5.2 per 100 encounters). There was no difference between male and female 
patients in the rate of prescription/supply of PPIs. 
The reason for encounter most often given by patients at encounters where a PPI was 
prescribed or supplied was a prescription request (47.2 per 100 PPI encounters). Other 
common reasons were for oesophageal disease (14.6 per 100) and test results (8.3 per 100).  
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Problems managed with a PPI 
Oesophageal disease accounted for almost 7 out of 10 problems managed with a PPI, while 
the GP labelled the problem under management as prescription request for 9.0%. Stomach 
function disorder (almost exclusively gastritis) accounted for 4.8% of problems managed 
with a PPI, abdominal/epigastric pain 2.2%, and dyspepsia/indigestion 2.1%. 
Individual PPIs prescribed or supplied 
There are five generic types of PPIs available in Australia. Esomeprazole accounted for 
48.7% of prescribed or supplied PPIs. The most common esomeprazole product was the 
40 mg tablet. Pantoprazole accounted for one-quarter of PPIs, rabeprazole made up 13.8%, 
and lansoprazole made up 2.1% of these medications. 
 
Problems managed with a PPI 
n = 3,200  
Per cent of problems(a) 
Oesophageal disease 69.1 
Prescription – all* 9.0 
Stomach function disorder 4.8 
Abdominal/epigastric pain(b) 2.2 
Dyspepsia/indigestion 2.1 
Peptic ulcer including duodenal ulcer 1.7 
Hypertension* 0.8 
Hiatus hernia 0.6 
Gastroenteritis* 0.6 
Back complaint* 0.4 
Proton pump inhibitors (PPIs) 
prescribed or supplied 
n = 3,210 (3.2 per 100 total encounters) 
The patients  
Sex  Per cent Rate(d) 
Males  43.7 3.3 
Females 56.3 3.2 
 
Age group  Per cent Rate(d) 
<1 years 0.2 0.3 
1–4 years 0.1 0.1 
5–14 years 0.3 0.2 
15–24 years 3.0 1.2 
25–44 years 12.9 1.9 
45–64 years 38.0 4.5 
65–74 years 21.4 5.2 
75+ years 24.2 4.8 
 
(a) Expressed as a per cent of problems managed with a PPI. 
(b) Combination of three ICPC-2 rubrics: abdominal pain/cramps, general (D01); abdominal pain, epigastric (D02); abdominal pain, 
localised, other (D06).  
(c) Expressed as a rate per 100 encounters at which a PPI was prescribed or supplied. 
(d) Age and sex-specific rate per 100 encounters in each age and sex group. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781743320181>). 
Figure 9.4: Proton pump inhibitors (PPIs) prescribed or supplied in general practice, 2011–12 
PPIs – prescribed or supplied 
n = 3,210 (100 per 100 PPI problems) 
Per cent of PPIs 
Esomeprazole 48.7 
Pantoprazole 24.4 
Rabeprazole 13.8 
Omeprazole 11.0 
Lansoprazole 2.1 
Reasons for encounter 
n = 6,107 (191 per 100 PPI encounters) 
Rate per 100 PPI encounters(c) 
Prescription – all* 47.2 
Oesophageal disease 14.6 
Abdominal/epigastric pain(b) 12.2 
Test results* 8.3 
Cardiovascular check-up* 6.4 
General check-up* 5.4 
Dyspepsia/indigestion 3.4 
Heartburn 3.3 
Cough 3.3 
Immunisation/vaccination – all* 3.2 
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9.6 Changes in medications over the decade 
2002–03 to 2011–12  
Data on medications are reported for each year from 2002–03 to 2011–12 in Chapter 9 of the 
companion report entitled A decade of Australian general practice activity 2002–03 to 2011–12.1 
In that report, changes over time are measured as change in the management of problems 
(that is, as a rate per 100 problems). This reflects change in how GPs are managing problems, 
and takes into account the significant increase in the number of problems managed per 
encounter over the decade to 2011–12 (see Section 7.9). 
The rate at which medications were prescribed did not change significantly from 2002–03 
(58.2 per 100 problems) to 2011–12 (56.5 per 100). Among the prescribed drug groups that 
increased significantly were agents acting on the renin-angiotensin system, 
psychoanaleptics, lipid modifying agents, antithrombotic agents and thyroid therapy. At the 
same time, prescribing rates of several drug groups decreased, including drugs for 
obstructive airways disease, systemic anti-inflammatory medications and sex hormones. 
At the individual generic level, significant increases were found in the prescribing rates of a 
number of medications. Among them were cephalexin, atorvastatin, oxycodone, 
esomeprazole, warfarin, metformin and perindopril. On the other hand, salbutamol, 
levonorgoestrel/ethinyloestradiol, and simvastatin were among the medications for which 
significant decreases in prescribing rates occurred over time.  
Other changes that occurred over the ten-year period were a steady rise in the proportion of 
prescriptions for which five repeats were recorded, and a corresponding decrease in those 
for which two, three or four repeats were recorded. There was a significant increase in the 
rate of vaccines supplied to the patient by GPs, and an increase in the rate of unspecified 
unspecified simple analgesics and in vitamin D advised for over-the-counter purchase. 
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10 Other treatments  
The BEACH survey form allows GPs to record up to two other (non-pharmacological) 
treatments for each problem managed at the encounter. Other treatments include all clinical 
and procedural treatments provided. These groups are defined in Appendix 4, Tables A4.4 
and A4.5. Routine clinical measurements or observations, such as measurements of blood 
pressure and physical examinations, were not included if they were undertaken by the GP. 
However GPs were instructed to record and indicate clinical measurements or observations 
if these were undertaken by the practice nurse (PN) or Aboriginal health worker (AHW) in 
conjunction with the GP at the encounter. 
In 2004, four Medicare item numbers were introduced into the MBS that allowed GPs to 
claim for specified tasks done by a PN under the direction of the GP.81 In 2005–06 the 
BEACH recording form was amended to capture this information. 
• GPs were allowed to record multiple (up to three) Medicare item numbers where 
appropriate, rather than be limited to one item number as had been the case in the past.  
• In the ‘other treatments’ section for each problem managed, GPs were asked to tick the 
‘practice nurse’ box if the treatment recorded was provided by the PN rather than by the 
GP. If the box was not ticked it was assumed the GP gave the treatment. 
In Sections 10.1–10.3 inclusive ‘other treatments’ are counted irrespective of whether they 
were done by the GP or by the PN/AHW. That is, the non-pharmacological management 
provided in general practice patient encounters is described, rather than management 
provided specifically by the GP. However in the analysis of procedural treatments, 
injections given in provision of vaccines were removed, as this action has already been 
counted and reported in medications.  
In Section 10.4 treatments provided by the PN/AHW (including the injections given for 
vaccination) are reported separately, to provide a picture of the work they undertake in 
association with GP–patient encounters. 
Routine clinical measurements or observations, such as measurements of blood pressure and 
physical examinations, were not included between 2002–03 and 2004–05. With the inclusion 
of PN activities in BEACH since 2005–06, clinical observations have been recorded, but only 
when done by the PN. 
Data on other treatments are reported for each year from 2002–03 to 2011–12 in the ten-year 
report A decade of Australian general practice activity 2002–03 to 2011–12.1  
10.1 Number of other treatments 
In 2011–12, a total of 53,395 other treatments were recorded, at a rate of 53.9 per 100 
encounters (Table 5.1). More than two-thirds (68.6%) of these were clinical treatments. At 
least one other treatment was provided at 40.5% of all encounters, for 30.7% of all problems 
managed. For every 100 problems managed, GPs provided 24.0 clinical treatments and 11.0 
procedures (Table 10.1).  
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Table 10.1: Summary of other treatments 
Variable Number 
Rate per 100 
encounters 
(n = 99,030) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 152,286) 
95% 
LCL 
95% 
UCL 
At least one other treatment 40,086 40.5 38.9 42.1 30.7 29.4 31.9 
Other treatments 53,395 53.9 51.2 56.6 35.1 33.5 36.7 
 Clinical treatments 36,610 37.0 34.6 39.3 24.0 22.6 25.5 
 Procedural treatments 16,785 16.9 16.1 17.8 11.0 10.5 11.5 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
Table 10.2 shows the relationship between other treatments and pharmacological treatments 
given for problems managed.  
• In 60.8% of the problems that were managed with an ‘other treatment’, no concurrent 
pharmacological treatment was provided. 
• At least one clinical treatment was provided in the management of 21.4% of problems. 
For 60.0% of these problems, no medication was prescribed/supplied or advised for that 
problem at that encounter.  
• At least one procedural treatment was undertaken in the management of 10.3% of 
problems, with no pharmacological management given for 61.8% of these problems. 
Table 10.2: Relationship between other treatments and pharmacological treatments 
Co-management of problems with other treatments 
Number of 
problems  
Per cent  
within class 
Per cent of  
problems 
(n = 152,286) 
95%  
LCL 
95%  
UCL 
At least one other treatment  46,729 100.0 30.7 29.4 31.9 
 Without pharmacological treatment 28,401 60.8 18.7 17.9 19.4 
At least one clinical treatment  32,556 100.0 21.4 20.2 22.6 
 Without pharmacological treatment 19,520 60.0 12.8 12.1 13.5 
At least one procedural treatment 15,664 100.0 10.3 9.8 10.7 
 Without pharmacological treatment  9,680 61.8 6.4 6.1 6.7 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
10.2 Clinical treatments 
Clinical treatments include general and specific advice, counselling or education, and 
administrative processes. During 2011–12, there were 36,610 clinical treatments recorded, at 
a rate of 37.0 per 100 encounters, or 24.0 per 100 problems managed (Table 10.1). 
Most frequent clinical treatments 
Table 10.3 lists the most common clinical treatments provided. Each clinical treatment is 
expressed as a percentage of all clinical treatments, as a rate per 100 encounters with 95% 
confidence limits and as a rate per 100 problems with 95% confidence limits. 
General advice and education was the most frequently recorded clinical treatment in  
2011–12 (5.9 per 100 encounters), accounting for 16.0% of all clinical treatments. This was 
followed by counselling about the problem under management (4.6 per 100 encounters), 
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counselling and advice about nutrition and weight (4.0 per 100), and advice and education 
about treatment (3.9 per 100). Psychological counselling was provided at a rate of 3.3 per 100 
encounters, and advice and education about medication at a rate of 3.2 per 100 encounters 
(Table 10.3). 
Several recorded clinical treatments related to preventive activities. The most common was 
counselling and advice about nutrition and weight, followed by counselling/advice for: 
exercise, smoking, life style, prevention, and alcohol. Together, these preventive treatments 
accounted for 20.8% of clinical treatments, provided at a rate of 7.7 per 100 encounters 
(Table 10.3). 
Table 10.3: Most frequent clinical treatments 
Clinical treatment Number 
Per cent of 
clinical 
treatments 
(n = 36,610) 
Rate per 100 
encounters 
(n = 99,030) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 152,286) 
95% 
LCL 
95% 
UCL 
Advice/education NEC* 5,855 16.0 5.9 5.2 6.6 3.8 3.4 4.3 
Counselling – problem* 4,565 12.5 4.6 3.8 5.4 3.0 2.5 3.5 
Counselling/advice – nutrition/weight* 3,951 10.8 4.0 3.6 4.4 2.6 2.3 2.9 
Advice/education – treatment* 3,849 10.5 3.9 3.5 4.3 2.5 2.3 2.8 
Counselling – psychological* 3,287 9.0 3.3 3.0 3.6 2.2 2.0 2.3 
Advice/education – medication* 3,189 8.7 3.2 2.9 3.5 2.1 1.9 2.3 
Other administrative procedure/ 
document (excl. sickness certificate)* 
2,148 5.9 2.2 2.0 2.4 1.4 1.3 1.5 
Sickness certificate* 1,741 4.8 1.8 1.5 2.0 1.1 1.0 1.3 
Reassurance, support*  1,525 4.2 1.5 1.3 1.8 1.0 0.9 1.1 
Counselling/advice – exercise* 1,248 3.4 1.3 1.1 1.5 0.8 0.7 0.9 
Counselling/advice – smoking* 758 2.1 0.8 0.7 0.9 0.5 0.4 0.6 
Counselling/advice – lifestyle* 755 2.1 0.8 0.6 0.9 0.5 0.4 0.6 
Counselling/advice – prevention* 547 1.5 0.6 0.4 0.7 0.4 0.3 0.4 
Counselling/advice – health/body* 430 1.2 0.4 0.3 0.5 0.3 0.2 0.3 
Observe/wait* 387 1.1 0.4 0.3 0.5 0.3 0.2 0.3 
Counselling/advice – alcohol* 359 1.0 0.4 0.3 0.4 0.2 0.2 0.3 
Family planning* 328 0.9 0.3 0.3 0.4 0.2 0.2 0.3 
Subtotal  34,922 95.4 — — — — — — 
Total clinical treatments 36,610 100.0 37.0 34.6 39.3 24.0 22.6 25.5 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.4 <purl.library.usyd.edu.au/sup/9781743320181>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NEC – not elsewhere classified. 
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Problems managed with a clinical treatment 
Table 10.4 lists the top ten problems managed with a clinical treatment. It also shows the 
extent to which clinical treatments were used for each problem, and the relationship 
between the use of a clinical treatment and the provision of medication for individual 
problems at that encounter.  
• A total of 32,556 problems (21.4% of all problems) involved one or more clinical 
treatments in their management (Table 8.2). 
• There was a very broad range of problems managed with clinical treatments, the top ten 
problems accounting for 29.4% of all problems for which clinical treatments were 
provided. 
• Depression represented the largest proportion of problems managed with a clinical 
treatment (5.5%), followed by upper respiratory tract infection (representing 5.2%), 
hypertension (3.4%) and diabetes (3.4%).  
• A clinical treatment was provided at 40.8% of depression contacts. Almost half (49.0%) 
of these did not involve medication for that problem at that encounter. 
• However, of the top ten problems acute stress reaction was the one most likely to be 
managed with a clinical treatment (at 73.7% of contacts). Of the contacts with acute 
stress reaction where a clinical treatment was provided, 88.3% did not result in 
concurrent medication prescribed/supplied or advised for that problem. 
• Two-thirds (66.5%) of lipid disorder contacts managed with a clinical treatment had no 
concurrent pharmacological treatment provided for that problem.  
Table 10.4: The ten most common problems managed with a clinical treatment 
Problem managed Number 
Per cent of 
problems 
with clinical 
 treatment  
Rate per 100 
encounters(a) 
(n = 99,030) 
95% 
LCL 
95% 
UCL 
Per cent 
 of this 
problem(b) 
Per cent of 
treated 
 problems no 
medications(c) 
Depression* 1,779 5.5 1.8 1.6 2.0 40.8 49.0 
Upper respiratory tract infection 1,696 5.2 1.7 1.5 1.9 28.7 54.4 
Hypertension* 1,123 3.4 1.1 1.0 1.3 12.5 41.6 
Diabetes – all* 1,114 3.4 1.1 1.0 1.2 27.0 61.7 
Lipid disorder 828 2.5 0.8 0.7 0.9 23.9 66.5 
Anxiety* 811 2.5 0.8 0.7 0.9 42.9 65.4 
Gastroenteritis* 651 2.0 0.7 0.6 0.7 43.4 52.9 
Acute stress reaction 536 1.6 0.5 0.5 0.6 73.7 88.3 
Test results* 534 1.6 0.5 0.4 0.6 29.5 89.9 
Back complaint* 516 1.6 0.5 0.5 0.6 18.7 43.5 
Subtotal  9,587 29.4 — — — — — 
Total problems with clinical 
treatments 32,556 100.0 32.9 30.9 34.9 — — 
(a) Rate of provision of clinical treatment for selected problem per 100 total encounters. 
(b) Percentage of contacts with this problem that generated at least one clinical treatment. 
(c) The numerator is the number of contacts with this problem that generated at least one clinical treatment but generated no medications.  
The denominator is the total number of contacts for this problem that generated at least one clinical treatment (with or without medications). 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <purl.library.usyd.edu.au/sup/9781743320181>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
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10.3 Procedural treatments 
Procedural treatments include therapeutic actions and diagnostic procedures undertaken at 
the encounter. Injections for immunisations (n = 3,359) are not counted here as these have 
been counted as medications (see Chapter 9). There were 16,785 other procedures recorded, 
16.9 per 100 encounters, 11.0 per 100 problems managed (Table 10.1). 
Most frequent procedures 
Table 10.5 lists the most common procedural treatments recorded. Each procedural 
treatment is expressed as a percentage of all procedural treatments, as a rate per 100 
encounters and as a rate per 100 problems, both with 95% confidence limits. Some of the 
procedures (for example INR test, electrical tracings, physical function test) are 
investigations undertaken at the encounter. These results do not include investigations that 
were ordered by the GP to be performed by an external provider. A summary of all 
investigations (both undertaken and ordered) is provided in Table 12.6. 
The most frequently recorded group of procedures was excision/removal tissue/biopsy/ 
destruction/debridement/cauterisation (2.8 per 100 encounters), accounting for 16.5% of 
recorded procedures, followed by dressing/pressure/compression/tamponade (2.5 per 
100), local injection/infiltration (excluding local injection/infiltrations performed for 
immunisations) (2.2) and physical medicine/rehabilitation (1.4 per 100) (Table 10.5). 
Table 10.5: Most frequent procedural treatments 
Procedural treatment Number 
Per cent of 
procedural 
treatments 
(n = 16,785) 
Rate per 100 
encounters 
(n = 99,030) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 152,286) 
95% 
LCL 
95% 
UCL 
Excision/removal tissue/biopsy/destruction/ 
debridement/cauterisation 
2,774 16.5 2.8 2.6 3.0 1.8 1.7 2.0 
Dressing/pressure/compression/tamponade* 2,523 15.0 2.5 2.3 2.7 1.7 1.5 1.8 
Local injection/infiltration*(a) 2,163 12.9 2.2 2.0 2.4 1.4 1.3 1.5 
Physical medicine/rehabilitation – all* 1,374 8.2 1.4 1.2 1.6 0.9 0.8 1.0 
Incision/drainage/flushing/aspiration/ 
removal body fluid* 1,140 6.8 1.2 1.0 1.3 0.7 0.7 0.8 
Repair/fixation – suture/cast/prosthetic device 
(apply/remove)* 
881 5.2 0.9 0.8 1.0 0.6 0.5 0.6 
Pap smear* 860 5.1 0.9 0.8 1.0 0.6 0.5 0.6 
Other therapeutic procedures/minor surgery*  791 4.7 0.8 0.6 1.0 0.5 0.4 0.6 
INR test*  683 4.1 0.7 0.6 0.8 0.4 0.4 0.5 
Electrical tracings* 648 3.9 0.7 0.6 0.7 0.4 0.4 0.5 
Check-up – PN/AHW* 585 3.5 0.6 0.4 0.7 0.4 0.3 0.5 
Physical function test* 557 3.3 0.6 0.4 0.7 0.4 0.3 0.4 
Other preventive procedures/high-risk medication* 516 3.1 0.5 0.4 0.6 0.3 0.3 0.4 
Subtotal  15,495 92.3 — — — — — — 
Total procedural treatments  16,785 100.0 16.9 16.1 17.8 11.0 10.5 11.5 
(a) Excludes all local injection/infiltrations performed for immunisations/vaccinations. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Tables A4.5 and A4.6, <purl.library.usyd.edu.au/sup/9781743320181>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NEC – not elsewhere classified; INR – international normalised ratio;  
PN/AHW – practice nurse/Aboriginal health worker. 
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Problems managed with a procedural treatment 
Table 10.6 lists the top ten problems managed with a procedural treatment. It also shows the 
proportion of contacts with each problem that was managed with a procedure, and the 
proportion of problems managed with a procedure without medication given concurrently. 
• One or more procedural treatments were provided in the management of 15,664 
problems (10.3% of all problems) (Table 8.2). 
• The top ten problems accounted for more than a third (34.4%) of all problems for which 
a procedure was used. 
• Laceration/cut accounted for 4.9% of all problems managed with procedures, followed 
by female genital check-up/pap smear (4.8%), solar keratosis/sunburn (4.4%), and 
excessive ear wax (3.5%). 
• Of the top ten problems, laceration/cut was the problem most likely to be managed 
with a procedural treatment with a procedure being undertaken at four-out-of-five 
(79.9%) contacts. Of these contacts with a laceration/cut where a procedural treatment 
was provided, 80.4% were not prescribed/supplied or advised a medication for that 
problem at that encounter. 
Table 10.6: The ten most common problems managed with a procedural treatment 
Problem managed Number 
Per cent of 
problems with 
procedure  
Rate per 100 
encounters(a) 
(n = 99,030) 
95% 
LCL 
95% 
UCL 
Per cent of 
this 
problem(b) 
Per cent of 
treated problems 
no medications(c) 
Laceration/cut  765 4.9 0.8 0.7 0.9 79.9 80.4 
Female genital check-up/ 
Pap smear* 747 4.8 0.8 0.7 0.9 45.0 98.3 
Solar keratosis/sunburn 697 4.4 0.7 0.6 0.8 66.6 97.8 
Excessive ear wax 546 3.5 0.6 0.5 0.6 72.8 92.0 
Chronic ulcer skin 
(including varicose ulcer) 
496 3.2 0.5 0.4 0.6 75.7 74.7 
Warts  487 3.1 0.5 0.4 0.6 77.2 95.0 
Malignant neoplasm of skin 482 3.1 0.5 0.4 0.6 45.7 94.3 
General check-up* 474 3.0 0.5 0.4 0.6 17.2 77.3 
Atrial fibrillation/flutter 382 2.4 0.4 0.3 0.5 27.8 55.4 
Back complaint* 317 2.0 0.3 0.3 0.4 11.5 33.1 
Subtotal  5,393 34.4 — — — — — 
Total problems with 
procedural treatments 15,664 100.0 15.8 15.1 16.5 — — 
(a) Rate of provision of procedural treatment for selected problem per 100 total encounters. 
(b) Percentage of contacts with this problem that generated at least one procedural treatment. 
(c) The numerator is the number of cases of this problem that generated at least one procedural treatment but generated no medications. The 
denominator is the total number of contacts (for this problem) that generated at least one procedural treatment (with or without 
medications). 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <purl.library.usyd.edu.au/sup/9781743320181>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
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10.4 Practice nurse/Aboriginal health worker activity 
This section describes the activities of PNs recorded in association with the GP–patient 
encounters recorded by the GP BEACH participants. 
In February 2004, two Medicare item numbers were introduced into the MBS that allowed 
GPs to claim for specified tasks undertaken by a PN under the direction of the GP. The 
BEACH recording form (see Appendix 1) was amended to allow the capture of this 
information from April 2005 onwards. 
• GPs were allowed to record multiple (up to three) Medicare item numbers where 
appropriate, rather than be limited to one item number. 
• In the ‘other treatments’ section, for each problem managed GPs were asked to tick the 
‘practice nurse’ box if the treatment recorded was provided by the PN rather than by the 
GP. If the box was not ticked it was assumed that the GP provided the ‘other treatment’. 
The survey form allows GPs to record up to two other treatments for each problem managed 
at the encounter (i.e. up to eight per encounter). Other treatments include all clinical and 
procedural treatments provided at the encounters. These groups are defined in Appendix 4, 
Tables A4.4 and A4.5. 
Over the years new PN item numbers were added to the MBS and some items were 
broadened to include work done by AHWs. In past years we have reported the results 
referring to PNs alone. However in 2011–12 a few GPs indicated (of their own accord) that 
the recorded action was done by an AHW rather than a PN. We have included this 
information in this section, which now refers to work undertaken at encounters by PNs and 
AHWs in conjunction with the GPs, though the vast majority will have been done by PNs.  
There is a limitation to this approach. Few GPs specifically indicated that the work was done 
by an AHW. Others may have thought that because the question referred specifically to 
PNs, and recording of work done by AHWs was not specifically requested. These results 
therefore have the potential to be an underestimate of the work undertaken at GP–patient 
encounters by PNs and AHWs. 
In January 2012 the Australian Government significantly altered the payment structure for 
practice nurse and AHW activities in general practice such that the range of claimable MBS 
item numbers was diminished and the Practice Nurse Incentive Program (PNIP) introduced. 
The PNIP “provides incentive payments to practices…by consolidating funding 
arrangements under the Practice Incentive Program (PIP) Practice Nurse Incentive”. Six of 
the Medicare Benefits Schedule (MBS) practice nurse items covering MBS immunisation, 
cervical smears and treatments of a person’s wound were removed and the funds redirected 
into a single payment to eligible general practices.82  
This means that Medicare claims for PN/AHW items recorded in BEACH from January 
2012 onwards were limited to a far smaller range of claimable items.83 This means that the 
2011–12 data presented here includes a period of nine months (April – December 2011) of 
the old payment system and three months of the new. Likewise the distribution of 
PN/AHW claims in BEACH and in the MBS claims data reflect this mix. 
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This change in payment systems as of 1 January 2012 must be remembered in the following 
section, which investigates:  
• the proportion of encounters involving the practice nurse  
• the proportion of these recorded as claimable under a Medicare item number  
• the distribution of the practice nurse items recorded; treatments provided by practice 
nurses in association with the GP-recorded encounters  
• the problems for which practice nurses provided treatments (in direct association with 
the GP-recorded encounters). 
When viewing these results, it must be remembered that these practice nurse data will not 
include activities undertaken by practice nurses during the GP’s BEACH recording period 
that were outside (not associated with) the recorded encounter. Such activities could include 
Medicare-claimable activities (for example, immunisations/vaccinations) provided under 
instruction from the GP but not provided at the time of the encounter recorded in BEACH, 
or provision of other services not currently claimable from Medicare (for example, dietary 
advice on a one-to-one basis, or in a group situation). 
Practice nurse/Aboriginal health worker Medicare claims 
There were 7,293 (GP–patient encounters 7.4% of all encounters) for which at least one 
practice nurse item and/or nurse activity was recorded. However, for 82 of these their 
activity was not described. At the remaining 7,210 encounters a practice nurse was involved 
in the management of 7,554 problems (5.0% of all problems managed at all encounters). 
Simple extrapolation of these results suggests that during 2011–12 practice nurses were 
involved in about 9 million GP–patient consultations across Australia.  
A PN/AHW Medicare item was recorded at only 1,997 encounters: 2.3% of the 87,323 with 
one or more MBS item number(s) (Table 5.2) and 27.4% of the 7,293 encounters involving a 
PN/AHW (Table 10.7), and 2,028 PN/AHW item numbers were recorded (Table 10.8).  
Table 10.7: Summary of PN or AHW involvement at encounters 
Variable Number 
Total encounters  99,030 
Encounters involving PN/AHW 7,293 
 Encounters at which PN/AHW activity described 7,210 
 Encounters with MBS PN/AHW item number(s) recorded but activity not described  82 
Encounters at which one or more MBS PN/AHW item numbers were recorded as claimable 1,997 
Total problems managed 152,286 
 Problems managed with PN/AHW involvement 7,554 
 Per cent (95% CI) 
Encounters involving PN/AHW as a proportion of total encounters  7.4 (7.6–8.0) 
Problems involving PN/AHW as a proportion of total problems 5.0 (4.5–5.4) 
PN/AHW claimable encounters as a proportion of total encounters with at least one MBS item 
recorded 
2.0 (1.7–2.3) 
Proportion of encounters involving PNs/AHWs for which one or more MBS practice nurse item 
numbers were recorded as claimable 
27.4 (24.3–30.4) 
Note: PN/AHW – practice nurse/Aboriginal health worker; MBS – Medicare Benefits Schedule; CI – confidence interval. 
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Distribution of practice nurse/Aboriginal health worker items claimed  
A total of 2,028 PN/AHW item numbers were recorded at 1,997 encounters. More than half 
(55.1%) of these were for immunisations and a further 33.3% were for wound treatments. 
Items recorded for practice nurse services to a person with chronic disease accounted for 
10.0%. There were few PN/AHW items claimed for cervical smears (with or without 
preventive checks) and for health assessments of a four year old, each accounting for 0.6% of 
all PN/AHW items claimed (Table 10.8).  
Comparison of the distribution of recorded practice nurse item numbers and the distribution 
of the approximately 4.7 million claims made for such items from Medicare in the same data 
period demonstrated a relatively good fit (Table 10.8). These results suggest that 
PNs/AHWs conduct of cervical smears were more likely to occur separately from the GP 
encounter, while their immunisations, wound treatments and services provided to people 
with a chronic disease were likely to be done in association with a GP encounter. 
Table 10.8: Distribution of PM/AHW worker item numbers recorded  
Medicare 
item 
number Short descriptor Number(a) 
Per cent 
 of total 
Per cent of 
Medicare 
PN/AHW item 
claims(b) 
(n = 4.7 million) 
10993 Immunisation by PN 1,117 55.1 
(50.2–59.9) 
55.7 
10996 Wound treatment (other than normal aftercare) by PN 676 33.3 
(29.1–37.5) 
30.0 
10997 Service provided to a person with a chronic disease by a PN or 
registered AHW 
211 10.4% 
(6.6–14.2) 
10.0 
10994 Cervical smear and preventive checks by PN 7 0.3 
(0.0–0.7) 
1.6 
10995 Cervical smear and preventive checks – women aged 20–69 
years, no smear in previous 4 years 
0 0 0.1 
10998 Cervical smear by PN 2 0.1 
(0.0–0.3) 
0.2 
10999 Cervical smear – women 20–69 years, no smear in past four 
years 
4 0.2  
(0.0–0.5) 
0.02 
10986 Health assessment of four year old who has had /is having 4 year 
old immunisation, by PN or AHW  
7 0.3 
(0.0–0.7) 
0.6 
82210 Professional attendance by a participating nurse practitioner(c) 2 0.1 (0.0–0.3) —(c) 
16400 Antenatal service provided by a midwife, PN or AHW 1 0.0 (0.0–0.3) Ŧ 1.1 
Total(b) All Medicare practice nurse item numbers 2,028 100.0 100.0 
(a) Three of the 2,031 PN/AHW/allied health worker item numbers (Table 5.6) were allied health worker item numbers and are excluded here 
as we have no data on their activity at the encounters. 
(b) Total Medicare PN claims (Source: Medicare health statistics, March 2011 – April 2012 <www.medicareaustralia.gov.au>). 
(c) Only two nurse practitioner item numbers were recorded in BEACH and we assume that by far the majority of these item numbers are 
being claimed by nurse practitioners working outside a general practitioner’s practice, so we have not included these items in the Medicare 
claims summary denominator. 
Note:  There were no recordings of items: 10950, 10983, 10984, 10987, 10988, 10989 and 81300, which together accounted for less than 0.5% of 
claims for PN/AHW MBS item numbers between 1 April 2011 and 31 March 2012 (Source: Medicare health statistics, March 2011 – April 
2012 <www.medicareaustralia.gov.au>). 
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Treatments provided by practice nurses or Aboriginal health 
worker at GP-patient encounters 
As shown in Section 10.1 GPs reported 53,395 other treatments at encounters. A further 1,823 
local injections in administration of immunisations were given by a PN/AHW and 1,636 by 
the recording GP (these were not reported in Section 10.2). So, in total 56,854 other 
treatments were recorded, PNs/AHWs accounting for 8,040 of these (representing 14.1% of 
all other treatments recorded at BEACH encounters) at a rate of 8.2 per 100 recorded 
encounters. The majority (89.0%) of the PN/AHW activity was procedural, and these 
procedures represented 35.4% of all procedures recorded. In contrast, clinical treatments 
accounted for 11.0% of PN/AHW activity at encounters, but PNs/AHWs provided only 
2.4% of all recorded clinical treatments. PNs/AHWs did just over half of the immunisation 
injections (52.7%) at GPs encounters (Table 10.9). 
Table 10.9: Summary of treatments given by GPs, and by PN or AHW at GP-patient encounters 
Treatment 
Performed/assisted by 
PN/AHW 
 
Performed by the GP 
Total number 
recorded(a) Number 
Row per cent  
of total  Number 
Row per cent  
of total 
Procedures(a) 7,158 35.4  13,086 64.6 20,244 
 (Immunisation injections) (1,823) (52.7)  (1,636) (47.3) (3,459) 
Clinical treatments 882 2.4  35,728 97.6 36,610 
All other treatments 8,040 14.1  48,814 85.9 56,854 
(a)  Procedural treatments here include all injections given by a PN/AHW or the GP for immunisations/vaccinations (n = 3,459).  
These are not included in the summary of the content of encounter in Table 5.1, summary of management in Table 8.1 or in the analyses of 
other treatments in Chapter 10, because the immunisation/vaccination is already counted as a prescription or GP-supplied medication. 
Note: PN/AHW – practice nurse/Aboriginal health worker. 
Of the 7,158 procedures performed by a PN/AHW, 35.8% were injections (71.2% of which 
were for immunisations), and a further 20.1% were dressing/pressure/compression/ 
tamponade. Together these accounted for 55.9% of all procedures undertaken by 
PNs/AHWs in association with the recorded GP-patient encounters. Check-ups made up 
8.0% of procedures undertaken by a PN/AHW followed by INR tests (6.7%), and 
incision/drainage/aspirations (5.5%). PNs/AHWs also undertook a wide range of other 
procedural activities in association with the GP-patient encounters. The most common are 
listed in Table 10.10. 
Other administrative procedure (which includes administrative/documentation work but 
excludes provision of sickness certificates) was the most frequently recorded clinical activity, 
accounting for 29.3% of the 882 clinical treatments provided by PNs/AHWs, followed by 
counselling the patient about their health problem (14.5%), general advice/education (9.2%), 
and counselling about a psychological problem (6.0%) (Table 10.10).  
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Table 10.10: Most frequent activities done by a PN or AHW at GP encounters 
Activity Number 
Per cent of 
group(a) 
Rate per 100 
encounters where 
PN/AHW activity 
described(a) 
 (n = 7,210) 
95% 
LCL 
95% 
UCL 
Procedural treatments 7,158 100.0 99.3 96.5 102.0 
 Local injection/infiltration* 2,561 35.8 35.5 32.4 38.6 
 Dressing/pressure/compression/tamponade* 1,441 20.1 20.0 18.2 21.8 
 Check-up – PN/AHW* 575 8.0 8.0 6.1 9.8 
 INR test* 477 6.7 6.6 5.4 7.8 
 Incision/drainage/flushing/aspiration/removal 
 body fluid* 
395 5.5 5.5 4.2 6.7 
 Electrical tracings* 377 5.3 5.2 4.5 6.0 
 Repair/fixation-suture/cast/prosthetic device  
 (apply/remove)* 
286 4.0 4.0 3.3 4.6 
 Excision/removal tissue/biopsy/destruction/ 
 debridement/cauterisation* 
263 3.7 3.7 2.8 4.5 
 Physical function test* 203 2.8 2.8 2.1 3.5 
 Urine test*  155 2.2 2.1 1.5 2.8 
 Glucose test* 88 1.2 1.2 0.8 1.7 
 Other diagnostic procedures* 59 0.8 0.8 0.4 1.2 
 Pregnancy test* 47 0.7 0.7 0.4 0.9 
 Pap smear* 45 0.6 0.6 0.3 0.9 
Clinical treatments 882 100.0 12.2 9.6 14.8 
Other administrative procedure/document 
(excluding sickness certificate)* 
258 29.3 3.6 2.8 4.4 
 Counselling – problem* 128 14.5 1.8 0.1 3.4 
 Advice/education NEC* 81 9.2 1.1 0.7 1.5 
 Counselling – psychological 53 6.0 0.7 0.2 1.3 
 Advice/education – medication* 52 5.9 0.7 0.4 1.1 
 Consultation with primary care provider* 42 5.4 0.7 0.1 1.2 
 Counselling/advice – nutrition/weight* 32 3.6 0.4 0.1 0.7 
(a) Only the most common individual treatments provided by practice nurses/Aboriginal health workers are included in this table. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Tables A4.4–A4.6 purl.library.usyd.edu.au/sup/9781743320181>). 
Note:  LCL – lower confidence limit; UCL – upper confidence limit; INR – international normalised ratio; PN/AHW – practice nurse/Aboriginal 
health worker; NEC – not elsewhere classified. 
Problems managed with practice nurse or Aboriginal health 
workers involvement at encounter 
PNs and AHWs were involved in management of a wide range of problems in association 
with the GP encounters. The problems managed most often were immunisation/vaccination 
(24.3% of all problems managed with the involvement of a PN or AHW), laceration/cut and 
check-ups (5.6% in both cases), chronic skin ulcer (4.6%) and diabetes (3.8%). Other common 
problems for which PNs or AHWs were involved at the GP-patient consultations are listed 
in Table 10.11. 
96
  
Table 10.11: The most common problems managed with involvement of PNs or AHWs at 
GP-patient encounters 
Problem managed Number 
Per cent  
of problems 
involving  
PN/AHW(a) 
(n = 7,554) 
Rate per 100 
encounters with 
recorded PN/AHW 
activity(b) 
(n = 7,210) 
95% 
LCL 
95% 
UCL 
Immunisation/vaccination – all* 1,839 24.3 25.5 22.7 28.3 
Laceration/cut 427 5.6 5.9 5.1 6.7 
Check-up – all* 422 5.6 5.8 4.9 6.8 
Chronic ulcer skin (including varicose ulcer) 351 4.6 4.9 4.1 5.6 
Diabetes – all* 284 3.8 3.9 3.2 4.7 
Atrial fibrillation/flutter 259 3.4 3.6 2.5 4.6 
Hypertension* 165 2.2 2.3 1.4 3.1 
Excessive ear wax 164 2.2 2.3 1.8 2.7 
Malignant neoplasm skin 161 2.1 2.2 1.7 2.8 
Blood test – all* 135 1.8 1.9 1.3 2.4 
Skin infection – post traumatic 125 1.6 1.7 1.3 2.1 
Vitamin/nutritional deficiency 117 1.5 1.6 1.2 2.0 
Administrative procedure – all* 92 1.2 1.3 0.7 1.8 
Asthma 82 1.1 1.1 0.8 1.5 
Other preventive procedures/high risk medication* 69 0.9 1.0 0.6 1.3 
Contraception, other 68 0.9 0.9 0.7 1.2 
Repair/fixation-suture/cast/prosthetic device 
(apply/remove)* 
68 0.9 0.9 0.7 1.2 
Urinary tract infection* 64 0.8 0.9 0.5 1.3 
Skin symptom/complaint – NOS/NEC 60 0.8 0.8 0.6 1.1 
Boil/carbuncle 60 0.8 0.8 0.5 1.1 
Burns/scalds 58 0.8 0.8 0.5 1.1 
Pregnancy* 56 0.7 0.8 0.4 1.1 
Observation/health education/advice/diet – all* 55 0.7 0.8 0.4 1.1 
Prescription – all*  52 0.7 0.7 0.5 1.0 
Abrasion/scratch/blister 52 0.7 0.7 0.5 1.0 
Dressing/pressure/compression/tamponade* 46 0.6 0.6 0.3 0.9 
Arthritis – all* 45 0.6 0.6 0.4 0.8 
Anaemia* 45 0.6 0.6 0.4 0.8 
Complication of medical treatment 44 0.6 0.6 0.4 0.9 
Chest pain NOS 44 0.6 0.6 0.4 0.8 
(a) Only those problems accounting for >0.5% of all problems managed at GP-patient encounters with involvement of a PN or AHW are 
included in this table.  
(b) Rate of nurse provision of treatment at encounter for selected problem per 100 total encounters in which a practice nurse or Aboriginal 
health worker was involved. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.3, <purl.library.usyd.edu.au/sup/9781743320181>).  
Note: LCL – lower confidence limit; UCL – upper confidence limit; NEC – not elsewhere classified; NOS – not otherwise stated; 
PN/AHW – practice nurse/Aboriginal health worker. 
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10.5 Changes in other treatments over the decade 
2002–03 to 2011–12 
An overview of changes in other treatments provided in general practice over the decade 
can be found in Chapter 10 of the companion report A decade of Australian general practice 
activity 2002–03 to 2011–12.1 A summary of the results is provided below. 
Clinical treatments 
The rate of clinical treatments provided in the management of patient problems did not 
differ in 2002–03 and 2011–12 but there were major changes within the decade.  
The rate of provision of clinical treatments remained steady from 2002–03 to 2004–05. 
Following the introduction of PN and AHW Medicare item numbers in 2004, there was a 
sudden and significant decrease in the rate in 2005–06. From 2006–07 onwards, the rate 
slowly increased to reach 24.0 clinical treatments per 100 problems in 2011–12, returning to 
the level provided ten years earlier.  
The rate at which counselling/advice about nutrition/weight and counselling/advice about 
exercise was provided significantly decreased in 2005–06 then remained steady at a 
significantly lower rate in 2011–12 than ten years earlier. We estimate 140,000 fewer 
occasions of counselling/advice about nutrition and weight, and 86,000 fewer occasions of 
counselling/advice about exercise in 2011–12 than in 2002–03. These changes are discussed 
in Section 10.4 of the accompanying report.  
Overall, there was no significant change in the proportion of problems managed with 
clinical treatments over the decade. However, the rate of clinical treatments provided for 
diabetes increased significantly, from 0.8 per 100 encounters in 2002–03 to 1.1 in 2011–12. 
Procedural treatments 
The rate at which procedures were recorded per 100 encounters increased significantly from 
14.6 per 100 encounters in 2002–03 to 16.9 per 100 in 2011–12. The extrapolated effect of this 
change is that nationally in 2011–12 there were an estimated 6.6 million more procedures 
undertaken than a decade earlier.  
There was an overall increase in the proportion of problems managed with procedural 
treatment(s) from 13.6% in 2002–03 to 15.8% in 2011–12 but there was no change in the rate 
at which procedures were performed per 100 problems managed. There were significant 
changes in rates of some specific types of procedures within this period.  
• The provision of local injections/infiltration (excluding immunisations) significantly 
increased over the decade. When extrapolated, the increase suggests provision of 
1.2 million more local injections/infiltrations nationally in 2011–12 than in 2002–03.  
• In contrast, there was a significant decrease in the rate of physical 
medicine/rehabilitation, Pap smear and other therapeutic procedures/surgery NEC.  
• There was a significant increase in the procedural rate in management of atrial 
fibrillation from 2002–03 to 2011–12. The coincided with a significant increase in the 
prescribing rate of warfarin sodium over the decade (see Chapter 9). INR testing is used 
to monitor patients on warfarin therapy and the provision of INR testing at the 
encounter significantly increased from one INR test per 1,000 encounters in 2006–07 to 
seven per 1,000 encounters in 2011–12.  
98
  
Practice nurse/Aboriginal health worker activity  
A comparison of PN/AHW activity from 2005–06 to 2011–12 is provided in Chapter 10 of 
the ten-year report A decade of Australian general practice activity 2002–03 to 2011–12.1 Changes 
are summarised below. 
As a proportion of all encounters, those involving a PN/AHW almost doubled from 4.2% in 
2005–06 to peak at 9.0% in 2009–10 then significantly decreased to 7.4% in 2011–12. The 
proportion of problems managed with a PN/AHW involvement also increased from 2.8% in 
2005–06 to peak to 6.1% in 2009–10 with no significant change by 2011–12 (5.0%).  
In 2005–06 GPs recorded at least one PN/AHW Medicare item number at 39% of encounters 
with recorded PN/AHW activity. This increased to 46% by 2009–10, and then decreased to 
40% in 2010–11. In 2011–12, which includes three months of data recorded after the change 
in practice nurse funding structure, the proportion decreased to 27%.  
There were two significant changes in between 2005–06 and 2011–12 in the distribution of 
practice nurse item numbers claimed for work associated with the BEACH encounters: in 
2011–12 PN/AHW services to a person with a chronic disease (first introduced in 2007–08), 
made up a significantly greater proportion of recorded items (3.6%) than in 2007–08; the 
proportion of claims accounted for by immunisations was significantly lower in 2011–12 
(55.1%) than in 2005–06 (69.5%).  
The rate at which procedures (including tests) were undertaken by PNs/AHWs at  
GP–patient encounters more than doubled from 4.0 per 100 encounters in 2005–06 to 9.2 per 
100 in 2009–10, but decreased in 2011–12 to 7.2 per 100 encounters. PNs/AHWs also took 
over an increasing proportion of the procedural work, increasing from 23% in 2005–06 to 
38% in 2010–11, with no statistical change in 2011–12. 
While their provision of clinical treatments (such as advice and health education) remained 
infrequent at GP–patient encounters, there was a significant increase over the study period, 
from 0.2 clinical treatments per 100 encounters in 2005–06 to 0.9 per 100 in 2011–12. Overall 
in 2011–12 PNs/AHWs provided 14.1% of all ‘other treatments’ recorded at the encounters, 
a significantly greater proportion than in 2005–06 (9.0%).  
Last year local injections/infiltrations had reverted to the 2005–06 level of about 41 per 100 
practice nurse involved encounters. In 2011–12 the rate decreased further to 36 per 100. This 
may be linked to the removal of the Medicare item number for immunisations in January 
2012. Check-ups by PNs/AHWs at GP-patient encounters doubled over the study period. 
International normalised ratio (INR) blood testing frequency more than tripled.  
In clinical treatments, PNs/AHWs carried out administrative procedures (excluding 
sickness certificates) at an ever increasing rate, rising from 0.7 per 100 PN/AHW-involved 
encounters in 2005–06, to 3.6 per 100 in 2011–12. Their provision of advice/education about 
medication also increased. 
There were significant increases in the rate at which PNs/AHWs were involved in 
management of check-ups, diabetes, atrial fibrillation/flutter and urinary tract infections. 
Some of these increases may well have been stimulated by the introduction of MBS item 
10997 for services provided to a person with a chronic disease, in 2007–08.  
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11 Referrals and admissions 
A referral is defined as the process by which the responsibility for part or all of the care of a 
patient is temporarily transferred to another health care provider. GPs were instructed only 
to record new referrals at the encounter (that is, not to record continuations). For each 
encounter, GPs could record up to two referrals, and each referral was linked by the GP to 
the problem(s) for which the patient was referred. Referrals included those to medical 
specialists, allied health services, hospitals for admission, emergency departments, and 
those to other services (including those to outpatient clinics and to other GPs). 
Data on referrals and admissions are reported for each of the most recent BEACH years 
from 2002–03 to 2011–12 in the ten-year report A decade of Australian general practice activity 
2002–03 to 2011–12.1  
11.1 Number of referrals and admissions 
Table 11.1 provides a summary of referrals and admissions, and the rates per 100 encounters 
and per 100 problems managed. The patient was given at least one referral at 13.3% of all 
encounters, and for 9.3% of all problems managed. 
There were 14,382 referrals made at a rate of 14.5 per 100 encounters, most often to medical 
specialists (8.6 per 100 encounters, 5.6 per 100 problems managed), followed by referrals to 
allied health services (4.7 per 100 encounters, 3.0 per 100 problems). Few patients were 
referred/admitted to hospital, or the emergency department. 
Table 11.1: Summary of referrals and admissions 
Variable Number 
Rate per 100 
encounters 
(n = 99,030) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 152,286) 
95% 
LCL 
95% 
UCL 
At least one referral(a) 13,219 13.3 12.8 13.8 9.3 9.0 9.7 
Referrals  14,382 14.5 13.9 15.1 9.4 9.1 9.8 
 Medical specialist* 8,488 8.6 8.2 8.9 5.6 5.3 5.8 
 Allied health services* 4,629 4.7 4.4 5.0 3.0 2.8 3.2 
 Hospital* 345 0.3 0.3 0.4 0.2 0.2 0.3 
 Emergency department* 311 0.3 0.3 0.4 0.2 0.2 0.2 
 Other referrals* 609 0.6 0.5 0.7 0.4 0.3 0.5 
Total referrals 14,382 14.5 13.9 15.1 9.4 9.1 9.8 
(a) At least one referral was given in the management of 14,228 problems at the 13,219 encounters.  
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.7, <purl.library.usyd.edu.au/sup/9781743320181>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
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11.2 Most frequent referrals 
Table 11.2 shows the medical specialists and allied health service groups to whom GPs most 
often referred patients. Referrals to medical specialists were most often to surgeons (9.8% of 
specialist referrals), orthopaedic surgeons (8.9%), and cardiologists (8.0%). The top ten 
specialists accounted for 65.3% of specialist referrals and for 42.3% of all referrals. 
Referrals to allied health services were most often to physiotherapists (28.2%), psychologists 
(19.2%), podiatrists/chiropodists (9.8%), dietitians/nutritionists (7.8%) and dentists (7.8%). 
The top ten allied health services accounted for 82.1% of allied health referrals and for 29.0% 
of all referrals. 
Table 11.2: Most frequent referrals, by type 
Professional/organisation Number 
Per cent 
of all 
referrals 
Per cent of 
referral group 
Rate per 100 
encounters 
(n = 99,030) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 152,286) 
95% 
LCL 
95% 
UCL 
Medical specialist* 8,488 64.7 100.0 8.6 8.2 8.9 5.6 5.3 5.8 
 Surgeon  832 6.3 9.8 0.8 0.8 0.9 0.5 0.5 0.6 
 Orthopaedic surgeon  756 5.8 8.9 0.8 0.7 0.8 0.5 0.4 0.5 
 Cardiologist  675 5.1 8.0 0.7 0.6 0.8 0.4 0.4 0.5 
 Dermatologist  665 5.1 7.8 0.7 0.6 0.7 0.4 0.4 0.5 
 Ophthalmologist  622 4.7 7.3 0.6 0.6 0.7 0.4 0.4 0.5 
 Gastroenterologist  522 4.0 6.2 0.5 0.5 0.6 0.3 0.3 0.4 
 Ear, nose and throat  462 3.5 5.4 0.5 0.4 0.5 0.3 0.3 0.3 
 Gynaecologist  453 3.5 5.3 0.5 0.4 0.5 0.3 0.3 0.3 
 Urologist  315 2.4 3.7 0.3 0.3 0.4 0.2 0.2 0.2 
 Neurologist  242 1.8 2.9 0.2 0.2 0.3 0.2 0.1 0.2 
 Subtotal: top ten medical  
 specialist referrals  5,545 42.3 65.3 — — — — — — 
Allied health services* 4,629 35.3 100.0 4.7 4.4 5.0 3.0 2.8 3.2 
 Physiotherapy  1,304 9.9 28.2 1.3 1.2 1.4 0.9 0.8 0.9 
 Psychologist  889 6.8 19.2 0.9 0.8 1.0 0.6 0.5 0.6 
 Podiatrist/chiropodist  454 3.5 9.8 0.5 0.4 0.5 0.3 0.3 0.3 
 Dietitian/nutritionist  360 2.7 7.8 0.4 0.3 0.4 0.2 0.2 0.3 
 Dentist  360 2.7 7.8 0.4 0.3 0.4 0.2 0.2 0.3 
 Optometrist  113 0.9 2.4 0.1 0.1 0.1 0.1 0.1 0.1 
 Exercise physiologist  90 0.7 2.0 0.1 0.1 0.1 0.1 0.0 0.1 
 Audiologist 84 0.6 1.8 0.1 0.1 0.1 0.1 0.0 0.1 
 Diabetes education  74 0.6 1.6 0.1 0.1 0.1 0.0 0.0 0.1 
 Counsellor  74 0.6 1.6 0.1 0.0 0.1 0.0 0.0 0.1 
 Subtotal: top ten allied  
 health referrals 3,801 29.0 82.1 — — — — — — 
Subtotal: all referrals listed 9,347 71.3 — — — — — — — 
Total allied health and 
medical specialist referrals 13,117 100.0 — 13.2 12.7 13.8 8.6 8.3 8.9 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.7, <purl.library.usyd.edu.au/sup/9781743320181>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
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11.3 Problems most frequently referred to a 
specialist 
The GP could link a single referral to multiple problems being managed at the encounter. 
Therefore, there are more problem–referral links than referrals. Table 11.3 shows the most 
common problems referred to a medical specialist, in decreasing frequency order of 
problem-referral links. 
The 8,488 referrals to a medical specialist were provided in management of 8,686 problems. 
The ten problems most often referred to a specialist accounted for only 20.0% of all 
problem–referral links, reflecting the breadth of problems referred to specialists. Diabetes 
accounted for 2.9% of problem-referral links, malignant skin neoplasm (2.6%), pregnancy 
(2.5%), and osteoarthritis (2.2%) (Table 11.3). The far right hand column of Table 11.3 shows 
the likelihood of referral to a medical specialist when each problem is managed. Malignant 
skin neoplasm resulted in a specialist referral at one in five (21.2%) GP contacts with this 
problem. This was followed by pregnancy (17.1%) and ischaemic heart disease (13.0%).  
Table 11.3: The ten problems most frequently referred to a medical specialist 
Problem managed Number 
Per cent of 
problem–referral 
links  
Rate per 100 
encounters 
(n = 99,030) 
95% 
LCL 
95% 
UCL 
Rate per 100 contacts 
with this problem(a) 
Diabetes – all* 251 2.9 0.3 0.2 0.3 6.1 
Malignant neoplasm skin 223 2.6 0.2 0.2 0.3 21.2 
Pregnancy* 221 2.5 0.2 0.2 0.3 17.1 
Osteoarthritis* 194 2.2 0.2 0.2 0.2 6.6 
Back complaint* 167 1.9 0.2 0.1 0.2 6.1 
Sleep disturbance 158 1.8 0.2 0.1 0.2 10.5 
Oesophageal disease 137 1.6 0.1 0.1 0.2 5.2 
Ischaemic heart disease* 136 1.6 0.1 0.1 0.2 13.0 
Abnormal test results* 131 1.5 0.1 0.1 0.2 11.2 
Depression* 117 1.3 0.1 0.1 0.1 2.7 
Subtotal: top ten problems 
referred to a medical specialist 1,735 20.0 — — — — 
Total problems referred to 
medical specialist  8,686 100.0 8.8 8.4 9.1 — 
(a) The proportion of GP contacts with this problem that was referred to a medical specialist. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781743320181>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
At a meeting of senior academic researchers at the 2011 North American Primary Care 
Research Group meeting in Canada, we identified an international paucity of information 
about what problems are referred by GPs to particular types of specialists. The following 
analyses goes some way to regressing this deficiency. 
When analysed by individual medical specialty, the top ten problems accounted for 39.9% of 
all referrals to surgeons (indicative of the broad range of conditions referred to them), and 
for 74.9% of all referrals to dermatologists, consistent with a more defined range (Tables 
11.3.1 to 11.3.10).  
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The two most common problems referred to a surgeon were inguinal hernia and 
haemorrhoids. Of the ten problems most commonly referred to a surgeon, the most likely to 
be referred at each GP contact with that problem were: inguinal hernia, cholecystitis and 
other abdominal hernia (Table 11.3.1).  
Table 11.3.1: The ten problems most frequently referred to a surgeon 
Problem managed Number 
Per cent of 
problems referred 
Rate per 100 contacts 
with this problem(a) 
Inguinal hernia 56 6.7 38.5 
Haemorrhoids 56 6.6 20.0 
Malignant neoplasm skin 43 5.1 4.1 
Cholecystitis/cholelithiasis 41 4.9 24.4 
Abdominal hernia, other 33 3.9 22.8 
Rectal bleeding 30 3.6 18.5 
Malignant neoplasm breast (female) 27 3.2 11.7 
Carpal tunnel syndrome 17 2.1 8.8 
Oesophageal disease 17 2.0 0.6 
Obesity (BMI > 30) 16 1.9 2.5 
Subtotal: top ten problems referred to a surgeon 337 39.9 — 
Total problems referred to a surgeon 844 100.0 — 
(a) The proportion of GP contacts with this problem that was referred to a surgeon.  
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781743320181>). 
Note: BMI – body mass index. 
The two most common problems referred to an orthopaedic surgeon were osteoarthritis and 
acute internal damage of the knee. Of the 10 problems most commonly referred to an 
orthopaedic surgeon, the most likely to be referred at each GP contact with that problem 
were: acute internal damage of the knee and knee symptom/complaint (Table 11.3.2).  
Table 11.3.2: The ten problems most frequently referred to an orthopaedic surgeon 
Problem managed Number 
Per cent of 
problems referred 
 Rate per 100 contacts 
with this problem(a) 
Osteoarthritis* 165 21.6  5.6 
Acute internal damage knee 86 11.3  27.6 
Injury musculoskeletal NOS 63 8.2  6.9 
Fracture* 48 6.3  5.3 
Sprain/strain* 39 5.2  2.8 
Bursitis/tendonitis/synovitis NOS 39 5.1  3.5 
Knee symptom/complaint 36 4.7  12.6 
Back complaint* 35 4.6  1.3 
Shoulder syndrome 31 4.1  5.9 
Musculoskeletal disease, other 17 2.2  3.7 
Subtotal: top ten problems referred to an orthopaedic surgeon 559 73.3  — 
Total problems referred to an orthopaedic surgeon 763 100.0  — 
(a) The proportion of GP contacts with this problem that was referred to an orthopaedic surgeon. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781743320181>). 
Note: NOS – not otherwise specified. 
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The two most common problems referred to a cardiologist were ischaemic heart disease and 
atrial fibrillation/flutter. Of the 10 problems most commonly referred, the most likely to be 
referred at each GP contact with that problem were: palpitations and heart disease (not 
otherwise specified), (apart from GP contact specifically for referral) (Table 11.3.3). 
Table 11.3.3: The ten problems most frequently referred to a cardiologist 
Problem managed Number 
Per cent of 
problems referred 
 Rate per 100 contacts 
with this problem(a) 
Ischaemic heart disease* 133 18.8  12.8 
Atrial fibrillation/flutter 72 10.1  5.2 
Hypertension* 57 8.1  0.6 
Chest pain NOS 42 5.9  16.5 
Heart failure 41 5.8  7.3 
Palpitations/awareness of heart 40 5.6  19.3 
Heart disease, other 38 5.4  18.4 
Refer physician/specialist/clinic/hospital cardiovascular 26 3.6  63.4 
Cardiac arrhythmia NOS 19 2.7  17.7 
Heart valve disease NOS 17 2.3  16.8 
Subtotal: top ten problems referred to a cardiologist 485 68.4  — 
Total problems referred to a cardiologist 709 100.0  — 
(a) The proportion of GP contacts with this problem that was referred to a cardiologist. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781743320181>). 
Note: NOS – not otherwise specified.  
The two most common problems referred to a dermatologist were malignant neoplasm of 
skin and contact/allergic dermatitis. Of the 10 problems most commonly referred to a 
dermatologist, the most likely to be referred at each GP contact with that problem were: skin 
check-up, rash and malignant neoplasm of skin (Table 11.3.4).  
Table 11.3.4: The ten problems most frequently referred to a dermatologist 
Problem managed Number 
Per cent of 
problems referred 
 Rate per 100 contacts 
with this problem(a) 
Malignant neoplasm skin 102 15.1  9.7 
Dermatitis, contact/allergic 71 10.5  3.9 
Solar keratosis/sunburn 68 10.2  6.5 
Skin symptom/complaint, other 57 8.4  9.0 
Skin check-up* 46 6.9  9.9 
Skin disease, other 37 5.5  4.8 
Acne 36 5.4  8.7 
Naevus/mole 35 5.1  8.8 
Rash* 26 3.9  9.8 
Psoriasis 26 3.9  9.6 
Subtotal: top ten problems referred to a dermatologist 504 74.9  — 
Total problems referred to a dermatologist 673 100.0  — 
(a) The proportion of GP contacts with this problem that was referred to a dermatologist. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781743320181>). 
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The two most common problems referred to an ophthalmologist were diabetes and cataract. 
Of the ten problems most commonly referred to an ophthalmologist, the most likely to be 
referred at each GP contact with that problem were: visual disturbance (not otherwise 
specified), cataract, refractive error and macular degeneration (apart from GP contact 
specifically for referral) (Table 11.3.5).  
Table 11.3.5: The ten problems most frequently referred to an ophthalmologist 
Problem managed Number 
Per cent of 
problems referred 
 Rate per 100 contacts 
with this problem(a) 
Diabetes – all* 98 15.5  2.4 
Cataract 81 12.8  54.0 
Glaucoma 53 8.3  28.3 
Visual disturbance, other 48 7.6  54.2 
Eye/adnexa disease, other 31 4.9  15.6 
Macular degeneration 28 4.4  49.9 
Blepharitis/stye/chalazion 26 4.1  10.6 
Refractive error 21 3.4  52.3 
Refer physician/specialist/clinic/hospital, eye 18 2.8  70.8 
Conjunctivitis, infectious 17 2.7  2.7 
Subtotal: top 10 problems referred to an ophthalmologist 420 66.3  — 
Total problems referred to an ophthalmologist 633 100.0  — 
(a) The proportion of GP contacts with this problem that was referred to an ophthalmologist. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781743320181>). 
The two most common problems referred to a gastroenterologist were oesophageal disease 
and rectal bleeding. Of the ten problems most commonly referred to a gastroenterologist, the 
most likely to be referred at each GP contact with that problem were: rectal bleeding and 
digestive neoplasm (benign or uncertain) (Table 11.3.6).  
Table 11.3.6: The ten problems most frequently referred to a gastroenterologist 
Problem managed Number 
Per cent of 
problems referred 
 Rate per 100 contacts 
with this problem(a) 
Oesophageal disease 88 16.4  3.3 
Rectal bleeding 40 7.6  24.8 
Irritable bowel syndrome 26 4.8  9.1 
Benign/uncertain neoplasm digestive 26 4.8  23.5 
Abdominal pain* 23 4.2  3.7 
Viral hepatitis 21 4.0  13.6 
Risk factor NOS 20 3.8  5.1 
Chronic enteritis/ulcerative colitis 19 3.6  12.9 
Diarrhoea 18 3.4  6.3 
Disease digestive system, other 17 3.2  6.5 
Subtotal: top ten problems referred to a gastroenterologist 298 55.8  — 
Total problems referred to a gastroenterologist 535 100.0  — 
(a) The proportion of GP contacts with this problem that was referred to a gastroenterologist. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781743320181>). 
Note: NOS – not otherwise specified. 
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The two most common problems referred to an ear, nose, and throat (ENT) specialist were 
sinusitis and tonsillitis. Of the ten problems most commonly referred to an ENT specialist, 
the most likely to be referred at each GP contact with that problem were: tinnitus and nose 
bleed (Table 11.3.7).  
Table 11.3.7: The ten problems most frequently referred to an ear, nose, and throat (ENT) specialist 
Problem managed Number 
Per cent of 
problems referred 
 Rate per 100 contacts 
with this problem(a) 
Sinusitis  33 7.1  2.8 
Tonsillitis* 33 7.1  3.7 
Nose bleed/epistaxis 27 5.8  24.5 
Otitis externa 21 4.5  3.7 
Upper respiratory infection 20 4.4  0.3 
Throat symptom/complaint 20 4.2  14.1 
Tinnitus, ringing/buzzing ear 20 4.2  25.7 
Acute otitis media/myringitis 19 4.1  1.9 
Respiratory disease, other 15 3.2  7.7 
Hearing complaint NEC 14 3.0  15.4 
Subtotal: top 10 problems referred to an ENT specialist 223 47.7  — 
Total problems referred to an ENT specialist  467 100.0  — 
(a) The proportion of GP contacts with this problem that was referred to an ENT specialist. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781743320181>). 
Note: NEC – not elsewhere classified; ENT – ear, nose and throat. 
The two most common problems referred to a gynaecologist were menstrual problems and 
female genital disease (not otherwise specified). Of the 10 problems most commonly 
referred to a gynaecologist, the most likely to be referred at each GP contact with that 
problem were: postmenopausal bleeding and uterovaginal prolapse (Table 11.3.8).  
Table 11.3.8: The problems most frequently referred to a gynaecologist 
Problem managed Number 
Per cent of 
problems referred 
 Rate per 100 contacts 
with this problem(a) 
Menstrual problems* 64 13.8  9.6 
Female genital disease, other  50 10.8  25.0 
Abnormal test results* 35 7.6  3.0 
Uterovaginal prolapse 27 5.8  38.9 
Female genital check-up* 18 3.8  1.1 
Female genital symptom/complaint, other  18 3.8  20.6 
Menopausal symptom/complaint 16 3.5  2.3 
Female infertility/subfertility  16 3.4  18.6 
Postmenopausal bleeding 15 3.2  39.1 
Endocrine/metabolic/nutritional disease, other 13 2.8  2.3 
Subtotal: top ten problems referred to a gynaecologist 272 58.4  — 
Total problems referred to a gynaecologist 465 100.0  — 
(a) The proportion of GP contacts with this problem that was referred to a gynaecologist. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781743320181>). 
106
  
The two problems most commonly referred to a urologist were benign prostatic 
hypertrophy and haematuria. Of the ten problems most often referred, those most likely to 
be referred at each GP contact with that problem were: malignant neoplasm of the bladder, 
haematuria, urinary calculus and benign prostatic hypertrophy (Table 11.3.9).  
Table 11.3.9: The ten problems most frequently referred to an urologist 
Problem managed Number 
Per cent of 
problems referred 
 Rate per 100 contacts 
with this problem(a) 
Benign prostatic hypertrophy 47 14.5  18.7 
Haematuria 31 9.7  21.7 
Abnormal test results* 30 9.3  2.6 
Malignant neoplasm prostate 28 8.6  8.2 
Urinary calculus 16 4.9  19.9 
Malignant neoplasm bladder 14 4.3  40.5 
Urinary frequency/urgency 12 3.7  9.7 
Urinary tract infection* 10 3.0  0.6 
Prostate symptom/complaint 9 2.9  11.2 
Urinary disease, other 9 2.7  11.7 
Subtotal: top 10 problems referred to a urologist 205 63.5  — 
Total problems referred to a urologist 323 100.0  — 
(a) The proportion of GP contacts with this problem that was referred to a urologist. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781743320181>). 
The two problems most commonly referred to a neurologist were epilepsy and carpal tunnel 
syndrome. Of the 10 problems most commonly referred to a neurologist, the most likely to 
be referred at each GP contact with that problem were: convulsions/seizures and tingling of 
fingers/toes (Table 11.3.10).  
Table 11.3.10: The ten problems most frequently referred to a neurologist 
Problem managed Number 
Per cent of 
problems referred 
 Rate per 100 contacts 
with this problem(a) 
Epilepsy 25 10.1  8.6 
Carpal tunnel syndrome 21 8.5  10.5 
Migraine 16 6.5  2.5 
Vertigo/dizziness 16 6.4  4.4 
Parkinsonism 12 4.8  7.3 
Neurological disease, other 10 4.2  4.0 
Peripheral neuritis/neuropathy 10 3.9  3.1 
Convulsions/seizures 9 3.8  20.3 
Tingling fingers/feet/toes 8 3.2  16.1 
Headache 8 3.2  2.7 
Subtotal: top 10 problems referred to a neurologist 134 54.6  — 
Total problems referred to a neurologist 245 100.0  — 
(a) The proportion of GP contacts with this problem that was referred to a neurologist. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781743320181>). 
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11.4 Problems most frequently referred to allied 
health services and hospitals  
The 4,629 referrals to an allied health service were provided in the management of 4,853 
problems. The ten most common referred problems accounted for 46.0% of all problem–
referral links. Depression was the problem accounting for the largest proportion of allied 
health referrals (10.6%), followed by diabetes (7.1%), back complaints (6.4%) and anxiety 
(4.2%). However, of the ten most common problems, the most likely to be referred to an 
allied health service was teeth/gum disease, referred at 27.8% all GP contacts with this 
problem (Table 11.4).  
Table 11.4: The ten problems most frequently referred to allied health services 
Problem managed Number 
Per cent of 
problem–
referral links  
Rate per 100 
encounters 
(n = 99,030) 
95% 
LCL 
95% 
UCL 
Rate per 100 
contacts with 
this problem(a) 
Depression* 515 10.6 0.5 0.5 0.6 11.8 
Diabetes – all*  342 7.1 0.3 0.3 0.4 8.3 
Back complaint* 310 6.4 0.3 0.3 0.4 11.3 
Anxiety*  205 4.2 0.2 0.2 0.2 10.8 
Sprain/strain* 199 4.1 0.2 0.2 0.2 14.1 
Osteoarthritis* 171 3.5 0.2 0.1 0.2 5.8 
Administrative procedure NOS 153 3.2 0.2 0.1 0.2 13.1 
Teeth/gum disease 138 2.8 0.1 0.1 0.2 27.8 
Bursitis/tendonitis/synovitis NOS  117 2.4 0.1 0.1 0.1 10.4 
Acute stress reaction 82 1.7 0.1 0.1 0.1 11.2 
Subtotal: top ten problems referred to AHS 2,234 46.0 — — — — 
Total problems referred to AHS  4,853 100.0 4.9 4.6 5.2 — 
(a) The proportion of GP contacts with this problem that was referred to allied health services. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <purl.library.usyd.edu.au/sup/9781743320181>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified; AHS – allied health service. 
The 345 referrals to a hospital were provided in the management of 354 problems.  
The ten problems most frequently referred to hospital are shown in Table 11.5. Pregnancy 
accounted for the highest proportion (6.5%) of these referrals, but appendicitis was the 
problem most likely to be referred (20.8%).  
The 311 referrals to an emergency department were provided in the management of 
316 problems. The ten problems most frequently referred to an emergency department are 
shown in Table 11.6. Fracture accounted for the highest proportion (8.4%) of these referrals, 
but appendicitis was the problem most likely to be referred (23.6%). 
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Table 11.5: The ten problems most frequently referred to hospital 
Problem managed Number 
Per cent of 
problems 
referred 
Rate per 100 
encounters 
(n = 99,030) 
95% 
LCL 
95% 
UCL 
Rate per 100 
contacts with 
this problem(a) 
Pregnancy*  23 6.5 0.02 0.01 0.04 1.8 
Fracture* 15 4.3 0.02 0.01 0.03 1.7 
Appendicitis 10 3.0 0.01 0.00 0.02 20.8 
Atrial fibrillation/flutter 8 2.3 0.01 0.00 0.02 0.6 
Depression* 8 2.3 0.01 0.00 0.01 0.2 
Ischaemic heart disease* 8 2.2 0.01 0.00 0.01 0.7 
Anaemia* 8 2.1 0.01 0.00 0.01 1.4 
Skin infection, other 7 2.0 0.01 0.00 0.01 2.2 
Chest pain NOS 6 1.8 0.01 0.00 0.01 2.5 
Gastroenteritis* 6 1.7 0.01 0.00 0.01 0.4 
Subtotal: top ten problems referred for 
admission 100 28.1 — — — — 
Total problems referred to hospital 354 100.0 0.36 0.29 0.42 — 
(a) The proportion of GP contacts with this problem that was referred to hospital. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <purl.library.usyd.edu.au/sup/9781743320181>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified. 
Table 11.6: The ten problems most frequently referred to an emergency department 
Problem managed Number 
Per cent of 
problems 
referred 
Rate per 100 
encounters 
(n = 99,030) 
95% 
LCL 
95% 
UCL 
Rate per 100 
contacts with 
this problem(a) 
Fracture* 26 8.4 0.03 0.01 0.04 2.9 
Chest pain NOS 12 3.9 0.01 0.00 0.02 4.9 
Appendicitis 12 3.8 0.01 0.00 0.02 23.6 
Pneumonia 12 3.8 0.01 0.01 0.02 4.3 
Ischaemic heart disease* 10 3.0 0.01 0.00 0.02 0.9 
Acute bronchitis/bronchiolitis 9 3.0 0.01 0.00 0.02 0.4 
Boil/carbuncle 8 2.6 0.01 0.00 0.02 1.5 
Abdominal pain* 8 2.4 0.01 0.00 0.01 1.2 
Dehydration 6 2.0 0.01 0.00 0.01 14.8 
Foreign body in skin 5 1.7 0.01 0.00 0.01 6.4 
Subtotal: top ten problems referred to 
emergency department 109 34.5 — — — — 
Total problems referred to emergency 
department 316 100.0 0.32 0.27 0.37 — 
(a) The proportion of GP contacts with this problem that was referred to an emergency department. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <purl.library.usyd.edu.au/sup/9781743320181>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified. 
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11.5 Changes in referrals over the decade 
2002–03 to 2011–12 
An overview of changes in referrals over the decade can be found in Chapter 11 of the 
companion report A decade of Australian general practice activity 2002–03 to 2011–12.1 In that 
report, changes over time are discussed in terms of change in the management of problems 
(that is, as a rate per 100 problems managed). This reflects change in how GPs are managing 
problems, and accounts for the significant increase in the number of problems managed per 
encounter over the decade (see Section 7.9).  
In summary, over the ten years there was a significant increase in the proportion of 
problems that were referred to other health providers: in 2002–03 at least one referral was 
made in the management of 7.7% of problems and this increased to 9.3% of problems 
managed in 2011–12.  
Referrals to medical specialists remained almost stable at 5.3 and 5.6 per 100 problems 
managed, with a small but significant increase in referrals to cardiologists, and a significant 
decrease in referrals to gynaecologists. However, referrals to allied health services almost 
doubled, from 1.7 to 3.0 per 100 problems managed. This was reflected in significant 
increases in referral rates per 100 problems, to psychologists, podiatrists or chiropodists, 
dietitians or nutritionists, and dentists. 
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12 Investigations 
The GPs participants were asked to record (in free text) any pathology, imaging or other 
tests ordered or undertaken at the encounter, and to nominate the patient problem(s) 
associated with each test order placed. This allows the linkage of test orders to a single 
problem or multiple problems. Up to five orders for pathology, and two for imaging and 
other tests could be recorded at each encounter. A single test may have been ordered for the 
management of multiple problems, and multiple tests may have been used in the 
management of a single problem. 
A pathology test order may be for a single test (for example, Pap smear, HbA1c) or for a 
battery of tests (for example, lipids, full blood count). Where a battery of tests was ordered, 
the battery name was recorded rather than each individual test. GPs also recorded the body 
site for any imaging ordered (for example, x-ray chest, CT head). 
Data on investigations are reported for each year from 2002–03 to 2011–12 in the ten-year 
report A decade of Australian general practice activity 2002–03 to 2011–12.1  
12.1 Number of investigations 
Table 12.1 shows the number of encounters and problems at which a pathology or imaging 
test was ordered. There were no tests recorded at three-quarters (75.7%) of encounters. 
At least one pathology test order was recorded at 18.1% of encounters (for 13.6% of 
problems managed), and at least one imaging test was ordered at 8.6% of encounters (for 
5.8% of problems managed). 
Table 12.1: Number of encounters and problems for which pathology or imaging was ordered 
Pathology/imaging test 
ordered 
Number of 
encounters  
Per cent of 
encounters 
(n = 99,030) 
95% 
LCL 
95% 
UCL 
Number of 
problems 
Per cent of 
problems 
(n = 152,286) 
95% 
LCL 
95% 
UCL 
Pathology and imaging ordered 2,430 2.5 2.3 2.6 1,772 1.2 1.1 1.3 
Pathology only ordered 15,464 15.6 15.1 16.2 18,930 12.4 12.0 12.9 
Imaging only ordered 6,132 6.2 5.9 6.4 7,116 4.7 4.5 4.9 
No pathology or imaging tests 
ordered 
75,004 75.7 75.0 76.5 124,467 81.7 81.2 82.3 
At least one pathology ordered 17,894 18.1 17.4 18.7 20,702 13.6 13.1 14.1 
At least one imaging ordered 8,562 8.6 8.3 9.0 8,888 5.8 5.6 6.1 
At least one other investigation 
ordered 
861 0.9 0.8 1.0 888 0.6 0.5 0.6 
At least one other investigation 
performed in the practice 
1,455 1.5 1.3 1.6 1,465 1.0 0.9 1.1 
At least one other investigation 
ordered or performed 
2,263 2.3 2.1 2.5 2,302 1.5 1.4 1.6 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
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12.2 Pathology ordering 
A report on changes in pathology ordering by GPs from 1998 to 2001 was produced in 
2003.19 A review of GP pathology orders in the National Health Priority Areas and other 
selected problems between 2000 and 2008 is reported in General practice in Australia, health 
priorities and policies 1998 to 2008.16 A report Evidence-practice gap in pathology test ordering: a 
comparison of BEACH pathology data and recommended testing was produced by the FMRC for 
the Australian Government Quality Use of Pathology Program in June 2009.18 Readers may 
wish to consider those reports in conjunction with the information presented below.  
Nature of pathology orders at encounter 
The GPs recorded 46,544 orders for pathology tests/batteries of tests, at a rate of 47.0 per 
100 encounters or 30.6 per 100 problems managed. The pathology tests recorded were 
grouped according to the categories set out in Appendix 4, Table A4.8. The main pathology 
groups reflect those used in the Medicare Benefits Schedule (MBS).84  
The distribution of pathology tests by MBS group, and the most common tests within each 
group are presented in Table 12.2. Each group and individual test is expressed as a 
proportion of all pathology tests, as a proportion of the group, as a rate per 100 encounters 
and as a rate per 100 problems managed with 95% confidence limits. 
Test orders classed as chemistry accounted for more than half the pathology test orders, the 
most common being: lipid tests, for which there were 4.4 orders per 100 encounters and 
2.9 per 100 problems; electrolytes, urea and creatinine (3.2; 2.1); multibiochemical analysis 
(2.9; 1.9); and thyroid function tests (2.7; 1.7). Haematology tests accounted for 18.0% of all 
pathology including the most frequently ordered individual pathology test, full blood count, 
at 14.1% of all pathology and 6.6 orders per 100 encounters and 4.3 per 100 problems 
managed. Microbiology accounted for 13.2% of pathology orders, with urine microscopy, 
culture and sensitivity being the most frequent in the group at 1.9 tests per 100 encounters 
and 1.3 per 100 problems managed. 
Table 12.2: Pathology orders by MBS pathology groups and most frequent individual test orders 
within group 
Pathology test ordered Number 
Per cent  
of all 
pathology  
Per cent  
of group 
Rate per 100 
encounters 
(n = 99,030) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 152,286 
95% 
LCL 
95% 
UCL 
Chemistry*  27,348 58.8 100.0 27.6 26.1 29.1 18.0 17.1 18.8 
 Lipids* 4,341 9.3 15.9 4.4 4.0 4.7 2.9 2.6 3.1 
 Electrolytes, urea and creatinine* 3,170 6.8 11.6 3.2 2.9 3.5 2.1 1.9 2.3 
 Multi-biochemical analysis* 2,861 6.1 10.5 2.9 2.6 3.2 1.9 1.7 2.1 
 Thyroid function* 2,632 5.7 9.6 2.7 2.5 2.8 1.7 1.6 1.8 
 Liver function* 2,615 5.6 9.6 2.6 2.4 2.9 1.7 1.6 1.9 
 Glucose/glucose tolerance* 2,578 5.5 9.4 2.6 2.4 2.8 1.7 1.6 1.8 
 Chemistry; other* 1,547 3.3 5.7 1.6 1.4 1.7 1.0 0.9 1.1 
 HbA1c* 1,368 2.9 5.0 1.4 1.2 1.5 0.9 0.8 1.0 
 Ferritin* 1,278 2.7 4.7 1.3 1.2 1.4 0.8 0.8 0.9 
 Prostate specific antigen* 946 2.0 3.5 1.0 0.9 1.1 0.6 0.6 0.7 
(continued) 
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Table 12.2 (continued): Pathology orders by MBS pathology groups and most frequent individual 
test orders within group 
Pathology test ordered Number 
Per cent  
of all 
pathology  
Per cent  
of group 
Rate per 100 
encounters 
(n = 99,030) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 152,286) 
95% 
LCL 
95% 
UCL 
 C reactive protein  911 2.0 3.3 0.9 0.8 1.0 0.6 0.5 0.7 
 Calcium/phosphate/magnesium* 880 1.9 3.2 0.9 0.8 1.0 0.6 0.5 0.6 
Haematology*  8,385 18.0 100.0 8.5 8.0 8.9 5.5 5.2 5.8 
 Full blood count*  6,578 14.1 78.4 6.6 6.3 7.0 4.3 4.1 4.6 
 Coagulation*  797 1.7 9.5 0.8 0.7 0.9 0.5 0.4 0.6 
 ESR 794 1.7 9.5 0.8 0.7 0.9 0.5 0.5 0.6 
Microbiology*  6,148 13.2 100.0 6.2 5.9 6.6 4.0 3.8 4.3 
 Urine M,C&S* 1,913 4.1 31.1 1.9 1.8 2.1 1.3 1.2 1.3 
 Microbiology; other* 938 2.0 15.3 0.9 0.9 1.0 0.6 0.6 0.7 
 Hepatitis serology* 440 0.9 7.2 0.4 0.4 0.5 0.3 0.2 0.3 
 Faeces M,C&S* 407 0.9 6.6 0.4 0.4 0.5 0.3 0.2 0.3 
 Chlamydia* 340 0.7 5.5 0.3 0.3 0.4 0.2 0.2 0.3 
 Vaginal swab M,C&S* 336 0.7 5.5 0.3 0.3 0.4 0.2 0.2 0.3 
 Venereal disease* 275 0.6 4.5 0.3 0.2 0.3 0.2 0.1 0.2 
 H Pylori* 232 0.5 3.8 0.2 0.2 0.3 0.2 0.1 0.2 
Cytopathology*  1,699 3.7 100.0 1.7 1.5 1.9 1.1 1.0 1.2 
 Pap smear*  1,662 3.6 97.8 1.7 1.5 1.9 1.1 1.0 1.2 
Other NEC*  909 2.0 100.0 0.9 0.7 1.1 0.6 0.5 0.7 
 Blood test  444 1.0 48.8 0.4 0.3 0.6 0.3 0.2 0.4 
 Other test NEC 256 0.6 28.2 0.3 0.2 0.3 0.2 0.1 0.2 
Tissue pathology*  781 1.7 100.0 0.8 0.7 0.9 0.5 0.4 0.6 
 Histology; skin 699 1.5 89.5 0.7 0.6 0.8 0.5 0.4 0.5 
Immunology*  790 1.7 100.0 0.8 0.7 0.9 0.5 0.5 0.6 
 Immunology, other* 433 0.9 54.8 0.4 0.4 0.5 0.3 0.2 0.3 
 Anti-nuclear antibodies 139 0.3 17.6 0.1 0.1 0.2 0.1 0.1 0.1 
 Rheumatoid factor 112 0.2 14.2 0.1 0.1 0.1 0.1 0.1 0.1 
Simple tests*  252 0.5 100.0 0.3 0.2 0.3 0.2 0.1 0.2 
Infertility/pregnancy* 234 0.5 100.0 0.2 0.2 0.3 0.2 0.1 0.2 
Total pathology tests  46,544 100.0 — 47.0 44.9 49.1 30.6 29.3 31.8 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.8, <purl.library.usyd.edu.au/sup/9781743320181>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; ESR – Erythrocyte sedimentation rate; M,C&S – microscopy, culture and 
sensitivity; H Pylori – test for Helicobacter pylori infection; NEC – not elsewhere classified. 
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Problems for which pathology tests were ordered 
Table 12.3 describes the problems for which pathology was commonly ordered, in 
decreasing frequency order of problem–pathology combinations. Diabetes, accounting for 
8.3% of all problem–pathology combinations, followed by hypertension, general check-ups 
and lipid disorder were the most common problems for which pathology tests were 
ordered. The two right-hand columns show the proportion of each problem that resulted in 
a pathology order, and the rate of pathology tests/batteries of tests per 100 specified 
problems when at least one test is ordered. For example, 32.7% of contacts with diabetes 
resulted in pathology orders, and when pathology was ordered for diabetes, 300 
tests/batteries of tests were ordered per 100 diabetes contacts that resulted in a pathology 
test order. In contrast, only 12.0% of contacts with hypertension problems resulted in a 
pathology test, but the resulting test orders accounted for almost as many tests (6.5%) as  
did diabetes (8.3%). 
Table 12.3: The ten problems for which pathology was most frequently ordered 
Problem managed 
Number of 
problems 
Number of 
problem–
pathology 
combinations(a) 
Per cent of 
problem–
pathology 
combinations(a) 
Per cent of 
problems with 
test(b) 
Rate of pathology 
orders per 100 
problems with 
pathology(c) 
Diabetes – all* 4,123 4,038 8.3 32.7 299.7 
Hypertension* 8,971 3,173 6.5 12.0 295.4 
General check-up* 2,757 2,684 5.5 27.9 349.4 
Lipid disorder 3,463 2,234 4.6 26.7 241.7 
Female genital check-up/ 
Pap smear*  
1,661 1,630 3.3 79.8 122.9 
Weakness/tiredness 599 1,532 3.1 64.2 398.2 
Urinary tract infection* 1,686 1,079 2.2 54.3 117.8 
Abnormal test results* 1,171 1,044 2.1 51.6 172.9 
Pregnancy* 1,287 1,029 2.1 36.8 217.2 
Blood test NOS 314 877 1.8 80.7 345.9 
Subtotal 26,032 19,320 39.6 — — 
Total problems 152,286 48,795 100.0 13.6 235.7 
(a) A test was counted more than once if it was ordered for the management of more than one problem at an encounter. There were 46,544 
pathology test orders and 48,795 problem–pathology combinations. 
(b) The percentage of total contacts with the problem that generated at least one order for pathology. 
(c) The rate of pathology orders placed per 100 problem contacts with at least one order for pathology. 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <purl.library.usyd.edu.au/sup/9781743320181>). 
Note: NOS – not otherwise specified. 
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12.3 Imaging ordering 
Readers wanting a more detailed study of imaging orders should consult the comprehensive 
report on imaging orders by GPs in Australia in 1999–00, by the FMRC using BEACH data, 
and published by the AIHW and the University of Sydney in 2001.85 
Nature of imaging orders at encounter 
There were 9,978 imaging test orders recorded, at a rate of 10.1 per 100 encounters and 6.6 
per 100 problems managed.  
The distribution of imaging tests by MBS group, and the most common tests within each 
group are presented in Table 12.4. Each group and individual test is expressed as a 
percentage of all imaging tests, as a percentage of the group, as a rate per 100 encounters, 
and as a rate per 100 problems with 95% confidence limits. Diagnostic radiology accounted 
for almost half (45.6%) of all imaging test orders, and ultrasound accounted for 39.4%. 
Table 12.4: Imaging orders by MBS imaging groups and the most frequent imaging tests ordered 
within group 
Imaging test ordered Number 
Per cent of 
all imaging  
 Per cent of 
group 
Rate per 100 
encounters 
(n = 99,030) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 152,286) 
95% 
LCL 
95% 
UCL 
Diagnostic radiology* 4,547 45.6 100.0 4.6 4.3 4.9 3.0 2.8 3.2 
 X-ray; chest 959 9.6 21.1 1.0 0.9 1.1 0.6 0.6 0.7 
 X-ray; knee 489 4.9 10.8 0.5 0.4 0.5 0.3 0.3 0.4 
 Mammography; female 284 2.9 6.2 0.3 0.2 0.3 0.2 0.2 0.2 
 X-ray; hip  272 2.7 6.0 0.3 0.2 0.3 0.2 0.2 0.2 
 Test; densitometry  266 2.7 5.9 0.3 0.2 0.3 0.2 0.1 0.2 
 X-ray; shoulder 252 2.5 5.5 0.3 0.2 0.3 0.2 0.1 0.2 
 X-ray; foot/feet 246 2.5 5.4 0.2 0.2 0.3 0.2 0.1 0.2 
 X-ray; ankle 169 1.7 3.7 0.2 0.1 0.2 0.1 0.1 0.1 
 X-ray; wrist  163 1.6 3.6 0.2 0.1 0.2 0.1 0.1 0.1 
 X-ray; spine; lumbar  144 1.4 3.2 0.1 0.1 0.2 0.1 0.1 0.1 
 X-ray; hand 124 1.2 2.7 0.1 0.1 0.2 0.1 0.1 0.1 
 X-ray; finger(s)/thumb 108 1.1 2.4 0.1 0.1 0.1 0.1 0.1 0.1 
 X-ray; abdomen  104 1.0 2.3 0.1 0.1 0.1 0.1 0.0 0.1 
 X-ray; spine; cervical 85 0.9 1.9 0.1 0.1 0.1 0.1 0.0 0.1 
 X-ray; spine; lumbosacral 84 0.8 1.8 0.1 0.1 0.1 0.1 0.0 0.1 
 X-ray; ribs 69 0.7 1.5 0.1 0.0 0.1 0.0 0.0 0.1 
Ultrasound* 3,936 39.4 100.0 4.0 3.8 4.2 2.6 2.5 2.7 
 Ultrasound; pelvis 646 6.5 16.4 0.7 0.6 0.7 0.4 0.4 0.5 
 Ultrasound; shoulder  462 4.6 11.7 0.5 0.4 0.5 0.3 0.3 0.3 
 Ultrasound; abdomen 388 3.9 9.9 0.4 0.3 0.4 0.3 0.2 0.3 
 Ultrasound; breast; female 265 2.7 6.7 0.3 0.2 0.3 0.2 0.1 0.2 
 Ultrasound; obstetric 258 2.6 6.6 0.3 0.2 0.3 0.2 0.1 0.2 
(continued) 
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Table 12.4 (continued): Imaging orders by MBS imaging groups and the most frequent imaging 
tests ordered within group  
Imaging test ordered Number 
Per cent of 
all imaging  
 Per cent of 
group 
Rate per 100 
encounters 
(n = 99,030) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 152,286) 
95% 
LCL 
95% 
UCL 
 Echocardiography 153 1.5 3.9 0.2 0.1 0.2 0.1 0.1 0.1 
 Ultrasound; leg  134 1.3 3.4 0.1 0.1 0.2 0.1 0.1 0.1 
 Test; Doppler 133 1.3 3.4 0.1 0.1 0.2 0.1 0.1 0.1 
 Ultrasound; kidney 127 1.3 3.2 0.1 0.1 0.2 0.1 0.1 0.1 
 Ultrasound; hip  94 0.9 2.4 0.1 0.1 0.1 0.1 0.0 0.1 
 Ultrasound; scrotum  90 0.9 2.3 0.1 0.1 0.1 0.1 0.0 0.1 
 Ultrasound; thyroid 89 0.9 2.3 0.1 0.1 0.1 0.1 0.0 0.1 
 Ultrasound; abdomen; upper 85 0.9 2.2 0.1 0.1 0.1 0.1 0.0 0.1 
 Ultrasound; foot/toe(s)  82 0.8 2.1 0.1 0.1 0.1 0.1 0.0 0.1 
Computerised tomography* 1,163 11.7 100.0 1.2 1.1 1.3 0.8 0.7 0.8 
 CT scan; brain 180 1.8 15.5 0.2 0.1 0.2 0.1 0.1 0.1 
 CT scan; abdomen  168 1.7 14.4 0.2 0.1 0.2 0.1 0.1 0.1 
 CT scan; spine; lumbar 135 1.4 11.6 0.1 0.1 0.2 0.1 0.1 0.1 
 CT scan; head  94 0.9 8.1 0.1 0.1 0.1 0.1 0.0 0.1 
 CT scan; chest  89 0.9 7.7 0.1 0.1 0.1 0.1 0.0 0.1 
 CT scan; spine; lumbosacral  78 0.8 6.7 0.1 0.1 0.1 0.1 0.0 0.1 
 CT scan; sinus 59 0.6 5.1 0.1 0.0 0.1 0.0 0.0 0.1 
Magnetic resonance imaging* 228 2.3 100.0 0.2 0.2 0.3 0.1 0.1 0.2 
Nuclear medicine* 105 1.0 100.0 0.1 0.1 0.1 0.1 0.1 0.1 
Total imaging tests 9,978 100.0 — 10.1 9.6 10.5 6.6 6.3 6.8 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.9 <purl.library.usyd.edu.au/sup/9781743320181>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; CT – computerised tomography. 
Problems for which imaging tests were ordered 
Table 12.5 lists the problems for which imaging was commonly ordered, in decreasing 
frequency order of problem–imaging combinations. Osteoarthritis accounted for 5.3% of all 
orders, this was followed by back complaint (4.8%), and musculoskeletal injury (3.6%). The 
two right-hand columns show the proportion of each problem that resulted in an imaging 
test, and the rate of imaging tests per 100 specified problems when at least one test was 
ordered. For example, 35.6% of contacts with fractures resulted in an imaging test, and 106.6 
tests were ordered per 100 fracture contacts when at least one test had been ordered. 
116
  
 
Table 12.5: The ten problems for which an imaging test was most frequently ordered 
Problem managed 
Number of 
problems 
Number of  
problem–imaging 
 combinations(a) 
Per cent of 
problem–imaging 
combinations 
Per cent  
of problems 
with test(b) 
Rate of imaging 
orders per 100 
problems with 
imaging(c) 
Osteoarthritis* 2,924 531 5.3 15.4 118.0 
Back complaint* 2,756 480 4.8 15.3 113.9 
Injury musculoskeletal NOS  905 364 3.6 34.5 116.8 
Sprain/strain* 1,409 363 3.6 20.9 123.6 
Bursitis/tendonitis/synovitis NOS  1,128 351 3.5 26.6 116.6 
Fracture*  908 345 3.4 35.6 106.6 
Pregnancy* 1,287 329 3.3 24.9 102.5 
Abdominal pain* 614 307 3.0 42.4 118.0 
Shoulder syndrome 525 255 2.5 37.9 128.2 
Breast lump/mass (female) 150 170 1.7 75.4 149.6 
Subtotal 12,606 3,495 34.7 — — 
Total problems 152,286 10,076 100.0 5.8 113.4 
(a) A test was counted more than once if it was ordered for the management of more than one problem at an encounter. There were 9,978 
imaging test orders and 10,076 problem–imaging combinations. 
(b) The percentage of total contacts with the problem that generated at least one order for imaging. 
(c) The rate of imaging orders placed per 100 tested problem contacts with at least one order for imaging. 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781743320181>). 
Note: NOS – not otherwise specified. 
12.4 Other investigations 
Other investigations include diagnostic procedures ordered by the GP at the encounter or 
undertaken by the GP or practice staff. GPs ordered 897 other investigations during the 
study year, and GPs or practice staff undertook 1,548 other investigations. There were, in 
total, 2,445 other investigations either ordered or undertaken in the practice (Table 12.6). 
The first part of Table 12.6 lists the other investigations ordered by GPs. The second part lists 
the other investigations undertaken in the practice by GPs or practice staff. The third part 
lists the total of other investigations either ordered, or undertaken in the practice. Each 
investigation is expressed as a percentage of total other investigations ordered or 
undertaken, as a rate per 100 encounters, and as a rate per 100 problems, each with 
95% confidence limits. Electrical tracings were the most common group of other 
investigations ordered or undertaken making up 44.1% of other investigations, followed by 
physical function test (29.9%). 
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12.5 Changes in investigations over the decade 
2002–03 to 2011–12 
Data on investigations are reported for each year from 2002–03 to 2011–12 in Chapter 12 of 
the companion report A decade of Australian general practice activity 2002–03 to 2011–12.1 In that 
report, changes over time are measured as change in the management of problems (that is, as 
a rate per 100 problems). This reflects change in how GPs are managing problems, and 
accounts for the significant increase in the number of problems managed per encounter over 
the decade (see Section 7.9). The major changes are highlighted below. 
• At least one pathology test was ordered for 11.4% of problems managed in 2002–03 
rising to 13.6% of problems in 2011–12. The largest increase was in orders for chemical 
pathology, which increased from 12.2 per 100 problems in 2002–03 to 18.0 per 
100 problems in 2011–12. Haematology increased at a slower rate, from 4.3 per 
100 problems in 2002–03 to 5.5 in 2011–12. Microbiology test orders increased from 
3.5 per 100 problems in 2002–03 to 4.0 in 2011–12.  
• Between 2002–03 and 2011–12 the number of problems managed per 100 encounters rose 
from 144.9 to 153.8 (Table 5.1). Both the rise in the number of tested problems and the 
rise in the number of problems managed at encounter contributed to an overall increase 
in the proportion of encounters involving a pathology test. These rose from 14.7% of 
encounters in 2002–03 to 18.1% in 2011–12, which suggests that in 2011–12 pathology 
was ordered at about 8 million more encounters nationally than in 2002–03. 
• The number of pathology tests ordered increased from 22.7 tests (or battery of tests) per 
100 problems managed in 2002–03 to 30.6 per 100 problems in 2011–12. The rate of 
pathology orders per 100 encounters increased from 32.9 per 100 encounters in 2002–03 
to 47.0 in 2011–12, which extrapolates to approximately 25.7 million more tests (or 
batteries of tests) ordered in 2011–12.  
• At least one imaging test was ordered for 5.3% of all problems managed in 2002–03, 
rising to 5.8% of all problems in 2011–12. The proportion of encounters generating 
imaging orders increased from 7.5% in 2002–03 to 8.6% in 2011–12, resulting in an 
estimated 3.3 million more encounters nationally at which imaging was ordered in  
2011–12. 
• The number of imaging tests ordered increased from 5.9 tests per 100 problems managed 
in 2002–03 to 6.6 per 100 problems in 2011–12. Total imaging orders per 100 encounters 
also increased significantly from 8.6 per 100 encounters in 2002–03 to 10.1 in 2011–12, 
suggesting there were 4 million more imaging orders in 2011–12 than in 2002–03. 
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12.6 Discussion 
Pathology testing underpins both the diagnostic and chronic disease monitoring processes of 
Australian general practice. It is thus a tool integral to the function of general practice and 
the management of patients.  
The volume of pathology ordering by general practitioners in Australia (which constitutes 
about 70% of all pathology orders claimed from Medicare16) has increased in every year since 
the inception of the BEACH program in 1998. This rising volume has resulted from an 
increase in the number of services delivered by GPs and an increase in the number of patient 
problems managed at encounters as well as an increase in the number of pathology tests or 
batteries of tests ordered on each occasion in the management of some problems.16 
There continue to be some problematic areas of pathology ordering which were reported in 
previous FMRC publications and continue in the present BEACH reporting year.16,19 
Examples include the ordering of full blood counts and ESR which have little support in 
guidelines for most of the indications for which they are ordered. FBC orders increased from 
4.3 per 100 encounters in 2002–03 to 6.6 per 100 encounters in 2011–12, an increase of almost 
4 million encounters in 2011–12 at which FBCs were ordered.86  
The largest rise in pathology orders has been in chemical pathology tests, led by tests for 
lipid levels which have increased from 3.3 per 100 encounters in 2002–03 to 4.4 per 100 
encounters in 2011–12.86 This extrapolates to an increase over the decade of approximately 
2.2 million more encounters where lipid tests were ordered, accounting for about 13% of the 
total increase in chemical pathology orders. This appears to have been driven by the changes 
in guidelines resulting from increasing evidence regarding the role of blood lipids in the 
genesis and prevention of cardiovascular disease. 
Prostate specific antigen (PSA) testing has become a very contentious issue with conflicting 
views as to its benefit in terms of patient outcomes. Conflicting guidelines for PSA tests make 
it difficult for GPs to decide when it is appropriate and limit the ability to measure the 
quality of GP ordering of PSA testing. Research conducted by the FMRC for the Quality Use 
of Pathology Program of the Department of Health and Ageing raised significant concerns 
regarding the quality of guidelines for pathology ordering.18  
While there was a significant increase in imaging orders overall, there was no increase in 
diagnostic radiology per 100 encounters and a significant decrease per 100 problems 
managed. The major change was in ultrasound orders which increased by the equivalent  
of 2.4 million encounters at which ultrasound was ordered in 2011–12 compared with  
2002–03.1 Of greater concern was CT scan orders which increased by the equivalent of 
690,000 CT scan encounters over the decade.1 There is a growing concern regarding the 
safety of CT scans,87,88 particularly in children, which has led to changes in Medicare 
Schedules rules to allow rebates for MRI scans ordered by general practitioners in the 
future.89 BEACH will monitor the effect of this policy change on the ordering of imaging 
tests in the future.  
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13 Patient risk factors 
General practice is a useful intervention point for health promotion because the majority of 
the population visit a GP at least once per year. In 2011–12, 83% of Australians visited a GP 
at least once (personal communication, DoHA, April 2012). GPs, through ongoing 
professional education, have substantial knowledge of population health, screening 
programs and other interventions. They are therefore in an ideal position to advise patients 
about the benefits of health screening, and to counsel patients individually about their 
lifestyle choices.  
Since the beginning of the BEACH program (1998), a section on the bottom of each encounter 
form has been used to investigate aspects of patient health or healthcare delivery not covered 
by general practice consultation-based information. These additional substudies are referred 
to as SAND (Supplementary Analysis of Nominated Data). The SAND methods are 
described in Section 2.6.  
The patient risk factors collected in BEACH include body mass index (BMI) (calculated using 
self-reported height and weight), self-reported alcohol consumption and self-reported 
smoking status. These patient risk factors are investigated for a subsample of 40 of the 100 
patient encounters recorded by each GP. An example of the encounter form with the patient 
risk factor SAND questions is included as Appendix 1. The methods used in the risk factor 
substudies reported in this chapter are described in each section below. 
Data on patient risk factors measured in SAND are reported for each of the ten most 
recent years in the companion report A decade of Australian general practice activity 2002–03 to  
2011–12.1  
Abstracts of results and the research tools used in other SAND substudies from April 1998 to 
March 2012 have been published. Those conducted: 
• from April 1998 to March 1999 were published in Measures of health and health care delivery 
in general practice in Australia26 
• from April 1999 to July 2006 were published in Patient-based substudies from BEACH: 
abstracts and research tools 1999–200627 
• since August 2006 have been published in each general practice annual reports28–32 
• in the 2011–12 BEACH year are provided in Chapter 14 of this publication. 
13.1 Body mass index 
From the most recent publicly available data, high body mass was the third highest 
contributor to the total burden of disease in Australia in 2003, accounting for 7.5% of the total 
burden,90 an increase from 4.3% of total burden and sixth rank in 1996.91 In 2010, the AIHW 
reported that based on OECD data, Australia’s obesity rates in 1987 and 2006 were among 
the highest in the world (10.8% and 25.6% of adults respectively).92 These figures rank 
Australia firmly in the worst third of OECD countries.92  
From the 2007–08 National Health Survey (NHS) it was estimated that, based on trained 
interviewer measured data 37% of Australians aged 18 years and over were overweight (BMI 
25–<30) and 25% were obese (BMI 30 or more). Men were more likely to be overweight (42%) 
than women (31%), but obesity rates were similar (26% in men, 24% in women).20  
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The 2007–08 NHS also reported that 25% of children aged 5–17 years were classified as 
overweight or obese, with boys and girls having similar rates of overweight/obesity (26% 
and 24% respectively).20 
Method 
Patient BMI was investigated for a subsample of 40 of each GP’s 100 patient encounters. Each 
GP was instructed to ask the patient (or their carer in the case of children): 
• What is your height in centimetres (without shoes)? 
• What is your weight in kilograms (unclothed)? 
Metric conversion tables (from feet and inches; from stones and pounds) were provided to 
the GP. 
The BMI for an individual was calculated by dividing weight (kilograms) by height (metres) 
squared. The WHO recommendations93 for BMI groups were used, which specify that an 
adult (18 years and over) with a BMI: 
• less than 18.5 is underweight 
• greater than or equal to 18.5 and less than 25 is normal weight 
• greater than or equal to 25 and less than 30 is overweight 
• of 30 or more is obese. 
The reported height for adult patients was checked against sex-appropriate upper and lower 
height limits from the Australian Bureau of Statistics (ABS).94 Adults whose self-reported 
height was outside the sex-appropriate limits were excluded from the analysis. 
The standard BMI cut-offs described above are not appropriate in the case of children. 
Cole et al. (2000 & 2007) developed a method that calculates the age–sex-specific BMI cut-off 
levels for underweight, overweight and obesity specific to children aged 2–17 years.95,96 
There are four categories defined for childhood BMI: underweight, normal weight, 
overweight and obese. This method, based on international data from developed Western 
cultures, is applicable in the Australian setting.  
The reported height of children was checked against age–sex-appropriate upper and lower 
height limits from the ABS and Centres for Disease Control (CDC).94,97 Children whose self-
reported height was outside the age–sex-appropriate limits were excluded from the analysis. 
The BEACH data on BMI are presented separately for adults (aged 18 years and over) and 
children (aged 2–17 years).  
Results 
Body mass index of adults 
The sample size was 32,372 patients aged 18 years and over at encounters with 984 GPs. 
• Over half (61.6%) of the patients were overweight (35.0%) or obese (26.6%) (Table 13.1). 
• Just over one-third (36.2%) of adult patients had a BMI in the normal range, 2.3% of 
adults were underweight (Table 13.1). Underweight was more prevalent among females 
than males. 
• Males were more likely to be overweight or obese (68.9%, 95% CI: 67.8–70.0) than 
females (56.9%, 95% CI: 56.9–57.9) (results not tabled). 
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• Overweight/obesity was most prevalent among male patients aged 65–74 years (76.8%) 
and 45–64 years (76.0%) (Figure 13.1). 
• Among female patients, overweight/obesity was most prevalent in those aged  
65–74 years (67.7%) and 45–64 years (64.5%) (Figure 13.1). 
• Underweight was most prevalent among patients aged 18–24 years (5.2%, 95% CI:  
4.2–6.2) (results not tabled).  
• Of young adults (18–24 years), 6.2% of females and 2.8% of males were underweight, 
and among those aged 75 years and over, 3.8% of females and 1.8% of males were 
underweight (Figure 13.2). 
Our overall and sex-specific prevalence estimates of overweight/obesity among patients at 
general practice encounters (62% of adults, 69% of males and 57% of females) are consistent 
with the ABS 2007–08 figures from the National Health Survey (based on measured BMI 
data), which reported that 62% of adults aged 18 and over (68% of men and 55% of females) 
were overweight or obese.20  
Readers interested in prevalence of the three WHO-defined levels of obesity will find more 
information and discussion in Chapter 7 of General practice in Australia, health priorities and 
policies 1998 to 2008.98  
Estimation of body mass index for the adult general practice patient population 
The BEACH study reports data about patient BMI from a sample of the patients attending 
general practice. As older people attend a GP more often than young adults, and females 
attend more often than males, they have a greater chance of being selected in the subsample. 
This leads to a greater proportion of older and female patients in the sample than in the total 
population who attend a GP at least once in a year. The 2011–12 BEACH sample was 
weighted to estimate the BMI of the GP–patient attending population (that is, the 
14.8 million adult patients who attended a GP at least once in 2011–12 (personal 
communication, DoHA, April 2012), using the method described by Knox et al. (2008).24 This 
statistical adjustment had little effect on the result. 
The estimates for the adult GP–patient attending population (after adjusting for age–sex 
attendance patterns) suggest that 26.1% of the adult patient population were obese, 34.9% 
were overweight, 36.9% were normal weight and 2.2% were underweight (Table 13.1).  
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Table 13.1: Patient body mass index (aged 18 years and over) 
 Male(a)  Female(a)  Total respondents 
BMI class 
Per cent in 
BEACH sample 
(95% CI) 
(n = 12,531) 
Per cent  
in patient 
population 
(95% CI)(b)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 19,605 
Per cent  
in patient 
population 
(95% CI)(b)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 32,372) 
Per cent  
in patient 
population 
(95% CI)(b) 
Obese 26.4 
(25.4–27.4) 
25.7 
(24.6–26.8)  
26.7 
(25.8–27.5) 
26.4 
(25.5–27.3)  
26.6 
(25.8–27.3) 
26.1 
(25.3–26.9) 
Overweight 42.5 
(41.5–43.5) 
41.5 
(40.4–42.5)  
30.2 
(29.5–30.9) 
29.3 
(28.5–30.0)  
35.0 
(34.4–35.6) 
34.9 
(34.2–35.5) 
Normal 29.9 
(28.8–30.9) 
31.5 
(30.4–32.7)  
40.2 
(39.3–41.2) 
41.5 
(40.4–42.5)  
36.2 
(35.3–37.0) 
36.9 
(36.0–37.8) 
Underweight 1.3 
(1.1–1.5) 
1.3 
(1.1–1.5)  
2.9 
(2.6–3.1) 
2.9 
(2.6–3.2)  
2.3 
(2.1–2.4) 
2.2 
(2.0–2.3) 
(a) Patient sex was not recorded for 236 respondents. 
(b) Estimation of BMI among the total adult general practice patient population (that is, patients aged 18 years and over who attended a GP at 
least once in 2011–12) (n = 14.8 million, source: unpublished Medicare data, personal communication, DoHA, April 2012). 
Note: BMI – body mass index; CI – confidence interval. 
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Figure 13.1: Age–sex-specific rates of overweight/obesity in sampled adults 
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Figure 13.2: Age–sex-specific rates of underweight in sampled adults 
 
Body mass index of children 
BMI was calculated for 3,093 patients aged 2–17 years at encounters with 818 GPs. 
• Just over one-quarter of children (28.7%, 95% CI: 26.8–30.6) were classed as overweight 
or obese – 11.1% (95% CI: 9.8–12.5) obese and 17.6% (95% CI: 16.2–19.0) overweight 
(results not tabled). 
• There was no difference in the prevalence of overweight/obesity among male (29.6%,  
95% CI: 26.9–32.3) and female children (27.9%, 95% CI: 25.5–30.3) (results not tabled). 
• The age-specific rates of obesity followed similar patterns for both sexes 
(Figures 13.3 and 13.4). 
Readers interested in further detail and discussion about overweight and obesity in children 
attending general practice will find more information in Cretikos et al. (2008) General practice 
management of overweight and obesity in children and adolescents in Australia.99 
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Figure 13.3: Age-specific rates of obesity, overweight, normal weight and underweight in 
sampled male children 
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Figure 13.4: Age-specific rates of obesity, overweight, normal weight and underweight in 
sampled female children  
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13.2 Smoking (patients aged 18 years and over) 
Tobacco smoking is the leading cause of ill health, drug-related death and hospital 
separations in Australia.100 It is a major risk factor for coronary heart disease, stroke, 
peripheral vascular disease, several cancers, respiratory disorders ad other diseases.101 It has 
been identified as the risk factor associated with the greatest disease burden, accounting for 
7.8% of the total burden of disease in Australia in 2003,90 a decrease from 9.7% of total 
burden in 1996.91 In 2010, the AIHW cited OECD data that showed Australia’s tobacco 
smoking rates steadily decreased between 1987 and 2006 (from 30.6% to 16.6% of daily 
smokers aged 15 years and over), with the ranking improving from middle third to best third 
when compared with other OECD nations.92 According to the 2010 National Drug Strategy 
Household Survey (NDSHS), 15.1% of Australians aged 14 years and over smoked daily: 
16.4% of males and 13.9% of females.102 
Method 
GPs were instructed to ask adult patients (18 years and over): 
• What best describes your smoking status?  Smoke daily 
 Smoke occasionally 
 Previous smoker 
 Never smoked 
Results 
The smoking status of 33,086 adult patients was established at encounters with 984 GPs. 
Table 13.2 shows that: 
• 14.7% of sampled adult patients were daily smokers 
• significantly more male (18.0%) than female patients (12.6%) were daily smokers 
• only 2.5% of sampled adult patients were occasional smokers 
• more than a quarter of sampled adults (27.9%) were previous smokers. 
Table 13.2: Patient smoking status (aged 18 years and over) 
 Male(a)  Female(a)  Total respondents 
Smoking status 
Per cent in 
BEACH sample 
(95% CI) 
(n = 12,777) 
Per cent in 
patient 
population 
(95% CI)(b)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 20,060) 
Per cent in 
patient 
population 
(95% CI)(b)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 33,086) 
Per cent in 
patient 
population 
(95% CI)(b) 
Daily 18.0 
(17.1–19.0) 
21.4 
(20.3–22.5)  
12.6 
(11.8–13.3) 
14.1 
(13.3–14.9)  
14.7 
(14.0–15.3) 
17.4 
(16.6–18.2) 
Occasional 2.9 
(2.6–3.3) 
3.8 
(3.3–4.2)  
2.2 
(2.0–2.4) 
2.6 
(2.3–2.9)  
2.5 
(2.3–2.7) 
3.2 
(2.9–3.5) 
Previous 36.3 
(35.1–37.4) 
30.4 
(29.3–31.5)  
22.6 
(21.8–23.5) 
21.7 
(20.8–22.5)  
27.9 
(27.2–28.7) 
25.7 
(24.9–26.4) 
Never 42.8 
(41.6–44.1) 
44.4 
(43.2–45.7)  
62.6 
(61.6–63.7) 
61.7 
(60.6–62.8)  
54.9 
(53.9–55.8) 
53.8 
(52.8–54.8) 
(a) Patient sex was not recorded for 249 respondents. 
(b) Estimation of smoking status among the total adult general practice patient population (that is, patients aged 18 years and over who 
attended a GP at least once in 2011–12) (n = 14.8 million, source: unpublished Medicare data, personal communication, DoHA, April 2012). 
Note: CI – confidence interval. 
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Daily smoking was least prevalent in older adults aged 65– 74 and 75 or more (8.9% and 
4.1% respectively) and most prevalent among adult patients aged 25–44 years (21.2%) 
(results not tabled). Over half (54%) of the male and 25% of the female patients aged 75 years 
and over were previous smokers, but only 5.7% of males and 3.1% of females in this age 
group were daily smokers (Figures 13.5 and 13.6). 
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Figure 13.5: Smoking status – male age-specific rates of sampled patients 
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Figure 13.6: Smoking status – female age-specific rates of sampled patients 
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Estimation of smoking in the adult general practice patient population 
The BEACH study reports data about patient smoking habits from a sample of patients 
attending general practice. As older people attend a GP more often than young adults, and 
females attend more often than males, they have a greater chance of being selected in the 
subsample. This leads to a greater proportion of older and female patients in the subsample 
than in the total population who attend a GP at least once in a year. We weighted the  
2011–12 BEACH smoking substudy to estimate smoking status of the GP–patient attending 
population (that is, the 14.8 million adult patients who attended a GP at least once in 2011–12 
[personal communication, DoHA, April 2012]), using the method described by Knox et al. 
(2008).24  
After adjusting for age–sex attendance patterns we estimated that 17.4% of the patient 
population were daily smokers, 3.2% were occasional smokers, 25.7% were previous smokers 
and 53.8% had never smoked. Male patients in the total general practice population were 
significantly more likely to be daily (21.4%), occasional (3.8%) and previous smokers (30.4%) 
than females patients (13.1%, 2.6% and 21.7%, respectively) (Table 13.2).  
13.3 Alcohol consumption (patients aged 18 years 
and over) 
In people aged 65 years and over, low to moderate consumption of alcohol has been found to 
have a preventive effect against selected causes of morbidity103 (in particular ischaemic heart 
disease).104 In a review of the evidence, the National Health and Medical Research Council 
(NHMRC) concluded that in young women there was no evidence of any cardiovascular 
mortality benefit from alcohol consumption, and in young men any benefit was outweighed 
by other alcohol-related causes of death.104 In 2003, alcohol consumption accounted for 
3.3% of the total burden of disease in Australia; however, after taking into account the benefit 
derived from low to moderate alcohol consumption, this fell to 2.3%.90 
The 2007–08 NHS classified alcohol use of those aged 15 years or more based on the 
estimated average daily consumption of alcohol during the previous week. They found that 
12.6% drank at levels considered to be risky (14.4% of males and 10.8% of females).20 
The 2010 National Drug Strategy Household Survey (NDSHS) found that 20.1% of people 
aged 14 years and over (29.0% of males and 11.3% of females) drank at levels considered to 
put them at risk of harm from alcohol-related disease or injury over their lifetime. The 
NDSHS also found that 28.4% of people aged 14 years or older (38.2% of males and 18.9% of 
females) drank, at least once in the previous month, in a pattern that placed them at risk of 
an alcohol-related injury from a single drinking occasion.102 These alcohol consumption risk 
levels were based on the NHMRC 2009 guidelines.105 
For consistency over time, this report uses the definitions of alcohol-related risk developed 
by WHO (see ‘Method’ below).106 This differs from the definition in the NHMRC guidelines. 
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Method 
To measure alcohol consumption, BEACH uses AUDIT-C107 which is the first three items 
from the WHO Alcohol Use Disorders Identification Test (AUDIT),106 with scoring for an 
Australian setting.108 The AUDIT-C has demonstrated validity and internal consistency and 
performs as well as the full AUDIT tool.109 The three AUDIT-C tool is practical and valid in a 
primary care setting to assess ‘at-risk’ alcohol consumption (heavy drinking and/or active 
alcohol dependence).107 The scores for each question range from zero to four. A total (sum of 
all three questions) score of five or more for males or four or more for females suggests that 
the person’s drinking level is placing him or her at risk.108 
GPs were instructed to ask adult patients (18 years and over): 
• How often do you have a drink containing alcohol? Never 
 Monthly or less 
 Once a week/fortnight 
 2–3 times a week 
 4 times a week or more 
• How many standard drinks do you have on a typical day when you are drinking?  
 _______________ 
• How often do you have six or more standard drinks on one occasion?  
 Never 
 Less than monthly 
 Monthly 
 Weekly 
 Daily or almost daily 
A standard drinks chart was provided to each GP to help the patient identify the number of 
standard drinks consumed. 
Results 
Patient self-reported alcohol consumption was recorded at 32,257 adult patient (18 years and 
over) encounters with 984 GPs. 
• About one-quarter of sampled adults reported drinking alcohol at at-risk levels (24.5%) 
(Table 13.3). 
• At-risk drinking was more prevalent among male (29.3%) than female patients (21.5%) 
(Table 13.3). 
• At-risk drinking was most prevalent in those aged 18–24 years, particularly among men. 
In this age group almost half the males and one in three females reported at-risk alcohol 
consumption (Figure 13.7). 
• The proportion of patients who were at-risk drinkers decreased with age for both males 
and females (Figure 13.7). 
These estimates are not comparable with the 2007–08 NHS20 or the 2010 NDSHS102 as they all 
use different concepts for defining alcohol consumption and risk, and different adult 
populations (patients aged 18 years or more for BEACH, persons aged 15 years or more for 
the NHS, and persons aged 14 years or more for the NDSHS).  
Readers interested in the relationship between morbidity managed and alcohol consumption 
will find more information in Proude et al. (2006) The relationship between self-reported alcohol 
intake and the morbidities managed by GPs in Australia.110  
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Table 13.3: Patient alcohol consumption (aged 18 years and over) 
 Male  Female  Total respondents 
Alcohol 
consumption 
Per cent in 
BEACH sample 
(95% CI) 
(n = 12,572) 
Per cent in 
patient 
population 
(95% CI)(a)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 19,685) 
Per cent in 
patient 
population 
(95% CI)(a)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 32,257) 
Per cent in 
patient 
population 
(95% CI)(a) 
At-risk drinker 29.3 
(28.1–30.5) 
33.3 
(32.0–34.7)  
21.5 
(20.6–22.5) 
23.2 
(22.2–24.2)  
24.5 
(23.7–25.4) 
27.9 
(26.9–28.9) 
Responsible drinker 46.7 
(45.5–48.0) 
44.3 
(43.1–45.6)  
41.8 
(40.8–42.8) 
42.6 
(41.5–43.6)  
43.7 
(42.9–44.6) 
43.4 
(42.5–44.3) 
Non-drinker 24.0 
(22.8–25.2) 
22.3 
(21.1–23.6)  
36.7 
(35.3–38.0) 
34.2 
(32.9–35.6)  
31.7 
(30.6–32.8) 
28.7 
(27.6–29.9) 
(a) Estimation of alcohol consumption among the total adult general practice patient population (that is, patients aged 18 years and over who 
attended a GP at least once in 2011–12) (n = 14.8 million, Source: personal communication, DoHA, April 2012). 
Note: CI – confidence interval. 
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Figure 13.7: Age–sex-specific rates of at-risk alcohol consumption in sampled patients 
Estimation of alcohol consumption levels in the adult general practice patient 
population 
The BEACH study reports data about patient alcohol consumption from a sample of the 
patients attending general practice. As older people attend a GP more often than young 
adults, and females attend more often than males, they have a greater chance of being 
selected in the subsample. This leads to a greater proportion of older and female patients in 
the sample than in the total population who attend a GP at least once in a year.  
Per cent 
Age group (years) 
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We weighted the 2011–12 BEACH sample to estimate alcohol consumption levels among the 
GP–patient attending population (that is, the 14.8 million adult patients who attended a GP 
at least once in 2011–12 [personal communication, DoHA, April 2012]), using the method 
described by Knox et al. (2008).24 After adjusting for age–sex attendance patterns we 
estimated that 27.9% of the patient population were at-risk drinkers, 43.4% were responsible 
drinkers and 28.7% were non-drinkers. Males in the general practice population were 
significantly more likely to be at-risk drinkers (33.3%) than females (23.2%) (Table 13.3).  
13.4 Risk factor profile of adult patients 
All patient risk factor questions (BMI, smoking and alcohol consumption) were asked of the 
same subsample of patients. This allows us to build a risk profile of this sample. For the 
purposes of this analysis, being overweight or obese, a daily smoker or an at-risk drinker 
were considered risk factors. A risk factor profile was prepared for the 31,401 adult patients 
for whom data were available in all three elements, with 981 GPs. (Table 13.4). 
• About half (52.1%) the sampled adult respondents had one risk factor. The most 
common was overweight (23.4% of adults) followed by obesity (18.3%). 
• Almost one in five patients (18.9%) had two risk factors, the most common combinations 
being: 
– overweight and at-risk alcohol consumption – 6.8% of patients 
– obesity and at-risk alcohol consumption – 4.5% of patients 
– daily smoking and at-risk alcohol consumption – 2.7% of patients. 
• A small group of patients (3.6%) had all three risk factors. 
Table 13.5 shows the number of risk factors by patient sex. 
• Females were significantly more likely to have no risk factors (29.5%) than males (18.9%). 
• Females were significantly less likely to have two or three risk factors (15.5% and 2.5% 
respectively) than males (24.3% and 5.4%). 
Estimation of the risk profile of the adult general practice patient population 
The 2011–12 BEACH sample was weighted to estimate the risk profile of the GP–patient 
attending population (that is, the 14.8 million adult patients who attended a GP at least once 
in 2011–12 (personal communication, DoHA, April 2012), using the method described by 
Knox et al. (2008).24  
After adjusting for age–sex attendance patterns we estimated that:  
• one-quarter of patients had no risk factors (24.1%) 
• half of the adult patients had one risk factor (50.2%), the most common being overweight 
(21.7% of adults) followed by obesity (16.9%) 
• one in five patients had two risk factors (21.2%), the most common combinations being 
overweight and at-risk alcohol consumption (7.5%), followed by obesity and at-risk 
alcohol consumption (4.8%) 
• 4.5% of patients who attend general practice had three risk factors (Table 13.4) 
• significantly more female than male patients had no risk factors (29.3% and 17.9% 
respectively). Male patients were also more likely to have one, two and three risk factors 
(48.8%, 26.7% and 6.5%) than females (51.4%, 16.4% and 2.8%) (Table 13.5). 
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Table 13.4: Risk factor profile of patients (aged 18 years and over) 
Number of risk factors Number 
Per cent in 
BEACH sample  
(n = 31,401) 
95% 
LCL 
95% 
UCL 
 Per cent in 
patient 
population(a) 
95% 
LCL 
95% 
UCL 
No risk factors 7,967 25.4 24.6 26.2  24.1 23.3 24.9 
One risk factor 16,365 52.1 51.4 52.8  50.2 49.5 50.9 
 Overweight only 7,360 23.4 22.8 24.1  21.7 21.0 22.3 
 Obese only 5,733 18.3 17.7 18.9  16.9 16.2 17.5 
 At-risk alcohol level only 2,225 7.1 6.6 7.5  7.8 7.3 8.3 
 Current daily smoker only 1,047 3.3 3.1 3.6  3.9 3.6 4.2 
Two risk factors 5,936 18.9 18.3 19.5  21.2 20.5 21.9 
 Overweight and at-risk alcohol level 2,136 6.8 6.4 7.2  7.5 7.1 7.9 
 Obese and at-risk alcohol level 1,405 4.5 4.2 4.8  4.8 4.5 5.1 
 Daily smoker and at-risk alcohol level 839 2.7 2.5 2.9  3.3 3.1 3.6 
 Overweight and current daily smoker 811 2.6 2.4 2.8  2.9 2.7 3.2 
 Obese and current daily smoker 745 2.4 2.2 2.6  2.6 2.4 2.9 
Three risk factors 1,133 3.6 3.3 3.9  4.5 4.2 4.9 
 Overweight and current daily smoker 
and at-risk alcohol level 
697 2.2 2.0 2.4  2.9 2.6 3.1 
 Obese and current daily smoker and 
at-risk alcohol level 
436 1.4 1.2 1.5  1.7 1.5 1.9 
(a) Estimation of risk factor profile among the total adult general practice patient population (that is, patients aged 18 years and over who 
attended a GP at least once in 2011–12) (n = 14.8 million). 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
Table 13.5: Number of risk factors, by patient sex 
 Male  Female 
Number of risk factors 
Per cent in BEACH 
sample (95% CI) 
(n = 12,252) 
Per cent in patient 
population 
(95% CI)(a)  
Per cent in BEACH 
sample (95% CI) 
(n = 19,149) 
Per cent in patient 
population 
(95% CI)(a) 
No risk factors 18.9 
(18.0–19.8) 
17.9 
(17.0–18.9)  
29.5 
(28.6–30.5) 
29.3 
(28.3–30.3) 
One risk factor 51.5 
(50.4–52.5) 
48.8 
(47.7–49.9)  
52.5 
(51.7–53.4) 
51.4 
(50.5–52.3) 
Two risk factors 24.3 
(23.3–25.2) 
26.7 
(25.7–27.8)  
15.5 
(14.8–16.1) 
16.4 
(15.7–17.1) 
Three risk factors 5.4 
(4.9–5.8) 
6.5 
(5.9–7.1)  
2.5 
(2.2–2.8) 
2.8 
(2.5–3.1) 
(a) Estimation of risk factor profile among the total adult general practice patient population (that is, patients aged 18 years and over who 
attended a GP at least once in 2011–12) (n = 14.8 million, source: personal communication, DoHA, April 2012). 
Note: CI – confidence interval. 
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13.5 Changes in patient risk factors over the 
decade 2002–03 to 2011–12 
To investigate changes over time in these patient risk factors, results are reported from the 
BEACH sample data for each year from 2002–03 to 2011–12 in the companion report A decade 
of Australian general practice activity 2002–03 to 2011–12.1  
The major changes between 2002–03 and 2011–12 are summarised below. 
• The prevalence of obesity in adults attending general practice increased significantly, 
from 20.9% to 26.6%, an increase apparent in both male and female patients. In parallel 
the prevalence of normal weight and underweight in adults attending general practice 
decreased significantly, from 42.4% and 2.9% to 36.2% and 2.3%. 
• The prevalence of overweight and obesity in children aged 2–17 years remained stable, 
with about 11–12% of children being obese and about 18% overweight. 
• Prevalence of daily and occasional smoking decreased significantly in adults aged  
18 years and over, from 17.2% and 4.1%, respectively, to 14.7% and 2.5%. 
• The prevalence of at-risk alcohol consumption among adults aged 18 years and over 
attending general practice remained stable at about 25–26%. 
• The number of adults aged 18 years and over with one risk factor (overweight/obesity, 
at-risk drinking, daily smoker) increased significantly from 48.1% to 52.1% and the 
number with zero risk factors decreased significantly from 28.6% to 25.4% between  
2002–03 and 2011–12. 
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14 SAND abstracts and research tools 
Since BEACH began in April 1998, a section on the bottom of each encounter form has been 
used to investigate aspects of patient health or healthcare delivery not covered by general 
practice consultation-based information. These additional substudies are referred to as 
SAND (Supplementary Analysis of Nominated Data). The SAND methods are described in 
Section 2.6. All substudies were approved by the Human Ethics Committee of the University 
of Sydney). 
The Family Medicine Research Centre (FMRC) and most of the organisations supporting the 
BEACH program select topics for investigation in the SAND studies. In each BEACH year, 
up to 20 substudies can be conducted in addition to the study of patient risk behaviours (see 
Chapter 13). Topics can be repeated to increase the size of the sample and its statistical 
power. 
This chapter includes the abstracts and research tools for SAND substudies conducted from 
April 2011 to March 2012. The subjects covered in the abstracts in this chapter are listed in 
Table 14.1, with the sample size for each topic. 
Table 14.1: SAND abstracts for 2011–12 and sample size for each  
Abstract 
number Subject 
Number of 
respondents  
Number  
of GPs 
180 Polypharmacy and adverse drug events in general practice patients aged 50 years and over 4,468 293 
181 
Influenza and pneumococcal infection risk and vaccination status among adult general 
practice patients 
2,437 99 
182 Chronic obstructive pulmonary disease (COPD) in general practice patients (2) 2,869 100 
183 
Cardiovascular disease, risk factors, antiplatelet use and gastrointestinal side effects among 
general practice patients 
2,743 92 
184 CKD and dyslipidaemia among general practice patients 5,674 192 
185 Diabetes management and self-monitoring in general practice patients 5,730 194 
186 Hepatitis B and travel vaccinations 2,826 95 
187 General practice patient behaviour in seeking help for depression 2,971 101 
188 Acute coronary syndrome among general practice patients 2,957 100 
189 Menopause symptoms among female general practice patients aged 40–69 years 673 100 
190 Benign prostatic hyperplasia (BPH) and symptoms among male general practice patients 
aged 40 years or older 
708 93 
191 NSAID use, gastrointestinal and cardiovascular risk in general practice patients with arthritis 5,429 186 
192 Influenza risk, vaccination and diagnosis among general practice patients 2,737 93 
193 Diabetes, macular oedema and dyslipidaemia among general practice patients 2,825 97 
194 Adult general practice patients’ cardiovascular risk and lipid medication use 2,531 100 
 
135
  
 
SAND abstract number 180: Polypharmacy and adverse drug 
events in general practice patients aged 50 years and over 
Organisation conducting this study: Family Medicine Research Centre 
Issues: Proportion of general practice patients aged 50 years or older on regular medication 
and the type and number of medications. Proportion of patients w ith an adverse drug event 
(ADE) in the preceding six months, type of medication causing the adverse event and the 
severity of the event. 
Sample: 4,468 patients aged 50 yrs or more from 293 GPs; data collection period:  
22/02/2011 – 28/03/2011 and 29/11/2011 – 20/02/2012.  
M ethod: Detailed in the paper titled SAND Method 2011–12 available at:  
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>. Drugs were classified using 
the WHO Anatomical Therapeutic Chemical (ATC) classification. 
Summary of results 
The sex distribution or patients in this sample did not differ from that of patients aged 
50 years or older at all BEACH encounters 2010–11. 
The number of regular medications recorded for each patient aged 50 years and over varied 
from none in 12.9%, one in 12.6%, five in 9.7% to ten or more in 8.9%, for an average number 
of medications of 4.4. There was no difference in the average number of medications per 
patient between male and female patients. The average number of medications per patient 
increased from 2.3 among those aged 50–54 years to 6.0 in patients aged 75 years and older. 
Of 17,878 medications for which details were recorded 32.2% were cardiovascular drugs and 
alimentary tract and metabolism medications made up 17.9% at ATC level 1. At ATC Level 4, 
statins were the most common (7.7%), followed by proton pump inhibitors (6.3%). 
Of 3,994 respondents to the ADE question, 449 (11.2%, 95% CI: 9.8–12.7) reported an ADE in 
the preceding six months. In the patients who recorded an ADE there was no difference in 
sex, location or Health Care Card status. Patients 75 years and older were more likely to have 
had ADEs (13.9%, 95% CI: 11.5–16.3) than those of 55–64 years (8.7%, 95% CI: 6.9–10.4). 
Likelihood of adverse events increased in a linear fashion with total number of medications 
taken, from 6.2% of those taking 1–2, to 23.8% of those taking 10 or more medications. 
For 449 ADE patients, GPs implicated a medication in 435; one medication was listed for 384 
(88.3%), and 44 (10.1%) listed two, a total of 493 implicated medications. Cardiovascular and 
nervous system drugs each accounted for about one-third of ADEs. There were significant 
differences between prescribing rates and rates of ADEs for some drug groups. At ATC level 
1, nervous system drugs accounted for 17.3% of all medications but 29.0% of medications 
implicated in the most recent ADE. At ATC level 2, analgesics accounted for 7.5% of all 
medications and 13.2% of implicated medications; lipid modifying agents accounted for 9.2% 
of medications but only 6.5% of implicated medications. At the more specific ATC level 3, 
opioids accounted for 2.6% of all medications listed and 11.8% of implicated medications.  
Of the 449 ADE respondents, 443 reported on severity of the event. Of these, 47.4% had a 
mild event, 41.5% had a moderate event and 11.1% a severe adverse drug event.  
The following pages contain the recording form and instructions with which the data in this substudy were collected.
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SAND abstract number 181: Influenza and pneumococcal infection 
risk and vaccination status among adult general practice patients 
Organisation collaborating for this study: CSL Biotherapies Pty Ltd  
Issues: The proportion of adult general practice patients who had: risk factors for influenza 
or pneumococcal infection; discussed influenza or pneumococcal vaccination with a health 
professional, and who initiated the discussion(s). Influenza and pneumococcal vaccination 
status, source of vaccine supply, and reason(s) for not vaccinating unvaccinated patients. 
Sample: 2,437 adult patients (aged 18 years and over) from 99 GPs; data collection period: 
29/03/2011 – 02/05/2011. 
M ethod: Detailed in the paper titled SAND Method 2011–12 available at:  
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>. Drugs were classified using 
the WHO Anatomical Therapeutic Chemical (ATC) classification.  
M ethods for this study: Risk factors for influenza and pneumococcal infection were adapted 
from those in the Australian Immunisation Handbook (9th Edition, 2008, National Health 
and Medical Research Council) and were supplied to participating GPs on a card. 
Summary of results 
The age and sex distributions of patients in this SAND sample did not differ significantly 
from all patients at 2010–11 BEACH encounters. 
Prevalence of at least one risk factor for influenza and/or pneumococcal infection was 53.0% 
(95% CI: 48.3–57.7) adult patients. Most risk factors were common to both influenza and 
pneumococcal, and the most common were: age 65 years and over (33.2%), chronic heart 
disease (8.9%), diabetes (8.5%), chronic lung disease (8.3%) and other chronic diseases (6.8%).  
Influenza vaccination: Of 2,340 adult respondents, 1,269 (54.2%) had discussed influenza 
vaccination with a health care professional in the previous 12 months. Of the 1,266 
respondents with at least one risk factor for influenza, 79.7% had discussed vaccination in 
the past year, and most were GP-initiated (79.2% of 1,260 respondents). Of 2,363 patients for 
whom vaccination status was given, 1,082 (45.8%) were vaccinated, 1,124 (47.6%) were not, 
and status was not known for 157 patients. Of 1,061 vaccinated respondents, 80.5% were 
supplied the vaccine free of charge (i.e. government supplied), for 3.4% the vaccine was PBS 
subsidised, and for 16.1% it was fully privately funded. There were 1,093 reasons for not 
being vaccinated given by 1,087 unvaccinated patients: 55.5% of patients were considered 
‘not at risk’, and 14.5% gave ‘patient objection’ as the reason. 
Pneumococcal vaccination: Of 2,265 adult respondents, 798 (35.2%) had discussed 
pneumococcal vaccination with a health care professional in the previous 5 years. Of the 
1,149 respondents with at least one risk factor for pneumococcal infection, 64.8% had 
discussed vaccination in the previous 5 years. GPs initiated the discussion in most cases 
(85.5% of 764 respondents). Of 2,193 patients with recorded vaccination status, 687 (31.3%) 
were vaccinated, 1,303 (59.4%) were not, and status was not known for 203 patients. Of 650 
vaccinated respondents, 94.5% were supplied the vaccine free of charge (i.e. government 
supplied), for 3.2% the vaccine was PBS subsidised, and for 2.3% it was fully privately 
funded. There were 1,202 reasons for not being vaccinated given by 1,198 unvaccinated 
patients: 66.5% of patients were considered ‘not at risk’, and 122 (10.2%) gave ‘patient 
objection’ as the reason. 
The following pages contain the recording form and instructions with which the data in this substudy were collected.
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SAND abstract number 182: Chronic obstructive pulmonary disease 
(COPD) in general practice patients (2) 
Organisation collaborating for this study: Novartis Pharmaceuticals Australia Pty Ltd  
Issues: Prevalence of diagnosed chronic obstructive pulmonary disease (COPD) with or 
without asthma among patients attending general practice; severity of COPD; factors (listed 
with tick boxes) contributing to diagnosis of COPD; proportion with asthma diagnosed 
before COPD; medications taken for management of COPD/COPD with asthma; proportion 
who had medication changes at the current encounter, and the reasons for these changes.  
Sample: 2,869 patients from 100 GPs; data collection period: 29/03/2011 – 2/05/2011. 
Method: Detailed in the paper titled SAND Method 2011–12 available at:  
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>. Drugs were classified using 
the WHO Anatomical Therapeutic Chemical (ATC) classification.  
Methods for this study: GOLD COPD guidelines were used to categorise severity of COPD 
<www.goldcopd.com/>. 
Summary of results 
The age and sex distributions of the sampled patients did not significantly differ from those 
of patients at all BEACH encounters in 2009–10.  
Of the 2,869 respondents, 244 patients (8.5%, 95% CI: 6.9–10.1) currently had diagnosed 
asthma without COPD, 89 (3.1%, 95% CI: 2.3–4.0) had COPD without asthma, 63 (2.2%, 95% 
CI: 1.5–2.9) had both COPD and asthma, and 2,473 (86.2%, 95% CI: 84.4–88.0) had neither. 
The highest prevalence of COPD (with or without asthma) was among patients aged 
75+ years. There was no significant difference in the prevalence of COPD between males and 
females.  
Of the 152 patients with COPD, severity was reported for 146: 43.2% had mild COPD; 34.9% 
had moderate COPD; 16.4% had severe COPD; and 5.5% had very severe COPD. 
Factors contributing to the diagnosis were reported for 150 patients with COPD (98.7%). 
Some were health states/risk factors, and some were diagnostic factors. Each section of this 
question had a different number of respondents: among 126 patients, ‘clinical 
history/symptoms’ was selected as a contributing factor for 125 (99.2%); among 71 patients, 
‘non-response to bronchodilator’ was selected for 30 (42.3%); among 123 patients, ‘smoking 
history’ was nominated for 115 (93.5%); among 52 patients, ‘environmental irritants’ was 
selected for 13 (25.0%); among 105 patients, spirometry testing was nominated for 93 (88.6%); 
and among 99 patients, chest x-ray was selected for 82 (82.8%).  
Of the 63 patients with both COPD and asthma, 41 of 57 respondents (71.9%) had been 
diagnosed with asthma before being diagnosed with COPD.  
Medication use questions were answered by 142 of the 152 patients with COPD, and 114 of 
these (80.3%) were taking at least one. These 114 patients reported a total of 221 medications, 
the most common being tiotropium (31.2% of 221 medications) and salbutamol (28.5%). For 
seven patients (6.2% of 113 respondents) medication was changed at the current encounter. 
For three patients, lack of efficacy was the reason for the change, and one patient had 
medication changed due to progression of disease. 
The following pages contain the recording form and instructions with which the data in this substudy were collected. 
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 Severity of Chronic Obstructive Pulmonary Disease (COPD) reference 
card 
 
 Severity Measure  Symptoms  
 Mild FEV1/FVC < 0.7 
FEV1 ≥80% predicted 
Characterised by mild airflow limitation. 
Symptoms of chronic cough and sputum 
production may be present. 
 
 Moderate FEV1/FVC < 0.7 
FEV1 ≥50 and <80% 
predicted 
 
Characterised by worsening airflow limitation. 
Shortness of breath typically developing on 
exertion, chronic cough and sputum 
production may also be present. 
 
 Severe FEV1/FVC < 0.7 
FEV1 ≥30 and <50% 
predicted 
 
Characterised by further worsening of airflow 
limitation. 
Greater shortness of breath, reduced exercise 
capacity, fatigue, and repeated exacerbations 
that almost always have an impact on patients’ 
quality of life. 
 
 Very severe FEV1/FVC < 0.7 
FEV1 <30% predicted 
or FEV1 <50% 
predicted plus 
chronic respiratory 
failure(a) 
Characterised by severe airflow limitation.  
Quality of life is very appreciably impaired and 
exacerbations may be life threatening. 
 
 (a) Respiratory failure is defined as arterial pressure of oxygen (PaO2) <8.0 kPa (60 mm Hg) with or without arterial partial 
pressure of CO2 (PaCO2)>6.7 kPa (50 mm Hg) while breathing at sea level. 
Note: FEV1 – post bronchodilator forced expiratory volume in one second; FVC – forced vital capacity (maximal 
inspiration); FEV1/FVC – ratio of forced expiratory volume to forced vital capacity. 
Source: Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P et al. 2007. Global strategy for the 
diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive 
summary. Am J Respir Crit Care Med 176(6):532–555 
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SAND abstract number 183: Cardiovascular disease, risk factors, 
antiplatelet use and gastrointestinal side effects among general 
practice patients  
Organisation collaborating for this study: AstraZeneca Pty Limited  
Issues: Among patients attending general practice: prevalence of listed cardiovascular 
disease (CVD) or CVD risk factors (as listed in results); proportion taking antiplatelet 
medication (APM); type, dose and duration of APM; and prevalence and management of 
gastrointestinal side effects (GI SEs) (present or at risk) due to APM.  
Sample: 2,743 patients from 92 GPs; data collection period: 03/05/2011 – 06/06/2011. 
Method: Detailed in the paper titled SAND Method 2011–12 available at:  
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>. Drugs were classified using 
the WHO Anatomical Therapeutic Chemical (ATC) classification. 
Summary of results 
Responses to either or both the CVD and APM questions were given for 2,743 patients; (2,693 
answered both, 30 the CVD question alone and 20 the APM question alone). When these 
respondents were compared with patients at all BEACH encounters in 2010–11, the sex 
distribution did not differ, but minor differences in age distribution were noted, with more 
1–4 and 25–44 year-olds and fewer 75 years and over.  
Among 2,723 respondents, prevalence of at least one CVD/risk factor was 59.8% (95% CI: 
55.9–63.6): 9.5% had diabetes; 26.4% hypertension; 18.7% high total cholesterol; 4.4% familial 
dyslipidaemia; 8.3% were current smokers; 2.4% had moderate or severe CKD; 9.0% existing 
CVD; 15.1% had a family history of CVD; 38.2% were aged 45–74 years; and 1.4% were 
Aboriginal or Torres Strait Island persons aged 35 years or more.  
Of 2,713 respondents, 12.1% were currently taking APM, 81.7% of these for more than 
one year. The proportion taking APM rose significantly with age: 12.4% of 45–64 year olds, 
30.2% of 65–74 year-olds, and 47.2% of those 75 years or more.  
Of 2,712 respondents to the APM questions, 10.0% were taking aspirin, 1.8% clopidogrel, 
nine (0.3%) aspirin/dipyridamole, eight (0.3%) aspirin/clopidogrel, and one other; (total 339 
medications). This equates to 10.6% taking aspirin (including combinations) and 2.1% 
clopidogrel (including combinations), with 21 patients in both groups.  
Of 1,607 respondents with at least one CV condition/risk factor, 20.2% were taking APM, 
81.8% of these for more than one year; 17.7% were taking aspirin (including combinations) 
and 3.6% taking clopidogrel (including combinations), including 21 patients taking both.  
Of 318 respondents on APM, 65 (20.4%) had had GI SEs, and a further 113 (37.5%) of 301 of 
these responding were at risk of GI SEs. All of the 65 with GI SEs were being managed for 
these: 90.8% with medication, 38.5% being monitored and 15.4% having investigations/tests. 
Of 58 detailed medication responses, 98.3% were using a proton pump inhibitor: 34.5% 
esomeprazole and 27.6% pantoprazole. 
The following pages contain the recording form and instructions with which the data in this substudy were collected.
144
  
145
  
SAND abstract number 184: CKD and dyslipidaemia among general 
practice patients  
Organisation collaborating for this study: Merck Sharp and Dohme (Australia) Pty Ltd 
Issues: The proportion of general practice patients who: had their kidney function assessed 
in the previous 12 months; had conditions or risk factors associated with chronic kidney 
disease (CKD); had diagnosed CKD and the stage of disease; were currently on dialysis. 
Recent lipid level results and current use of lipid-lowering medication.  
Sample: 5,674 patients from 192 GPs; data collection period: 3/05/2011 – 11/07/2011. 
Method: Detailed in the paper titled SAND Method 2011–12 available at:  
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>. Drugs were classified using 
the WHO Anatomical Therapeutic Chemical (ATC) classification 
Summary of results 
Patient age was provided at 5,643 encounters. A significantly greater proportion of patients 
in the sample were aged 25–44 years and a smaller proportion were 45–74 years than the 
patients at all BEACH encounters 2010–11. The sex of the patient was provided at 5,640 
encounters and distribution did not differ from that at all BEACH encounters.  
Among 5,659 respondents to the question on kidney function testing, 53.5% had had at least 
one kidney function test in the previous 12 months: 42.5% had had a serum creatinine test, 
1.0% had had a proteinuria/microalbuminuria test, and 9.9% had had both tests. 
Of 5,534 respondents to the question about CKD, 387 (7.0%, 95% CI: 5.7–8.3) had diagnosed 
CKD. Four out of five of these patients were diagnosed by a GP. Prevalence rose with age 
from 4.5% of patients aged 45–64 years to 29.0% of those aged 75 years or older. There was 
no difference between male and female patients in the prevalence of CKD. 
The stage of CKD was known for 385 patients: 17.7% were at stage 1, 24.7% were at stage 2, 
42.6% were at stage 3, 7.3% were at stage 4 and 1.8% were at stage 5. Among 308 patients for 
whom dialysis status was known, 1.0% were currently receiving dialysis.  
Test status was available for 386 CKD patients: 96.6% had had at least one kidney function 
test in the previous 12 months: 92.7% of patients with stage 1 CKD, 99.0% of those in stage 2, 
96.9% of those at stage 3, and all patients at stage 4 and 5. 
Of 5,588 patients who gave information on associated conditions or risk factors, 26.2% had 
hypertension, 18.7% had dyslipidaemia, 9.1% were current smokers and 8.9% had diabetes. 
Among 382 CKD patients, 79.8% had hypertension, 50.5% had dyslipidaemia, 35.1% had 
diabetes, and 5.0% were current smokers. 
Total cholesterol level was known for 338 CKD patients, and the average level was 4.6. The 
average LDL cholesterol level was 2.5 for 297 CKD respondents, and average HDL was 1.3 
for 302 CKD patients. Average triglyceride level for 327 patients was 1.7. 
Among 370 patients with CKD, 46.0% were not taking any lipid medication. Just over half 
(51.6%) were currently taking one lipid medication, and nine patients (2.4%)were taking two. 
A total of 200 CKD patients were taking 209 lipid-lowering medications. Atorvastatin 
accounted for 40.2% and simvastatin made up 22.0% of these medications. 
The following pages contain the recording form and instructions with which the data in this substudy were collected. 
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SAND abstract number 185: Diabetes management and self-
monitoring in general practice patients  
Organisation collaborating for this study: Sanofi-Aventis Australia Pty Ltd. 
Issues: Proportion of sampled patients with diagnosed type 1 or type 2 diabetes; HbA1c 
measures; patient BMI; self-measurement of blood glucose (BG) (fasting and post-prandial); 
medication management; changes in medication at encounter and reasons for change.  
Sample: 5,730 patients from 194 GPs; data collection period: 07/06/2011 – 15/08/2012. 
M ethod: Detailed in the paper titled SAND Method 2011–12 available at:  
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>. Drugs were classified using 
the WHO Anatomical Therapeutic Chemical (ATC) classification 
Summary of results 
The age and sex distributions of respondents differed slightly from all patients at 2010–11 
BEACH encounters, with a greater proportion of males (42.9% c.f. 39.5), and a smaller 
proportion aged 65–74 years (11.2% c.f. 13.3%). Of the 5,730 respondents, 507 (8.8%, 95% CI: 
7.8–9.9) had either type 1 (0.8%; n = 43) or type 2 (8.1%; n = 464) diabetes. 
Prevalence of any diabetes was significantly higher among males (11.1%, 95% CI: 9.4–12.8) 
than females (7.3%, 95% CI: 6.2–8.4), and increased with patient age, peaking at 21.7% in 
those aged 65–74 years and 19.1% in those aged 75 years or older. 
The most recent HbA1c level was known for 469 patients, and of these, 49.7% had HbA1c of 
<7%. The mean result was 7.3%. Of 486 respondents with diabetes, 38.5% (n = 187) reported 
measuring fasting BG daily, while 27.2% (n = 132) measured fasting BG weekly. Fasting BG 
was tested daily by 63.4% of patients with type 1 diabetes, and by 36.2% of those with type 2 
diabetes. Of 451 respondents with diabetes, 29.3% (n = 132) measured post-prandial BG 
daily, and 25.7% (n = 116) measured weekly. Post-prandial BG was tested daily by 62.5% of 
patients with type 1 diabetes, and by 26.0% of patients with type 2 diabetes. 
Of 474 patients for whom height and weight were reported (using WHO categories of BMI 
status in adults), 0.8% were underweight; 19.4% were in the normal weight range; 33.3% 
were overweight and 46.4% were obese. 
Responses about medication management were recorded for 501 patients with diabetes: 
75.4% were currently taking medication for BG management and 24.6% were not; 55.3% 
were currently taking oral medication only, 9.6% were taking only insulin, and 10.6% were 
taking insulin and an oral medication. Of the 378 patients currently taking BG medication, 
70.6% were taking metformin; 40.5% were taking a sulfonamide, and 26.7% were on insulin. 
More than half (53.4%) of the 378 patients taking BG medication were on mono therapy and 
39.2% on dual therapy. Metformin taken as mono therapy was the most common, taken by 
30.7%, followed by dual therapy of metformin plus a sulfonamide (21.7%). 
Of 504 respondents with diabetes, 8.5% had medication changed at the recorded encounter. 
Four patients with type 1 (9.3% of those with type 1 diabetes) and 39 patients with type 2 
(8.5% of those with type 2 diabetes) had medication changed, and the most common reason 
for change was poor HbA1c (69.8%, n = 43) followed by poor fasting control (30.2%, n = 43).  
The following pages contain the recording form and instructions with which the data in this substudy were collected. 
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SAND abstract number 186: Hepatitis B and travel vaccinations  
Organisation collaborating for this study: GlaxoSmithKline Australia Pty Ltd  
Issues: Proportion of surveyed patients who had been vaccinated for hepatitis B; reason(s) 
for vaccination; proportion who had travelled overseas in the previous 12 months; countries 
and regions visited; proportion who sought travel advice prior to travel; vaccines and 
prophylaxis medication(s) given; proportion who stayed in areas for which hepatitis B 
vaccination and/or malaria prophylaxis was recommended.  
Sample: 2,826 patients from 95 GPs; data collection period: 12/07/2011 – 15/08/2011. 
M ethod: Detailed in the paper titled SAND Method 2011–12 available at:  
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>. M ethods for this substudy: 
Destinations were coded using the Australian Bureau of Statistics (ABS) Standard Australian 
Classification of Countries. Information on hepatitis B and malaria risk was drawn from the 
Centres for Disease Control and Prevention website: <www.cdc.gov/travel> 
Summary of results 
The age and sex distributions of the 2,826 patients in this sample did not significantly differ 
from those of all patients at 2010–11 BEACH encounters. 
Of 2,823 respondents, 976 (34.6%, 95% CI: 31.0–38.2) had received hepatitis B vaccination and 
were immune, 96 (3.4%, 95% CI: 2.3–4.5) had started a course of hepatitis vaccination; 
making a total of 1,072 patients (38.0%) either fully or partial vaccinated. There were 1,266 
patients (44.8%) not vaccinated, and 485 (17.2%) did not know if they had been vaccinated.  
The 1,072 patients who were fully or partially vaccinated gave 1,061 reasons for hepatitis B 
vaccination. The most common reasons were because it was part of the Immunisation 
Schedule (53.5% of reasons), for overseas travel (20.9%), and for employment (20.1%). 
Among 2,750 respondents, 387 (14.1%) had travelled overseas in the previous year. Of 515 
destinations recorded by 382 travellers, the most frequently visited individual countries were 
the United States of America (10.5%) and New Zealand (8.5%). The most frequently visited 
regions were South-East Asia (25.5%of 462 regions) and Oceania/Antarctica (15.8%). 
Overnight rural stays were most common in New Zealand and South Africa. 
Among 380 respondents who had travelled overseas, 145 (38.2%) had sought travel advice: 
132 sought advice from a GP, nine from a travel clinic, and four from another health 
professional. Of 141 respondents who sought travel advice, the majority (60.3%) had sought 
advice one to six months before their trip.  
Travel vaccination status was provided for 234 respondents who travelled overseas: 77 
(32.9%) had been given a vaccine and/or prophylaxis medication prior to travel and 157 
(67.1%) had not. The 77 patients received 157 prophylaxis medications, the most common 
being typhoid vaccine (23.6%), hepatitis A vaccine (16.6%) and influenza vaccine (13.4%).  
Of 233 respondents who specified they visited a country for which hepatitis B vaccination 
was recommended, 139 (59.7%) were fully or partially immunised against hepatitis B. Of 43 
respondents who specified that they had travelled to a country where malaria prophylaxis 
was recommended, four (9.3%) were given prophylaxis medication prior to their trip. 
The following pages contain the recording form and instructions with which the data in this substudy were collected.
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SAND abstract number 187: General practice patient behaviour in 
seeking help for depression  
Organisation collaborating for this study: Pfizer Australia Pty Ltd 
Issues: The proportion of general practice patients who have ever been diagnosed with 
depression. The proportion with a current depression diagnosis; duration of the current 
episode and percentage of patients for whom it was a first episode; treatments tried for 
depression symptoms before diagnosis (tick boxes, see form for list of treatments); length of 
time symptoms were present before consulting a healthcare professional; reasons for seeking 
treatment; reasons for delay in seeking treatment. 
Sample: 2,971 patients from 101 GPs; data collection period: 16/08/2011 – 19/09/2011. 
M ethod: Detailed in the paper titled SAND Method 2011–12 available at:  
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>.  
Summary of results 
The age and sex distributions of the 2,971 patients who responded to the question on 
diagnosed depression did not differ from those of all patients at 2010–11 BEACH encounters. 
Of the 2,971 patients, 422 (14.2%, 95% CI: 11.8–16.6) were currently diagnosed with 
depression and 337 (11.3%, 95% CI: 9.6–13.1) had previously been diagnosed, giving a total 
of 759 patients (25.6%, 95% CI: 22.6–28.5) who at some stage had been diagnosed with 
depression. The proportion of patients ever diagnosed with depression rose significantly 
from those aged 15–24 years (16.2%, 95% CI: 10.0–22.3) to patients aged 25–44 years (34.3%, 
95% CI: 29.1–39.4) then remained steady until it decreased significantly for those aged  
65–74 years (24.1%, 95% CI: 19.7–28.6) and remained steady for those aged 75 years and over. 
A marginally greater proportion of female patients (28.4%, 95% CI: 24.8–31.9) than male 
patients (21.5%, 95% CI: 18.2–24.8) had been diagnosed with depression at some stage. 
Almost three-quarters (72.3%) of 418 respondents with current depression had been 
diagnosed more than 12 months earlier. For 140 patients (36.9% of 379 respondents) this was 
their first episode of depression.  
Among 404 respondents with current depression, over half (56.4%) had used none of the 
listed treatments prior to diagnosis, 29.2% had used relaxation techniques and 22.6% diet 
and exercise.  
Of 406 respondents with current depression, 39.9% sought help from a health professional 
less than three months after the first symptom was experienced, 26.4% waited 3–5 months, 
and 33.7% waited six months or longer. Reasons for seeking professional help were provided 
by 412 patients with current depression. ‘Not coping’ was the most common issue (given by 
14.8%). Low mood/feeling depressed, insomnia, problems with work or school were other 
common reasons for seeking professional care for depression.  
Of the 137 patients who delayed seeking treatment by six months or more, 127 responded to 
the question on reason for delay. “Didn’t realise they had depression” was the most common 
reason for delay, described for 26.8% of respondents. “Hoping they would get through it by 
themselves” was also a common reason (22.8%). 
 
The following pages contain the recording form and instructions with which the data in this substudy were collected. 
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SAND abstract number 188: Acute coronary syndrome among 
general practice patients  
Organisation collaborating for this study: AstraZeneca Pty Ltd 
Issues: The proportion of general practice patients who had an acute coronary syndrome 
(ACS) event in the previous three years; types of ACS events experienced; length of time 
since an ACS event; treatments used for ACS; details of clopidogrel use in patients who 
experienced an ACS event, including duration of present use and reasons for cessation. 
Sample: 2,957 patients from 100 GPs; data collection period: 16/08/2011 – 19/09/2011. 
M ethod: Detailed in the paper titled SAND Method 2011–12 available at:  
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>. 
Summary of results 
The age and sex distributions of the 2,957 patients who responded to the initial question 
about ACS did not differ from those of patients at all BEACH encounters in 2010–11.  
Of the 2,957 respondents, 106 (3.6%, 95% CI: 2.7–4.5) had experienced at least one ACS event 
in the previous three years. Two of these patients were aged less than 45 years (0.3% of 
patients aged 25–44 years). An ACS event was reported by 3.7% of patients aged 45–64 years, 
8.0% of those aged 65–74 years and 7.3% of those aged 75 years and over. 
There were 112 ACS events reported by the 106 patients who reported at least one event. The 
ACS event reported most often was unstable angina (46.2% of patients with ACS), followed 
by an unspecified ACS event (22.6%), non-ST-elevated myocardial infarction (21.7%) and ST-
elevated myocardial infarction (15.1%).  
One-third of 102 ACS patients reported that their most recent ACS event was 2–3 years ago 
(32.4%), and 26.5% of patients had their most recent ACS event more than one, but less than 
two years ago. For 15 patients (14.7%), their most recent event was less than three months 
ago. 
There were 103 respondents to the question on treatments for ACS. Of these, 54.4% stated 
they had been treated with at least one of the specified ACS treatments: 35.9% with 
percutaneous coronary intervention (i.e. a stent); 17.5% with coronary artery bypass and 
4.9% with fibrinolytic reperfusion. 
Reporting clopidogrel use (n = 104), 43.3% of patients had not used clopidogrel after their 
most recent ACS event. Nearly two-fifths of patients (38.5%) were currently using 
clopidogrel, and 14.4% had ceased using clopidogrel. Four patients did not know whether 
they had used clopidogrel. 
Of the 35 patients who were currently taking clopidogrel and reported on duration of use, 
nearly three-quarters (74.3%) had been taking clopidogrel for more than one year.  
Of those who had ceased taking clopidogrel since their most recent ACS event (n = 14), 50.0% 
had used it for more than one year. The decision to cease use of clopidogrel was made by a 
cardiologist for 10 of the 14 patients (71.4%). The reason(s) for ceasing clopidogrel were 
reported for 13 patients. Guideline recommendation was the most common reason (61.5%), 
followed by side-effects (30.8%).  
The following pages contain the recording form and instructions with which the data in this substudy were collected.
154
  
155
  
SAND abstract number 189: Menopause symptoms among female 
general practice patients aged 40–69 years 
Organisation collaborating for this study: Pfizer Australia Pty Ltd 
Issues: The proportion of female general practice patients aged 40–69 years who are: pre-
menopausal; peri-menopausal; post-menopausal; oophorectomy-induced menopausal. Their 
frequency of hot flushes/sweating episodes; vaginal dryness; irregular bleeding/spotting; 
depressive mood. For each symptom: time since onset; current treatment; patient satisfaction 
with their symptom management.  
Sample: 673 female patients aged 40–69 years from 100 GPs. 
M ethod: Detailed in the paper titled SAND Method 2011–12 available at:  
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>.  
Methods for this substudy: A card listing treatment options for menopausal symptoms was 
supplied to participating GPs for reference. 
Summary of results 
There were 673 female patients aged 40–69 years who responded to the initial question. The 
age distribution of this sample differed significantly from that of patients at all 2010–11 
BEACH encounters with female patients aged 40–69 years including a smaller proportion of 
61–64 year olds (14.4%, 95% CI: 11.6–17.2) compared with (18.1%, 95% CI: 17.5–18.7).  
Of the 673 respondents, 181 (26.9%) were considered by the GP to be pre-menopausal, 101 
(15.0%) were peri-menopausal, 378 (56.2%) were post-menopausal, and 13 being 
oophorectomy-induced menopausal. At least one menopausal symptom was experienced by 
407 women (62.3% of 653 respondents).  
Of 643 patients, 246 (38.3%) said they had hot flushes/sweating episodes some or all of the 
time. Of 235 respondents, almost half (49.4%) had experienced hot flushes for more than 
two years. Of 228 respondents with hot flushes, 140 (61.4%) were not currently receiving 
treatment and 31 (13.6%) were taking hormone replacement therapy (HRT). Of 31 
respondents on HRT, 21 were satisfied or very satisfied with their symptom management.  
Among 636 respondents, 230 (36.2%) had vaginal dryness some or all of the time. Of 216 
respondents, more than half (55.1%) had experienced vaginal dryness for more than 
two years. Of 214 respondents, more than half (51.9%) were not having treatment, 43 (20.1%) 
were taking HRT, 25 (11.7%) were using OTC products, and 23 (10.7%) were using other 
prescription medication for vaginal dryness. Of 60 respondents using any prescribed 
medication for vaginal dryness, 41 (68.3%) were satisfied or very satisfied with the treatment.  
Of 636 respondents, 81 (12.7%) had experienced irregular bleeding/spotting some or all of 
the time, and 555 (87.3%) did not. Among 633 respondents, 223 (35.2%) had depressive mood 
some or all of the time. Of 216 respondents, 63.4% had experienced depressive mood for 
more than two years. Of 214 respondents, 73 (34.1%) were using no treatment, 18 (8.4%) were 
taking HRT, and 83 (38.8%) were using other prescribed medications. Of 98 respondents 
using any prescribed medication for depressive mood, 58 (59.2%) were satisfied or very 
satisfied with the treatment.  
The following pages contain the recording form and instructions with which the data in this substudy were collected. 
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SAND abstract number 190: Benign prostatic hyperplasia (BPH) and 
symptoms among male general practice patients aged 40 years or 
older  
Organisation collaborating for this study: CSL Biotherapies Pty Ltd  
Issues: Among male general practice patients aged 40+ years: prevalence of BPH; urinary 
symptoms experienced (dribbling post-urination, urinary retention, incontinence, nocturia, 
hesitancy, urgency, pain/bleeding with urination, frequency, weak stream, straining to 
urinate or none); duration of symptoms prior to seeking treatment for BPH or symptoms; 
prompt for the initial consultation; managements used for symptoms; duration of use, 
initiator and side-effects (if any) for each medication used.  
Sample: 708 male patients aged 40 years or older from 93 GPs; data collection period: 
20/09/2011 – 24/10/2011.  
Method: Detailed in the paper titled SAND Method 2011–12 available at:  
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>.  
Summary of results 
The age distribution of these 708 patients did not significantly differ from that of the same 
age–sex cohort at all encounters during the April 2010 – March 2011 BEACH year.  
Of 707 respondents, 150 (21.2%, 95% CI: 17.3–25.1) had been diagnosed with BPH. There was 
a significant stepwise increase in prevalence with age from 0% in the 40–49 year age group, 
to 6.5% (95% CI: 2.3–10.7) among 50–59 year olds, 17.5% (95% CI: 10.8–24.3) among  
60–69 year olds, and 35.3% (95% CI: 27.6–43.0) among 70–79 year olds. Prevalence remained 
high among 80–89 year olds, (49.5%, 95% CI: 40.1–58.9) and those of 90 years or more, 
(53.3%, 95% CI: 29.6–77.0).  
At least one of the listed symptoms of BPH was reported by 247 (40.9%, 95% CI: 35.1–46.7) of 
604 respondents to this question. The most common symptoms were: nocturia, 25.7%; post-
urination dribbling, 19.0%; weak stream, 16.9%; and frequency, 14.6%. At least one symptom 
was present in 14.1% of 40–49 year age group, 40.5% of 60–69 and 66.7% of those 80 years 
and older. Of 232 symptomatic patients, 46.1% had waited more than two years before 
seeking treatment. Discussion about symptoms had been initiated by the GP for 53.4% and 
by the patient for 39.1% of 238 symptomatic respondents.  
Of 243 symptomatic respondents, 109 (44.9%) were currently being treated for BPH or 
symptoms, of whom 45 (41.3%) were taking 45 medications, the most common being 
tamsulosin (40.0%) and prazosin (28.9%). For 40 respondents, the average duration on 
medication was 13 months. Medication had been initiated by the GP for 53.5% and by the 
specialist for 44.2% of 43 respondents. Only one side-effect was reported (postural 
hypotension from tamsulosin) from 27 respondents.  
Non-pharmacological management had been used for BPH or symptoms by 21 (8.6%) of 243 
respondents, the most common (n = 12) being transurethral resection of the prostate (TURP). 
Of 243 symptomatic patients, 72 (29.6%) had been referred to an urologist.  
The following pages contain the recording form and instructions with which the data in this substudy were collected.  
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SAND abstract number 191: NSAID use, gastrointestinal and 
cardiovascular risk in general practice patients with arthritis 
Organisation collaborating for this study: AstraZeneca Pty Ltd (Australia) 
Issues: Prevalence of arthritis in general practice patients and use of non-steroidal anti-
inflammatory drugs (NSAIDs); gastrointestinal (GI) and cardiovascular (CV) risk profile of 
patients with arthritis; use of NSAIDs by patients with different risk profiles. 
Sample: 5,429 patients from 186 GPs; data collection period: 25/10/2011 – 16/01/2012. 
M ethod: Detailed in the paper titled SAND Method 2011–12 available at:  
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>.  
Methods for this substudy: GI risk was defined using the Gastroenterology Society of 
Australia (GESA) guideline “NSAIDs and the gastrointestinal tract”, 2008. CV risk was 
calculated using “Guidelines for the assessment of absolute cardiovascular disease risk”, 
National Vascular Disease Prevention Alliance, 2009. 
Summary of results 
The age and sex distributions of patients in this SAND sample did not differ significantly 
from that of patients at all 2010–11 BEACH encounters. 
Almost one-third (32.3%, 95% CI: 29.8–34.9) of the surveyed patients had arthritis. 
Prevalence increased significantly with age from 3.3% (95% CI: 1.6–5.1) of patients aged  
15–24 years to 74.6% (95% CI: 70.5–78.6) in patients aged 75 years and over. Osteoarthritis 
was the most common type of arthritis (29.8%, 95% CI: 27.3–32.3), followed by rheumatoid 
arthritis (1.3%, 95% CI: 0.9–1.7), gout (0.8%, 95% CI: 0.5–1.0) and other types of arthritis 
(1.5%, 95% CI: 1.0–1.9) (multiple types of arthritis could be recorded).  
Of the 1,755 patients with arthritis, 1,682 provided details of NSAID and aspirin use and 
43.3% (95% CI: 40.2–46.3) of these were currently taking aspirin and/or NSAID. NSAIDs 
were taken by 21.2% (95% CI: 18.2–24.3) of patients with arthritis, and 12.8% of patients with 
arthritis had taken a NSAID continuously for more than three months. Aspirin was taken by 
24.6% (95% CI: 21.9–27.3) of patients with arthritis. Most of these patients used aspirin as an 
antiplatelet medication, the mean and median daily dose being 110.2mg and 100.0mg 
respectively, and 97.3% of patients using aspirin had taken it continuously for more than 
three months. 
GI risk was calculated for 1,596 arthritis patients: 40.1% had high risk, 49.1% moderate and 
10.8% low GI risk. There were 1,579 patients for whom details of NSAID use and GI risk 
were provided. Of the 336 arthritis patients taking a NSAID: 58.0% had high risk, 36.6% 
moderate, and 5.4% were at low GI risk. Use of GI protection medication (e.g. proton pump 
inhibitors) was recorded for 1,556 patients: 19.1% of patients with low GI risk took GI 
protection medication (most of these patients had GORD); 38.2% of patients with moderate 
GI risk, and 50.5% of patients with high GI risk took GI protection medication. 
CV risk was calculated for 1,299 arthritis patients: 65.4% had high CV risk, 9.0% moderate 
and 25.6% low CV risk. There were 1,250 patients who provided details of NSAID use and 
CV risk. Of the 244 arthritis patients taking a NSAID: 54.9% were at high risk, 10.2% 
moderate, and 34.8% were at low CV risk.  
The following pages contain the recording form and instructions with which the data in this substudy were collected.
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SAND abstract number 192: Influenza risk, vaccination and 
diagnosis among general practice patients  
Organisation collaborating for this study: GlaxoSmithKline Australia Pty Ltd  
Issues: The proportion of general practice patients who were ‘at risk’ of influenza (had one 
or more risk factors – see attached card for risk factors); proportion of at risk patients aware 
they were eligible for a free influenza vaccine; proportion of at risk patients vaccinated; 
reasons why at risk patients were not vaccinated; proportion of patients diagnosed with 
influenza in previous year and any complications or hospitalisations due to influenza.  
Sample: 2,737 patients from 93 GPs; data collection period: 25/10/2011 – 28/11/2011. 
M ethod: Detailed in the paper titled SAND Method 2011–12 available at:  
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>.  
Summary of results 
There was no significant difference between the sex distribution of patients in this SAND 
and patients at all 2010–11 BEACH encounters. There was a significantly greater proportion 
of patients in the 75+ age group in this SAND (21.2%, 95% CI: 17.6–24.8) than at all 2010–11 
BEACH encounters (16.3%, 95% CI: 15.5–17.1). 
Among the 2,737 respondents, 1,317 (48.1%) had one or more influenza risk factor: one-third 
(33.0%) were aged 65+ years; 10.9% had cardiac disease; 9.6% had diabetes; 8.0% had chronic 
respiratory disease; 1.8% had impaired immunity; 1.7% were Indigenous aged 15 years and 
older; and 0.7% had a neurological condition impacting respiratory function. There was no 
difference between male and female patients in the proportion that were at risk. 
Of 1,298 at risk respondents, 980 (75.5%) had been vaccinated in 2011, while 291 (22.4%) had 
not. Of 1,255 at risk respondents, 1,150 (91.6%) were aware that influenza vaccination was 
available free to them through the Immunise Australia Program. Four out of five patients 
(79.8%) who were aware that influenza vaccination was available free had been vaccinated 
compared with only 26.2% of those who were not aware of this. 
Of the 291 at risk patients who were not vaccinated in 2011, 284 gave 296 reasons for not 
being vaccinated. The most common of the listed reason was patient objection (27.8% of the 
284 patients), followed by patients considering themselves not at risk (25.4%), patient belief 
they could get the flu from the vaccination (9.5%), cost (1.4%) and 40.1% gave other reasons. 
Among 1,278 respondents, 50 (3.9%) had been diagnosed with influenza in the 
previous year. Of 950 at risk patients who had been vaccinated in 2011, 36 (3.8%) had been 
diagnosed with influenza in the previous year, while among 290 patients not vaccinated, 13 
(4.5%) had been diagnosed with influenza in the previous year. Of 49 respondents diagnosed 
with influenza, 28 (57.1%) had at least one complication, the most common being bronchitis  
(n = 23, 46.9%) followed by pneumonia (n = 6, 12.2%). Of the 36 patients vaccinated in 2011 
who had influenza in the previous year, 20 (55.6%) had had complications from it, while 
among 12 patients who were not vaccinated, 7 (58.3%) had had complications. Of 44 
respondents with influenza, 8 (18.2%) had been hospitalised for influenza or its 
complications in the previous year. Among 31 vaccinated respondents, 6 (19.4%) had been 
hospitalised, while among 12 respondents who were not vaccinated, 1 (8.3%) had been 
hospitalised. 
The following pages contain the recording form and instructions with which the data in this substudy were collected.
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SAND abstract number 193: Diabetes, macular oedema and 
dyslipidaemia among general practice patients  
Organisation collaborating for this study: Novartis Pharmaceuticals Australia Pty Ltd 
Issues: The proportion of general practice patients who have diagnosed type 1 and 2 
diabetes; the length of time since diabetes was diagnosed; most recent HbA1c result; current 
medications used to manage diabetes; proportion of patients with diabetes that also have 
diagnosed macular oedema and its current management; proportion of patients with 
diabetes and macular oedema that also have dyslipidaemia and its current management.  
Sample: 2,825 patients from 97 GPs; data collection period: 17/01/2012 – 20/02/2012. 
M ethod: Detailed in the paper titled SAND Method 2011–12 available at:  
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>.  
Summary of results 
The age distribution of patients in this sample did not differ from that of patients at all  
2010–11 BEACH encounters, however, in this sample there was a significantly higher 
proportion of females (61.5%, 95% CI: 58.2–64.7% c.f. 57.1%, 95% CI: 56.3–58.0). 
Of the 2,825 respondents, 308 had diabetes (10.9%, 95% CI: 9.3–12.6): 29 (1.0%) had type 1 
diabetes only; 276 (9.8%) had type 2 diabetes only; and 3 patients had both type 1 and type 2 
diabetes. The age-specific prevalence of diabetes were highest among patients aged  
65–74 years (23.9%) followed by patients aged 75 years and older (16.4%) and those aged  
45–64 years (11.9%). Sex-specific prevalence of diabetes was significantly higher among 
males (14.7%, 95% CI: 12.1–17.3) than females (8.5%, 95% CI: 6.8–10.3). Time since diagnosis 
was known for 297 patients: two-thirds (66.0%) had been diagnosed more than 5 years 
earlier, and 26.6% between one and five years earlier. 
Most recent HbA1c test results were reported for 265 diabetes patients. The mean HbA1c 
level was 7.4% and the median was 6.9%. Among 289 respondents with diabetes, 233 (80.6%) 
were using 386 medication to manage their diabetes. Metformin accounted for 42.5% of 
these. The various types of insulin together made up over one-quarter of medications. 
Among 303 respondents with diabetes, 25 (8.3%) had macular oedema, 218 (71.9%) had been 
tested and did not have macular oedema, while 60 patients (19.8%) did not know or had 
never been tested. Of the 23 patients with macular oedema who responded, the majority 
(65.2%) reported no visual impairment and the macular oedema was not actively managed, 3 
patients had impairment but no management, 3 had received laser treatment, and 2 were on 
medication. 
Over two-thirds of patients with diabetes (72.8%) were known to have dyslipidaemia. 
Information about dyslipidaemia status was given for 24 of the 25 diabetes patients with 
macular oedema. Twenty (83.3%) of these patients had dyslipidaemia, and 4 had been tested 
and did not have dyslipidaemia. Of the 20 patients with all three conditions, dyslipidaemia 
was managed with: medication only for 14 patients; a combination of diet, exercise and 
medication for 3; diet and exercise for 2 patients and no management recorded for 1 patient. 
The following pages contain the recording form and instructions with which the data in this substudy were collected. 
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SAND abstract number 194: Adult general practice patients’ 
cardiovascular risk and lipid medication use 
Organisation collaborating for this study: AstraZeneca Pty Ltd (Australia) 
Issues: The proportion of adults attending general practice who: have at least one listed 
cardiovascular disease/risk factor; are classed as low, medium, and high cardiovascular risk; 
are using lipid lowering agents.  
Sample: 2,531 adult (18+ years) patient from 100 GPs; data collection period:  
21/02/2012 – 26/03/2012. 
M ethod: Detailed in the paper titled SAND Method 2011–12 available at:  
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>.  
M ethods for this substudy: Cardiovascular risk was defined as per the ‘Guidelines for the 
assessment of absolute cardiovascular disease risk’ (National Vascular Disease Prevention 
Alliance, 2009).  
Step 1: The patient is assessed as automatic high risk if they have any of: cardiovascular 
disease (CVD) including ischaemic heart disease, angina, previous MI, previous stroke, other 
CVD/event; diabetes and are 60 years of older; diabetes and microalbuminuria; 
moderate/severe chronic kidney disease (CKD); total cholesterol >7.5 mmol/L.  
Step 2: For those not high risk in step 1, CV risk calculated with Framingham equation.  
Step 3: For those still not assessed as high risk, 5% added (New Zealand cardiovascular 
guidelines handbook, 2009) to calculated risk score if one or more factors for consideration 
present, including: family history of premature heart disease; obesity (calculated using BMI 
from reported height and weight); age 35+ for Indigenous patients. 
Summary of results 
The age and sex distribution of sampled adults did not differ from that of adults at all 
BEACH encounters in 2010–11.  
Of 2,525 patients the prevalence of one or more CVD and/or risk factors for CVD was 67.2% 
(95% CI: 63.9–70.6), and 34.4% (n = 868) were automatically classed as high CVD risk  
(Step 1). 
At Step 2 Framingham could only be calculated for 1,464 patients (58.0%) of the sample 
because the equation requires complete data in all variables surveyed. Calculation was made 
for 653 (75.2%) of the 868 patients already identified as at high risk and 811 (48.9%) of the 
1,658 not classed as high risk in Step 1. Of the 811 patients not classed as at high risk in Step 
1: 84.2% were classed as at low risk, 11.3% at moderate risk, and 4.4% at high risk.  
When 5% was added to the Framingham result for each individual with one or more of the 
listed additional factors (Step 3), 25 moved from moderate to high risk, and 90 moved from 
low to moderate risk class. So at the end of Step 3, of the 1677 patients whose risk level could 
be measured: 929 (55.4%) were at high risk; 9.4% at moderate risk, and 35.2% at low risk.  
Lipid-lowering medication(s) were used by 33.8% of 2,382 respondents to this question, by 
24.3% of low CVD risk patients; 44.7% of moderate risk, and 62.3% of high risk patients. 
There were 841 patients not taking lipid medications for whom CVD risk could be 
calculated. Of these, 50.3% were at low risk, 10.0% at moderate, and 39.7% were at high risk.  
The following pages contain the recording form and instructions with which the data in this substudy were collected. 
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Abbreviations 
ABS Australian Bureau of Statistics 
ACE angiotensin-converting enzyme  
ACRRM Australian College of Rural and Remote Medicine 
ACS acute coronary syndrome 
ADE adverse drug event  
AHS allied health service 
AHW Aboriginal health worker 
AIHW Australian Institute of Health and Welfare 
APM antiplatelet medication 
ASGC Australian Standard Geographical Classification 
ATC Anatomical Therapeutic Chemical (classification) 
BEACH Bettering the Evaluation and Care of Health 
BMI body mass index 
BG blood glucose 
BPH Benign prostatic hyperplasia 
CAPS Coding Atlas for Pharmaceutical Substances 
CI confidence interval (in this report 95% CI is used) 
CKD chronic kidney disease 
COPD chronic obstructive pulmonary disease 
CT computerised tomography 
CV cardiovascular 
CVD cardiovascular disease 
DoHA Australian Government Department of Health and Ageing 
DVA Australian Government Department of Veterans’ Affairs 
ENT Ear, nose and throat 
FMRC Family Medicine Research Centre 
FTE full-time equivalent 
GI gastrointestinal 
GI SE gastrointestinal side effect 
GP general practitioner 
HbA1c haemoglobin, type A1c 
HRT hormone replacement therapy 
ICPC International Classification of Primary Care 
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ICPC-2 International Classification of Primary Care – Version 2 
ICPC-2 PLUS a terminology classified according to ICPC-2 
INR international normalised ratio 
LCL lower confidence limit 
MBS Medicare Benefits Schedule 
M,C&S microscopy, culture and sensitivity 
NDSHS National Drug Strategy Household Survey 
NESB non-English-speaking background 
NHMRC National Health and Medical Research Council 
NHS National Health Survey 
NSAIDs non-steroidal anti-inflammatory drugs 
OTC over-the-counter (medications advised for over-the-counter purchase) 
PBS Pharmaceutical Benefits Scheme 
PN Practice nurse 
RACGP Royal Australian College of General Practitioners 
RFE reason for encounter 
RRMA Rural, Remote and Metropolitan Area classification 
SAND Supplementary Analysis of Nominated Data 
SAS Statistical Analysis System 
UCL upper confidence limit 
URTI upper respiratory tract infection  
WHO World Health Organization 
Wonca World Organization of Family Doctors 
Symbols 
— not applicable 
< less than 
> more than 
NEC not elsewhere classified 
n number 
NOS not otherwise specified 
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Glossary 
A1 Medicare items: see MBS/DVA items: A1 Medicare items. 
Aboriginal: The patient identifies himself or herself as an Aboriginal person. 
Activity level: The number of general practice A1 Medicare items claimed during the previous 
3 months by a participating GP. 
Allied health services: Clinical and other specialised health services provided in the 
management of patients by allied and other health professionals including physiotherapists, 
occupational therapists, dietitians, dentists and pharmacists. 
Chapters (ICPC-2): The main divisions within ICPC-2. There are 17 chapters primarily 
representing the body systems. 
Chronic problem: see Diagnosis/problem: Chronic problem. 
Commonwealth concession card: An entitlement card provided by the Australian Government, 
which entitles the holder to reduced-cost medicines under the Pharmaceutical Benefits 
Scheme and some other concessions from state and local government authorities. 
Complaint: A symptom or disorder expressed by the patient when seeking care. 
Component (ICPC-2): In ICPC-2 there are seven components that act as a second axis across all 
chapters. 
Consultation: See Encounter. 
Diagnosis/problem: A statement of the provider’s understanding of a health problem 
presented by a patient, family or community. GPs are instructed to record at the most 
specific level possible from the information available at the time. It may be limited to the 
level of symptoms. 
• New problem: The first presentation of a problem, including the first presentation of a 
recurrence of a previously resolved problem, but excluding the presentation of a 
problem first assessed by another provider. 
• Old problem: A previously assessed problem that requires ongoing care, including 
follow-up for a problem or an initial presentation of a problem previously assessed by 
another provider. 
• Chronic problem: A medical condition characterised by a combination of the following 
characteristics: duration that has lasted or is expected to last 6 months or more, a pattern 
of recurrence or deterioration, a poor prognosis, and consequences or sequelae that 
impact on an individual’s quality of life. (Source: O’Halloran J, Miller GC, Britt H 2004. 
Defining chronic conditions for primary care with ICPC-2. Fam Pract 21(4):381–6).  
• Work-related problem: Irrespective of the source of payment for the encounter, it is likely 
in the GP’s view that the problem has resulted from work-related activity or workplace 
exposure, or that a pre-existing condition has been significantly exacerbated by work 
activity or workplace exposure. 
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Encounter (enc): Any professional interchange between a patient and a GP. 
• Indirect: Encounter where there is no face-to-face meeting between the patient and the GP 
but a service is provided (for example, prescription, referral). 
• Direct: Encounter where there is a face-to-face meeting of the patient and the GP. 
Direct encounters can be further divided into: 
– MBS/DVA-claimable: Encounters for which GPs have recorded at least one MBS item 
number as claimable, where the conditions of use of the item require that the patient 
be present at the encounter.  
– Workers compensation: Encounters paid by workers compensation insurance. 
– Other paid: Encounters paid from another source (for example, state). 
General practitioner (GP): A medical practitioner who provides primary comprehensive and 
continuing care to patients and their families within the community (Royal Australian 
College of General Practitioners). 
GP consultation service items: Includes GP services provided under the MBS professional 
services category including MBS items classed as A1, A2, A5, A6, A7, A14, A17, A18, A19, 
A20, A22 and selected items provided by GPs classified in A11, A15 and A27. 
GP consultation service items: see MBS/DVA items: GP consultation service items.  
MBS/DVA items: MBS item numbers recorded as claimable for activities undertaken by GPs 
and staff under the supervision of GPs. In BEACH a MBS item number may be funded by 
Medicare or by the Department of Veterans’ Affairs (DVA). 
• A1 Medicare items: Medicare item numbers 1, 2, 3, 4, 13, 19, 20, 23, 24, 25, 33, 35, 36, 37, 38, 
40, 43, 44, 47, 48, 50, 51, 601, 602. 
• GP consultation service items: Includes GP services provided under the MBS professional 
services category including MBS items classed as A1, A2, A5, A6, A7, A14, A17, A18, 
A19, A20, A22 and selected items provided by GPs classified in A11, A15 and A27. 
• MBS/DVA item categories: (Note: item numbers recorded in BEACH in earlier years 
which are no longer valid are mapped to the current MBS groups) 
– Surgery consultations: identified by any of the following item numbers: short 3, 52, 
5000, 52003; standard 23, 53, 5020, 5203; long 36, 54, 5040; prolonged 44, 57, 5060, 
5208. 
– Residential aged care facility: identified by any of the following item numbers: 20, 35, 
43, 51, 92, 93, 95, 96, 5010, 5028, 5049, 5067, 5260, 5263, 5265, 5267. 
– Home or institution visits (excluding residential aged care facilities): identified by any of 
the following item numbers:: 4, 19, 24, 33, 37, 40, 47, 50, 58, 59, 60, 65, 87, 89, 90, 91, 
503, 507, 5003, 5023, 5043, 5063, 5220, 5223, 5227, 5228. 
– GP mental health care: identified by any of the following item numbers: 2700, 2701, 
2702, 2704, 2705, 2710, 2712, 2713, 2715, 2717, 2721, 2723, 2725. 
– Chronic disease management items: identified by any of the following item numbers: 
720, 721, 722, 723, 724, 725, 726, 727, 729, 730, 731, 732. 
– Health assessments: identified by any of the following item numbers: 700, 702, 703, 
704, 705, 706, 707, 708, 709, 710, 712, 713, 714, 715, 717, 718, 719. 
– Case conferences: identified by any of the following item numbers: 734, 735, 736, 738, 
739, 740, 742, 743, 744, 750, 762, 765, 773, 775, 778. 
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– Attendances associated with Practice Incentives Program payments: identified by any of 
the following item numbers: 2497, 2501, 2503, 2504, 2506, 2507, 2509, 2517, 2518, 2521, 
2522, 2525, 2526, 2546, 2547, 2552, 2553, 2558, 2559, 2574, 2575, 2577, 2598, 2600, 2603, 
2606, 2610, 2613, 2616, 2620, 2622, 2624, 2631, 2633, 2635, 2664, 2666, 2667, 2668, 2673, 
2675, 2677, 2704, 2705. 
– GP bulk-billed incentive payment: identified by any of the following item numbers: 
10990,10991,10992,74990,74991. 
– Practice nurse/Aboriginal health worker/allied health worker services: identified by any of 
the following item numbers: 711, 10950, 10951, 10960, 10966, 10970, 10986, 10987, 
10989, 10993, 10994, 10995, 10996, 10997, 10998, 10999, 16400, 82210. 
– Acupuncture: identified by any of the following item numbers: 173, 193, 195, 197, 199. 
– Diagnostic procedures and investigations: identified by item numbers: 11000–12533. 
– Therapeutic procedures: identified by item numbers: 13015–25205 (excluding 16400). 
– Surgical operations: identified by item numbers: 30001–53706. 
– Diagnostic imaging services: identified by item numbers: 55028–64991. 
– Pathology services: identified by item numbers: 65060–74999. 
Medication: Medication that is prescribed, provided by the GP at the encounter or advised for 
over-the-counter purchase. 
Medication rates: The rate of use of all medications, including medications that were 
prescribed, supplied by the GP and advised for over-the-counter purchase. 
Medication status: 
• New: The medication prescribed/provided at the encounter/advised is being used for 
the management of the problem for the first time. 
• Continued: The medication prescribed/provided at the encounter/advised is a 
continuation or repeat of previous therapy for this problem. 
• Old: See Continued. 
Morbidity: Any departure, subjective or objective, from a state of physiological wellbeing. 
In this sense, sickness, illness and morbid conditions are synonymous. 
Patient status: The status of the patient to the practice. 
• New patient: The patient has not been seen before in the practice. 
• Patient seen previously: The patient has attended the practice before. 
Prescribed rates: The rate of use of prescribed medications (that is, does not include 
medications that were GP-supplied or advised for over-the-counter purchase). 
Problem managed: See Diagnosis/problem. 
Provider: A person to whom a patient has access when contacting the healthcare system. 
Reasons for encounter (RFEs): The subjective reasons given by the patient for seeing or 
contacting the general practitioner. These can be expressed in terms of symptoms, diagnoses 
or the need for a service. 
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Recognised GP: A medical practitioner who is: 
• vocationally recognised under Section 3F of the Health Insurance Act, or 
• a holder of the Fellowship of the Royal Australian College of General Practitioners who 
participates in, and meets the requirements for, quality assurance and continuing 
medical education as defined in the Royal Australian College of General Practitioners 
(RACGP) Quality Assurance and Continuing Medical Education Program, or 
• undertaking an approved placement in general practice as part of a training program for 
general practice leading to the award of the Fellowship of the Royal Australian College 
of General Practitioners, or undertaking an approved placement in general practice as 
part of some other training program recognised by the RACGP as being of equivalent 
standard. (Source: Commonwealth Department of Health and Aged Care 2001. Medicare 
benefits schedule book. Canberra: DHAC).  
Referral: The process by which the responsibility for part or all of the care of a patient is 
temporarily transferred to another health care provider. Only new referrals to specialists and 
allied health services, and for hospital and residential aged care facility admissions arising at 
a recorded encounter are included. Continuation referrals are not included. Multiple 
referrals can be recorded at any one encounter. 
Repatriation health card: An entitlement card provided by the Department of Veterans’ Affairs 
that entitles the holder to access a range of Repatriation health care benefits, including access 
to prescription and other medications under the Pharmaceutical Benefits Scheme. 
Rubric: The title of an individual code in ICPC-2. 
Significant: This term is used to refer to a statistically significant result. Statistical significance 
is measured at the 95% confidence level in this report.  
Torres Strait Islander: The patient identifies himself or herself as a Torres Strait Islander 
person. 
Work-related problem: See Diagnosis/problem. 
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Appendices 
Appendix 1: Example of a 2011–12 recording form 
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Appendix 2: GP characteristics questionnaire, 
2011–12 
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Appendix 3: Patient information card, 2011–12 
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Appendix 4: Code groups from ICPC-2 and 
ICPC-2 PLUS 
Available at: <purl.library.usyd.edu.au/sup/9781743320181>, see ‘Electronic editions and 
downloads’. 
Table A4.1:  Code groups from ICPC-2 and ICPC-2 PLUS – reasons for encounter  
and problems managed 
Table A4.2: Code groups from ICPC-2 and ICPC-2 PLUS – chronic problems 
Table A4.3: Code groups from ICPC-2 and ICPC-2 PLUS – problems managed by  
practice nurses 
Table A4.4: Code groups from ICPC-2 and ICPC-2 PLUS – clinical treatments 
Table A4.5: Code groups from ICPC-2 and ICPC-2 PLUS – procedures 
Table A4.6: Code groups from ICPC-2 and ICPC-2 PLUS – clinical measurements 
Table A4.7: Code groups from ICPC-2 and ICPC-2 PLUS – referrals 
Table A4.8:  Code groups from ICPC-2 and ICPC-2 PLUS – pathology test orders  
(MBS groups) 
Table A4.9:  Code groups from ICPC-2 and ICPC-2 PLUS – imaging test orders  
(MBS groups) 
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From April 2011 to March 2012, 984 general practitioners 
recorded details about 98,400 GP–patient encounters, 
at which patients presented 153,218 reasons for 
encounter and 152,286 problems were managed. For 
an ‘average’ 100 problems managed, GPs recorded: 70 
medications (including 57 prescribed, six supplied to 
the patient and seven advised for over-the-counter 
purchase); 11 procedures; 24 clinical treatments (advice 
and counselling); six referrals to specialists and three to 
allied health services; orders for 31 pathology tests and 
seven imaging tests. 
A subsample study of more than 31,000 patients suggests 
prevalence of the following measured risk factors in the 
attending adult (18 years and over) patient population: 
obesity—27%; overweight—35%; daily smoking—15%; 
at-risk alcohol consumption—25%. One in four people 
in the attending population had at least two of these 
risk factors.
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